CA2067133C - Liposome microreservoir composition and method - Google Patents
Liposome microreservoir composition and methodInfo
- Publication number
- CA2067133C CA2067133C CA002067133A CA2067133A CA2067133C CA 2067133 C CA2067133 C CA 2067133C CA 002067133 A CA002067133 A CA 002067133A CA 2067133 A CA2067133 A CA 2067133A CA 2067133 C CA2067133 C CA 2067133C
- Authority
- CA
- Canada
- Prior art keywords
- composition
- liposome
- liposomes
- compound
- growth factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/5537—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom the heteroring containing the structure -C(=O)-N-C(=O)- (both carbon atoms belong to the heteroring)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
A liposome composition for extended release of a therapeutic compound into the bloodstream. The liposomes are composed of vesicle-forming lipids and between l-20 mole percent of a vesicle-forming lipid derivatized with hydrophilic polymer, have sizes in a selected size range between 0.1 and 0.4 microns, and contain the therapeutic compound in liposome-entrapped form. The dosage form of the composition contains at least about three times the dose of the compound required for intravenous injection in free form. Also disclosed is a method for extending to at least 24 hours the period in which an intravenously administered therapeutic compound is therapeutically active in the blood-stream, and novel liposomes for practicing the method.
Description
2 0 6 7 1 3 3 Pcr/us9o/o6o34 LIPOSOrE MIcRoREs~voIp~cn~osITIo~ ~T~O~
1. Field of the Invention The present invention relates to a liposome composition and method for administering a therapeutic compound into the bloodstream over an extended period~
2. References Allen, T.M., (1981) Biochem. Biophys. Acta 640. 385397.
Allen, T.M., and Everest, J. (1983) J. Pharmacol. Exp.
Therap. 226. 539-544.
Ashwell, G., and Morell, A.G. (1974) Adv. Enzymology 41, 99-128.
Banga, A.K., et al., Int J Pharm, 48:15 (1988).
Czop, J.K. (1978) Proc. Natl. Acad. Sci. USA 75:3831.
Durocher, J.P., et al. (1975) Blood 45:11.
Ellens, H., et al. (1981) Biochim. Biophys. Acta 674:
10-18.
Gregoriadis, G., and Ryman, B.E. (1972) Eur. J. Biochem.
24, 485-491.
Gregoriadis, G., and Neerunjun, D. (1974) Eur. J. Biochem.
47, 179-185.
Gregoriadis, G., and Senior, J. (1980) FEBS Lett. 119, 43-46.
Greenberg, J.P., et al (1979) Blood 53:916.
Hakomori, S. (1981) Ann. Rev. Biochem. 50, 733-764.
WO91/05~5 2 0 6 7 1 3 3 PCT/USgo/~o~
Hwang, K.J., et al. (1980) Proc. Natl. Acad. Sci. USA
77:4030.
Jonah, M.M., et al. (1975) Biochem. Biophys. Acta 401, 336-348.
Juliano, R.L., and Stamp, D. (1975) Biochem. Biophys.
Res. Commun. 63. 651-658.
Karlsson, K.A. (1982) In: Biological Membranes, Vol. 4, D. Chapman (ed.) Academic Press, N.Y., pp. 1-74.
Kimelberg, H.K., et al. (1976) Cancer Res. 36,2949-2957.
Lee, K.C., et al., J. Immunology 125:86 (1980).
Lee, V.H.L., Pharm Int, 7:208 (1986).
Lee, V.H.L., Biopharm Manuf, 1:24 (1988).
Lopez-Berestein, G., et al. (1984) Cancer Res. 44, 375-378.
Okada, N. (1982) Nature 299:261.
Poste, G., et al., in "Liposome Technology" Volume 3, page 1 (Gregoriadis, G., et al, eds.), CRC Press, Boca Raton (1984);
Poznansky, M.J., and Juliano, R.L. (1984) Pharmacol. Rev.
36. 277-336.
Richardson, V.J., et al. (1979) Br. J. Cancer 40, 3543.
Scherphof, T., et al. (1978) Biochim.Biophys. Acta 542, 296-307.
Senior, J., and Gregoriadis, G. (1982) FEBS Lett. 145, 109-114.
Senior, J., et al. (1985) Biochim. Biophys. Acta 839, 1-8.
Szoka, F., Jr., et al. (1978) Proc. Natl. Acad. Sci. USA
75:4194.
Szoka, F., Jr., et al. ~1980) Ann. Rev. Biophys. Bioe... g.
9:467.
Woodruff, J.J., et al. (1969) J. Exp. Med. 129:551.
WO91/05~5 ~ 2 0 6 7 1 3 3 PCT/US~/~o~
1. Field of the Invention The present invention relates to a liposome composition and method for administering a therapeutic compound into the bloodstream over an extended period~
2. References Allen, T.M., (1981) Biochem. Biophys. Acta 640. 385397.
Allen, T.M., and Everest, J. (1983) J. Pharmacol. Exp.
Therap. 226. 539-544.
Ashwell, G., and Morell, A.G. (1974) Adv. Enzymology 41, 99-128.
Banga, A.K., et al., Int J Pharm, 48:15 (1988).
Czop, J.K. (1978) Proc. Natl. Acad. Sci. USA 75:3831.
Durocher, J.P., et al. (1975) Blood 45:11.
Ellens, H., et al. (1981) Biochim. Biophys. Acta 674:
10-18.
Gregoriadis, G., and Ryman, B.E. (1972) Eur. J. Biochem.
24, 485-491.
Gregoriadis, G., and Neerunjun, D. (1974) Eur. J. Biochem.
47, 179-185.
Gregoriadis, G., and Senior, J. (1980) FEBS Lett. 119, 43-46.
Greenberg, J.P., et al (1979) Blood 53:916.
Hakomori, S. (1981) Ann. Rev. Biochem. 50, 733-764.
WO91/05~5 2 0 6 7 1 3 3 PCT/USgo/~o~
Hwang, K.J., et al. (1980) Proc. Natl. Acad. Sci. USA
77:4030.
Jonah, M.M., et al. (1975) Biochem. Biophys. Acta 401, 336-348.
Juliano, R.L., and Stamp, D. (1975) Biochem. Biophys.
Res. Commun. 63. 651-658.
Karlsson, K.A. (1982) In: Biological Membranes, Vol. 4, D. Chapman (ed.) Academic Press, N.Y., pp. 1-74.
Kimelberg, H.K., et al. (1976) Cancer Res. 36,2949-2957.
Lee, K.C., et al., J. Immunology 125:86 (1980).
Lee, V.H.L., Pharm Int, 7:208 (1986).
Lee, V.H.L., Biopharm Manuf, 1:24 (1988).
Lopez-Berestein, G., et al. (1984) Cancer Res. 44, 375-378.
Okada, N. (1982) Nature 299:261.
Poste, G., et al., in "Liposome Technology" Volume 3, page 1 (Gregoriadis, G., et al, eds.), CRC Press, Boca Raton (1984);
Poznansky, M.J., and Juliano, R.L. (1984) Pharmacol. Rev.
36. 277-336.
Richardson, V.J., et al. (1979) Br. J. Cancer 40, 3543.
Scherphof, T., et al. (1978) Biochim.Biophys. Acta 542, 296-307.
Senior, J., and Gregoriadis, G. (1982) FEBS Lett. 145, 109-114.
Senior, J., et al. (1985) Biochim. Biophys. Acta 839, 1-8.
Szoka, F., Jr., et al. (1978) Proc. Natl. Acad. Sci. USA
75:4194.
Szoka, F., Jr., et al. ~1980) Ann. Rev. Biophys. Bioe... g.
9:467.
Woodruff, J.J., et al. (1969) J. Exp. Med. 129:551.
WO91/05~5 ~ 2 0 6 7 1 3 3 PCT/US~/~o~
3. Background of the Invention With recent advances in biotechnology, the development of medicinal peptides or proteins has become an integral partl of the pharmaceutical industry (Lee, 1986, 1988). Several thera-peutic proteins have been successfully produced through recom-binant DNA technology, such as human growth hormone, human insulin, ~-interferon, interleukin-2, TPA, and a variety of peptide vaccines, all of which are now commercially available (Banga). As oral administration generally does not result in therapeutic responses, the parenteral route is preferred.
However, when administered parenterally, most peptides and proteins have an extremely short half-life in the bloodstream, typically less than 2 hours, and thus require large doses and multiple daily injections or infusions. Often, the therapeu-tic regimens employed require close medical supervision andare difficult for most patients to accept.
Liposomes have been proposed as a carrier for intraven-ously (IV) administered compounds. However, the use of lipo-somes for slow release of liposome-entrapped material into the bloodstream has been severely restricted by the rapid clear-ance of liposomes from the bloodstream by cells of the reti-culoendothelial system (RES). Typically, the RES will remove 80-95% of IV injected liposomes within one hour, and effec-tively remove circulating liposomes from the bloodstream within of 4-6 hours.
A variety of factors which influence the rate of RES
uptake of liposomes have been reported (e.g., Gregoriadis, 1974; Jonah; Gregoriadis, 1972; Juliano; Allen, 1983;
Kimelberg, 1976; Richardson; Lopez-Berestein; Allen, 1981;
30Scnerph~ regoriadis, 1980; Hwang; Patel, 19&3; Senior, 1985; Allen, 1983; Ellens; Senior, 1982; Hwang; Ashwell;
Hakomori; Karlsson; Schauer; Durocher; Greenberg; Woodruff;
Czop; and Okada). Briefly, liposome size, charge, degree of WO91/~ ~5 PCT/US90/~0~
':~ 206713~
lipid saturation, and surface moieties have all been impli-cated in liposome clearance by the RES. However, no single factor identified to date has been effective to provide long blood halflife, and more particularly, a relatively high per-centage of liposomes in the bloodstream than 1 day or moreafter IV administration.
One factor which does favor longer liposome lifetime in the bloodstream is small liposome size, typically in the size range of small unilamellar vesicles (S Ws): 0.03-0.07 microns.
However, the intravesicular volume of S Ws is quite limited, to the extent that loading S Ws with a peptides or proteins in a therapeutically effective dose range is not practical for parenteral administration.
However, when administered parenterally, most peptides and proteins have an extremely short half-life in the bloodstream, typically less than 2 hours, and thus require large doses and multiple daily injections or infusions. Often, the therapeu-tic regimens employed require close medical supervision andare difficult for most patients to accept.
Liposomes have been proposed as a carrier for intraven-ously (IV) administered compounds. However, the use of lipo-somes for slow release of liposome-entrapped material into the bloodstream has been severely restricted by the rapid clear-ance of liposomes from the bloodstream by cells of the reti-culoendothelial system (RES). Typically, the RES will remove 80-95% of IV injected liposomes within one hour, and effec-tively remove circulating liposomes from the bloodstream within of 4-6 hours.
A variety of factors which influence the rate of RES
uptake of liposomes have been reported (e.g., Gregoriadis, 1974; Jonah; Gregoriadis, 1972; Juliano; Allen, 1983;
Kimelberg, 1976; Richardson; Lopez-Berestein; Allen, 1981;
30Scnerph~ regoriadis, 1980; Hwang; Patel, 19&3; Senior, 1985; Allen, 1983; Ellens; Senior, 1982; Hwang; Ashwell;
Hakomori; Karlsson; Schauer; Durocher; Greenberg; Woodruff;
Czop; and Okada). Briefly, liposome size, charge, degree of WO91/~ ~5 PCT/US90/~0~
':~ 206713~
lipid saturation, and surface moieties have all been impli-cated in liposome clearance by the RES. However, no single factor identified to date has been effective to provide long blood halflife, and more particularly, a relatively high per-centage of liposomes in the bloodstream than 1 day or moreafter IV administration.
One factor which does favor longer liposome lifetime in the bloodstream is small liposome size, typically in the size range of small unilamellar vesicles (S Ws): 0.03-0.07 microns.
However, the intravesicular volume of S Ws is quite limited, to the extent that loading S Ws with a peptides or proteins in a therapeutically effective dose range is not practical for parenteral administration.
4. Summary of the Invention It is therefore one general object of the invention to provide a liposome composition and method for administering a therapeutic compound for an extended period in the blood-stream.
The invention includes, in one aspect, a liposome compo-sition effective to extend to at least 24 hours, the period of effective activity of an therapeutic compound which can be administered intravenously in a therapeutically effective amount, and which has a blood halflife, in free form, of less than about 4 hours. The composition includes liposomes (i) composed of vesicle-forming lipids and between 1-20 mole per-cent of a vesicle-forming lipid derivatized with a biocompa-tible hydrophilic polymer, and (ii) having a selected mean particle diameter in the size range between about 0.1 to 0.4 m~crons, and the compound in 'iposo,..e-er.trapped f~~rm. The composition is intended for intravenous administration at a dose which contains an amount of the liposome-entrapped compound which is at least three times the therapeutically WO gl/05~45 PCr/US90/06034 ~0 671 3 3 effective dose for the compound in free form.
In one preferred embodiment, the hydrophilic polymer is polyethyleneglycol having a molec~ r weight between about 1,000-5,000 daltons, and the polymer is derivatized with the polar head groupof a phospholipid, such a phosphatidylethanol-amine (PE). Alternatively, the polymer may be other suitable biocompatible hydrophilic polymers, such as polylactic acid and polyglycolic acid.
Also in one preferred embodiment, the composition is effective to extend to at least 48 hours, the period of thera-peutic activity of an intravenously injected polypeptide which can be ~m; n; stered intravenously in a therapeutically effec-tive amount. The polypeptide may be a peptide or protein, such as superoxide dismutase, glucocerebrosidase, asparagi-nase, adenosine ~P~m~n~ce~ interferons (alpha, ~eta, andgamma), interleukin (1,2,3,4,5,6,7), tissue necrosis factor (TNF - alpha, beta), colony st;m~ ting factors (M-CSF (macro-phage), G-CSF (granulocyte), GM-CSF (granulocyte, macrophage), TPA, prourok~n~se, and urok1n~se, HIV-1 vaccine, hepatitis B
v~r~e, malaria vaccine, and melanoma ~accine, erythropoietin (EPO), factor VIII, bone growth factor, fibroblast growth factor, insulin-like growth factor, nerve growth factor, platelet-derived growth factor, tumor growth factors (alpha, beta), somatomedin C (I OE -1), and a ribosome inhibitor pro-tein, which is theLa~euLically active when ~m~ n~ stered intra-venously. Where the polypeptide is active in the picogram/ml range, such as is vasopressin, the compos~tion is effective to deliver a therapeutically effective amount of the peptide into the bloodstream for a period of between 5-10 days.
Also forming part of the invention is a method for exten-ding to at least 24 hours, the period of effective activity of a therapeutic compound which can be ~m~n;stered intravenous-ly in a therapeutically effective amount, and which has a ~:' 2~ fi7 ~ ~ 3 halflife in the blood, in free form, of less than about 4 hours. In this method, a liposome composition of the type described above is administered intravenously to a subject at a dose which contains an amount of the compound which is at least three times such therapeutically effective amount.
Also disclosed is a liposome composition effective to extend to at least one week, the period of effective activity of an therapeutic compound which can be administered intra-venously in a therapeutically effective amount. The composi-tion includes liposomes (i) composed of vesicle-forming lipids and between 1-20 mole percent of a vesicle-forming lipid deri-vatized with a biocompatible hydrophilic polymer, and ~ii) having a selected mean particle diameter in the slze range between about 0.07-.lS microns, and the compound in liposome-entrapped form. The composition is intended for subcutaneousadministration at a dose which contains an amount of the lipo-some-entrapped compound which is at least ten times such therapeutically effective intravenously administered amount.
The liposome composition is used in a method for extending the period of release of a therapeutic compound, preferably a polypeptide, in a therapeutically active amount, for a period of at least 2 weeks.
In another aspect, the invention includes a liposome composition composed of vesicle-forming lipids and a vesicle-forming lipid derivatized with polylactic acid or polyglycolicacid, and a lipid composition composed of a vesicle-forming lipid having a polar head group, and a polylactic acid or polyglycolic acid moiety derivatized to the lipid's head group.
WO91/~ ~5 2 0 6 7 1 3 3 PCT/USgo/~O~
Brief Description of the Drawings Figure l illustrates a general reaction scheme for derivatizing a vesicle-forming lipid amine with a polyalkyl-ether;
Figure 2 is a reaction scheme for preparing phosphati-dylethanolamine (PE) derivatized with polyethyleneglycol via a cyanuric chloride linking agent;
Figure 3 illustrates a reaction scheme for preparing phosphatidylethanolamine (PE) derivatized with polyethylene-glycol by means of a diimidazole activating reagent;
Figure 4 illustrates a reaction scheme for preparing phosphatidylethanolamine (PE) derivatized with polyethylene-glycol by means of a trifluoromethane sulfonate reagent;
Figure 5 illustrates a vesicle-forming lipid derivatized with polyethyleneglycol through a peptide (A), ester ~B), and disulfide ~C) linkage;
Figure 6 illustrates a reaction scheme for preparing phosphatidylethanolamine ~PE) derivatized with polylactic acid;
Figure 7 is a plot of liposome retention time in the blood, expressed in terms of percent injected dose as a function of hours after IV injection, for PEG-PE liposomes containing different amounts of phosphatidylglycerol;
Figure 8 is a plot similar to that of Figure 7, showing retention times in the blood of liposomes composed of predomi-nantly unsaturated phospholipid components;
Figure 9 is a plot similar to that of Figure 7, showing retention times in the blood of PEG liposomes ~solid tri-~ngles) and conventional liposomes ~solid ciLcles);
Figure lO is a plot of blood lifetimes of PEG-liposomes sized by extrusion through O.l micron ~solid squares), 0.2 micron ~solid circles), and 0.4 micron ~solid triangles) WO91/~ ~5 ~ 2 0 6 ~ 1 3 3 PCT/US9O/~O~
polycarbonate membranes;
Figure 11 is a plot of blood retention times in liposomes containing a vesicle-forming lipid derivatized with polylactic acid (solid squares) and polyglycolic acid (open triangles);
Figure 12 shows urine flow rates in rats, as a percentage of predosage rate, after surgery and IV administration of saline (control, open circles) and of aqueous solutions of vasopressin at total doses of 0.2 ~g (closed squares), 0.8 ~g (closed triangles), and 2 ~g (closed circles);
Figure 13 shows urine flow rates in rats, as a percentage of predosage rate, after surgery and IV administration of saline (control, open circles) and of PEG-liposomes containing entrapped vasopressin at total doses of 2 ~g (closed squares), 8 ~g (closed triangles), and 24 ~g (closed circles);
Figure 14 shows urine flow rates in rats, as a percentage of predosage rate, after surgery and IV administration of saline (control, open circles) and of PEG-liposomes containing entrapped vasopressin at a total dose of 8 ~g and mole percent of cholesterol in the liposomes of 33% (closed circles), 16%
(closed triangles), and 0% (closed squares);
Figure 15 shows the blood clearance kinetics of free macrophage-colony stimulating factor (M-CSF) (solid triangles), PEG-liposomes containing 30 mole percent cholesterol (solid triangles), and M-CSF associated with the PEG-liposomes (solid circles);
Figure 16 shows the blood clearance kinetics of free M-CSF
(solid triangles), cholesterol-free PEG-liposomes (solid triangles), and M-CSF associated with the PEG-liposomes ~solid circles);
Figure 17 is a plot of percent release of M-CSF into the blood from PEG liposomes containing 30 (solid circles) and 0 (solid triangles) mole percent cholesterol; and NO91/05545 PCTrUS90/OfiO34 ~ Q 6 7 1 3 3 Figure 18A shows urine flow rates in rats, as a percentage of predosage rate, after surgery and subcutaneous ~m~ n~stra-tion of saline (control, open circles) and free vasopressin, in an amount 2 ~g (solid triangles), 25 ~g (solid circles), and 50 ~g ~solid ~; ~monri.C); a~d Figure 18B shows urine flow rates in rats, as a percentage of predosage rate, after surgery and subcutaneous A~m; n~ stra-tion of saline (control, open circles) and vasopressin en-trapped in PEG-liposomes, in an amount 25 ~g (solid triang-les), 100 ~g (solid circles), and gO0 ~g (solid dizmonds).
Detailed Description of the Invention I. Preparation of Derivatized Lipids Figure 1 shows a general reaction scheme for preparing a vesicle-forming lipid derivatized with a bio-compatible, hydrophilic polymer, as exemplified by polyethylene glycol (PEG), poly-lactic acid, and polyglycolic acid, all of which are readily water soluble, can be coupled to vesicle-forming lipids, and are tolerated in ~i~o without toxic effects. The hydrophilic polymer which is employed, e.g., PEG, is preferably capped by a methoxy, ethoxy or other unreactive group at one end, or is one in which one end is more reactive than the other, such as polylactic acid.
The polymer is activated at one end by reaction with a suitable activating agent, such as cyanuric ac$d, diimadozle, anhydride reagent, or the like, as described below. The activated compound is then reacted with a vesicle-forming lipid, such as phosphatidylethanol (PE), to produce the 3û derivaiized iipid.
Alternatively, the polar group in the vesicle-forming lipid may be activated for reaction with the polymer, or the ~ , WO9l/05~5 ~ 2 ~ 6 7 1 3 ~ PCT/USgo/~o~
two groups may be joined in a concerted coupling reaction, according to known coupling methods. PEG capped at one end with a methoxy or ethoxy group can be obtained commercially in a variety of polymer sizes, e.g., 500-20,000 dalton molecular weights.
The vesicle-forming lipid is preferably one having two hydrocarbon chains, typically acyl chains, and a polar head group. Included in this class are the phospholipids, such as phosphatidylcholine (PC), PE, phosphatidic acid (PA), phospha-tidylinositol (PI), and sphingomyelin (SM), where the twohydrocarbon ch~; ns are typically between about 14-22 carbon atoms in length, and have varying degrees of unsaturation.
Also included in this class are the glycolipids, such as cere-broside and gangliosides.
Another vesicle-forming lipid which may be employed is cholesterol and related sterols. In general, cholesterol may be less tightly anchored to a lipid bilayer membrane, particu-larly when derivatized with a high molecular weight polyalkyl-ether, and therefore be less effective in promoting liposome evasion of the RES in the bloodstream.
More generally, and as defined herein, "vesicle-forming lipid" is intended to include any amphipathic lipid having hydrophobic and polar head group moieties, and which (a) by itself can form spontaneously into bilayer vesicles in water, as exemplified by phospholipids, or (b) is stably incorporated into lipid bilayers in combination with phospholipids, with its hydrophobic moiety in contact with the interior, hydro-phobic region of the bilayer membrane, and its polar head group moiety oreinted toward the exterior, polar surface of 3Q the membrane. An example of ~ latter type of vesicle-forming lipid is cholesterol and cholesterol derivatives, such as cholesterol sulfate and cholesterol hemisuccinate.
According to one important feature of the invention, the WO91/0~5 PCT/USgO/~34 20 67 ~ 3 ~
vesicle-forming lipid may be a relatively fluid lipid, me~ng that the lipid phase has a relatively low liquid-to-liquid crystal phase-transition temperature, e.g., at or below room temperature, or relatively rigid lipid, ~n~ng that the lipid has a relati~ely high melting temperature, e.g., up to 50~C.
As a rule, the more rigid, i.e., saturated lipids, contribute to greater membrane rigidity in a lipid bilayer structure and also contribute to greater bilayer stability in serum. Other lipid components, such as cholesterol, are also known to contribute to membrane rigidity and stability ir. lipid bilayer structures. Phospholipids whose acyl c-h~ns have a variety of degrees of saturation can be obtained commercially, or prepared according to published methods.
Figure 2 shows a reaction scheme for producing a PE-PEG
lipid in which the PEG is derivatized to PE through a cyanuric chloride group. Details of the reaction are pro~ided in Example 1. Briefly, methoxy-capped PEG is acti~ated with cyanuric chloride in the presence in sodium carbonate under conditions which produce the activated PEG compound IV in the figure. This material is purified to remove unreacted cyanuric a~id. The activated PEG compound is reacted with PE
in the presence of triethyl amine to produce the desired P~-PEG compound shown at VII in the figure. The yield is about 8-10% with respect to initial quantities of ~EG.
The method just describéd may be applied to a variety of lipid amines, including PE, cholesteryl amine, and glycolipids with sugar-amine groups.
A second method of coupling a polyalkylether, such as capped PEG to a lipid amine is illustrated in Figure 3. Here the capped PEG is acti~atad with a carbonyl diimidazole coupling reagent, to form the activated imidazole compound shown at X in Figure 3. Reaction with a llpid amine, such as P~ leads to PEG coupling to the lipid through an amlde 5~5 2Q 6 7 1 3 3 PCT/US90/060~
linkage, as illustrated in the PEG-PE compound shown at XI in the figure. Details of the reaction are given in Example 2.
A third reaction method for coupling a capped poly-alkylether to a lipid amine is shown in Figure 4. Here PEG is first protected at its OH end by a trimethylsilane group. The end-protection reaction is shown at A in the figure, and involves the reaction of trimethylsilylchloride with PEG in the presence of triethylamine. The protected PEG is then reacted with the anhydride of trifluoromethyl sulfonate (compound XVI in Figure 4) to form the PEG compound activated with trifluoromethyl sulfonate. Reaction of the activated compound with a lipid amine, such as PE, in the presence of triethylamine, gives the desired derivatized lipid product, such as the PEG-PE compound, in which the lipid amine group is coupled to the polyether through the terminal methylene carbon in the polyether polymer. The trimethylsilyl protective group can be released by acid treatment, as indicated at H+ in the figure, or by reaction with a quaternary amine fluoride salt, such as the fluoride salt of tetrabutylamine.
It will be appreciated that a variety of known coupling reactions, in addition to those just described, are suitable for preparing vesicle-forming lipids derivatized with hydro-philic polymers such as PEG. For example, the sulfonate anhydride coupling reagent illustrated in Figure 4 can be used to join an activated polyalkylether to the hydroxyl group of an amphipathic lipid, such as the 5'-OH of cholesterol. Other reactive lipid groups, such as an acid or ester lipid group may also be used for coupling, according to known coupling methods. For example, the acid group of phosphatidic acid can bc ~ctivated to form an active lipid anhydride, by reactlon with a suitable anhydride, such as acetic anhydride, and the reactive lipid can then be joined to a protected polyalkyl-amine by reaction in the presence of an isothiocyanate WO gl/OS545 PCr/US90/06034 reagent.
In another embodiment, the derivatized lipid components are prepared to include a labile lipid-polymer linkage, such as a peptide, ester, or disulfide linkage; which can be cleaved under selective physiological conditions, such as in the presence of peptidase or esterase enzymes present in the bloodstream. Figure 5 shows exemplary lipids which are linked through (A) peptide, ~B), ester, and (C), disulfide containing linkages. The peptide-linked compound can be prepared, for example, by first coupling a polyalkylether with the N-terminal amine of the tripeptide shown, e.g., via the reaction shown in Figure 3. The peptide carboxyl group can then be coupled to a lipid amine group through a carbodiimide coupling reagent conventionally. The ester linked compound can be prepared, for example, by coupling a lipid acid, such as phosphatidic acid, to the ~erri n~ 1 alcohol group of a poly-alkylether, using alcohol via an anhydride coupling agent.
Alternatively, a short linkage fragment cont~;n;ng an inter-nal ester bond and suitable end groups, such as primary amine groups can be used to couple the polyalkylether to the amphi-pathic lipid through amide or carbamate linkages. Similarly, the linkage fragment may contain an internal disulfide link-age, for use in forming the compound shown at C in Fi~ure 5.
Figure 6 illustrates a method for derivatizing polylactic acid with PE. The polylactic acid is reacted, in the presence of PE, with dicyclohexylcarboimide (DCCI), as detailed in Example 4. S~ rly, a vesicle-forming lipid deri~atized wit~ polyglycolic acid may be formed by reaction of polygly-colic acid or glycolic acid with PE in the presence of a suitable coupling agent, such as DCCI, also as detailed in Example 4. The vesicle-forming lipids derivatized with either polylactic acid or polyglycolic acid form part of the inven-tion herein. Also forming part of the invention are liposomes WO91/05~5 ~ 20~71~ PCT/US~/~o~
containing these derivatized lipids, in a 1-20 mole percent.
II. Preparation of Liposome Composition A. Lipid Components The lipid components used in forming the liposomes of the invention may be selected from a variety of vesicle-forming lipids, typically including phospholipids and sterols. As will be seen, one requirement of the liposomes of the present invention is long blood circulation lifetime. It is therefore useful to establish a standardized measure of blood lifetime which can be used for evaluating the effect of lipid component on blood halflife.
One method used for evaluating liposome circulation time in vivo measures the distribution of IV injected liposomes in the bloodstream and the primary organs of the RES at selected times after injection. In the standardized model which is used herein, RES uptake is measured by the ratio of total liposomes in the bloodstream to total liposomes in the liver and spleen, the principal organs of the RES. In practice, age and sex matched mice are injected intravenously ~IV) through the tail vein with a radiolabeled liposome composition, and each time point is determined by measuring total blood and combined liver and spleen radiolabel counts, as detailed in Example 6.
- Since the liver and spleen account for nearly 100% of the initial uptake of liposomes by the RES, the blood/RES ratio just described provides a good approximation of the extent of uptake from the blood to the RES in vivo. For example, a ratio of about 1 or greater indicates a predomin~nce of injected liposomes remaining in the bloodstream, and a ratio below about 1, a predom;n~nce of liposomes in the RES. For most of the lipid compositions of interest, blood/RES ratios were calculated at 1,2, 3, 4, and 24 hours.
WO 91/05~4~ PCr/US90/06034 ~0 671 3 3 The liposomes of the present invention include 1-20 mole percent of the vesicle-forming lipid derivatized with a hydro-philic polymer, described in Section I. According to one aspect of the invention, it has been discovered that blood circulation halflives in these liposomes is largely indepen-dent o~ the degree of saturation of the phospholipid compo-nents making up the liposomes. That is, the phospholipid components may be composed predominantly of fluidic, relatively unsaturated, acyl ch~ns~ or of more saturated, rigidifying acyl chain components. This feature of the invention is seen in Example 7, which ~m; nes blood/RES
ratios in liposomes formed with PEG-PE, cholesterol, and PC
having varying degrees of saturation ~Table 4). As seen from the data in Table 5 in the example, high blood/RES ratios were achieved with substantially all of the liposome formula-tions, independent of the extent of lipid unsaturation in the bulk PC phospholipid, and no systematic trend, as a function of degree of lipid saturation, was observed.
Accordingly, the vesicle-forming lipids may be selected to achieve a selected degree of fluidity or rigidity, to control the stability of the liposomes in serum and the rate of release of entrapped drug from the liposomes in the blood-stream and/or tumor. The vesicle-forming lipids may also be selected, in lipid saturation characteristics, to achieve desired liposome preparation properties. It is generally the case, for example, that more fluidic lipids are easier to formulate and down-size by extrusion or homogenization than more rigid lipid components, In general~ more fluidic lipids (low transition temperature) are preferred because of high 3Q compou~.d-release rates in the bloodstream.
Similarly, it has been found that the percentage of cholesterol in the liposomes may be varied over a wide range without significant effect on observed blood/RES ratios. The .
WO91/05~5 PCT/US90/06034 studies presented in Example 8A, with reference to Table 6 therein, show virtually no change in blood/RES ratios in the range of cholesterol between 0-30 mole percent.
Cholesterol, or related cholesterol derivatives may be important, however, in regulating the rate of release of lipo-some entrapped therapeutic compounds into the bloodstream.
The studies reported in Examples 1-5 and 16, for example, indicate that the rate of release of encapsulated polypeptide (peptide or protein) from liposomes in vitro in human serum or in vivo is strongly dependent on cholesterol concentration.
PEG-liposome formulations containing high cholesterol (e.g., 30 mole percent or greater) released very little peptide or protein into serum in vitro, whereas decreasing amounts of cholesterol produce increasing loss of encapsulated poly-peptide. Similarly, and as described below, increased chol-esterol in intravenously ~m; n; stered PEG-liposomes produced reduced release of encapsulated compound into the bloodstream (Example 18) and reduced physiological effect (Example 16).
Thus, in accordance with one feature of the invention, the rate of release of compound from long-circulating liposomes ~an be controlled by the percent cholesterol included in the liposomes.
It has also been found, in studies conducted in support of the invention, that blood/RES ratios are also relatively 2~ unaffected by the presence of charged lipid components, such as phosphatidylglycerol (PG). This can be seen from Figure 7, which plots percent loss of encapsulated marker for PEG-PE
liposomes containing either 4.7 mole percent PG ~triangles) or 14 mole percent PG (circles). Virtually no difference in liposome retention in the bloodstre&" over â 24 hour period was observed.
The vesicle-forming lipid derivatized with a hydrophilic polymer is present in an amount preferably between about 1-20 WO91/OS545 PCT/US9O/060~
~0 ~7 ~ ~ ~
mole percent, on the basis of moles of derivatized lipid as a percentage of total moles of vesicle-forming lipids. It will be appreciated that a lower mole ratio, such as 0.1 mole percent, may be appropriate for a ltpid derivatized with a large molecular weight polymer, such as one having a molecular weight greater than 100 kilodaltons. As noted in Section I, the hydrophilic polymer in the derivatized lipid preferably has a molecular weight between about 200-20,000 daltons, and more preferably between about 1,000-5,000 daltons. Example 8B, which ex~m;ne~ the effect of very short ethoxy ether moieties on blood/RES ratios~indicates that polyether moieties of greater than about 5 carbon ether are required to achieve significant enhancement of blood/RES ratios.
B. Preparing the Liposome Composition The liposomes may be prepared by a variety of techniques, such as those detailed in Szoka et al, 1980. One method for preparing drug-cont A; n ~ ~g liposomes is the reverse phase evaporation method described by Szoka et al and in U.S. Patent No. 4,235,871. The reverse phase evaporation vesicles (R~Vs) have typical average sizes between about 2-4 microns and are pre~om;n~ntly oligolamellar, that is, contain one or a few lipid ~ilayer shells. The method is detailed in Example SA.
This method is generally preferred for preparing liposomes 2~ wlth encapsulated proteins High encapsulation efficiencies (up to 50~) are possible, and thus protein loss or problems of recovery and purification of non-encapsulated protein are reduced.
Multilamellar vesicles (M1Vs) can be formed by simple lipid-film hydration techniques. In this procedure, a mixture of liposome-forming lipids of the type detailed above dis-solved in a suitable solvent is evaporated in a vessel to form a thin film, which is then covered by an aqueous medium, as WO gl/05545 Pcr/usso/o~034 - 20 67 ~ 3 3 detailed in Example 5B. The lipid film hydrates to form MLVs, typically with sizes between about 0.1 to 10 microns.
In accordance with one important aspect of the invention, the liposomes for intravenous injection are prepared to have substantially homogeneous sizes in a selected size range between about 0.1 and 0.4, and preferably 0.1 to 0.2 micron size ranges. Liposomes in this size range have sufficiently high encapsulation volumes for carrying therapeutically effec-tive amounts of the compound to be ~m;n;stered. At lower liposome sizes, the ratio of liposome-encapsulated compound to free compound may be too low to achieve a requisite initial dose level of liposome-encapsulated compound in the bloodstream or may not remain in circulation due to extravasation. At the same time, 0.1-0.4 micron liposomes are small enough to give long blood circulation times, as discussed below, and also to allow sterilization by sterile filtration.
One effective sizing method for REVs and MLVs involves extruding an aqueous suspension of the liposomes through a polycarbonate membrane having a selected uniform pore size, typically 0.4, 0.2, and/or 0.1 micron pore sizes. The pore size of the membrane is proportional to the largest sizes of the liposomes which are produced, particularly where the pre-paration is extruded two or more times through the same size membrane. This method of liposome sizing is used in preparing homogeneous-size REV and MLV compositions described in the examples below. A more recent method involves extrusion through an asymmetric ceramic filter. The method is detailed in U.S. Patent 4,737,323, titled Liposome Extrusion Method, issued April 12, 1988. Homogenization methods are also useful for down-sizing liposomes.
C. Compound ~oading In one embodiment, the composition of the invention is WO 91/05545 ~ ~ 2 0 6 7 1 3 :~ Pcr/us9o/o6o34 used for slow-release delivery into the bloodstream or a poly-peptide (peptide or protein) which is therapeutically active in the bloodstream when administered IV, but which in free form has a short blood halflife, typically 4 hours or less.
Examples of such polypeptides include hormones, such as vaso-pressin, calcitonin, oxytocin, somatotropin, human growth hormone, atrial naturectic factor (ANF), and insulin; enzymes, such as superoxide dismutase, glucocerebrosidase, asparagin-ase, and adenosine deAm;nAse; immunomodulators, such as inter-ferons (alpha, beta, and gamma), interleukin (1,2,3,4,5,6,7), tissue necrosis factor (TNF - alpha, beta), and colony stimu-lating factors (M-CSF (macrophage), G-CSF (granulocyte), GM-CSF (granulocyte, macrophage); anticoagulants, such as TPA, prourokinase, and urokinase; vaccines, such as HIV-1 vaccine, hepatitis B vaccine, malaria vaccine, and melanoma vaccine;
and other polypeptides (peptides and proteins), such as erythropoietin (EPO), factor VIII, bone growth factor, fibro-blast growth factor, insulin-like growth factor, nerve growth factor, platelet-derived growth factor, tumor growth factors (alpha, beta), and somatomedin C (IGF-1); and ribosome-inhibi-tor proteins, such as pokeweed antiviral protein and gelonin.
The polypeptides useful in the invention typically have relatively short blood halflives, on the order of 2-4 hours or less, and are active in the picogram/ml to nanogram/ml concen-tration range in the blood.
As noted above, polypeptide is preferably loaded passivelyby the reverse-phase emulsion method for preparing liposomes, although many other methods, such as solvent injection or lipid hydration may be employed. After liposome formation and si7ins, free (unbound) drug can be remo-ved by a variety o, methods, for example, by gel filtration or ion exchange chromatography or diafiltration. Typically the amount of free peptide in the final sterilized composition is less than about WO 91/05545 2 0 6 7 1 ~ 3 pcr/us9o/o6o34 20%, and preferably less than 10% of the total polypeptide contained in the composition.
At the same time, the encapsulated compound is preferably present in an amount which, in a selected liposome dose, is between 3-20 times the amount of compound which would be given as a therapeutic dose in free form by IV administration.
Thus, if the therapeutic dose of a peptide in free form is 1 ~g for IV administration, a selected liposome dose will pre-ferably contain between about 3-20 ~g of the peptide. Since 10-20% of this compound, e.g., 2-4 ~g, may be in non-encapsu-lated form, it will be appreciated that the total amount of liposome which can be administered may be limited by the maxi-mum tolerated dose of the free compound. It is clear that larger doses of liposomes can be administered by achieving higher ratios of encapsulated to non-encapsulated compound.
In general, this ratio is increased with larger liposomes, more complete free drug removal from the liposome composition, and greater liposome stability on storage.
The composition is also useful for slow-release delivery of a variety of non-peptide, water-soluble compounds which are effective in treating circulating cancers such as leukemias, for example, cytarabine, cyclophosphamide, carmustine, thio-guanine, bleomycin, daunorubicin, vinblastine, vincristine, and asparaginase.
Also useful in therapeutic delivery by the present invention are antibiotics, such as gentamicin, tobramycin, amikacin, netilmicin, kanamycin, and streptomycin, cefotaxime, ceftizoxime, and ceftriaxone, and anti-viral agents, such as AZT (zidovidine), DDI (dideoxyinosine), DDC (didioxycytidine), ganciclov r, D4T (didehydrodeoxythymidine), phosphonoformate, ribavirin, and acyclovir.
WO91/05545 PCT/US~/~
-2 ~ 3 3 Such compounds may be encapsulated by passive loading, as above, during liposome formation by reverse evaporation phase, lipid hydration, solvent injection, or other liposome forma-tion methods, and remo~ed, after sizing by gel filtration or the like.
Alternatively, drugs which form weak bases at physiological pH may be actively loaded into the liposomes at high drug concentration in the liposomes. One method for active loading drugs into liposomes is described in co-owned u.s. Patent 5,192,549. In this method, liposomes are prepared in the presence of a relatively high ammonium ion, such as 0.125 M
A~mon~um sulfate. After sizing the liposomes to a desired size, the liposome suspension is treated to create an inside-to-outside ammonium ion gradient across the liposomal membranes. The gradient may be created by d~alysis against a non~ o~1um contA~ning medium, such as an isotonic glucose medium, or by gel filtration, such as on a Sephadex G-50 column equilibrated with 0.15 M NaCl or KCl, effecti~ely replacing ~onium ions in the exterior phase with sodium or potassium ions. Alternatively, the liposome suspension may be diluted with a non-ammonium solution, thereby reducing the exterior-phase concentration of ~rmon;um ions. The ammonium concentration inside the liposomes is preferably at least 10 times, and more pre~erably at least 100 to 1000 times that ln the external liposome phase.
The ammonium ion gradient across the liposomes in turn creates a pH gradient, as ~r~on;a is released across the lipo-some membrane, and protons are trapped in the internal lipo-3Q some phz~e. To 102d liposomes with the selected drug, a rela-tively dilute suspension of the liposomes, e.g., less than about 50 mM lipid, is mixed with an aqueous solution of the drug, and the mixture is allowed to equilibrate over an WO91/05~5 PCT/US90/06034 7 ~ ~ 3 extended period, e.g., 24 hours at room temperature. In one typical method, a suspension of liposomes having a lipid con-centration of 25 mg/ml is mixed with an equal volume of anthracycline drug at a concentration of about 10 mg/ml. At the end of the incubation period, the suspension is treated to remo~e free (unbound) drug.
III. Intravenous ~m; n; ~tration A. Extended Lifetime in the Bloodstream One of the requirements for extended compound release into the bloodstream, in accordance with the invention, is an extended liposome lifetime in the bloodstream with IV_liposome administration. One measure of liposome lifetime in the bloodstream is the blood/RES ratio determined at a selected time after liposome ~m; n; stration, as discussed above.
Blood/RES ratios for a variety of liposome compositions are given in Table 3 of Example 6. In the absence of PEG-derivatized lipids, blood/RES ratios were 0.03 or less. In the presence of PEG-derivatized lipids, the blood/~ES ratio ranged from 0.2, for low-moler~ r weight PEG, to between 1.7-4 for several o~ the formulations, one of which lac~s cholesterol, and three of which lack a charged phospholipid (e.g., PG).
The data presented in Table 5 in Example 7 show blood/RES
2~ ratios (excluding two points with low percent recovery) between about 1.26 and 3.27, consistent with the data given in Table 3. As noted in Section II above, the blood lifetime values are substantially independent of degree Of saturation of the liposome lipids, presence of cholesterol~ and presence of ch~rged lipids.
The blood/RES values reported above can be compared with blood/RES values reported in co-owned U.S. Patent No.
4,920,016, which used blood/RES measuL~.el~L methods identical WO91/05~5 PCT/US90/~0~
~ Q ~ 7 1 3 3 to those used for the data presented in Tables 3 and 5.
The best of the 24-hour blood/RES ratios which were reported in the above-noted patent was 0.9, for a formulation composed of GMl, saturated PC, and cholesterol The next best formulations gave 24-hour blood/RES values of about 0.5. Thus, typical 24-hour blood/RES ratios obtained in a number of the current formulations were more than twice as high as the best formula-tions reported which have been reported to date. Further, ability to achieve high blood/RES with GMl or HPI lipids was dependent on the presence of prP~om~n~tly saturated lipids in the liposomes.
Plasma kinetics of a liposomal marker in the bloodstream can provide another measure of the enhanced liposome lifetime which is achieved by the liposome formulations of the present invention. Figure 7 and 8 discussed above show the slow loss of liposomal marker over a 24 hour period in typical PEG-lipo-some formulations, substantially independent of whether the marker is a lipid or an encapsulated water-soluble compound ~Figure 8). In both plots, the amount of liposomal marker present 24 hours after liposome injection is greater than 10%
of the originally injected material.
Figure 9 shows the kinetics of liposome loss from the bloodstream for a typical PEG-liposome forml~lAt~on and the same liposomes in the absence of a PEG-derivatized lipid. After 24 2S hours, the percent marker remaining in the PEG-liposomes was greater than about 20~, whereas the conventional liposomes showed less than 5% retention in the blood after 3 hours, and virtually no detectable marker at 24 hours.
The results seen in Figures 7-9 are consistent with 24 hour blood liposome values measured for a variety of liposome formulations, and reported in Tables 3 and 5-7 in Example 6-9 below. As seen in Table 3 in Example 6 the present dose r~ ;ng at 24 hours was less than 1% for conventional l$po-WO91/0554~ PCT/US90/06034 somes, versus at least 5% for the PEG-liposomes. In the best formulations, values between about 20-40~ were obtained.
Similarly in Table 5 from Example 7, liposome le~els in the blood after 24 hours (again neglecting two low recovery ~alues) were between 12 and about 25 percent of total dose given. Similar results are reported in Tables 6 and 7 of Example 8.
The effect of liposome size on blood lifetime has been investigated by comparing loss of liposomal marker in intra-venously injected liposomes having selected sizes betweenabout 0.1 and 0.25 microns. Experimental details are given in Example 10. The results, given in Figure 10, show about 10%
or greater liposome marker present in the blood after 24 hours for each of the liposome formulations. Highest blood life-1~ times were achieved with the smallest liposomes. Thus, although all of the liposome preparations give high blood lifetimes, it is also clear that liposome size can be selected to produce desired increase or decrease in total drug release time.
The enhancement in liposome blood circulation time achieved with two other biocompatible hydrophilic polymers, polylactic acid and polyglycolic acid, is seen in Figure 11, which shows loss of liposome marker during the 24-hour period after intravenous liposome injection. The percent marker rPm~;n;ng at 24 hours is about 4.3 percent for polylactic acid (solid squares), and about 6~ for polyglycolic acid (open triangles). These values compare with the 0.1-1~ retention seen in conventional liposomes after 24 hours.
The data relating to both blood/R$S ratios and to liposome 3Q rete~tio~ time in the bloodstream which were obtained frGm an model animal system can be reasonably extrapolated to ~ c and veterinary ~;m~ls of interest. This is because upta~e of liposomes by li~er and spleen has been found to occur at WO91/05545 PCT/US90/~
~n ~71 3 3 similar rates in several m~mm~l ~an species, including mouse, rat, monkey, and human ~Gregoriadis, 1974; Kimelberg, 1976;
Juliano; Richardson; Lopez-Berestein). This result likely reflects the fact that the biochemical factors which appear to be most important in liposome uptake by the ~BS -- including opsinization by serum lipoproteins, size-dependent uptake effects, and cell shielding by surface moieties -- are common features of all ~mm~ 1 ian species which have been e~Am~ned.
B. Compound Release in the Bloodstream In addition to long circulating halflives, another important property of the liposomes of the present invention is the ability to release entrapped compound at the thera-peutically effective dose rate in the bloodstream.
As discussed above, the liposome size between 0.1 and 0.4 microns allows relatively high compound loading in the lipo-somes, for effective compound release as the percentage of liposomes in the bloodstream even at relatively low liposome concentrations in the bloodstream. This is typically an important consideration since the total amount of liposomes which can be A~m; n~ stered will be limited, due to the unavoidable presence of some free compound in injected composition.
Another consideration is the ability of entrapped compound to be released from the liposomes during circulation in the blood. This feature is illustrated in the studies described in Example 15 below. Here PEG-liposomes containing entrapped vasopressin (a 1 kilodalton peptide) were prepared with increasing concentrations of cholesterol, from 0 to about 30 mole percent. In vitro mea--urements on peptide release from the liposomes in serum showed substantially less peptide release with greater amounts of cholesterol. The rate of release of the peptide hormone in vivo was determined by WO 91/0~545 PCr/US90/06034 ~0 ~71~ 3 diuretic effect, as measured by decreased urine ouL~u~, in a period 1-8 days following intravenous administration of t~e liposomes. Details of the study are given in Example 15. As seen ~n Figure 14, the short-term effect on~ urine flow was dependent on cholesterol content, the PEG-liposomes with highest cholesterol producing the greates~ hormone effect.
Similarly, in the period 2-8 days following IV administration of the liposomes, the two PEG-liposome formulations having the lowest cholesterol concentration gave the greatest hormone effect, indicating higher release rates from the liposomes.
The study reported in ~xample 16 ~mon ctrateS a similar ability to control release rates of large proteins from long-circulating liposomes. Here PEG-liposomes containing encapsu-lated M-CSF (a 55 kilodalton protein) were eX~m;ne~ for per-cent retention in the bloodstream of both lipid and proteincomponents. The data plotted in Figure 15 show liposome lipid (solid triangles) and protein (solid ci'rcles) kinetics 2g hours after IV injection for a PEG-lipsome formulation con-t~~ n; ng 30 mole percent cholesterol. The data indicate about 20% loss of encapsulated material over 24 hours, as discussed in ~xample 16.
Figure 17 shows a s; m; 1 ~r plot for PEG-liposomes without cholesterol. The data here show a 40-50~ loss of M-CSF after 24 hours. When normalized lipid and protein markers are compared at selected time points o~er 24 hours, the plots of protein release from cholesterol (solid circles) and no-cholesterol (solid triangles) PEG-liposomes are obtained. The plots illustrate the markedly different protein release kinetics which can be obtained with long circulating lipo-some~, by varying cholesterol content of the liposomes.Another feature of the data shown in Figure 17 is the relatively high percent ~at least 3%) of initially injected protein which is released at 24 hours in both formulations.
_n WO gl/05545 PCr/US90/06034 - ~ 0 6 7 ~ 3 3 IV. Intravenous Liposome Treatment The invention includes, in one aspect, a method for extending to at least 24 hours, the period of effective activity of an therapeutic compound. The compound is one which can be ~mt n1 stered intravenously in a therapeutically effective amount, and which has a halflife in the bloodstream, in free form, of less than about 4 hours.
In practicing the method, there is provided a liposome composition such as described above, containing the compound in liposome-entrapped form. The size, lipid composition, and extent of compound loading of the drug are selected, according to the desired release rates and total release times, as considered in Section III above.
The composition is injected intravenously to a subject at a dose which contains an amount of the compound which is at least 3, and typically 5-20 times the therapeutically effec-tive dose. Thus, for example, if a therapeutically effective dose of a compound is 10 ~g/Kg body weight, the liposome com-position would be injected at a liposome dose of at least 30 ~g compound/Kg, and typically ~etween 50-200 ~g compound/Kg body weight. As noted above, the amount of material which can be injected is generally limited by the maX1mllm tolerated dose of free compound, since 5-20% or more of the compound may be in free (non-entrapped) form when the composition is adml-nistered. Thus, for example, if the ~x1~llm tolerated dose of a compound in free form is 2 ~g/Kg body weight, and the lipo-some composition contains 10~ non-entrapped compound, the highest dose of liposome composition which can be given is 20 ~g/Kg body weight.
Studies on the treatment of L1210 lellkpm~ A in mice with cytosine arabinoside (araC), in free form and entrapped in WO gl/0~ PCr/US90/06~34 - 20 67 ~ 3 3 PEG-liposomes,indicates that the liposome composition produced about a 250-300~ increase in survival time when a~m;n;~tered in PEG-liposomal form, compared with about a 120~ increase in survival time for the drug in free form.
The ability to achieve long drug release times, on the order of several days, by the method of the invention is illu-strated by the studies on IV vasopressin administration repor-ted in Examples 13-15. The s~udies were carried out on Brattle-boro rats which are genetically diabetic by virtue of vaso-pressin deficiency. Figure 13 sh-ows the effect, measured in percent predosage urine flow, of IV injection of free vaso-pressin at dose levels of 0.2 ~g (solid squares), 0.8 ~g (solid triangles) and 2.0 ~g (solid circles). The reduction in urine flow is ~x;m~lm after 1 day, but returns to control levels (open circles) by day 2.
~ igure 14 shows the effect on urine flow by vasopressin ~m; n; stered IV in PEG-liposomes, at dosage levels of 2 ~g (solid squares), 8 ~g (solid triangles) and 24 ~g (solid cir-cles). A pronounced reduction in urine flow was observed within one day, with a slight rebound t~ward control values by day 2 -- an effect likely due, in part, to free peptide in the liposome formulation. In addition, a marked reduction in urine flow was observed for at least 7 days following IV
~min; stration. It is noted that the long-term therapeutic effect is saturated at an 8 ~g dose, with no further effect observed at 24 ~g. The same long-term therapeutic effect of vasopressin was observed in PEG-liposomes containing various amounts of cholesterol, as seen in Figure 14, and as discussed above. The data in this figure also illustrate increased short-term (1-2 days) and decreased long-term (2-8 days) effect seen with low cholesterol liposomes having the highest peptide release rates.
~' WO91/05S45 PCT/US90/060~
~ 0 6 7 ~ 3 3 More generally, it will be appreciated that a variety of polypeptides which are active in the picogram-to-nanogram/ml range may be ~; nl stered over a several-day period by the method o~ the invention. The data presented in Figures 15-17, for example, ~monstrate that (a) large proteins may be se-questered in the bloodstream, for slow release in therapeutic amounts over an extended period and (b) the rate of release of the protein into the bloodstream can be selectively con~rolled by liposome composition.
V. Subcutaneous Liposome Treatment In accordance with another aspect of the invention, it has been discovered that the long-circulatory liposome composition of the invention is also effective for slow release of a liposome-entrapped compound from a subcutaneous (SubQ) site into the bloodstream. In particular, it has been discovered that therapeutic effects of up to 3 weeks or more can be achieved by a single subcutaneous injection of the liposome composition of the invention.
The experimental model used to ~emo~strate this method is the vasopressin model described above, and detailed in Example 17. Briefly, a treatment method involving SubQ injection of free vasopressin was compared, for duration of physiological effect, with ~asopressin a~; n~ stered SubQ in ~G-liposomes.
Figure 18A shows the depression in urine production observed with SubQ ~; n; stration of free vasopressin at doses of-2 ~g ~solid triangles), 25 ~g (solid circles), 50 ~g (solid squares), and 100 ~g (solid diamonds). With the higher doses, a pronounced reduction in urine production at day 1 was observed, with a reboun~ ~o control levels (open circles) by day 4.
.~ .
WO91/05~45 PCT/USgO/06034 2Q ~7 ~ 3 ~
Figure 18B shows the ef~ect of SubQ administration of the peptide in PEG liposomes. The lowest dose ~d~;n;stered, 2S ~g (closed triangles) gave a slight prolongation of activity, to about 8 days. A vasopressin dose of 100 ~g (closed circles) showed a significant reduction in urine ou~uL to about 20 days. An even longer effect, of at least 24 days, was observed at a dose of 400 ~g (closed squares).
The treatment method employing ~asopressin is designed for treatment of diabetes insipidus, by long-term ~m;n; stration of vasopressin from a SubQ site. More generally, the method is designed for extendlng to at least one wee~, the per~od of effective activity of a therapeutic compound which can be ~m~ n; stered intravenously in a therapeutically effective amount. The method utilizes liposomes (i) composed of 1~ vesicle-forming lipids and between 1-~0 mole percent of a vesicle-fo~ming lipid derivatized with a hydrophilic polymer, and (ii) having a selected mean particle diameter in the size range preferably between about 0.07-.15 microns, and having the compound in liposome-entrapped form.
The liposome composition is ~m; n; stered subcutaneously at a dose of the composition which cont2ins an amount o~ the liposome-entrapped compound which is at least ten times the therapeutically effective intravenously a~ n~ qtered amount.
For compounds, such as vasopressin~ which are active in the bloodstream in the picogram-to-nanogram/ml concentration, such as a variety of peptide and proteins, the method can be used for therapeutic delivery of the compound over a several-week period.
The ability of the liposome composition of the invention 30 tG produce a long-term therapeutic effect from a SubQ site suggests that the liposomes taken up from this site through the lymphatics may be able to successfully evade the normal ~' ,.
lymphatic clearance mechanisms, including ~upfer cells. This mechanism is supported by studies on araC administration by the interperitoneal (IP) route by PEG-liposomes. Briefly, it was found that PEG-liposomes containing entrapped araC and 5administered by IP route produced a 250-300% increase in survial in A~im~ls having L1210 leukemias, compared with about 120% increase in survival with the free drug given by the IP
route. The results suggests that PEG-liposomes are capable of migrating from the peritoneum through the lymphatics into the bloodstream.
The following examples illustrate the invention.
15Materials Cholesterol (Chol) was obtained from Sigma (St. Louis, MO). Sphingomyelin (SM), egg phosphatidylcholine (lecithin or PC), partially hydrogenated PC having the composition IV40, IV30, IV20, IV10, and IV1, phosphatidylglycerol (PG), phospha-tidylethanolamine ~PE), dipalmitoyl-phosphatidyl glycerol (DPPG), dipalmitoyl PC (DPPC), dioleyl PC (DOPC) and distear-oyl PC (DSPC) were obtained from Avanti Polar Lipids (Birming-ham, AL) or Austin Chemical Co (C~icago, I1).
[~5I]-tyraminyl-inulin was made according to published procedures. "Gallium citrate was supplied by NEN Neoscan (Boston, MA). Vasopressin and macrophage colony stimulating factor were obtained from Sigma (St. Louis,Mo), and Cetus (Emeryville,Ca), respectively.
30Example 1 Preparation of PEG-PE Linked by Cyanuric Chloride A. Preparation of activated PEG
2-0-Methoxypolyethylene glycol 1900-4,6-dichloro-1,3,5 WO91/05~5 PCT/US90/060~
206~133 .. ~ ~ ....
,; ~
triazine previously called activated PEG was prepared as described in J. Biol. Chem., 252:3582 (1977) with the fol-lowing modifications.
Cyanuric chloride (5.5 g; 0.03 mol) was dissolved in 400 ml of anhydrous benzene containing 10 g of anhydrous sodium carbonate, and PEG-1900 (19 g; 0.01 mol) was added and the mixture was stirred overnight at room temperature. The solu-tion was filtered, and 600 ml of petroleum ether (boiling range, 35-60~) was added slowly with stirring. The finely divided precipitate was collected on a filter and redissolved in 400 ml of benzene. The precipitation and filtration pro-cess was repeated several times until the petroleum ether was free of residual cyanuric chloride as determined by high pres-sure liquid chromatography on a column (250 x 3.2 mm) of 5-m "LiChrosorb" ~E. Merck), developed with hexane, and detected with an ultraviolet detector. Titration of activated PEG-l900 with silver nitrate after overnight hydrolysis in aqueous buffer at pH 10.0, room temperature, gave a value of 1.7 mol of chloride liberated/mol of PEG.
TLC analysis of the product was effected with TLC
reversed-phase plates obtained from Baker using methanol:-water, 4:1 (v/v) as developer and exposure to iodine vapor for visualization. Under these conditions, the starting methoxy polyglycol l900 appeared at R~=0.54 to 0.60. The activated PEG appeared at Rf=O . 41. Unreacted cyanuric chloride appeared at Rf=O. 88 and was removed.
The activated PEG was analyzed for nitrogen and an appropriate correction was applied in selecting the quantity of reactant to use in further synthetic steps. Thus, when the product contained only 20~ Gf the theoretical amount of nitrogen, the quantity of material used in the next synthetic step was increased by 100/20, or 5-fold. When the product contained 50% of the theoretical amount of nitrogen, only WO91/~ ~5 2 ~ 6 7 1 3 ~ PCT/USgo/~
, 100/50 or a 2-fold increase was needed.
B. Preparation of N-(4-Chloro-polyglycol 1900)-1,3,5-triazinyl egg phosphatidylethanolamine.
In a screw-capped test tube, 0.74 ml of a 100 mg/ml (0.100 mmole) stock solution of egg phosphatidylethanolamine in chloroform was evaporated to dryness under a stream of nitrogen and was added to the residue of the activated PEG
described in section A, in the amount to provide 205 mg ~0.100 mmole). To this mixture, 5 ml anhydrous dime'hyl formamide was added. 27 microliters (0.200 mmole) triethylamine was added to the mixture, and the air was displaced with nitrogen gas. The mixture was heated overnight in a sand bath maintained at 110~C.
The mixture was then evaporated to dryness under vacuum and a pasty mass of crystalline solid was obtained. This solid was dissolved in 5 ml of a mixture of 4 volumes of acetone and 1 volume of acetic acid. The resulting mixture was placed at the top of a 21 mm X 240 mm chromatographic absorption column packed with silica gel (Merck Kieselgel 60, 70-230 mesh) which had first been moistened with a solvent composed of acetone acetic acid, 80/20; v/v.
The column chromatography was developed with the same sol-vent mixture, and separate 20 to 50 ml aliquots of effluent were collected. Each portion of effluent was assayed by TLC
on silica gel coated plates, using 2-butanone/acetic acid/water; 40/25/5; v/v/v as developer and iodine vapor exposure for ~isualization. Fractions containing only material of Rf=about O.79 were combined and evaporated to 3C dryness ur,der ~acuum. Drying to constant weight under high vacuum afforded 86 mg (31.2 micromoles) of nearly colorless solid N-(4-chloro-polyglycol 1900)-1,3,5-triazinyl egg phosphatidylethanolamine containing phosphorous.
WO91/05~5 - ~ PCT/US~/~0~
2~ 133 The solid compound was taken up in 24 ml of ethanol/-I chloroform; 50/S0 chloroform and centrifuged to remove I insoluble material. Evaporation of the clarified solution to dryness under vacuum afforded 21 mg (7.62 micromoles) of colorless solid.
Example 2 Preparation of the Carbamate-Linked PEG-PE
A. Preparation of the imidazole carbamate of polyethylene glycol methyl ether 1900.
9.5 grams (5 mmoles) of polyethylene glycol methyl ether 1900 obtained from Aldrich Chemical Co. was dissolved in 45 ml benzene which has been dried over molecular sieves. 0.89 grams (5.5 mmoles) of pure carbonyl diimidazole was added. The purity was checked by an infra-red spectrum. The air in the reaction vessel was displaced with nitrogen. Vessel was enclosed and heated in a sand bath at 75~C for 16 hours.
The reaction mixture was cooled and the clear solution formed at room temperature. The solution was diluted to 50.0 ml with dry benzene and stored in the refrigerator as a 100 micromole/ml stock solution of the imidazole carbamate of PEG
ether 1900.
B. Preparation of the phosphatidylethanolamine carbamate of polyethylene glycol methyl ether 1900.
10.0 ml (lmmol) of the 100 mmol/ml stock solution of the imidazole carbamate of polyethylene glycol methyl ether 1900 (compound X) was pipetted into a 10 ml pear-shaped flask. The solvent was removed under vacuum. 3.7 ml of a 100 mg/ml solution of egg phosphatidyl ethanolamine (V~ in ohioroform (0.5 mmol) was added. The solvent was evaporated under vacuum. 2 ml of 1,1,2,2-tetrachloroethylene and 139 micro-liters (1.0 mmol) of triethylamine VI was added. The vessel WO91/~ ~5 2 0 6 71 3 3 PCT/US9O/~0~
was closed and heated in a sand bath maintained at 95~C for 6 hours. At this time, thin-layer chromatography was performed with fractions of the above mixture to determine an extent of conjugation on SiO2 coated TLC plates, using butanone/acetic acid/water; 40/5/5; v/viv; was performed as developer. I2 vapor visualization revealed that most of the free phosphati-dyl ethanolamine of Rf=0.68, had reacted, and was replaced by a phosphorous-containing lipid at Rf=O . 78 to 0.80.
The solvent from the remaining reaction mixture was evapo-rated under vacuum. The residue was taken up in 10 mlmethylene chloride and placed at the top of a 21 mm x 270 mm chromatographic absorption column packed with Merck Kieselgel 60 (70-230 mesh silica gel), which has been first rinsed with methylene chloride. The mixture was passed through the column, in sequence, using the following solvents.
Table 1 Volume % of Volume % Methanol ml Methylene Chloride With 2% Acetic Acid 100 100% 0%
200 95% 5%
200 90% 10%
200 85% 15%
200 60% 40~
50 ml portions of effluent were collected and each portion was assayed by TLC on SiO2 - coated plates, using 12 vapor absorption for visualization after development with chloro-form/methanol/water/concentrated ammonium hydroxide;130/70/8/0.5%; v/v/v/v. Most of the phosphates were found in fractions 11, 12, 13 and 14.
These fractions were combined, evapGrated ~o dryness under vacuum and dried in high vacuum to constant weight. They yielded 669 mg of colorless wax of phosphatidyl etha-nolamine carbamate of polyethylene glycol methyl ether. This WO91/05~5 ~ 71~3 PCT/USgo/~o~
represented 263 micromoles and a yield of 52.6% based on the phosphatidyl ethanolamine.
An NMR spectrum of the product dissolved in deutero--chloroform showed peaks corresponding to the spectrum for egg PE, together with a strong singlet due to the methylene groups of the ethylene oxide chain at Delta = 3.4 ppm. The ratio of methylene protons from the ethylene oxide to the terminal methyl protons of the PE acyl groups was large enough to confirm a molecular weight of about 2000 for the polyethylene oxide portion of the molecule of the desired product polyethylene glycol conjugated phosphatidyethanolamine carbamate, M.W. 2,654.
Example 3 Preparation of Ethylene-Linked PEG-PE
A. Preparation of I-trimethylsilyloxy-polyethylene glycol is illustrated in Reaction Scheme 3A.
15.0 gm (10 mmoles) of polyethylene glycol) M.Wt. 1500, (Aldrich Chemical) was dissolved in 80 ml benzene. 1.40 ml (11 mmoles) of chlorotrimethyl silane (Aldrich Chemical Co.) and 1.53 ml (lmmoles) of triethylamine was added. The mixture was stirred at room temperature under an inert atmosphere for 5 hours.
The mixture was filtered with suction to separate crystals of triethylammonium chloride and the crystals were washed with 5 ml benzene. Filtrate and benzene wash liquids were combined. This solution was evaporated to dryness under vacuum to provide 15.83 grams of colorless oil which solidi-fied on standing.
TLC of the product on Si-Cl~ reversed-ph~se plates using mixture of 4 volumes of ethanol with 1 volume of water as developer, and iodine vapor visualization, revealed that all the polyglycol 1500 (Rf=O . 93) has been consumed, and was WO91/05~5 PCT/USgO/~O~
~0 ~7 ~ 3 3 replaced by a material of R~=O.82. An infra-red spectrum revealed absorption peaks characteristic only of polyglycols.
Yield of I-trimethylsilyoxypolyethylene glycol, M.W. lS00 was nearly quantitative.
B. Preparation of trifluoromethane sulfonyl ester of ltrimethylsilyloxy-polyethylene glycol.
15.74 grams (10 mmol) of the crystalline I-trimethyl-silyloxy polyethylene glycol obtained above was dissolved in 40 ml anhydrous benzene and cooled in a bath of crushed ice.
1.53 ml (11 mmol) triethylamine and 1.85 ml (11 mmol) of trifluoromethanesulfonic anhydride obtained from Aldrich Chemical Co. were added and the mixture was stirred over-night under an inert atmosphere until the reaction mixture changed to a brown color.
The solvent was then evaporated under reduced pressure and the residual syrupy paste was diluted to 100.0 ml with methylene chloride. Because of the great reactivity of tri-fluoromethane sulfonic esters, no further purification of the trifluoromethane sul~onyl ester of I-trimethylsilyloxy poly-ethylene glycol was done.
C. Preparation of N-1-trimethylsilyloxy polyethylene glycol 1500 PE.
10 ml of the methylene chloride stock solution of the trifluoromethane sulfonyl ester of 1-trimethylsilyloxy poly-ethylene glycol was evaporated to dryness under vacuum to obtain about 1.2 grams of residue (approximately 0.7 mmoles).
To this residue, 3.72 ml o~ ~ chloro~oxm solution co~t~in;n~
372 mg (0.5 mmoles) egg PE was added. To the resulting solu-tion, 139 microliters (1.0 mmole) of triethylamir,e was added and the solvent was evaporated under vacuum. To the obtained residue, 5 ml dry dimethyl formamide and 70 microliters (0.50 mmoles) triethylamine (VI) was added. Air from the reaction 2 0 ~ 7 ~ ~ 3 vessel was displaced with nitrogen. The vessel was closed and heated in a sand bath 110~C for 22 hours. The solvent was evaporated under vacuum to obtain 1.58 grams of brownish-colored oil.
A 21 X 260 mm chromatographic absorption column filled with Kieselgel 60 silica 70-230 mesh was prepared and rinsed with a solvent composed of 40 volumes of butanone, 25 volumes acetic acid and 5 volumes of water. The crude product was disso~ved in 3 ml of the same solvent and transferred to the top of the chromatography column. T~e chromatogram was developed with the same solvent and sequential 30 ml portions of effluent were assayed each by TLC.
The TLC assay system used silica gel coated glass plates, with solvent combination butanone/acetic acid/water; 40/25/5;
v/v/v. Iodine vapor absorption served for visualization. In this solvent system, the N-l-trimethylsilyloxy polyethylene glycol 1500 PE appeared at ~=0.78. Unchanged PE appeared at Rf=0.68.
The desired N-1-trimethylsilyloxy polyethylene glycol 1500 PE was a chief constituent of the 170-300 ml portions of column effluent. When evaporated to dryness under vacuum these portions afforded 111 mg of pale yellow oil of compound.
D. Preparation of N-polyethylene glycyl 1500: phospha-tidyl-ethanolamine acetic acid deprotection.
Once-chromatographed, P~ compound was dissolve~ in 2 ~1 Q~
tetrahydrofuran. To this, 6 ml acetic acid and 2 ml water was added. The resulting solution was allowed to stand for3 days at 23~C. The solvent from the reaction mixture was evaporated under vacuum and dried to constant weight to obtain 7~ mg of pale yellow wax. TLC on Si-C18 reversed-phase plates,~
. , , WO 91/05~45 Pcr/us9o/o6o34 ~ fi7 ~ 3 ~
developed with a mixture of 4 volumes ethanol, 1 volume water, indicated that some free PE and some polyglycol-like material formed during the hydrolysis.
The residue was dissolved in 0.5 ml tetrahydrofuran and diluted with 3 ml of a solution of ethanol water; 80:20; v:v.
The mixture was applied to the top of a 10 mm X 250 mm chroma-tographic absorption column packed with octadecyl bonded phase silica gel and column was developed with ethanol water 80:20 by volume, collecting sequential 20 ml portions of effluent.
The effluent was assayed by reversed phase TLC. Fractions containing only product of Rf=0.08 to 0.15 were combined.
This was typically the 20-100 ml portion of effluent. When evaporated to dryness, under vacuum, these portions afforded 33 mg of colorless wax PEG-~ corresponding to a yield of only 3%, based on the starting phosphatidyl ethano~ ne.
NMR analysis indicated that the product incorporated both PE residues and polyethylene glycol residues, but that ~n spite of the favorable-appearing elemental analysis, the chain length of the polyglycol chain has been reduced to about three to four ethylene oxide residues. The product prepared was used for a preparation of PEG-PE liposomes.
E. Preparation of N-Polyethylene glycol 1500 P.E. by fluoride deprotectio~.
500 mg of crude N-1-trimethylsilyloxy polyethylene glycol PE was dissolved in 5 ml tetrahydrofuran and 189 mg ~0.600 r; 11 ;moles) of tetrabutyl ~mmon~um fluoride was added and agitated until dissolved. The reactants were allowed to stand over night at 20~C.
The solv~nt was evaporated under reduced pressure znd the residue was dissolved in 10 ml chloroform, washed with two successive 10 ml portions of water, and centrifuged to separate chloroform and water phases. The chloroform phase WO91/05~5 2 0 6 71 3 3 PCT/US~/~o~
was evaporated under vacuum to obtain 390 mg of orange-brown wax, which was determined to be impure N-polyethylene glycol l500 PE compound.
The wax was re-dissolved in 5 ml chloroform and trans-ferred to the top of a 21 X 270 mm column of silica gelmoistened with chloroform. The column was developed by passing l00 ml of solvent through the column. The Table 2 solvents were used in sequence:
Table 2 Volume %Volume % Methanol Containing Chloroform2% Conc. Ammonium Hydroxide/methanol 15 100% 0%
95% 5%
90% 10~
85% 15%
80% 20%
70% 30%
60~ 40%
50% 50%
o% 100%
Separated 50 ml fractions of column effluent were saved.
The fractions of the column were separated by TLC on Si-Cl8 reversed-phase plates. TLC plates were developed with 4 volumes of ethanol mixed with l volume of water. Visualiza-tion was done by exposure to iodine vapor.
Only those fractions containing an iodine-absorbing lipid of ~ about 0.20 were combined and evaporated to dryness under vacuum and dried in high vacuum to constant weight. In this way 94 mg of waxy crystalline solid was obtained of M.W. 2226.
The proton NMR spectrum of this material dissolved in deutero-chloroform showed the expected peaks due to the phosphatidyl ethanolamine portion of the molecule, together with a few methylene protons attributable to polyethylene glycol. (Delta WO91/05~5 ~ 2 0 6 7 1~ ~ PCT/USgo/~o~
-= 3.7)-Example 4 Preparation of PE-Hydrophylic Poly~ers A. Preparation of PE polylactic acid.
200 mg (0.1 mmoles) poly (lactic acid), m. wt. = 2,000 (ICN, Cleveland, Ohio) was dissolved in 2.0 ml dimethyl sulfoxide by heating while stirring to dissolve the material completely. Then the solution was cooled immediately to 65~C
and poured onto a mixture of 75 mg (0.1 mmoles) of distearylphosphatidyl-ethanolamine (Cal. Biochem, La Jolla) and 41 mg (0.2 mmoles) dicyclohexylcarbodiimide (DCCI). Then 28 ml (0.2 mmoles) of triethylamine was added, the air swept out of the tube with nitrogen gas, the tube capped, and heated at 65~C for 48 hours.
After this time, the tube was cooled to room temperature, and 6 ml of chloroform added. The chloroform solution was washed with three successive 6 ml volumes of water, centrifuged after each wash, and the phases separated with a Pasteur pipette. The r~;n'ng chloroform phase was filtered with suction to remove suspended distearolyphosphatidyl-ethanolamine. The filtrate was dried under vacuum to obtain 212 mg of semi-crystalline solid.
This solid was dissolved in 15 ml of a mixture of 4 volumes ethanol with 1 volume water and passed through a 50 mm deep and 21 mm diameter bed of H~ Dowex 50 cation exchange resin, and washed with 100 ml of the same solvent.
The filtrate was evaporated to dryness to obtain 131 mg colorless wax. 291 mg of such wax was dissolved in 2.5 ml 3Q chlorQfQrm and transferred to the top of a 1 mm x 280 ~m column of silica gel wetted with chloroform. The chromatogram was developed by passing through the column, in sequence, 100 ml each of:
WO91/05~5 ' 2 0 6 7 1 ~ 3 PCT/US~/~o~
100% chloroform, 0% (1% NH40H in methanol);
90% chloroform, 10% (1% NH40H in methanol);
85% chloroform, 15% (1~ NH40H in methanol);
80% chloroform, 20% (1% NH40H in methanolJ;
70% chloroform, 30% (1% NH40H in methanol);
Individual 25 ml portions of effluent were saved and assayed by TLC on SFO2-coated plates, using CHC13, CH30H, H20, con. NH40H, 130, 70, 8, 0.5 v/v as developer and I2 vapor absorption for visualization. The 275-325 ml portions of column effluent contained a single material, P04 +, of Rf =
0.89. nhen combined and evaporated to dryness, these afforded 319 mg colorless wax.
Phosphate analysis agrees with a molecular weight of possibly 115,000. Apparently, the polymerization of the poly (lactic acid) occurred at a rate comparable to that at which it reacted with phosphatidylethanolamine.
This side-reaction could probably be ml n' m; zed by working with more dilute solutions of the reactants.
B. Preparation of poly (glycolic acid) amide of DSPE
A mixture of 266 mg. (3.50 mmoles) glycolic acid, 745 mg (3.60 mmoles) dicyclohexyl carbodiimide, 75 mg. (0.10 mmoles) distearoyl phosphatidyl ethanolamine, 32 microliters (0.23 mmoles triethyl amine, and 5.0 ml dry dimethyl sulfoxide was heated at 75~ C, under a nitrogen atmosphere, cooled to room temperature, then diluted with an equal volume of chloroform, and then washed with three successive equal volumes of water to remove dimethyl sulfoxide. Centrifuge and separate phases with a Pasteur pipette each time.
Filter the chloroform phase with suction to remove 2 small amount of suspended material and vacuum evaporate the filtrate to dryness to obtain 572 mg. pale amber wax.
Re-dissolve this material in 2.5 ml chloroform and WO 91/~ 2 0 6 7 1 3 3 PCT/US~/060~
transfer to the top of a 21 mm X 270 mm column of silica gel (Merck Hieselgel 60) which has been wetted with chloroform.
Develop the chromatogram by passing through the column, in sequence, 100 ml each of: ~
100% chloroform, O % (1% NH40H in methanol);
90% chloroform, 10% (1% NH40H in methanol);
85% chloroform, 15% (1% NH40H in methanol);
80% chloroform, 20% (1% NH40H in methanol);
70% chloroform, 30% (1% NH40H in methanol).
Collect individual 25 ml portions of effluent and assay each by TLC on Si)2-coated plates, using CH C13, CH3 OH, H20, con-NH40H; 130, 70, 8, 0.5 v/v as developer.
Almost all the P04 ~ material will be in the 275-300 ml portion of effluent. Evaporation of this to dryness under vacuum, followed by high-vacuum drying, affords 281 mg of colorless wax.
Phosphate analysis suggests a molecular weight of 924,000.
Manipulation of solvent volume during reaction and molar ratios of glycolic acid and dicyclohexyl carbodiimide would probably result in other sized molecules.
Example 5 Preparation of REVs and MLVs A. Sized REVs A total of 15 ~moles of the selected lipid components, in the mole ratios indicated in the examples below, were dis-solved in chloroform and dried as a thin film by rotary evapo-ration. This lipid film was dissolved in 1 ml of diethyl ether washed with distilled water. To this lipid solution was add~d C.34 ml cf an aqueous buffer solution containing 5 mM
Tris, 100 mM NaCl, 0.1 mM EDTA, pH 7.4, and the mixture was emulsified by sonication for 1 minute, maintaining the tempe-rature of the solution at or below room temperature. Where WO 91/05545 ~ 2 0 6 7 1 3 ~ pcr/us9o/o6o34 the liposomes were prepared to contain encapsulated [125I]
tyraminyl-inulin, such was included in the phosphate buffer at a concentration of about 4 uCi/ml buffer.
The ether solvent was removed under reduced pressure at room temperature, and the resulting gel was taken up in 0.1 ml of the above buffer, and shaken vigorously. The resulting R~V
suspension had particle sizes, as determined by microscopic examination, of between about 0.1 to 20 microns, and was com-posed predominantly of relatively large (greater than micron) vesicles having one or only a few bilayer lamellae.
The liposomes were extruded twice through a polycarbonate filter (Szoka, 1978), having a selected pore size of 0.4 microns or 0.2 microns. Liposomes extruded through the 0.4 micron filter averaged 0.17+ (0.05) micron diameters, and through the 0.2 micron filter, 0.16 (0.05) micron diameters.
Non-encapsulated [125I] tyraminyl-inulin was removed by passing the extruded liposomes through Sephadex G-50 (Phar-macia).
B. Sized MLVs Multilamellar vesicle (MLV) liposomes were prepared according to standard procedures by dissolving a mixture of lipids in an organic solvent containing primarily CHCl3 and drying the lipids as a thin film by rotation under reduced pressure. In some cases a radioactive label for the lipid phase was added to the lipid solution before drying. The lipid film was hydrated by addition of the desired aqueous phase and 3 mm glass beads followed by agitation with a vortex and shaking above the phase transition temperature of the 3Q phospholipid component fc_ at least 1 hour. In SGme cases a radioactive label for the aqueous phase was included in the buffer. In some cases the hydrated lipid was repeatedly frozen and thawed three times to provide for ease of the WO91/05~5 PCT/US90/~34 - 20 67 ~ ~ 3 following extrusion step.
The size of the liposome samples was controlled by extru-sion through defined pore polycarbonate filters using pres-surized nitrogen gas. In one procedure, the liposomes were S extruded one time through a filter with pores of 0.4 ~m and then ten times through a filter with pores of 0.1 ~m. In another procedure, the liposomes were extruded three t~mes through a filter with 0.2 ~m pores followed ~y repeated extrusion with 0.05 ~m pores until the mean diameter of the particles was below 100 nm as determined by DLS. Unencapsu-lated aqueous components were removed by passing the extruded sample through a gel permeation column separating the lipo-somes in the void volume from the small molecules in the included volume.
lS
C. Loading 6'Ga Into DF-Contalning Liposomes The protocol for preparation of Ga6'-DF labeled liposomes is adapted from known procedures (Gabizon). Briefly, lipo-somes were prepared with the ion chelator desferal mesylate encapsulated in the internal aqueous phase to bind irre~er-sibly Ga transported through the bilayer by hydroxyquinoline (oxine).
D. Dynamic ~ight Scattering ~iposome particle size distribution measurements were obtained by DLS using a NICOMP Model 200 with a Brookhaven Instruments BI-2030AT autocorrelator attached. The instru-ments were operated according to the manufacturer's instruc-tions. The NICOMP results were expressed as the mean diameter and standard deviation of a Gaussian distri~ution of vesicles by relative volume.
Al - ' ~1 WO91/05~5 PCT/US90/~O~
~0 ~7 ~ 3 3 Example 6 ~iposome Blood Lifetime Measurementc A. Measuring Blood Circulation Time and Blood/~ES Ratios In vivo studies of liposomes were performed in two dif-ferent ~ l models: Swiss-Webster mice at 25 g each and laboratory rats at 200-300 g each. The studies in mice involved tail vein injection of liposome samples at 1 ~M
phospholipid/mouse followed by ~n; m~ 1 sacrifice after a defined time and tissue removal for label quantitation by gamma counting. The weight and percent of the injected dose in each tissue were determined. The studies in rats involved establishment of a chronic catheter in a femoral vein for removal of blood samples at defined times after injection of liposome samples via a catheter in the other femoral artery at 3-4 ~M phospholipid~rat. The percent of the injected dose remA; n; ng in the blood at several time points up to 24 hours was determined.
B. Time Course of Liposome Retention in the Bloodstream PEG-PE composed of methoxy PEG, molecular weight 1900 and 1-palmitoyl-2-oleyl-PE (POPE) was prepared as in Example 2.
The PEG-POPE lipid was com~ined with partially hydrogen-ated egg PC (PHEPC) in a lipid:lipid mole ratio of about 0.1:2, and the lipid mixture was hydrated and extruded through a 0.1 micron polycarbonate membrane, as described in ~xample 4, to produce MLV's with average size about 0.1 micron. The M~V lipids included a small amount of radiolabeled lipid marker l4C-cholesteryl oleate, and the encapsulated marker 3H-inulin.
The liposome co~position was in ~ cted and the percen~
initial injected dose in mice was deter~;~e~ as described in Example 4, at 1, 2, 3, 4 and 24 hours after injection. The time ~' WO 91/05545 2 0 6 7 1 3 3 pcr/us9o/o6o34 course of loss of radiolabeled material is seen in Figure 7 which is a plot of percent injected dose for encapsulated inulin (solid circles), inulin marker corrected to the initial injection point of 100% (open circles), and lipid marker (closed triangles), over a 24-hour period post injection. As seen, both lipid and encapsulated markers showed greater than 10~ of original injected dose after 24 hours.
C. 24 Hour Blood Liposome Levels Studies to determine percent injected dose in the blood, and blood/RES ratios of a liposomal marker, 24 hours after intravenous liposome injection, were carried out as described above. Liposome formulations having the compositions shown at the left in Table 3 below were prepared as described above.
Unless otherwise noted, the lipid-derivatized PEG was PEG-1900, and the liposome size was 0.1 micron. The percent dose remaining in the blood 24 hours after intravenous administra-tion, and 24-hour blood/RES ratios which were measured are shown in the center and right columns in the table, respectively.
Table 3 Lipid Composition* 24 Hours After IV Dose % Injected Dose in Blood B/RES
PG:PC:Chol (.75:9.25:5) 0.2 0.01 PC:Chol ~10:5) 0.8 0.03 PEG-DSPE:PC:Chol 23.0 3.0 PEG-DSPE:PC:Chol ~250 nm) g,o 0,5 PEG5000-DSPE:PC:Chol21.0 2.2 PEGlzO-DSPE:PC:Chol5,0 2.0 PEG-DSPE:PC ~0.75:9.25) 22.0 0.2 PEG-DSPE:PG:PC:Chol40.0 4 0 (0.75:2.25:7:5) PEG-DSPE:NaCholSO,:PC:Chol 25.0 2.5 ~0.75:0.75:9.25:4.25) 40 *All formulations cor~t~; n 33% cholesterol and 7.5% charged component and were 100 nm mean diameter except as noted. PEG-DSPE consisted of PEGl,oo except as noted.
WO91/05~5 ~ PCT/US90/060~
As seen, percent dose remaining in the blood 24 hours after injection ranged between 5-40% for liposomes containing PEG-derivatized lipids. By contrast, in both liposome formu-lations lacking PEG-derivatized lipids, less than 1% of lipo-some marker remained after 24 hours. Also as seen in Table 3, blood/RES ratios increased from 0.01-0.03 in control liposomes to at least 0.2, and as high as 4.0 in liposomes containing PEG-derivatized liposomes.
Example 7 Effect of Phospholipid Acyl-Chain Saturation on Blood/RES Ratios in PEG-P~ Liposomes PEG-PE composed of methoxy PEG, molecular weight 1900 and distearylPE (DSPE) was prepared as in Example 2. The PEG-PE
lipids were formulated with selected lipids from among sphin-gomyelin (SM), fully hydrogenated soy PC (PC), cholesterol (Chol), partially hydrogenated soy PC (PHSPC), and partially hydrogenated PC lipids identified as PC IV1, IV10, IV20, IV30, and IV40 in Table 4. The lipid components were mixed in the molar ratios shown at the left in Table 5, and used to form MLV's sized to 0.1 micron as described in Example 4.
Table 4 Phase Transition Egg PC Temperature Range Mole % Fatty Acid Comp.
Form ~13C. 18:0 18:1 18:2 20:0 20:1-4 22:0 22:1-6 Native <20 12 30 15 0 3 0 5 IV 30 c20-30 20 22 o 1 2 1 3 IV 20 23-45 30 lo o 2 1 2 3 IV 10 37-50 42 4 o 3 1 4 2 IV 1 49-54 56 o 0 5 0 6 0 WO 91/0554~ PCr/US90/0603~
20 ~71 3 3 '~
Table 5 Blood RES B/RES%
R~m~; n; rlg PEG-PE:SM:PC:Chol 0.2:1:1:1 19.23 6.58 2.92 49.23 PEG-PE:PHSPC:Chol 0.15:1.85:1 20.54 7.17 2.86 55.14 PEG-PE:PC IVl:Chol 0.15:1.85:1 17.24 13.71 1.26 60.44 PEG-PE:PC IVl:Chol ~two ~n; ~1 s ) 0.15:1.85:1 19.16 10.07 1.90 61.87 PEG-PE:PC IVlO:Chol (two ~n; m~ 1 S ) 0.15:1.85:1 12.19 7.31 1.67 40.73 PEG-PE:PC IVlO:Chol 0.15:1.85:1 2.4 3.5 0.69 12.85 PEG-PE:PC IV20:Chol 0.15:1.85:1 24.56 7.52 3.27 62.75 PEG-PE:PC IV20:Chol 0.15:1.85:1 5.2 5.7 0.91 22.1 ~EG-PE:PC IV40:Chol 0.15:1.85:1 19.44 8.87 2.19 53.88 PEG-PE:PC IV:Chol 0.15:1.85:0.5 20.3 8.8 2.31 45.5 PEG-PE:EPC:Chol 0.15:1.85:1 15.3 9.6 1.59 45.9 24 hours after iniection, the percent material injected (as measured by percent of 67Ga-desferal)remaining in the blood and in the liver (L) and spleen (S) were determined, and these values are shown in the two data columns at the left in Table 4. The blood and L~S (RES) values were used to calculate a F.~
~3 ~O91/05~5 PCr/US~/~
~ ~7 ~ 3 3 blood/R~S value for each composition. The column at the right in Table 4 shows total amount of radioactivity recovered. The two low total recovery values in the table indicate anomalous clearance behavior.
The results from the table demonstrate that the blood/RES
ratios are largely independent of the fluidity, or degree of saturation of the phospholipid components forming the lipo-somes. In particular, there was no systematic change in blood/RES ratio observed zmong liposomes containing largely saturated PC components (e.g., IVl and IV10 PC's), largely unsaturated PC components ~IV40), and intermediate-saturation components (e.g., IV20).
In addition, a comparison of blood/R~S ratios obtained using the relatively saturated PEG-DSPE compound and the rela-tively unsaturated PEG-POPE compound (Example 5) indicates that the degree of saturation o~ the derivatized lipid is itself not critical to the ability of the liposomes to evade uptake by the RES.
Example 8 Effect of Cholesterol and Ethoxylated Cholesterol on Blood/RES Ratios in PEG-PE Liposomes A. Effect of added cholesterol PEG-PE composed of methoxy PEG, molecular weight 1900 and was derivatized DSPE as described in Example 6. The PEG-PE
lipids were formulated with selected lipids from among sphin-gomyelin (SM), fully hydrogenated soy PC (PC), and cholesterol (Chol), as indicated in the column at the left in Table 5 below. The three formulations shown in the table contain about 30, 15, and 0 mole percent cholesterol. Both REV's (0.3 micron size) and MLV's (0.1 micron size) were prepared, sub-stantially as in Example 4, with encapsulated tritium-labeled ~ , rB
WO91/05~ PCT/US90/~0~
7~33 inulin .
The percent encapsulated inulin rem~; n' ng in the blood 2 and 24 hours after ~m; ~; stration, given at the right in Table 6 below, show no measurable effect of cholesterol, in the range 0-30 mole percent.
Table 6 ~ Injected Dose 3H-Inulin In Blood 2 HR. 24 HR. 2 HR. 24 HR.
'H Aqueous Label l4C - Lipid Label (Leakage) 1) SM:PC:Chol:PEG-DSPE
1: 1: 1: 0.2 100 nm MLV 19 5 48 24 300 nm REV 23 15 67 20 2) SM:PC:Chol:PEG-DSPE
1: 1: 0.5: 0.2 300 nm REV 23 15 71 17 3) SM:PC:PEG-DSPE
1: 1: 0.2 100 nm M~V 19 6 58 24 300 nm REV 32 23 76 43 rB B
WO91/05~5 PCT/US90/~
B. Effect of ethoxylated cholesterol Methoxy-ethyoxy-cholesterol was prepared by coupling methoxy ethanol to cholesterol ~ia the trifluorosulfonate coupling method described in Section I. PEG-PE composed of methoxy PEG, molecular weight 1900 and was derivatized DSPE as described in Example 6. The PEG-PE lipids were formulated with selected lipids from among distearylPC (DSPC), partially hydrogenated soy PC (~HSPC), cholesterol, and ethoxylated cholesterol, as indicated at the right in Table 7. The data show that (a) ethoxylated cholesterol, in combination with PEG-PE, gives about the same degree of enhancement of liposome lifetime in the blood as PEG-PE alone. By itself, the ethoxy-lated cholesterol provides a moderate degree of enhancement of liposome lifetime, but substantially less than that provided by PEG-PE.
Table 7 Formulation % Iniected Dose In Blood 'C-Chol-Oleate 2 HR. 24 HR.
HSPC:Chol:PEG-DSPE 55 9 1.85: 1: 0.15 HSPC:Chol:PEG-DSPE:PEG5-Chol57 9 1.85: 0.85: 0.15: 0.15 HSPC: Chol: HPC: PEG5-Chol 15 2 1.85: 0.85: 0.15: 0.15 HSPC: Chol: HPG 4 1.85: 1: 0.15 .
WO91/05~5 PCT/US90/~
2~ ~7 ~ ~ 3 Example 9 Effect of Charged Lipid Components on Blood/RES Ratios in PEG-PE Liposomes PEG-PE composed of methoxy PEG, molecular weight 1900 and was derivatized DSPE as described in Example 6. The PEG-~E lipids were formulated with lipids selected from among egg PG ~PG), partially hydrogenated egg PC ~PHEPC), and choleste-rol (Chol), as indicated in the Figure 6. The two formula-tions shown in the figure contained about 4.7 mole percent (triangles) or 14 mole percent (circles) PG. The 1ipids were prepared as MIV's, sized to 0.1 micron as in Example 4.
The percent of injected liposome dose present 0.25, 1, 2, 4, and 24 hours after injection are plotted for both formula-tions in Figure 6. As seen, the percent PG in the composition had little or no effect on liposome retention in the bloodstr-eam. The rate of loss of encapsulated marker seen is also similar to that observed for similarly prepared liposomes containing no PG.
Example 10 Effect of Liposome Size on Blood Lifetime P~G-DS~E, prepared as above with PEG-1900, was formulated with partially hydrogenated egg PC (PHEPC), and cholesterol (Chol), at a mole ratio of 0.15: 1.85: 1. The liposomes were sized by extrusion through 0.25, 0.15 or 0.1 micron polycarbo-nate filters, to produce liposome sizes of about 0.4, 0.2, and 0.1 microns, respectively. Non-encapsulated 3H-inulin was removed by gel filtration, Each of the three liposome were injected intra~enously, 2nd the percer.t of injected liposome marker in the ~lood -~as measured at 1, 2, 3, 4, and 24 hours, with the results shown in Figure 10. All three formulations show long blood half-lives, as evidenced by at least about 10% liposome marker ~O91/05545 PCT/US90/~034 ~ ~7 ~ ~ ~
rem~;n;ng after 24 hours. The 0.1 micron formulation (solid squares) is longer lived than the 0.2 micron formulation (solid circles) which is in turn longer lived than the 0.4 micron formulation.
Example 11 Effect of Other Hydrophilic Polymers on Blood Lifetime Polylactic acid-DSP~ or polyglycolic acid-DSPF, prepared as above, was formulated with lipids selected from among hydrogenated soy PC (HSPC), and cholesterol (Chol), at a weight ratio of either 2: 3.5: 1 or 1: 3.5: 1. The liposomes were sized by extrusion through a 0.1 micron polycarbonate filter. The liposomes were labeled by Ga-DF as described in Example 5.
These liposome formulations were injected intravenously, and the percent of injected liposome marker in the blood was measured at 1, 2, 3, 4, and 24 hours, with the results shown in Figure 11. When normalized at 15 minutes, about 3.9~ of the liposome marker was present after 24 hours with polylactic acid-DSPE (solid squares). An average value of about 6% of the liposome marker was present 24 hours after injection with polyglycolic acid-DSPE (open triangles).
Example 12 Plasma Kinetics of PEG-Coated and Uncoated Liposomes PEG-PE composed of methoxy PEG, molecular weight 1900 and distearyl PE (DSPE) was prepared as in Example 2. The PEG-PE
lipids were formulated with PH~PC, and cholesterol, in a mole ratio of 0.15:1.85:1. A second lipid mixture contained the ~ame lipids, but without ~EG- E. ~iposomes were prepared from the two lipid mixtures as described in Example 5, by lipid hydration in the presence of DF followed by sizing to 0.1 micron, removal of non-entrapped DF by gel filtration, and Ga WO91/05~5 PCT/US9O/~
~ B7 ~ ~ 3 labeling as described in Example 5. Both compositions contained 10 ~M lipid/ml in 0.15 M NaClf 0.5 mM desferal.
The two liposome compositions (0.4 ml) were in~ected IV
in ~n;m~l S~ as described in Example 6. At time 0.25, 1, 3 or 5, and 24 hours after injection, blood samples were removed and assayed for amount inulin rPm~; n; ~g in the blood, expressed as a percentage of the amount measured ; mm~ tely after injection. The results are shown in Figure 9. As seen, the PEG-coated liposomes have a blood halflife of about 11 hours, and nearly 30% of the injected material is present in the blood after 24 hours. By contrast, uncoated liposomes showed a halflife in the blood of less than 1 hour. At 24 hours, the amount of injected material was undetectable.
Example 13 Treatment with Free Vasopressin Male adult rats of the Brattleboro strain, congenitally deficient for VP (Valtin and Schroeder, 1964), were acclimated to metabolic cages for at least three days before treatment.
In most experiments, anesthesia was induced using a mixture of Nitrous oxide 2100 cc/min, oxygen 400 cc/min, and 5~ Iso-flurane (Aerrane). Anesthesia was maintained throughout sur-gery with the same gas mixture but with a reduced percentage of iso~lurane (2~). In other experiments, inhaled ethyl ether was used for the anesthetic.
A. Surgery The neck and ventral sides of both hindlimbs were shaved.
A small incision was made at the midpoint between the ears at the neck to 211OW the c~nnllla to ~e externa'ized o~lt the r.eck.
The rat was placed on its back and stabilized. An incision was made on the ventral hindlimb at the inguinal area, and fascia was tweezed apart to expose the femoral vascular B
WO91/OS~5 PCT/US~/~O~
2~ ~7 1 3 3 complex. ~urther blunt dissection isolated the ~emoral ~ein or artery. For the vein, blood flow was occluded by passing a 3-0 silk tie ~Davis-Geck, Danbury, CT) beneath the vessel distally and applying tension to the vein while clam.ping the vessel proX~m7l~y with a bulldog clamp. This allowed the vein to become distended and easier to cut. Using small scissors, the ~ein was nicked and a bevelled 6-inch section of poly-ethylene catheter tubing (PE_50 Clay-Adams) filled with normal saline (0.9%) or 5~ dextrose was inserted into the vein.
Correct placement was verified by venous drawback and flush using a 1 cc syringe. The catheter was anchored loosely to the vein by passing a small tie under the vessel and knotting it around the cannula.
B. Dose A~; n; stration Once animals had been surgically prepared, 150-1000 ~1 of test solution was a~; n; stered intravenously. The dose ~olume administered was adjusted to give the desired total amount of vasopressin, for example 0.2, 0.8, and 3~g of aqueous vaso-pressin. The venous catheter was then removed, the femoral vein was tied off, and both leg incisions were closed. The ~n;~l S were allowed to regain consciousness.
C. Urine Production Studies After a control period in which the rats showed diabetes insipidus and the urine volume was well established, the ~n;m~lS were weighed and anesthetized with inhaled anesthesia.
The femoral vein was cannulated and the dose ~m; ni stered ~y the surgical procedures described. The ~n;m~l S were main-tzined ir. met~bolic cages and the urine was collected over the course of several days after dose administration. The urine volume was determlne~ hourly immediately after dose WO9l/05545 PCT/US90/06034 2~ ~7 11 ~ 3 ~m; n; stration and thereafter at least twice each day.
Figure 12 shows the percent predosage urine flow in ~n~m~l s treated with saline (open circles) or 0.2 ~g (solid squares) 0.8 ~g (solid triangles), and 2 ~g ~solid circles) vasopressin solution. At day 1 after drug ~Am; ~ stration, urine production showed a dose-dependent drop. At day 2 and thereafter, urine production was substantially back to control levels.
Example 14 Treatment with P~G-~iposomal Vasopressin Large lln~ 1 ~mel 1 ~r liposomes were prepared according to the reverse phase evaporation procedure (Szoka and Papahad-jopoulos, 1978). The lipid composition used in preparing the liposomes was PEG-DSPE, PC, sphingomyelin, and cholesterol, in a mole ratio 0.2: 1: 1: 1. Lipid mixtures for a 1 ml final volume of liposomes with a phospholipid concentration of 10 ~mol/ml were dissolved in chloroform and evaporated to dryness under reduced pressure. After residual solvent was removed by high vacuum for 1 hour the mixture was dissolved in ethyl ether freshly washed with phosphate buffer at pH 7. Then, 0.34 ml of aqueous buffer (5 mM Tris, 100 mM NaCl, 0.1 mM
EDTA) containing sufficient arginine vasopressin to give a final drug concentration of 510 ~g/ml was added to the lipids in ether. A trace amount of 3H-labeled vasopressin was added to the vasopressin solution for determ;n~tion of protein concentrations. Then the ether was removed by controlled rotoevaporation, and additional drug-free buffer added to gi~e a 1 ml solution i mmPA; ately after gel dispersion. The vasopressin content of the resulting liposomes was determined by separatlng Lre~ drug from liposome-bound by gel filtration of Bio-Gel A15.
WO91/05~5 PCT/US90/06034 The liposomes were extruded through 0.4 ~m Nuclepore filters (Olsen et al., 1979) and particle size distribution measured by dynamic light scattering with a Nicomp model 200.
Mean diameter ranged between 0.2 ~m and 0.5 ~m and showed a low polydispersity. Unbound vasopressin was removed by dialysis and monitored by gel chromatography as above.
PEG-liposome preparations from above were administered intravenously to rats prepared as in Example 13, at liposomal doses 2 ~g (solid squares) 8 ~g (solid triangles), and 24 ~g (closed circles) vasopressin solution. Percent predosage urine flow was measured as above, with the results shown in Figure 14. The data show substantially the same dose-dependent depression in urine production in the first dayafter drug ~m; n~ stration, presumably resulting pre~o~ tly from non-entrapped vasopressin in the liposome formulations.
In contrast to free peptide administration, however, all three formulation produced a significant inhibition in urine production with respect to control (open circles) over a 2-8 day period after liposome ~m; n~ stration.
Example 15 Treatment with ~G-Liposomal Vasopressin:
Effect of Liposome Cholesterol Concentration Large unilamellar liposomes were prepared as in Example 14, with liposomes containing either 33, 16, or 0 mole percent cholesterol. Vasopressin encapsulation, liposome sizing, and free peptide removal was carried out as in Example 1~.
- The three PEG-liposome preparations were administered intravenously to rats prepared as in ~xample 13, at liposomal 30 doses giving 8 ~g vasopressin, and the percent predosage urine production was measured over a 9 day period following liposome ~; n; ~tration. The results are shown in Figure 15, for WO91/OS~5 PCTlUS90/060~
~ ~713 ~
saline control (open circles) and P~G-liposomes with O (solid squares), 16 (solid triangles), and 33 (solid circles) mole percent cholesterol.
The day-1 response shows a marked depend~nce on percent cholesterol, with the greatest effect on urine flow being produced in liposomes with the lowest mole ratio of choleste-rol. This result is consistent with in vitro stability studies of ~asopressin release from PEG-liposomes in serum:
In the presence of serum, little release of vasopressin was seen in liposomes cont~;n;ng greater than 30 mole percent cholesterol. By contrast, formulations containing reduced amounts of cholesterol showed increasingly higher release rates of encapsulated peptide. Thus, it would appear that the significantly higher diuretic effect seen after 1 day with low and no cholesterol formulations is due to the presence of free peptide released from the liposomes in serum.
Interes~ingly, all three formulations produced a marked, and substantially similar diuretic effect over a 2-8 day period following liposome drug ~m;n; stration, as was seen in the method described in Example 14.
~xample 16 Blood Clearance Kinetics of M-CSF from PEG-Liposomes A lipid film cont~ n; ng PEG-DSPE, PH~PC IV-40, cholesterol, and a-tocopherol, in a mole ratio 5:61:33:1, was hydrated with distilled water, and the resulting MLVs were sonicated for 30 minutes to form SWs. M-CS~ was concentrated and a portion of the protein was labeled with U125I-iodine.
E~ual volumes (2 ml) of the protein solution and S Ws 3G were mixed, and t~le mixture was frozen in an acetone/dry bath, and lyophilized overnight. The dried material was rehydrated in 0.8 ml of distilled water, and the resulting liposome WO91/05~5 PCT~US90/~0~
-3 ~
suspension was extruded 1 time through a 0.4 ~ polycarbonate - filter, and 3 times through a 0.2 ~ filter. The sized liposomes were diluted to 10 ml in distilled water, washed two times with high speed centrifugation, and the washed pellet was resuspended in 0.9 ~1 of sterile buffer, to a final con~entration of 40 ~mol lipid/ml and between 0.5 and 1.25 mg protein/ml.
PEG-liposome preparations from above were ~dm; ~; stered intravenously to ~nim~l S as in Example 6, and the blood levels of M-CSF were measured at 1, 2, 4, and 24 hours after injection in rats prepared as in Example i4, at liposomal doses 2 ~g (solid squares) 8 ~g (solid triangles), and 24 ~g (closed circles) vasopressin solution. Similar measurements were made for an equi~alent amount of M-CSF ~m; nistered in solution form. The plasma kinetics for the PEG-liposome formulation cont~t n; ng 30 mole percent cholesterol are shown in Figure 15. The data show rapid clearance of free protein (solid triangles) with less than 1% protein rem~;n;ng in the blood at 24 hours, compared with about 8% for liposome-associated protein ~solid circles). Percent liposomes r~m~ln;~g in the ~loodstream, as judged by percent lipid marker, was slightly greater than 10%.
A comparison of the clearance rates of the lipid and pro-tein markers indicates that about 20~ of the protein marker was released from the liposomes by 24 hours post injection.
The plasma kinetics obtained with cholesterol-free PEG-liposomes is shown in Figure 16. Percent liposomes rem~; n; ng after 24 hours was about 8.5 (solid triangles) compared with about 4.5% for liposome-associated M-CSF. The results indica-ted that about 40-50~ of the originally encapsulated protein leaked from the liposomes in the 24-hour period post injection.
WO gl/05~45 PCr/US90/06034 -2~ ~71 3 3 The radioactive counts in the liposome lipid marker and in the encapsulated protéin were normalized to 100% initial ~alues, and the percent injected dose released into the blood-stream over time was then deter~;neA from the difference be-tween the normalized protein and normalized liposome markerradioactivity levels. A plot of the calculated values of percent protein released at 1, 2, 4, and 24 hours post injec-tion is shown in Figure 17.
The plot for the cholesterol-free formulation (solid triangles~ shows a protein release peak at 2 hours, with a gradual decline in amount released in the 2-24 hour period in the no-cholesterol formulation (solid triangles). The amount of protein released from the liposomes at 24 hours was between 3-4 percent of the total ~m~ n; stered.
The plot for the formulation cont~;n;ng 30 mole percent cholesterol (solid circles) shows a gradual increase in protein release rate over 24 hours. The amount of protein released from the liposomes at 24 hours was about 3 percent of the total ~m; n; stered. Thus, both formulations showed relatively high levels of protein release (3% or greater) at 24 hours.
Example 17 Subcutaneously ~m; n ~ stered Liposomes MLVs were prepared by thin-film hydration as described in Example 5. The lipid composition of the thin film was PEG-DSPE, HEPC, and cholesterol, in a mole ratio 0.15:1.85:1. The thin film was hydrated with an aqueous buffer (5 mM Tris, 100 mM NaCl, 0.1 mM EDTA) containing arginine vasopressin at 7.5 mgs/ml. The MLVs were sized by repeated extrusion through a O.1 micron polycarbonate membrane, and free (non-encapsulated) peptide was removed by gel filtration, as in Example 15. The final concentration of PEG-liposomes in the suspension was 100 E~
WO gl/05545 ' ' PCr/US90/06034 20 ~71 3 3 ~M/ml.
Vasopressin in free form was a~m~ n~ stered subcutaneously (1 ml) to Brattleboro rats, as in Example 13. The site of subcutaneous injection was the dorsal neck region. The doses 5 ~m; n~ stered were 2 ~g (solid triangles), 25 ~g ~solid circles), 50 ~g (solid squares), and 100 ~g (solid diamonds).
The percent of predosage urine flow observed is plotted in Figure 18A.
vasopressin encapsulated in PEG-liposomes, prepared as above, was ~m;n;stered subcutaneously (1 ml) to ~nim~ls as above. The doses ~m; n; stered were 25 ~g (solid triangles), 100 ~g (solid circles), and 400 ~g (solid squares). The percent of predosage urine flow observed is plotted in Figure lBB.
Although the in~ention has been described and illustrated with respect to specific liposome formulations, liposome-entrapped compounds, and treatment methods, it will be apparent that a variety of related compositions, compounds and treatment methods without departing from the invention.
B
The invention includes, in one aspect, a liposome compo-sition effective to extend to at least 24 hours, the period of effective activity of an therapeutic compound which can be administered intravenously in a therapeutically effective amount, and which has a blood halflife, in free form, of less than about 4 hours. The composition includes liposomes (i) composed of vesicle-forming lipids and between 1-20 mole per-cent of a vesicle-forming lipid derivatized with a biocompa-tible hydrophilic polymer, and (ii) having a selected mean particle diameter in the size range between about 0.1 to 0.4 m~crons, and the compound in 'iposo,..e-er.trapped f~~rm. The composition is intended for intravenous administration at a dose which contains an amount of the liposome-entrapped compound which is at least three times the therapeutically WO gl/05~45 PCr/US90/06034 ~0 671 3 3 effective dose for the compound in free form.
In one preferred embodiment, the hydrophilic polymer is polyethyleneglycol having a molec~ r weight between about 1,000-5,000 daltons, and the polymer is derivatized with the polar head groupof a phospholipid, such a phosphatidylethanol-amine (PE). Alternatively, the polymer may be other suitable biocompatible hydrophilic polymers, such as polylactic acid and polyglycolic acid.
Also in one preferred embodiment, the composition is effective to extend to at least 48 hours, the period of thera-peutic activity of an intravenously injected polypeptide which can be ~m; n; stered intravenously in a therapeutically effec-tive amount. The polypeptide may be a peptide or protein, such as superoxide dismutase, glucocerebrosidase, asparagi-nase, adenosine ~P~m~n~ce~ interferons (alpha, ~eta, andgamma), interleukin (1,2,3,4,5,6,7), tissue necrosis factor (TNF - alpha, beta), colony st;m~ ting factors (M-CSF (macro-phage), G-CSF (granulocyte), GM-CSF (granulocyte, macrophage), TPA, prourok~n~se, and urok1n~se, HIV-1 vaccine, hepatitis B
v~r~e, malaria vaccine, and melanoma ~accine, erythropoietin (EPO), factor VIII, bone growth factor, fibroblast growth factor, insulin-like growth factor, nerve growth factor, platelet-derived growth factor, tumor growth factors (alpha, beta), somatomedin C (I OE -1), and a ribosome inhibitor pro-tein, which is theLa~euLically active when ~m~ n~ stered intra-venously. Where the polypeptide is active in the picogram/ml range, such as is vasopressin, the compos~tion is effective to deliver a therapeutically effective amount of the peptide into the bloodstream for a period of between 5-10 days.
Also forming part of the invention is a method for exten-ding to at least 24 hours, the period of effective activity of a therapeutic compound which can be ~m~n;stered intravenous-ly in a therapeutically effective amount, and which has a ~:' 2~ fi7 ~ ~ 3 halflife in the blood, in free form, of less than about 4 hours. In this method, a liposome composition of the type described above is administered intravenously to a subject at a dose which contains an amount of the compound which is at least three times such therapeutically effective amount.
Also disclosed is a liposome composition effective to extend to at least one week, the period of effective activity of an therapeutic compound which can be administered intra-venously in a therapeutically effective amount. The composi-tion includes liposomes (i) composed of vesicle-forming lipids and between 1-20 mole percent of a vesicle-forming lipid deri-vatized with a biocompatible hydrophilic polymer, and ~ii) having a selected mean particle diameter in the slze range between about 0.07-.lS microns, and the compound in liposome-entrapped form. The composition is intended for subcutaneousadministration at a dose which contains an amount of the lipo-some-entrapped compound which is at least ten times such therapeutically effective intravenously administered amount.
The liposome composition is used in a method for extending the period of release of a therapeutic compound, preferably a polypeptide, in a therapeutically active amount, for a period of at least 2 weeks.
In another aspect, the invention includes a liposome composition composed of vesicle-forming lipids and a vesicle-forming lipid derivatized with polylactic acid or polyglycolicacid, and a lipid composition composed of a vesicle-forming lipid having a polar head group, and a polylactic acid or polyglycolic acid moiety derivatized to the lipid's head group.
WO91/~ ~5 2 0 6 7 1 3 3 PCT/USgo/~O~
Brief Description of the Drawings Figure l illustrates a general reaction scheme for derivatizing a vesicle-forming lipid amine with a polyalkyl-ether;
Figure 2 is a reaction scheme for preparing phosphati-dylethanolamine (PE) derivatized with polyethyleneglycol via a cyanuric chloride linking agent;
Figure 3 illustrates a reaction scheme for preparing phosphatidylethanolamine (PE) derivatized with polyethylene-glycol by means of a diimidazole activating reagent;
Figure 4 illustrates a reaction scheme for preparing phosphatidylethanolamine (PE) derivatized with polyethylene-glycol by means of a trifluoromethane sulfonate reagent;
Figure 5 illustrates a vesicle-forming lipid derivatized with polyethyleneglycol through a peptide (A), ester ~B), and disulfide ~C) linkage;
Figure 6 illustrates a reaction scheme for preparing phosphatidylethanolamine ~PE) derivatized with polylactic acid;
Figure 7 is a plot of liposome retention time in the blood, expressed in terms of percent injected dose as a function of hours after IV injection, for PEG-PE liposomes containing different amounts of phosphatidylglycerol;
Figure 8 is a plot similar to that of Figure 7, showing retention times in the blood of liposomes composed of predomi-nantly unsaturated phospholipid components;
Figure 9 is a plot similar to that of Figure 7, showing retention times in the blood of PEG liposomes ~solid tri-~ngles) and conventional liposomes ~solid ciLcles);
Figure lO is a plot of blood lifetimes of PEG-liposomes sized by extrusion through O.l micron ~solid squares), 0.2 micron ~solid circles), and 0.4 micron ~solid triangles) WO91/~ ~5 ~ 2 0 6 ~ 1 3 3 PCT/US9O/~O~
polycarbonate membranes;
Figure 11 is a plot of blood retention times in liposomes containing a vesicle-forming lipid derivatized with polylactic acid (solid squares) and polyglycolic acid (open triangles);
Figure 12 shows urine flow rates in rats, as a percentage of predosage rate, after surgery and IV administration of saline (control, open circles) and of aqueous solutions of vasopressin at total doses of 0.2 ~g (closed squares), 0.8 ~g (closed triangles), and 2 ~g (closed circles);
Figure 13 shows urine flow rates in rats, as a percentage of predosage rate, after surgery and IV administration of saline (control, open circles) and of PEG-liposomes containing entrapped vasopressin at total doses of 2 ~g (closed squares), 8 ~g (closed triangles), and 24 ~g (closed circles);
Figure 14 shows urine flow rates in rats, as a percentage of predosage rate, after surgery and IV administration of saline (control, open circles) and of PEG-liposomes containing entrapped vasopressin at a total dose of 8 ~g and mole percent of cholesterol in the liposomes of 33% (closed circles), 16%
(closed triangles), and 0% (closed squares);
Figure 15 shows the blood clearance kinetics of free macrophage-colony stimulating factor (M-CSF) (solid triangles), PEG-liposomes containing 30 mole percent cholesterol (solid triangles), and M-CSF associated with the PEG-liposomes (solid circles);
Figure 16 shows the blood clearance kinetics of free M-CSF
(solid triangles), cholesterol-free PEG-liposomes (solid triangles), and M-CSF associated with the PEG-liposomes ~solid circles);
Figure 17 is a plot of percent release of M-CSF into the blood from PEG liposomes containing 30 (solid circles) and 0 (solid triangles) mole percent cholesterol; and NO91/05545 PCTrUS90/OfiO34 ~ Q 6 7 1 3 3 Figure 18A shows urine flow rates in rats, as a percentage of predosage rate, after surgery and subcutaneous ~m~ n~stra-tion of saline (control, open circles) and free vasopressin, in an amount 2 ~g (solid triangles), 25 ~g (solid circles), and 50 ~g ~solid ~; ~monri.C); a~d Figure 18B shows urine flow rates in rats, as a percentage of predosage rate, after surgery and subcutaneous A~m; n~ stra-tion of saline (control, open circles) and vasopressin en-trapped in PEG-liposomes, in an amount 25 ~g (solid triang-les), 100 ~g (solid circles), and gO0 ~g (solid dizmonds).
Detailed Description of the Invention I. Preparation of Derivatized Lipids Figure 1 shows a general reaction scheme for preparing a vesicle-forming lipid derivatized with a bio-compatible, hydrophilic polymer, as exemplified by polyethylene glycol (PEG), poly-lactic acid, and polyglycolic acid, all of which are readily water soluble, can be coupled to vesicle-forming lipids, and are tolerated in ~i~o without toxic effects. The hydrophilic polymer which is employed, e.g., PEG, is preferably capped by a methoxy, ethoxy or other unreactive group at one end, or is one in which one end is more reactive than the other, such as polylactic acid.
The polymer is activated at one end by reaction with a suitable activating agent, such as cyanuric ac$d, diimadozle, anhydride reagent, or the like, as described below. The activated compound is then reacted with a vesicle-forming lipid, such as phosphatidylethanol (PE), to produce the 3û derivaiized iipid.
Alternatively, the polar group in the vesicle-forming lipid may be activated for reaction with the polymer, or the ~ , WO9l/05~5 ~ 2 ~ 6 7 1 3 ~ PCT/USgo/~o~
two groups may be joined in a concerted coupling reaction, according to known coupling methods. PEG capped at one end with a methoxy or ethoxy group can be obtained commercially in a variety of polymer sizes, e.g., 500-20,000 dalton molecular weights.
The vesicle-forming lipid is preferably one having two hydrocarbon chains, typically acyl chains, and a polar head group. Included in this class are the phospholipids, such as phosphatidylcholine (PC), PE, phosphatidic acid (PA), phospha-tidylinositol (PI), and sphingomyelin (SM), where the twohydrocarbon ch~; ns are typically between about 14-22 carbon atoms in length, and have varying degrees of unsaturation.
Also included in this class are the glycolipids, such as cere-broside and gangliosides.
Another vesicle-forming lipid which may be employed is cholesterol and related sterols. In general, cholesterol may be less tightly anchored to a lipid bilayer membrane, particu-larly when derivatized with a high molecular weight polyalkyl-ether, and therefore be less effective in promoting liposome evasion of the RES in the bloodstream.
More generally, and as defined herein, "vesicle-forming lipid" is intended to include any amphipathic lipid having hydrophobic and polar head group moieties, and which (a) by itself can form spontaneously into bilayer vesicles in water, as exemplified by phospholipids, or (b) is stably incorporated into lipid bilayers in combination with phospholipids, with its hydrophobic moiety in contact with the interior, hydro-phobic region of the bilayer membrane, and its polar head group moiety oreinted toward the exterior, polar surface of 3Q the membrane. An example of ~ latter type of vesicle-forming lipid is cholesterol and cholesterol derivatives, such as cholesterol sulfate and cholesterol hemisuccinate.
According to one important feature of the invention, the WO91/0~5 PCT/USgO/~34 20 67 ~ 3 ~
vesicle-forming lipid may be a relatively fluid lipid, me~ng that the lipid phase has a relatively low liquid-to-liquid crystal phase-transition temperature, e.g., at or below room temperature, or relatively rigid lipid, ~n~ng that the lipid has a relati~ely high melting temperature, e.g., up to 50~C.
As a rule, the more rigid, i.e., saturated lipids, contribute to greater membrane rigidity in a lipid bilayer structure and also contribute to greater bilayer stability in serum. Other lipid components, such as cholesterol, are also known to contribute to membrane rigidity and stability ir. lipid bilayer structures. Phospholipids whose acyl c-h~ns have a variety of degrees of saturation can be obtained commercially, or prepared according to published methods.
Figure 2 shows a reaction scheme for producing a PE-PEG
lipid in which the PEG is derivatized to PE through a cyanuric chloride group. Details of the reaction are pro~ided in Example 1. Briefly, methoxy-capped PEG is acti~ated with cyanuric chloride in the presence in sodium carbonate under conditions which produce the activated PEG compound IV in the figure. This material is purified to remove unreacted cyanuric a~id. The activated PEG compound is reacted with PE
in the presence of triethyl amine to produce the desired P~-PEG compound shown at VII in the figure. The yield is about 8-10% with respect to initial quantities of ~EG.
The method just describéd may be applied to a variety of lipid amines, including PE, cholesteryl amine, and glycolipids with sugar-amine groups.
A second method of coupling a polyalkylether, such as capped PEG to a lipid amine is illustrated in Figure 3. Here the capped PEG is acti~atad with a carbonyl diimidazole coupling reagent, to form the activated imidazole compound shown at X in Figure 3. Reaction with a llpid amine, such as P~ leads to PEG coupling to the lipid through an amlde 5~5 2Q 6 7 1 3 3 PCT/US90/060~
linkage, as illustrated in the PEG-PE compound shown at XI in the figure. Details of the reaction are given in Example 2.
A third reaction method for coupling a capped poly-alkylether to a lipid amine is shown in Figure 4. Here PEG is first protected at its OH end by a trimethylsilane group. The end-protection reaction is shown at A in the figure, and involves the reaction of trimethylsilylchloride with PEG in the presence of triethylamine. The protected PEG is then reacted with the anhydride of trifluoromethyl sulfonate (compound XVI in Figure 4) to form the PEG compound activated with trifluoromethyl sulfonate. Reaction of the activated compound with a lipid amine, such as PE, in the presence of triethylamine, gives the desired derivatized lipid product, such as the PEG-PE compound, in which the lipid amine group is coupled to the polyether through the terminal methylene carbon in the polyether polymer. The trimethylsilyl protective group can be released by acid treatment, as indicated at H+ in the figure, or by reaction with a quaternary amine fluoride salt, such as the fluoride salt of tetrabutylamine.
It will be appreciated that a variety of known coupling reactions, in addition to those just described, are suitable for preparing vesicle-forming lipids derivatized with hydro-philic polymers such as PEG. For example, the sulfonate anhydride coupling reagent illustrated in Figure 4 can be used to join an activated polyalkylether to the hydroxyl group of an amphipathic lipid, such as the 5'-OH of cholesterol. Other reactive lipid groups, such as an acid or ester lipid group may also be used for coupling, according to known coupling methods. For example, the acid group of phosphatidic acid can bc ~ctivated to form an active lipid anhydride, by reactlon with a suitable anhydride, such as acetic anhydride, and the reactive lipid can then be joined to a protected polyalkyl-amine by reaction in the presence of an isothiocyanate WO gl/OS545 PCr/US90/06034 reagent.
In another embodiment, the derivatized lipid components are prepared to include a labile lipid-polymer linkage, such as a peptide, ester, or disulfide linkage; which can be cleaved under selective physiological conditions, such as in the presence of peptidase or esterase enzymes present in the bloodstream. Figure 5 shows exemplary lipids which are linked through (A) peptide, ~B), ester, and (C), disulfide containing linkages. The peptide-linked compound can be prepared, for example, by first coupling a polyalkylether with the N-terminal amine of the tripeptide shown, e.g., via the reaction shown in Figure 3. The peptide carboxyl group can then be coupled to a lipid amine group through a carbodiimide coupling reagent conventionally. The ester linked compound can be prepared, for example, by coupling a lipid acid, such as phosphatidic acid, to the ~erri n~ 1 alcohol group of a poly-alkylether, using alcohol via an anhydride coupling agent.
Alternatively, a short linkage fragment cont~;n;ng an inter-nal ester bond and suitable end groups, such as primary amine groups can be used to couple the polyalkylether to the amphi-pathic lipid through amide or carbamate linkages. Similarly, the linkage fragment may contain an internal disulfide link-age, for use in forming the compound shown at C in Fi~ure 5.
Figure 6 illustrates a method for derivatizing polylactic acid with PE. The polylactic acid is reacted, in the presence of PE, with dicyclohexylcarboimide (DCCI), as detailed in Example 4. S~ rly, a vesicle-forming lipid deri~atized wit~ polyglycolic acid may be formed by reaction of polygly-colic acid or glycolic acid with PE in the presence of a suitable coupling agent, such as DCCI, also as detailed in Example 4. The vesicle-forming lipids derivatized with either polylactic acid or polyglycolic acid form part of the inven-tion herein. Also forming part of the invention are liposomes WO91/05~5 ~ 20~71~ PCT/US~/~o~
containing these derivatized lipids, in a 1-20 mole percent.
II. Preparation of Liposome Composition A. Lipid Components The lipid components used in forming the liposomes of the invention may be selected from a variety of vesicle-forming lipids, typically including phospholipids and sterols. As will be seen, one requirement of the liposomes of the present invention is long blood circulation lifetime. It is therefore useful to establish a standardized measure of blood lifetime which can be used for evaluating the effect of lipid component on blood halflife.
One method used for evaluating liposome circulation time in vivo measures the distribution of IV injected liposomes in the bloodstream and the primary organs of the RES at selected times after injection. In the standardized model which is used herein, RES uptake is measured by the ratio of total liposomes in the bloodstream to total liposomes in the liver and spleen, the principal organs of the RES. In practice, age and sex matched mice are injected intravenously ~IV) through the tail vein with a radiolabeled liposome composition, and each time point is determined by measuring total blood and combined liver and spleen radiolabel counts, as detailed in Example 6.
- Since the liver and spleen account for nearly 100% of the initial uptake of liposomes by the RES, the blood/RES ratio just described provides a good approximation of the extent of uptake from the blood to the RES in vivo. For example, a ratio of about 1 or greater indicates a predomin~nce of injected liposomes remaining in the bloodstream, and a ratio below about 1, a predom;n~nce of liposomes in the RES. For most of the lipid compositions of interest, blood/RES ratios were calculated at 1,2, 3, 4, and 24 hours.
WO 91/05~4~ PCr/US90/06034 ~0 671 3 3 The liposomes of the present invention include 1-20 mole percent of the vesicle-forming lipid derivatized with a hydro-philic polymer, described in Section I. According to one aspect of the invention, it has been discovered that blood circulation halflives in these liposomes is largely indepen-dent o~ the degree of saturation of the phospholipid compo-nents making up the liposomes. That is, the phospholipid components may be composed predominantly of fluidic, relatively unsaturated, acyl ch~ns~ or of more saturated, rigidifying acyl chain components. This feature of the invention is seen in Example 7, which ~m; nes blood/RES
ratios in liposomes formed with PEG-PE, cholesterol, and PC
having varying degrees of saturation ~Table 4). As seen from the data in Table 5 in the example, high blood/RES ratios were achieved with substantially all of the liposome formula-tions, independent of the extent of lipid unsaturation in the bulk PC phospholipid, and no systematic trend, as a function of degree of lipid saturation, was observed.
Accordingly, the vesicle-forming lipids may be selected to achieve a selected degree of fluidity or rigidity, to control the stability of the liposomes in serum and the rate of release of entrapped drug from the liposomes in the blood-stream and/or tumor. The vesicle-forming lipids may also be selected, in lipid saturation characteristics, to achieve desired liposome preparation properties. It is generally the case, for example, that more fluidic lipids are easier to formulate and down-size by extrusion or homogenization than more rigid lipid components, In general~ more fluidic lipids (low transition temperature) are preferred because of high 3Q compou~.d-release rates in the bloodstream.
Similarly, it has been found that the percentage of cholesterol in the liposomes may be varied over a wide range without significant effect on observed blood/RES ratios. The .
WO91/05~5 PCT/US90/06034 studies presented in Example 8A, with reference to Table 6 therein, show virtually no change in blood/RES ratios in the range of cholesterol between 0-30 mole percent.
Cholesterol, or related cholesterol derivatives may be important, however, in regulating the rate of release of lipo-some entrapped therapeutic compounds into the bloodstream.
The studies reported in Examples 1-5 and 16, for example, indicate that the rate of release of encapsulated polypeptide (peptide or protein) from liposomes in vitro in human serum or in vivo is strongly dependent on cholesterol concentration.
PEG-liposome formulations containing high cholesterol (e.g., 30 mole percent or greater) released very little peptide or protein into serum in vitro, whereas decreasing amounts of cholesterol produce increasing loss of encapsulated poly-peptide. Similarly, and as described below, increased chol-esterol in intravenously ~m; n; stered PEG-liposomes produced reduced release of encapsulated compound into the bloodstream (Example 18) and reduced physiological effect (Example 16).
Thus, in accordance with one feature of the invention, the rate of release of compound from long-circulating liposomes ~an be controlled by the percent cholesterol included in the liposomes.
It has also been found, in studies conducted in support of the invention, that blood/RES ratios are also relatively 2~ unaffected by the presence of charged lipid components, such as phosphatidylglycerol (PG). This can be seen from Figure 7, which plots percent loss of encapsulated marker for PEG-PE
liposomes containing either 4.7 mole percent PG ~triangles) or 14 mole percent PG (circles). Virtually no difference in liposome retention in the bloodstre&" over â 24 hour period was observed.
The vesicle-forming lipid derivatized with a hydrophilic polymer is present in an amount preferably between about 1-20 WO91/OS545 PCT/US9O/060~
~0 ~7 ~ ~ ~
mole percent, on the basis of moles of derivatized lipid as a percentage of total moles of vesicle-forming lipids. It will be appreciated that a lower mole ratio, such as 0.1 mole percent, may be appropriate for a ltpid derivatized with a large molecular weight polymer, such as one having a molecular weight greater than 100 kilodaltons. As noted in Section I, the hydrophilic polymer in the derivatized lipid preferably has a molecular weight between about 200-20,000 daltons, and more preferably between about 1,000-5,000 daltons. Example 8B, which ex~m;ne~ the effect of very short ethoxy ether moieties on blood/RES ratios~indicates that polyether moieties of greater than about 5 carbon ether are required to achieve significant enhancement of blood/RES ratios.
B. Preparing the Liposome Composition The liposomes may be prepared by a variety of techniques, such as those detailed in Szoka et al, 1980. One method for preparing drug-cont A; n ~ ~g liposomes is the reverse phase evaporation method described by Szoka et al and in U.S. Patent No. 4,235,871. The reverse phase evaporation vesicles (R~Vs) have typical average sizes between about 2-4 microns and are pre~om;n~ntly oligolamellar, that is, contain one or a few lipid ~ilayer shells. The method is detailed in Example SA.
This method is generally preferred for preparing liposomes 2~ wlth encapsulated proteins High encapsulation efficiencies (up to 50~) are possible, and thus protein loss or problems of recovery and purification of non-encapsulated protein are reduced.
Multilamellar vesicles (M1Vs) can be formed by simple lipid-film hydration techniques. In this procedure, a mixture of liposome-forming lipids of the type detailed above dis-solved in a suitable solvent is evaporated in a vessel to form a thin film, which is then covered by an aqueous medium, as WO gl/05545 Pcr/usso/o~034 - 20 67 ~ 3 3 detailed in Example 5B. The lipid film hydrates to form MLVs, typically with sizes between about 0.1 to 10 microns.
In accordance with one important aspect of the invention, the liposomes for intravenous injection are prepared to have substantially homogeneous sizes in a selected size range between about 0.1 and 0.4, and preferably 0.1 to 0.2 micron size ranges. Liposomes in this size range have sufficiently high encapsulation volumes for carrying therapeutically effec-tive amounts of the compound to be ~m;n;stered. At lower liposome sizes, the ratio of liposome-encapsulated compound to free compound may be too low to achieve a requisite initial dose level of liposome-encapsulated compound in the bloodstream or may not remain in circulation due to extravasation. At the same time, 0.1-0.4 micron liposomes are small enough to give long blood circulation times, as discussed below, and also to allow sterilization by sterile filtration.
One effective sizing method for REVs and MLVs involves extruding an aqueous suspension of the liposomes through a polycarbonate membrane having a selected uniform pore size, typically 0.4, 0.2, and/or 0.1 micron pore sizes. The pore size of the membrane is proportional to the largest sizes of the liposomes which are produced, particularly where the pre-paration is extruded two or more times through the same size membrane. This method of liposome sizing is used in preparing homogeneous-size REV and MLV compositions described in the examples below. A more recent method involves extrusion through an asymmetric ceramic filter. The method is detailed in U.S. Patent 4,737,323, titled Liposome Extrusion Method, issued April 12, 1988. Homogenization methods are also useful for down-sizing liposomes.
C. Compound ~oading In one embodiment, the composition of the invention is WO 91/05545 ~ ~ 2 0 6 7 1 3 :~ Pcr/us9o/o6o34 used for slow-release delivery into the bloodstream or a poly-peptide (peptide or protein) which is therapeutically active in the bloodstream when administered IV, but which in free form has a short blood halflife, typically 4 hours or less.
Examples of such polypeptides include hormones, such as vaso-pressin, calcitonin, oxytocin, somatotropin, human growth hormone, atrial naturectic factor (ANF), and insulin; enzymes, such as superoxide dismutase, glucocerebrosidase, asparagin-ase, and adenosine deAm;nAse; immunomodulators, such as inter-ferons (alpha, beta, and gamma), interleukin (1,2,3,4,5,6,7), tissue necrosis factor (TNF - alpha, beta), and colony stimu-lating factors (M-CSF (macrophage), G-CSF (granulocyte), GM-CSF (granulocyte, macrophage); anticoagulants, such as TPA, prourokinase, and urokinase; vaccines, such as HIV-1 vaccine, hepatitis B vaccine, malaria vaccine, and melanoma vaccine;
and other polypeptides (peptides and proteins), such as erythropoietin (EPO), factor VIII, bone growth factor, fibro-blast growth factor, insulin-like growth factor, nerve growth factor, platelet-derived growth factor, tumor growth factors (alpha, beta), and somatomedin C (IGF-1); and ribosome-inhibi-tor proteins, such as pokeweed antiviral protein and gelonin.
The polypeptides useful in the invention typically have relatively short blood halflives, on the order of 2-4 hours or less, and are active in the picogram/ml to nanogram/ml concen-tration range in the blood.
As noted above, polypeptide is preferably loaded passivelyby the reverse-phase emulsion method for preparing liposomes, although many other methods, such as solvent injection or lipid hydration may be employed. After liposome formation and si7ins, free (unbound) drug can be remo-ved by a variety o, methods, for example, by gel filtration or ion exchange chromatography or diafiltration. Typically the amount of free peptide in the final sterilized composition is less than about WO 91/05545 2 0 6 7 1 ~ 3 pcr/us9o/o6o34 20%, and preferably less than 10% of the total polypeptide contained in the composition.
At the same time, the encapsulated compound is preferably present in an amount which, in a selected liposome dose, is between 3-20 times the amount of compound which would be given as a therapeutic dose in free form by IV administration.
Thus, if the therapeutic dose of a peptide in free form is 1 ~g for IV administration, a selected liposome dose will pre-ferably contain between about 3-20 ~g of the peptide. Since 10-20% of this compound, e.g., 2-4 ~g, may be in non-encapsu-lated form, it will be appreciated that the total amount of liposome which can be administered may be limited by the maxi-mum tolerated dose of the free compound. It is clear that larger doses of liposomes can be administered by achieving higher ratios of encapsulated to non-encapsulated compound.
In general, this ratio is increased with larger liposomes, more complete free drug removal from the liposome composition, and greater liposome stability on storage.
The composition is also useful for slow-release delivery of a variety of non-peptide, water-soluble compounds which are effective in treating circulating cancers such as leukemias, for example, cytarabine, cyclophosphamide, carmustine, thio-guanine, bleomycin, daunorubicin, vinblastine, vincristine, and asparaginase.
Also useful in therapeutic delivery by the present invention are antibiotics, such as gentamicin, tobramycin, amikacin, netilmicin, kanamycin, and streptomycin, cefotaxime, ceftizoxime, and ceftriaxone, and anti-viral agents, such as AZT (zidovidine), DDI (dideoxyinosine), DDC (didioxycytidine), ganciclov r, D4T (didehydrodeoxythymidine), phosphonoformate, ribavirin, and acyclovir.
WO91/05545 PCT/US~/~
-2 ~ 3 3 Such compounds may be encapsulated by passive loading, as above, during liposome formation by reverse evaporation phase, lipid hydration, solvent injection, or other liposome forma-tion methods, and remo~ed, after sizing by gel filtration or the like.
Alternatively, drugs which form weak bases at physiological pH may be actively loaded into the liposomes at high drug concentration in the liposomes. One method for active loading drugs into liposomes is described in co-owned u.s. Patent 5,192,549. In this method, liposomes are prepared in the presence of a relatively high ammonium ion, such as 0.125 M
A~mon~um sulfate. After sizing the liposomes to a desired size, the liposome suspension is treated to create an inside-to-outside ammonium ion gradient across the liposomal membranes. The gradient may be created by d~alysis against a non~ o~1um contA~ning medium, such as an isotonic glucose medium, or by gel filtration, such as on a Sephadex G-50 column equilibrated with 0.15 M NaCl or KCl, effecti~ely replacing ~onium ions in the exterior phase with sodium or potassium ions. Alternatively, the liposome suspension may be diluted with a non-ammonium solution, thereby reducing the exterior-phase concentration of ~rmon;um ions. The ammonium concentration inside the liposomes is preferably at least 10 times, and more pre~erably at least 100 to 1000 times that ln the external liposome phase.
The ammonium ion gradient across the liposomes in turn creates a pH gradient, as ~r~on;a is released across the lipo-some membrane, and protons are trapped in the internal lipo-3Q some phz~e. To 102d liposomes with the selected drug, a rela-tively dilute suspension of the liposomes, e.g., less than about 50 mM lipid, is mixed with an aqueous solution of the drug, and the mixture is allowed to equilibrate over an WO91/05~5 PCT/US90/06034 7 ~ ~ 3 extended period, e.g., 24 hours at room temperature. In one typical method, a suspension of liposomes having a lipid con-centration of 25 mg/ml is mixed with an equal volume of anthracycline drug at a concentration of about 10 mg/ml. At the end of the incubation period, the suspension is treated to remo~e free (unbound) drug.
III. Intravenous ~m; n; ~tration A. Extended Lifetime in the Bloodstream One of the requirements for extended compound release into the bloodstream, in accordance with the invention, is an extended liposome lifetime in the bloodstream with IV_liposome administration. One measure of liposome lifetime in the bloodstream is the blood/RES ratio determined at a selected time after liposome ~m; n; stration, as discussed above.
Blood/RES ratios for a variety of liposome compositions are given in Table 3 of Example 6. In the absence of PEG-derivatized lipids, blood/RES ratios were 0.03 or less. In the presence of PEG-derivatized lipids, the blood/~ES ratio ranged from 0.2, for low-moler~ r weight PEG, to between 1.7-4 for several o~ the formulations, one of which lac~s cholesterol, and three of which lack a charged phospholipid (e.g., PG).
The data presented in Table 5 in Example 7 show blood/RES
2~ ratios (excluding two points with low percent recovery) between about 1.26 and 3.27, consistent with the data given in Table 3. As noted in Section II above, the blood lifetime values are substantially independent of degree Of saturation of the liposome lipids, presence of cholesterol~ and presence of ch~rged lipids.
The blood/RES values reported above can be compared with blood/RES values reported in co-owned U.S. Patent No.
4,920,016, which used blood/RES measuL~.el~L methods identical WO91/05~5 PCT/US90/~0~
~ Q ~ 7 1 3 3 to those used for the data presented in Tables 3 and 5.
The best of the 24-hour blood/RES ratios which were reported in the above-noted patent was 0.9, for a formulation composed of GMl, saturated PC, and cholesterol The next best formulations gave 24-hour blood/RES values of about 0.5. Thus, typical 24-hour blood/RES ratios obtained in a number of the current formulations were more than twice as high as the best formula-tions reported which have been reported to date. Further, ability to achieve high blood/RES with GMl or HPI lipids was dependent on the presence of prP~om~n~tly saturated lipids in the liposomes.
Plasma kinetics of a liposomal marker in the bloodstream can provide another measure of the enhanced liposome lifetime which is achieved by the liposome formulations of the present invention. Figure 7 and 8 discussed above show the slow loss of liposomal marker over a 24 hour period in typical PEG-lipo-some formulations, substantially independent of whether the marker is a lipid or an encapsulated water-soluble compound ~Figure 8). In both plots, the amount of liposomal marker present 24 hours after liposome injection is greater than 10%
of the originally injected material.
Figure 9 shows the kinetics of liposome loss from the bloodstream for a typical PEG-liposome forml~lAt~on and the same liposomes in the absence of a PEG-derivatized lipid. After 24 2S hours, the percent marker remaining in the PEG-liposomes was greater than about 20~, whereas the conventional liposomes showed less than 5% retention in the blood after 3 hours, and virtually no detectable marker at 24 hours.
The results seen in Figures 7-9 are consistent with 24 hour blood liposome values measured for a variety of liposome formulations, and reported in Tables 3 and 5-7 in Example 6-9 below. As seen in Table 3 in Example 6 the present dose r~ ;ng at 24 hours was less than 1% for conventional l$po-WO91/0554~ PCT/US90/06034 somes, versus at least 5% for the PEG-liposomes. In the best formulations, values between about 20-40~ were obtained.
Similarly in Table 5 from Example 7, liposome le~els in the blood after 24 hours (again neglecting two low recovery ~alues) were between 12 and about 25 percent of total dose given. Similar results are reported in Tables 6 and 7 of Example 8.
The effect of liposome size on blood lifetime has been investigated by comparing loss of liposomal marker in intra-venously injected liposomes having selected sizes betweenabout 0.1 and 0.25 microns. Experimental details are given in Example 10. The results, given in Figure 10, show about 10%
or greater liposome marker present in the blood after 24 hours for each of the liposome formulations. Highest blood life-1~ times were achieved with the smallest liposomes. Thus, although all of the liposome preparations give high blood lifetimes, it is also clear that liposome size can be selected to produce desired increase or decrease in total drug release time.
The enhancement in liposome blood circulation time achieved with two other biocompatible hydrophilic polymers, polylactic acid and polyglycolic acid, is seen in Figure 11, which shows loss of liposome marker during the 24-hour period after intravenous liposome injection. The percent marker rPm~;n;ng at 24 hours is about 4.3 percent for polylactic acid (solid squares), and about 6~ for polyglycolic acid (open triangles). These values compare with the 0.1-1~ retention seen in conventional liposomes after 24 hours.
The data relating to both blood/R$S ratios and to liposome 3Q rete~tio~ time in the bloodstream which were obtained frGm an model animal system can be reasonably extrapolated to ~ c and veterinary ~;m~ls of interest. This is because upta~e of liposomes by li~er and spleen has been found to occur at WO91/05545 PCT/US90/~
~n ~71 3 3 similar rates in several m~mm~l ~an species, including mouse, rat, monkey, and human ~Gregoriadis, 1974; Kimelberg, 1976;
Juliano; Richardson; Lopez-Berestein). This result likely reflects the fact that the biochemical factors which appear to be most important in liposome uptake by the ~BS -- including opsinization by serum lipoproteins, size-dependent uptake effects, and cell shielding by surface moieties -- are common features of all ~mm~ 1 ian species which have been e~Am~ned.
B. Compound Release in the Bloodstream In addition to long circulating halflives, another important property of the liposomes of the present invention is the ability to release entrapped compound at the thera-peutically effective dose rate in the bloodstream.
As discussed above, the liposome size between 0.1 and 0.4 microns allows relatively high compound loading in the lipo-somes, for effective compound release as the percentage of liposomes in the bloodstream even at relatively low liposome concentrations in the bloodstream. This is typically an important consideration since the total amount of liposomes which can be A~m; n~ stered will be limited, due to the unavoidable presence of some free compound in injected composition.
Another consideration is the ability of entrapped compound to be released from the liposomes during circulation in the blood. This feature is illustrated in the studies described in Example 15 below. Here PEG-liposomes containing entrapped vasopressin (a 1 kilodalton peptide) were prepared with increasing concentrations of cholesterol, from 0 to about 30 mole percent. In vitro mea--urements on peptide release from the liposomes in serum showed substantially less peptide release with greater amounts of cholesterol. The rate of release of the peptide hormone in vivo was determined by WO 91/0~545 PCr/US90/06034 ~0 ~71~ 3 diuretic effect, as measured by decreased urine ouL~u~, in a period 1-8 days following intravenous administration of t~e liposomes. Details of the study are given in Example 15. As seen ~n Figure 14, the short-term effect on~ urine flow was dependent on cholesterol content, the PEG-liposomes with highest cholesterol producing the greates~ hormone effect.
Similarly, in the period 2-8 days following IV administration of the liposomes, the two PEG-liposome formulations having the lowest cholesterol concentration gave the greatest hormone effect, indicating higher release rates from the liposomes.
The study reported in ~xample 16 ~mon ctrateS a similar ability to control release rates of large proteins from long-circulating liposomes. Here PEG-liposomes containing encapsu-lated M-CSF (a 55 kilodalton protein) were eX~m;ne~ for per-cent retention in the bloodstream of both lipid and proteincomponents. The data plotted in Figure 15 show liposome lipid (solid triangles) and protein (solid ci'rcles) kinetics 2g hours after IV injection for a PEG-lipsome formulation con-t~~ n; ng 30 mole percent cholesterol. The data indicate about 20% loss of encapsulated material over 24 hours, as discussed in ~xample 16.
Figure 17 shows a s; m; 1 ~r plot for PEG-liposomes without cholesterol. The data here show a 40-50~ loss of M-CSF after 24 hours. When normalized lipid and protein markers are compared at selected time points o~er 24 hours, the plots of protein release from cholesterol (solid circles) and no-cholesterol (solid triangles) PEG-liposomes are obtained. The plots illustrate the markedly different protein release kinetics which can be obtained with long circulating lipo-some~, by varying cholesterol content of the liposomes.Another feature of the data shown in Figure 17 is the relatively high percent ~at least 3%) of initially injected protein which is released at 24 hours in both formulations.
_n WO gl/05545 PCr/US90/06034 - ~ 0 6 7 ~ 3 3 IV. Intravenous Liposome Treatment The invention includes, in one aspect, a method for extending to at least 24 hours, the period of effective activity of an therapeutic compound. The compound is one which can be ~mt n1 stered intravenously in a therapeutically effective amount, and which has a halflife in the bloodstream, in free form, of less than about 4 hours.
In practicing the method, there is provided a liposome composition such as described above, containing the compound in liposome-entrapped form. The size, lipid composition, and extent of compound loading of the drug are selected, according to the desired release rates and total release times, as considered in Section III above.
The composition is injected intravenously to a subject at a dose which contains an amount of the compound which is at least 3, and typically 5-20 times the therapeutically effec-tive dose. Thus, for example, if a therapeutically effective dose of a compound is 10 ~g/Kg body weight, the liposome com-position would be injected at a liposome dose of at least 30 ~g compound/Kg, and typically ~etween 50-200 ~g compound/Kg body weight. As noted above, the amount of material which can be injected is generally limited by the maX1mllm tolerated dose of free compound, since 5-20% or more of the compound may be in free (non-entrapped) form when the composition is adml-nistered. Thus, for example, if the ~x1~llm tolerated dose of a compound in free form is 2 ~g/Kg body weight, and the lipo-some composition contains 10~ non-entrapped compound, the highest dose of liposome composition which can be given is 20 ~g/Kg body weight.
Studies on the treatment of L1210 lellkpm~ A in mice with cytosine arabinoside (araC), in free form and entrapped in WO gl/0~ PCr/US90/06~34 - 20 67 ~ 3 3 PEG-liposomes,indicates that the liposome composition produced about a 250-300~ increase in survival time when a~m;n;~tered in PEG-liposomal form, compared with about a 120~ increase in survival time for the drug in free form.
The ability to achieve long drug release times, on the order of several days, by the method of the invention is illu-strated by the studies on IV vasopressin administration repor-ted in Examples 13-15. The s~udies were carried out on Brattle-boro rats which are genetically diabetic by virtue of vaso-pressin deficiency. Figure 13 sh-ows the effect, measured in percent predosage urine flow, of IV injection of free vaso-pressin at dose levels of 0.2 ~g (solid squares), 0.8 ~g (solid triangles) and 2.0 ~g (solid circles). The reduction in urine flow is ~x;m~lm after 1 day, but returns to control levels (open circles) by day 2.
~ igure 14 shows the effect on urine flow by vasopressin ~m; n; stered IV in PEG-liposomes, at dosage levels of 2 ~g (solid squares), 8 ~g (solid triangles) and 24 ~g (solid cir-cles). A pronounced reduction in urine flow was observed within one day, with a slight rebound t~ward control values by day 2 -- an effect likely due, in part, to free peptide in the liposome formulation. In addition, a marked reduction in urine flow was observed for at least 7 days following IV
~min; stration. It is noted that the long-term therapeutic effect is saturated at an 8 ~g dose, with no further effect observed at 24 ~g. The same long-term therapeutic effect of vasopressin was observed in PEG-liposomes containing various amounts of cholesterol, as seen in Figure 14, and as discussed above. The data in this figure also illustrate increased short-term (1-2 days) and decreased long-term (2-8 days) effect seen with low cholesterol liposomes having the highest peptide release rates.
~' WO91/05S45 PCT/US90/060~
~ 0 6 7 ~ 3 3 More generally, it will be appreciated that a variety of polypeptides which are active in the picogram-to-nanogram/ml range may be ~; nl stered over a several-day period by the method o~ the invention. The data presented in Figures 15-17, for example, ~monstrate that (a) large proteins may be se-questered in the bloodstream, for slow release in therapeutic amounts over an extended period and (b) the rate of release of the protein into the bloodstream can be selectively con~rolled by liposome composition.
V. Subcutaneous Liposome Treatment In accordance with another aspect of the invention, it has been discovered that the long-circulatory liposome composition of the invention is also effective for slow release of a liposome-entrapped compound from a subcutaneous (SubQ) site into the bloodstream. In particular, it has been discovered that therapeutic effects of up to 3 weeks or more can be achieved by a single subcutaneous injection of the liposome composition of the invention.
The experimental model used to ~emo~strate this method is the vasopressin model described above, and detailed in Example 17. Briefly, a treatment method involving SubQ injection of free vasopressin was compared, for duration of physiological effect, with ~asopressin a~; n~ stered SubQ in ~G-liposomes.
Figure 18A shows the depression in urine production observed with SubQ ~; n; stration of free vasopressin at doses of-2 ~g ~solid triangles), 25 ~g (solid circles), 50 ~g (solid squares), and 100 ~g (solid diamonds). With the higher doses, a pronounced reduction in urine production at day 1 was observed, with a reboun~ ~o control levels (open circles) by day 4.
.~ .
WO91/05~45 PCT/USgO/06034 2Q ~7 ~ 3 ~
Figure 18B shows the ef~ect of SubQ administration of the peptide in PEG liposomes. The lowest dose ~d~;n;stered, 2S ~g (closed triangles) gave a slight prolongation of activity, to about 8 days. A vasopressin dose of 100 ~g (closed circles) showed a significant reduction in urine ou~uL to about 20 days. An even longer effect, of at least 24 days, was observed at a dose of 400 ~g (closed squares).
The treatment method employing ~asopressin is designed for treatment of diabetes insipidus, by long-term ~m;n; stration of vasopressin from a SubQ site. More generally, the method is designed for extendlng to at least one wee~, the per~od of effective activity of a therapeutic compound which can be ~m~ n; stered intravenously in a therapeutically effective amount. The method utilizes liposomes (i) composed of 1~ vesicle-forming lipids and between 1-~0 mole percent of a vesicle-fo~ming lipid derivatized with a hydrophilic polymer, and (ii) having a selected mean particle diameter in the size range preferably between about 0.07-.15 microns, and having the compound in liposome-entrapped form.
The liposome composition is ~m; n; stered subcutaneously at a dose of the composition which cont2ins an amount o~ the liposome-entrapped compound which is at least ten times the therapeutically effective intravenously a~ n~ qtered amount.
For compounds, such as vasopressin~ which are active in the bloodstream in the picogram-to-nanogram/ml concentration, such as a variety of peptide and proteins, the method can be used for therapeutic delivery of the compound over a several-week period.
The ability of the liposome composition of the invention 30 tG produce a long-term therapeutic effect from a SubQ site suggests that the liposomes taken up from this site through the lymphatics may be able to successfully evade the normal ~' ,.
lymphatic clearance mechanisms, including ~upfer cells. This mechanism is supported by studies on araC administration by the interperitoneal (IP) route by PEG-liposomes. Briefly, it was found that PEG-liposomes containing entrapped araC and 5administered by IP route produced a 250-300% increase in survial in A~im~ls having L1210 leukemias, compared with about 120% increase in survival with the free drug given by the IP
route. The results suggests that PEG-liposomes are capable of migrating from the peritoneum through the lymphatics into the bloodstream.
The following examples illustrate the invention.
15Materials Cholesterol (Chol) was obtained from Sigma (St. Louis, MO). Sphingomyelin (SM), egg phosphatidylcholine (lecithin or PC), partially hydrogenated PC having the composition IV40, IV30, IV20, IV10, and IV1, phosphatidylglycerol (PG), phospha-tidylethanolamine ~PE), dipalmitoyl-phosphatidyl glycerol (DPPG), dipalmitoyl PC (DPPC), dioleyl PC (DOPC) and distear-oyl PC (DSPC) were obtained from Avanti Polar Lipids (Birming-ham, AL) or Austin Chemical Co (C~icago, I1).
[~5I]-tyraminyl-inulin was made according to published procedures. "Gallium citrate was supplied by NEN Neoscan (Boston, MA). Vasopressin and macrophage colony stimulating factor were obtained from Sigma (St. Louis,Mo), and Cetus (Emeryville,Ca), respectively.
30Example 1 Preparation of PEG-PE Linked by Cyanuric Chloride A. Preparation of activated PEG
2-0-Methoxypolyethylene glycol 1900-4,6-dichloro-1,3,5 WO91/05~5 PCT/US90/060~
206~133 .. ~ ~ ....
,; ~
triazine previously called activated PEG was prepared as described in J. Biol. Chem., 252:3582 (1977) with the fol-lowing modifications.
Cyanuric chloride (5.5 g; 0.03 mol) was dissolved in 400 ml of anhydrous benzene containing 10 g of anhydrous sodium carbonate, and PEG-1900 (19 g; 0.01 mol) was added and the mixture was stirred overnight at room temperature. The solu-tion was filtered, and 600 ml of petroleum ether (boiling range, 35-60~) was added slowly with stirring. The finely divided precipitate was collected on a filter and redissolved in 400 ml of benzene. The precipitation and filtration pro-cess was repeated several times until the petroleum ether was free of residual cyanuric chloride as determined by high pres-sure liquid chromatography on a column (250 x 3.2 mm) of 5-m "LiChrosorb" ~E. Merck), developed with hexane, and detected with an ultraviolet detector. Titration of activated PEG-l900 with silver nitrate after overnight hydrolysis in aqueous buffer at pH 10.0, room temperature, gave a value of 1.7 mol of chloride liberated/mol of PEG.
TLC analysis of the product was effected with TLC
reversed-phase plates obtained from Baker using methanol:-water, 4:1 (v/v) as developer and exposure to iodine vapor for visualization. Under these conditions, the starting methoxy polyglycol l900 appeared at R~=0.54 to 0.60. The activated PEG appeared at Rf=O . 41. Unreacted cyanuric chloride appeared at Rf=O. 88 and was removed.
The activated PEG was analyzed for nitrogen and an appropriate correction was applied in selecting the quantity of reactant to use in further synthetic steps. Thus, when the product contained only 20~ Gf the theoretical amount of nitrogen, the quantity of material used in the next synthetic step was increased by 100/20, or 5-fold. When the product contained 50% of the theoretical amount of nitrogen, only WO91/~ ~5 2 ~ 6 7 1 3 ~ PCT/USgo/~
, 100/50 or a 2-fold increase was needed.
B. Preparation of N-(4-Chloro-polyglycol 1900)-1,3,5-triazinyl egg phosphatidylethanolamine.
In a screw-capped test tube, 0.74 ml of a 100 mg/ml (0.100 mmole) stock solution of egg phosphatidylethanolamine in chloroform was evaporated to dryness under a stream of nitrogen and was added to the residue of the activated PEG
described in section A, in the amount to provide 205 mg ~0.100 mmole). To this mixture, 5 ml anhydrous dime'hyl formamide was added. 27 microliters (0.200 mmole) triethylamine was added to the mixture, and the air was displaced with nitrogen gas. The mixture was heated overnight in a sand bath maintained at 110~C.
The mixture was then evaporated to dryness under vacuum and a pasty mass of crystalline solid was obtained. This solid was dissolved in 5 ml of a mixture of 4 volumes of acetone and 1 volume of acetic acid. The resulting mixture was placed at the top of a 21 mm X 240 mm chromatographic absorption column packed with silica gel (Merck Kieselgel 60, 70-230 mesh) which had first been moistened with a solvent composed of acetone acetic acid, 80/20; v/v.
The column chromatography was developed with the same sol-vent mixture, and separate 20 to 50 ml aliquots of effluent were collected. Each portion of effluent was assayed by TLC
on silica gel coated plates, using 2-butanone/acetic acid/water; 40/25/5; v/v/v as developer and iodine vapor exposure for ~isualization. Fractions containing only material of Rf=about O.79 were combined and evaporated to 3C dryness ur,der ~acuum. Drying to constant weight under high vacuum afforded 86 mg (31.2 micromoles) of nearly colorless solid N-(4-chloro-polyglycol 1900)-1,3,5-triazinyl egg phosphatidylethanolamine containing phosphorous.
WO91/05~5 - ~ PCT/US~/~0~
2~ 133 The solid compound was taken up in 24 ml of ethanol/-I chloroform; 50/S0 chloroform and centrifuged to remove I insoluble material. Evaporation of the clarified solution to dryness under vacuum afforded 21 mg (7.62 micromoles) of colorless solid.
Example 2 Preparation of the Carbamate-Linked PEG-PE
A. Preparation of the imidazole carbamate of polyethylene glycol methyl ether 1900.
9.5 grams (5 mmoles) of polyethylene glycol methyl ether 1900 obtained from Aldrich Chemical Co. was dissolved in 45 ml benzene which has been dried over molecular sieves. 0.89 grams (5.5 mmoles) of pure carbonyl diimidazole was added. The purity was checked by an infra-red spectrum. The air in the reaction vessel was displaced with nitrogen. Vessel was enclosed and heated in a sand bath at 75~C for 16 hours.
The reaction mixture was cooled and the clear solution formed at room temperature. The solution was diluted to 50.0 ml with dry benzene and stored in the refrigerator as a 100 micromole/ml stock solution of the imidazole carbamate of PEG
ether 1900.
B. Preparation of the phosphatidylethanolamine carbamate of polyethylene glycol methyl ether 1900.
10.0 ml (lmmol) of the 100 mmol/ml stock solution of the imidazole carbamate of polyethylene glycol methyl ether 1900 (compound X) was pipetted into a 10 ml pear-shaped flask. The solvent was removed under vacuum. 3.7 ml of a 100 mg/ml solution of egg phosphatidyl ethanolamine (V~ in ohioroform (0.5 mmol) was added. The solvent was evaporated under vacuum. 2 ml of 1,1,2,2-tetrachloroethylene and 139 micro-liters (1.0 mmol) of triethylamine VI was added. The vessel WO91/~ ~5 2 0 6 71 3 3 PCT/US9O/~0~
was closed and heated in a sand bath maintained at 95~C for 6 hours. At this time, thin-layer chromatography was performed with fractions of the above mixture to determine an extent of conjugation on SiO2 coated TLC plates, using butanone/acetic acid/water; 40/5/5; v/viv; was performed as developer. I2 vapor visualization revealed that most of the free phosphati-dyl ethanolamine of Rf=0.68, had reacted, and was replaced by a phosphorous-containing lipid at Rf=O . 78 to 0.80.
The solvent from the remaining reaction mixture was evapo-rated under vacuum. The residue was taken up in 10 mlmethylene chloride and placed at the top of a 21 mm x 270 mm chromatographic absorption column packed with Merck Kieselgel 60 (70-230 mesh silica gel), which has been first rinsed with methylene chloride. The mixture was passed through the column, in sequence, using the following solvents.
Table 1 Volume % of Volume % Methanol ml Methylene Chloride With 2% Acetic Acid 100 100% 0%
200 95% 5%
200 90% 10%
200 85% 15%
200 60% 40~
50 ml portions of effluent were collected and each portion was assayed by TLC on SiO2 - coated plates, using 12 vapor absorption for visualization after development with chloro-form/methanol/water/concentrated ammonium hydroxide;130/70/8/0.5%; v/v/v/v. Most of the phosphates were found in fractions 11, 12, 13 and 14.
These fractions were combined, evapGrated ~o dryness under vacuum and dried in high vacuum to constant weight. They yielded 669 mg of colorless wax of phosphatidyl etha-nolamine carbamate of polyethylene glycol methyl ether. This WO91/05~5 ~ 71~3 PCT/USgo/~o~
represented 263 micromoles and a yield of 52.6% based on the phosphatidyl ethanolamine.
An NMR spectrum of the product dissolved in deutero--chloroform showed peaks corresponding to the spectrum for egg PE, together with a strong singlet due to the methylene groups of the ethylene oxide chain at Delta = 3.4 ppm. The ratio of methylene protons from the ethylene oxide to the terminal methyl protons of the PE acyl groups was large enough to confirm a molecular weight of about 2000 for the polyethylene oxide portion of the molecule of the desired product polyethylene glycol conjugated phosphatidyethanolamine carbamate, M.W. 2,654.
Example 3 Preparation of Ethylene-Linked PEG-PE
A. Preparation of I-trimethylsilyloxy-polyethylene glycol is illustrated in Reaction Scheme 3A.
15.0 gm (10 mmoles) of polyethylene glycol) M.Wt. 1500, (Aldrich Chemical) was dissolved in 80 ml benzene. 1.40 ml (11 mmoles) of chlorotrimethyl silane (Aldrich Chemical Co.) and 1.53 ml (lmmoles) of triethylamine was added. The mixture was stirred at room temperature under an inert atmosphere for 5 hours.
The mixture was filtered with suction to separate crystals of triethylammonium chloride and the crystals were washed with 5 ml benzene. Filtrate and benzene wash liquids were combined. This solution was evaporated to dryness under vacuum to provide 15.83 grams of colorless oil which solidi-fied on standing.
TLC of the product on Si-Cl~ reversed-ph~se plates using mixture of 4 volumes of ethanol with 1 volume of water as developer, and iodine vapor visualization, revealed that all the polyglycol 1500 (Rf=O . 93) has been consumed, and was WO91/05~5 PCT/USgO/~O~
~0 ~7 ~ 3 3 replaced by a material of R~=O.82. An infra-red spectrum revealed absorption peaks characteristic only of polyglycols.
Yield of I-trimethylsilyoxypolyethylene glycol, M.W. lS00 was nearly quantitative.
B. Preparation of trifluoromethane sulfonyl ester of ltrimethylsilyloxy-polyethylene glycol.
15.74 grams (10 mmol) of the crystalline I-trimethyl-silyloxy polyethylene glycol obtained above was dissolved in 40 ml anhydrous benzene and cooled in a bath of crushed ice.
1.53 ml (11 mmol) triethylamine and 1.85 ml (11 mmol) of trifluoromethanesulfonic anhydride obtained from Aldrich Chemical Co. were added and the mixture was stirred over-night under an inert atmosphere until the reaction mixture changed to a brown color.
The solvent was then evaporated under reduced pressure and the residual syrupy paste was diluted to 100.0 ml with methylene chloride. Because of the great reactivity of tri-fluoromethane sulfonic esters, no further purification of the trifluoromethane sul~onyl ester of I-trimethylsilyloxy poly-ethylene glycol was done.
C. Preparation of N-1-trimethylsilyloxy polyethylene glycol 1500 PE.
10 ml of the methylene chloride stock solution of the trifluoromethane sulfonyl ester of 1-trimethylsilyloxy poly-ethylene glycol was evaporated to dryness under vacuum to obtain about 1.2 grams of residue (approximately 0.7 mmoles).
To this residue, 3.72 ml o~ ~ chloro~oxm solution co~t~in;n~
372 mg (0.5 mmoles) egg PE was added. To the resulting solu-tion, 139 microliters (1.0 mmole) of triethylamir,e was added and the solvent was evaporated under vacuum. To the obtained residue, 5 ml dry dimethyl formamide and 70 microliters (0.50 mmoles) triethylamine (VI) was added. Air from the reaction 2 0 ~ 7 ~ ~ 3 vessel was displaced with nitrogen. The vessel was closed and heated in a sand bath 110~C for 22 hours. The solvent was evaporated under vacuum to obtain 1.58 grams of brownish-colored oil.
A 21 X 260 mm chromatographic absorption column filled with Kieselgel 60 silica 70-230 mesh was prepared and rinsed with a solvent composed of 40 volumes of butanone, 25 volumes acetic acid and 5 volumes of water. The crude product was disso~ved in 3 ml of the same solvent and transferred to the top of the chromatography column. T~e chromatogram was developed with the same solvent and sequential 30 ml portions of effluent were assayed each by TLC.
The TLC assay system used silica gel coated glass plates, with solvent combination butanone/acetic acid/water; 40/25/5;
v/v/v. Iodine vapor absorption served for visualization. In this solvent system, the N-l-trimethylsilyloxy polyethylene glycol 1500 PE appeared at ~=0.78. Unchanged PE appeared at Rf=0.68.
The desired N-1-trimethylsilyloxy polyethylene glycol 1500 PE was a chief constituent of the 170-300 ml portions of column effluent. When evaporated to dryness under vacuum these portions afforded 111 mg of pale yellow oil of compound.
D. Preparation of N-polyethylene glycyl 1500: phospha-tidyl-ethanolamine acetic acid deprotection.
Once-chromatographed, P~ compound was dissolve~ in 2 ~1 Q~
tetrahydrofuran. To this, 6 ml acetic acid and 2 ml water was added. The resulting solution was allowed to stand for3 days at 23~C. The solvent from the reaction mixture was evaporated under vacuum and dried to constant weight to obtain 7~ mg of pale yellow wax. TLC on Si-C18 reversed-phase plates,~
. , , WO 91/05~45 Pcr/us9o/o6o34 ~ fi7 ~ 3 ~
developed with a mixture of 4 volumes ethanol, 1 volume water, indicated that some free PE and some polyglycol-like material formed during the hydrolysis.
The residue was dissolved in 0.5 ml tetrahydrofuran and diluted with 3 ml of a solution of ethanol water; 80:20; v:v.
The mixture was applied to the top of a 10 mm X 250 mm chroma-tographic absorption column packed with octadecyl bonded phase silica gel and column was developed with ethanol water 80:20 by volume, collecting sequential 20 ml portions of effluent.
The effluent was assayed by reversed phase TLC. Fractions containing only product of Rf=0.08 to 0.15 were combined.
This was typically the 20-100 ml portion of effluent. When evaporated to dryness, under vacuum, these portions afforded 33 mg of colorless wax PEG-~ corresponding to a yield of only 3%, based on the starting phosphatidyl ethano~ ne.
NMR analysis indicated that the product incorporated both PE residues and polyethylene glycol residues, but that ~n spite of the favorable-appearing elemental analysis, the chain length of the polyglycol chain has been reduced to about three to four ethylene oxide residues. The product prepared was used for a preparation of PEG-PE liposomes.
E. Preparation of N-Polyethylene glycol 1500 P.E. by fluoride deprotectio~.
500 mg of crude N-1-trimethylsilyloxy polyethylene glycol PE was dissolved in 5 ml tetrahydrofuran and 189 mg ~0.600 r; 11 ;moles) of tetrabutyl ~mmon~um fluoride was added and agitated until dissolved. The reactants were allowed to stand over night at 20~C.
The solv~nt was evaporated under reduced pressure znd the residue was dissolved in 10 ml chloroform, washed with two successive 10 ml portions of water, and centrifuged to separate chloroform and water phases. The chloroform phase WO91/05~5 2 0 6 71 3 3 PCT/US~/~o~
was evaporated under vacuum to obtain 390 mg of orange-brown wax, which was determined to be impure N-polyethylene glycol l500 PE compound.
The wax was re-dissolved in 5 ml chloroform and trans-ferred to the top of a 21 X 270 mm column of silica gelmoistened with chloroform. The column was developed by passing l00 ml of solvent through the column. The Table 2 solvents were used in sequence:
Table 2 Volume %Volume % Methanol Containing Chloroform2% Conc. Ammonium Hydroxide/methanol 15 100% 0%
95% 5%
90% 10~
85% 15%
80% 20%
70% 30%
60~ 40%
50% 50%
o% 100%
Separated 50 ml fractions of column effluent were saved.
The fractions of the column were separated by TLC on Si-Cl8 reversed-phase plates. TLC plates were developed with 4 volumes of ethanol mixed with l volume of water. Visualiza-tion was done by exposure to iodine vapor.
Only those fractions containing an iodine-absorbing lipid of ~ about 0.20 were combined and evaporated to dryness under vacuum and dried in high vacuum to constant weight. In this way 94 mg of waxy crystalline solid was obtained of M.W. 2226.
The proton NMR spectrum of this material dissolved in deutero-chloroform showed the expected peaks due to the phosphatidyl ethanolamine portion of the molecule, together with a few methylene protons attributable to polyethylene glycol. (Delta WO91/05~5 ~ 2 0 6 7 1~ ~ PCT/USgo/~o~
-= 3.7)-Example 4 Preparation of PE-Hydrophylic Poly~ers A. Preparation of PE polylactic acid.
200 mg (0.1 mmoles) poly (lactic acid), m. wt. = 2,000 (ICN, Cleveland, Ohio) was dissolved in 2.0 ml dimethyl sulfoxide by heating while stirring to dissolve the material completely. Then the solution was cooled immediately to 65~C
and poured onto a mixture of 75 mg (0.1 mmoles) of distearylphosphatidyl-ethanolamine (Cal. Biochem, La Jolla) and 41 mg (0.2 mmoles) dicyclohexylcarbodiimide (DCCI). Then 28 ml (0.2 mmoles) of triethylamine was added, the air swept out of the tube with nitrogen gas, the tube capped, and heated at 65~C for 48 hours.
After this time, the tube was cooled to room temperature, and 6 ml of chloroform added. The chloroform solution was washed with three successive 6 ml volumes of water, centrifuged after each wash, and the phases separated with a Pasteur pipette. The r~;n'ng chloroform phase was filtered with suction to remove suspended distearolyphosphatidyl-ethanolamine. The filtrate was dried under vacuum to obtain 212 mg of semi-crystalline solid.
This solid was dissolved in 15 ml of a mixture of 4 volumes ethanol with 1 volume water and passed through a 50 mm deep and 21 mm diameter bed of H~ Dowex 50 cation exchange resin, and washed with 100 ml of the same solvent.
The filtrate was evaporated to dryness to obtain 131 mg colorless wax. 291 mg of such wax was dissolved in 2.5 ml 3Q chlorQfQrm and transferred to the top of a 1 mm x 280 ~m column of silica gel wetted with chloroform. The chromatogram was developed by passing through the column, in sequence, 100 ml each of:
WO91/05~5 ' 2 0 6 7 1 ~ 3 PCT/US~/~o~
100% chloroform, 0% (1% NH40H in methanol);
90% chloroform, 10% (1% NH40H in methanol);
85% chloroform, 15% (1~ NH40H in methanol);
80% chloroform, 20% (1% NH40H in methanolJ;
70% chloroform, 30% (1% NH40H in methanol);
Individual 25 ml portions of effluent were saved and assayed by TLC on SFO2-coated plates, using CHC13, CH30H, H20, con. NH40H, 130, 70, 8, 0.5 v/v as developer and I2 vapor absorption for visualization. The 275-325 ml portions of column effluent contained a single material, P04 +, of Rf =
0.89. nhen combined and evaporated to dryness, these afforded 319 mg colorless wax.
Phosphate analysis agrees with a molecular weight of possibly 115,000. Apparently, the polymerization of the poly (lactic acid) occurred at a rate comparable to that at which it reacted with phosphatidylethanolamine.
This side-reaction could probably be ml n' m; zed by working with more dilute solutions of the reactants.
B. Preparation of poly (glycolic acid) amide of DSPE
A mixture of 266 mg. (3.50 mmoles) glycolic acid, 745 mg (3.60 mmoles) dicyclohexyl carbodiimide, 75 mg. (0.10 mmoles) distearoyl phosphatidyl ethanolamine, 32 microliters (0.23 mmoles triethyl amine, and 5.0 ml dry dimethyl sulfoxide was heated at 75~ C, under a nitrogen atmosphere, cooled to room temperature, then diluted with an equal volume of chloroform, and then washed with three successive equal volumes of water to remove dimethyl sulfoxide. Centrifuge and separate phases with a Pasteur pipette each time.
Filter the chloroform phase with suction to remove 2 small amount of suspended material and vacuum evaporate the filtrate to dryness to obtain 572 mg. pale amber wax.
Re-dissolve this material in 2.5 ml chloroform and WO 91/~ 2 0 6 7 1 3 3 PCT/US~/060~
transfer to the top of a 21 mm X 270 mm column of silica gel (Merck Hieselgel 60) which has been wetted with chloroform.
Develop the chromatogram by passing through the column, in sequence, 100 ml each of: ~
100% chloroform, O % (1% NH40H in methanol);
90% chloroform, 10% (1% NH40H in methanol);
85% chloroform, 15% (1% NH40H in methanol);
80% chloroform, 20% (1% NH40H in methanol);
70% chloroform, 30% (1% NH40H in methanol).
Collect individual 25 ml portions of effluent and assay each by TLC on Si)2-coated plates, using CH C13, CH3 OH, H20, con-NH40H; 130, 70, 8, 0.5 v/v as developer.
Almost all the P04 ~ material will be in the 275-300 ml portion of effluent. Evaporation of this to dryness under vacuum, followed by high-vacuum drying, affords 281 mg of colorless wax.
Phosphate analysis suggests a molecular weight of 924,000.
Manipulation of solvent volume during reaction and molar ratios of glycolic acid and dicyclohexyl carbodiimide would probably result in other sized molecules.
Example 5 Preparation of REVs and MLVs A. Sized REVs A total of 15 ~moles of the selected lipid components, in the mole ratios indicated in the examples below, were dis-solved in chloroform and dried as a thin film by rotary evapo-ration. This lipid film was dissolved in 1 ml of diethyl ether washed with distilled water. To this lipid solution was add~d C.34 ml cf an aqueous buffer solution containing 5 mM
Tris, 100 mM NaCl, 0.1 mM EDTA, pH 7.4, and the mixture was emulsified by sonication for 1 minute, maintaining the tempe-rature of the solution at or below room temperature. Where WO 91/05545 ~ 2 0 6 7 1 3 ~ pcr/us9o/o6o34 the liposomes were prepared to contain encapsulated [125I]
tyraminyl-inulin, such was included in the phosphate buffer at a concentration of about 4 uCi/ml buffer.
The ether solvent was removed under reduced pressure at room temperature, and the resulting gel was taken up in 0.1 ml of the above buffer, and shaken vigorously. The resulting R~V
suspension had particle sizes, as determined by microscopic examination, of between about 0.1 to 20 microns, and was com-posed predominantly of relatively large (greater than micron) vesicles having one or only a few bilayer lamellae.
The liposomes were extruded twice through a polycarbonate filter (Szoka, 1978), having a selected pore size of 0.4 microns or 0.2 microns. Liposomes extruded through the 0.4 micron filter averaged 0.17+ (0.05) micron diameters, and through the 0.2 micron filter, 0.16 (0.05) micron diameters.
Non-encapsulated [125I] tyraminyl-inulin was removed by passing the extruded liposomes through Sephadex G-50 (Phar-macia).
B. Sized MLVs Multilamellar vesicle (MLV) liposomes were prepared according to standard procedures by dissolving a mixture of lipids in an organic solvent containing primarily CHCl3 and drying the lipids as a thin film by rotation under reduced pressure. In some cases a radioactive label for the lipid phase was added to the lipid solution before drying. The lipid film was hydrated by addition of the desired aqueous phase and 3 mm glass beads followed by agitation with a vortex and shaking above the phase transition temperature of the 3Q phospholipid component fc_ at least 1 hour. In SGme cases a radioactive label for the aqueous phase was included in the buffer. In some cases the hydrated lipid was repeatedly frozen and thawed three times to provide for ease of the WO91/05~5 PCT/US90/~34 - 20 67 ~ ~ 3 following extrusion step.
The size of the liposome samples was controlled by extru-sion through defined pore polycarbonate filters using pres-surized nitrogen gas. In one procedure, the liposomes were S extruded one time through a filter with pores of 0.4 ~m and then ten times through a filter with pores of 0.1 ~m. In another procedure, the liposomes were extruded three t~mes through a filter with 0.2 ~m pores followed ~y repeated extrusion with 0.05 ~m pores until the mean diameter of the particles was below 100 nm as determined by DLS. Unencapsu-lated aqueous components were removed by passing the extruded sample through a gel permeation column separating the lipo-somes in the void volume from the small molecules in the included volume.
lS
C. Loading 6'Ga Into DF-Contalning Liposomes The protocol for preparation of Ga6'-DF labeled liposomes is adapted from known procedures (Gabizon). Briefly, lipo-somes were prepared with the ion chelator desferal mesylate encapsulated in the internal aqueous phase to bind irre~er-sibly Ga transported through the bilayer by hydroxyquinoline (oxine).
D. Dynamic ~ight Scattering ~iposome particle size distribution measurements were obtained by DLS using a NICOMP Model 200 with a Brookhaven Instruments BI-2030AT autocorrelator attached. The instru-ments were operated according to the manufacturer's instruc-tions. The NICOMP results were expressed as the mean diameter and standard deviation of a Gaussian distri~ution of vesicles by relative volume.
Al - ' ~1 WO91/05~5 PCT/US90/~O~
~0 ~7 ~ 3 3 Example 6 ~iposome Blood Lifetime Measurementc A. Measuring Blood Circulation Time and Blood/~ES Ratios In vivo studies of liposomes were performed in two dif-ferent ~ l models: Swiss-Webster mice at 25 g each and laboratory rats at 200-300 g each. The studies in mice involved tail vein injection of liposome samples at 1 ~M
phospholipid/mouse followed by ~n; m~ 1 sacrifice after a defined time and tissue removal for label quantitation by gamma counting. The weight and percent of the injected dose in each tissue were determined. The studies in rats involved establishment of a chronic catheter in a femoral vein for removal of blood samples at defined times after injection of liposome samples via a catheter in the other femoral artery at 3-4 ~M phospholipid~rat. The percent of the injected dose remA; n; ng in the blood at several time points up to 24 hours was determined.
B. Time Course of Liposome Retention in the Bloodstream PEG-PE composed of methoxy PEG, molecular weight 1900 and 1-palmitoyl-2-oleyl-PE (POPE) was prepared as in Example 2.
The PEG-POPE lipid was com~ined with partially hydrogen-ated egg PC (PHEPC) in a lipid:lipid mole ratio of about 0.1:2, and the lipid mixture was hydrated and extruded through a 0.1 micron polycarbonate membrane, as described in ~xample 4, to produce MLV's with average size about 0.1 micron. The M~V lipids included a small amount of radiolabeled lipid marker l4C-cholesteryl oleate, and the encapsulated marker 3H-inulin.
The liposome co~position was in ~ cted and the percen~
initial injected dose in mice was deter~;~e~ as described in Example 4, at 1, 2, 3, 4 and 24 hours after injection. The time ~' WO 91/05545 2 0 6 7 1 3 3 pcr/us9o/o6o34 course of loss of radiolabeled material is seen in Figure 7 which is a plot of percent injected dose for encapsulated inulin (solid circles), inulin marker corrected to the initial injection point of 100% (open circles), and lipid marker (closed triangles), over a 24-hour period post injection. As seen, both lipid and encapsulated markers showed greater than 10~ of original injected dose after 24 hours.
C. 24 Hour Blood Liposome Levels Studies to determine percent injected dose in the blood, and blood/RES ratios of a liposomal marker, 24 hours after intravenous liposome injection, were carried out as described above. Liposome formulations having the compositions shown at the left in Table 3 below were prepared as described above.
Unless otherwise noted, the lipid-derivatized PEG was PEG-1900, and the liposome size was 0.1 micron. The percent dose remaining in the blood 24 hours after intravenous administra-tion, and 24-hour blood/RES ratios which were measured are shown in the center and right columns in the table, respectively.
Table 3 Lipid Composition* 24 Hours After IV Dose % Injected Dose in Blood B/RES
PG:PC:Chol (.75:9.25:5) 0.2 0.01 PC:Chol ~10:5) 0.8 0.03 PEG-DSPE:PC:Chol 23.0 3.0 PEG-DSPE:PC:Chol ~250 nm) g,o 0,5 PEG5000-DSPE:PC:Chol21.0 2.2 PEGlzO-DSPE:PC:Chol5,0 2.0 PEG-DSPE:PC ~0.75:9.25) 22.0 0.2 PEG-DSPE:PG:PC:Chol40.0 4 0 (0.75:2.25:7:5) PEG-DSPE:NaCholSO,:PC:Chol 25.0 2.5 ~0.75:0.75:9.25:4.25) 40 *All formulations cor~t~; n 33% cholesterol and 7.5% charged component and were 100 nm mean diameter except as noted. PEG-DSPE consisted of PEGl,oo except as noted.
WO91/05~5 ~ PCT/US90/060~
As seen, percent dose remaining in the blood 24 hours after injection ranged between 5-40% for liposomes containing PEG-derivatized lipids. By contrast, in both liposome formu-lations lacking PEG-derivatized lipids, less than 1% of lipo-some marker remained after 24 hours. Also as seen in Table 3, blood/RES ratios increased from 0.01-0.03 in control liposomes to at least 0.2, and as high as 4.0 in liposomes containing PEG-derivatized liposomes.
Example 7 Effect of Phospholipid Acyl-Chain Saturation on Blood/RES Ratios in PEG-P~ Liposomes PEG-PE composed of methoxy PEG, molecular weight 1900 and distearylPE (DSPE) was prepared as in Example 2. The PEG-PE
lipids were formulated with selected lipids from among sphin-gomyelin (SM), fully hydrogenated soy PC (PC), cholesterol (Chol), partially hydrogenated soy PC (PHSPC), and partially hydrogenated PC lipids identified as PC IV1, IV10, IV20, IV30, and IV40 in Table 4. The lipid components were mixed in the molar ratios shown at the left in Table 5, and used to form MLV's sized to 0.1 micron as described in Example 4.
Table 4 Phase Transition Egg PC Temperature Range Mole % Fatty Acid Comp.
Form ~13C. 18:0 18:1 18:2 20:0 20:1-4 22:0 22:1-6 Native <20 12 30 15 0 3 0 5 IV 30 c20-30 20 22 o 1 2 1 3 IV 20 23-45 30 lo o 2 1 2 3 IV 10 37-50 42 4 o 3 1 4 2 IV 1 49-54 56 o 0 5 0 6 0 WO 91/0554~ PCr/US90/0603~
20 ~71 3 3 '~
Table 5 Blood RES B/RES%
R~m~; n; rlg PEG-PE:SM:PC:Chol 0.2:1:1:1 19.23 6.58 2.92 49.23 PEG-PE:PHSPC:Chol 0.15:1.85:1 20.54 7.17 2.86 55.14 PEG-PE:PC IVl:Chol 0.15:1.85:1 17.24 13.71 1.26 60.44 PEG-PE:PC IVl:Chol ~two ~n; ~1 s ) 0.15:1.85:1 19.16 10.07 1.90 61.87 PEG-PE:PC IVlO:Chol (two ~n; m~ 1 S ) 0.15:1.85:1 12.19 7.31 1.67 40.73 PEG-PE:PC IVlO:Chol 0.15:1.85:1 2.4 3.5 0.69 12.85 PEG-PE:PC IV20:Chol 0.15:1.85:1 24.56 7.52 3.27 62.75 PEG-PE:PC IV20:Chol 0.15:1.85:1 5.2 5.7 0.91 22.1 ~EG-PE:PC IV40:Chol 0.15:1.85:1 19.44 8.87 2.19 53.88 PEG-PE:PC IV:Chol 0.15:1.85:0.5 20.3 8.8 2.31 45.5 PEG-PE:EPC:Chol 0.15:1.85:1 15.3 9.6 1.59 45.9 24 hours after iniection, the percent material injected (as measured by percent of 67Ga-desferal)remaining in the blood and in the liver (L) and spleen (S) were determined, and these values are shown in the two data columns at the left in Table 4. The blood and L~S (RES) values were used to calculate a F.~
~3 ~O91/05~5 PCr/US~/~
~ ~7 ~ 3 3 blood/R~S value for each composition. The column at the right in Table 4 shows total amount of radioactivity recovered. The two low total recovery values in the table indicate anomalous clearance behavior.
The results from the table demonstrate that the blood/RES
ratios are largely independent of the fluidity, or degree of saturation of the phospholipid components forming the lipo-somes. In particular, there was no systematic change in blood/RES ratio observed zmong liposomes containing largely saturated PC components (e.g., IVl and IV10 PC's), largely unsaturated PC components ~IV40), and intermediate-saturation components (e.g., IV20).
In addition, a comparison of blood/R~S ratios obtained using the relatively saturated PEG-DSPE compound and the rela-tively unsaturated PEG-POPE compound (Example 5) indicates that the degree of saturation o~ the derivatized lipid is itself not critical to the ability of the liposomes to evade uptake by the RES.
Example 8 Effect of Cholesterol and Ethoxylated Cholesterol on Blood/RES Ratios in PEG-PE Liposomes A. Effect of added cholesterol PEG-PE composed of methoxy PEG, molecular weight 1900 and was derivatized DSPE as described in Example 6. The PEG-PE
lipids were formulated with selected lipids from among sphin-gomyelin (SM), fully hydrogenated soy PC (PC), and cholesterol (Chol), as indicated in the column at the left in Table 5 below. The three formulations shown in the table contain about 30, 15, and 0 mole percent cholesterol. Both REV's (0.3 micron size) and MLV's (0.1 micron size) were prepared, sub-stantially as in Example 4, with encapsulated tritium-labeled ~ , rB
WO91/05~ PCT/US90/~0~
7~33 inulin .
The percent encapsulated inulin rem~; n' ng in the blood 2 and 24 hours after ~m; ~; stration, given at the right in Table 6 below, show no measurable effect of cholesterol, in the range 0-30 mole percent.
Table 6 ~ Injected Dose 3H-Inulin In Blood 2 HR. 24 HR. 2 HR. 24 HR.
'H Aqueous Label l4C - Lipid Label (Leakage) 1) SM:PC:Chol:PEG-DSPE
1: 1: 1: 0.2 100 nm MLV 19 5 48 24 300 nm REV 23 15 67 20 2) SM:PC:Chol:PEG-DSPE
1: 1: 0.5: 0.2 300 nm REV 23 15 71 17 3) SM:PC:PEG-DSPE
1: 1: 0.2 100 nm M~V 19 6 58 24 300 nm REV 32 23 76 43 rB B
WO91/05~5 PCT/US90/~
B. Effect of ethoxylated cholesterol Methoxy-ethyoxy-cholesterol was prepared by coupling methoxy ethanol to cholesterol ~ia the trifluorosulfonate coupling method described in Section I. PEG-PE composed of methoxy PEG, molecular weight 1900 and was derivatized DSPE as described in Example 6. The PEG-PE lipids were formulated with selected lipids from among distearylPC (DSPC), partially hydrogenated soy PC (~HSPC), cholesterol, and ethoxylated cholesterol, as indicated at the right in Table 7. The data show that (a) ethoxylated cholesterol, in combination with PEG-PE, gives about the same degree of enhancement of liposome lifetime in the blood as PEG-PE alone. By itself, the ethoxy-lated cholesterol provides a moderate degree of enhancement of liposome lifetime, but substantially less than that provided by PEG-PE.
Table 7 Formulation % Iniected Dose In Blood 'C-Chol-Oleate 2 HR. 24 HR.
HSPC:Chol:PEG-DSPE 55 9 1.85: 1: 0.15 HSPC:Chol:PEG-DSPE:PEG5-Chol57 9 1.85: 0.85: 0.15: 0.15 HSPC: Chol: HPC: PEG5-Chol 15 2 1.85: 0.85: 0.15: 0.15 HSPC: Chol: HPG 4 1.85: 1: 0.15 .
WO91/05~5 PCT/US90/~
2~ ~7 ~ ~ 3 Example 9 Effect of Charged Lipid Components on Blood/RES Ratios in PEG-PE Liposomes PEG-PE composed of methoxy PEG, molecular weight 1900 and was derivatized DSPE as described in Example 6. The PEG-~E lipids were formulated with lipids selected from among egg PG ~PG), partially hydrogenated egg PC ~PHEPC), and choleste-rol (Chol), as indicated in the Figure 6. The two formula-tions shown in the figure contained about 4.7 mole percent (triangles) or 14 mole percent (circles) PG. The 1ipids were prepared as MIV's, sized to 0.1 micron as in Example 4.
The percent of injected liposome dose present 0.25, 1, 2, 4, and 24 hours after injection are plotted for both formula-tions in Figure 6. As seen, the percent PG in the composition had little or no effect on liposome retention in the bloodstr-eam. The rate of loss of encapsulated marker seen is also similar to that observed for similarly prepared liposomes containing no PG.
Example 10 Effect of Liposome Size on Blood Lifetime P~G-DS~E, prepared as above with PEG-1900, was formulated with partially hydrogenated egg PC (PHEPC), and cholesterol (Chol), at a mole ratio of 0.15: 1.85: 1. The liposomes were sized by extrusion through 0.25, 0.15 or 0.1 micron polycarbo-nate filters, to produce liposome sizes of about 0.4, 0.2, and 0.1 microns, respectively. Non-encapsulated 3H-inulin was removed by gel filtration, Each of the three liposome were injected intra~enously, 2nd the percer.t of injected liposome marker in the ~lood -~as measured at 1, 2, 3, 4, and 24 hours, with the results shown in Figure 10. All three formulations show long blood half-lives, as evidenced by at least about 10% liposome marker ~O91/05545 PCT/US90/~034 ~ ~7 ~ ~ ~
rem~;n;ng after 24 hours. The 0.1 micron formulation (solid squares) is longer lived than the 0.2 micron formulation (solid circles) which is in turn longer lived than the 0.4 micron formulation.
Example 11 Effect of Other Hydrophilic Polymers on Blood Lifetime Polylactic acid-DSP~ or polyglycolic acid-DSPF, prepared as above, was formulated with lipids selected from among hydrogenated soy PC (HSPC), and cholesterol (Chol), at a weight ratio of either 2: 3.5: 1 or 1: 3.5: 1. The liposomes were sized by extrusion through a 0.1 micron polycarbonate filter. The liposomes were labeled by Ga-DF as described in Example 5.
These liposome formulations were injected intravenously, and the percent of injected liposome marker in the blood was measured at 1, 2, 3, 4, and 24 hours, with the results shown in Figure 11. When normalized at 15 minutes, about 3.9~ of the liposome marker was present after 24 hours with polylactic acid-DSPE (solid squares). An average value of about 6% of the liposome marker was present 24 hours after injection with polyglycolic acid-DSPE (open triangles).
Example 12 Plasma Kinetics of PEG-Coated and Uncoated Liposomes PEG-PE composed of methoxy PEG, molecular weight 1900 and distearyl PE (DSPE) was prepared as in Example 2. The PEG-PE
lipids were formulated with PH~PC, and cholesterol, in a mole ratio of 0.15:1.85:1. A second lipid mixture contained the ~ame lipids, but without ~EG- E. ~iposomes were prepared from the two lipid mixtures as described in Example 5, by lipid hydration in the presence of DF followed by sizing to 0.1 micron, removal of non-entrapped DF by gel filtration, and Ga WO91/05~5 PCT/US9O/~
~ B7 ~ ~ 3 labeling as described in Example 5. Both compositions contained 10 ~M lipid/ml in 0.15 M NaClf 0.5 mM desferal.
The two liposome compositions (0.4 ml) were in~ected IV
in ~n;m~l S~ as described in Example 6. At time 0.25, 1, 3 or 5, and 24 hours after injection, blood samples were removed and assayed for amount inulin rPm~; n; ~g in the blood, expressed as a percentage of the amount measured ; mm~ tely after injection. The results are shown in Figure 9. As seen, the PEG-coated liposomes have a blood halflife of about 11 hours, and nearly 30% of the injected material is present in the blood after 24 hours. By contrast, uncoated liposomes showed a halflife in the blood of less than 1 hour. At 24 hours, the amount of injected material was undetectable.
Example 13 Treatment with Free Vasopressin Male adult rats of the Brattleboro strain, congenitally deficient for VP (Valtin and Schroeder, 1964), were acclimated to metabolic cages for at least three days before treatment.
In most experiments, anesthesia was induced using a mixture of Nitrous oxide 2100 cc/min, oxygen 400 cc/min, and 5~ Iso-flurane (Aerrane). Anesthesia was maintained throughout sur-gery with the same gas mixture but with a reduced percentage of iso~lurane (2~). In other experiments, inhaled ethyl ether was used for the anesthetic.
A. Surgery The neck and ventral sides of both hindlimbs were shaved.
A small incision was made at the midpoint between the ears at the neck to 211OW the c~nnllla to ~e externa'ized o~lt the r.eck.
The rat was placed on its back and stabilized. An incision was made on the ventral hindlimb at the inguinal area, and fascia was tweezed apart to expose the femoral vascular B
WO91/OS~5 PCT/US~/~O~
2~ ~7 1 3 3 complex. ~urther blunt dissection isolated the ~emoral ~ein or artery. For the vein, blood flow was occluded by passing a 3-0 silk tie ~Davis-Geck, Danbury, CT) beneath the vessel distally and applying tension to the vein while clam.ping the vessel proX~m7l~y with a bulldog clamp. This allowed the vein to become distended and easier to cut. Using small scissors, the ~ein was nicked and a bevelled 6-inch section of poly-ethylene catheter tubing (PE_50 Clay-Adams) filled with normal saline (0.9%) or 5~ dextrose was inserted into the vein.
Correct placement was verified by venous drawback and flush using a 1 cc syringe. The catheter was anchored loosely to the vein by passing a small tie under the vessel and knotting it around the cannula.
B. Dose A~; n; stration Once animals had been surgically prepared, 150-1000 ~1 of test solution was a~; n; stered intravenously. The dose ~olume administered was adjusted to give the desired total amount of vasopressin, for example 0.2, 0.8, and 3~g of aqueous vaso-pressin. The venous catheter was then removed, the femoral vein was tied off, and both leg incisions were closed. The ~n;~l S were allowed to regain consciousness.
C. Urine Production Studies After a control period in which the rats showed diabetes insipidus and the urine volume was well established, the ~n;m~lS were weighed and anesthetized with inhaled anesthesia.
The femoral vein was cannulated and the dose ~m; ni stered ~y the surgical procedures described. The ~n;m~l S were main-tzined ir. met~bolic cages and the urine was collected over the course of several days after dose administration. The urine volume was determlne~ hourly immediately after dose WO9l/05545 PCT/US90/06034 2~ ~7 11 ~ 3 ~m; n; stration and thereafter at least twice each day.
Figure 12 shows the percent predosage urine flow in ~n~m~l s treated with saline (open circles) or 0.2 ~g (solid squares) 0.8 ~g (solid triangles), and 2 ~g ~solid circles) vasopressin solution. At day 1 after drug ~Am; ~ stration, urine production showed a dose-dependent drop. At day 2 and thereafter, urine production was substantially back to control levels.
Example 14 Treatment with P~G-~iposomal Vasopressin Large lln~ 1 ~mel 1 ~r liposomes were prepared according to the reverse phase evaporation procedure (Szoka and Papahad-jopoulos, 1978). The lipid composition used in preparing the liposomes was PEG-DSPE, PC, sphingomyelin, and cholesterol, in a mole ratio 0.2: 1: 1: 1. Lipid mixtures for a 1 ml final volume of liposomes with a phospholipid concentration of 10 ~mol/ml were dissolved in chloroform and evaporated to dryness under reduced pressure. After residual solvent was removed by high vacuum for 1 hour the mixture was dissolved in ethyl ether freshly washed with phosphate buffer at pH 7. Then, 0.34 ml of aqueous buffer (5 mM Tris, 100 mM NaCl, 0.1 mM
EDTA) containing sufficient arginine vasopressin to give a final drug concentration of 510 ~g/ml was added to the lipids in ether. A trace amount of 3H-labeled vasopressin was added to the vasopressin solution for determ;n~tion of protein concentrations. Then the ether was removed by controlled rotoevaporation, and additional drug-free buffer added to gi~e a 1 ml solution i mmPA; ately after gel dispersion. The vasopressin content of the resulting liposomes was determined by separatlng Lre~ drug from liposome-bound by gel filtration of Bio-Gel A15.
WO91/05~5 PCT/US90/06034 The liposomes were extruded through 0.4 ~m Nuclepore filters (Olsen et al., 1979) and particle size distribution measured by dynamic light scattering with a Nicomp model 200.
Mean diameter ranged between 0.2 ~m and 0.5 ~m and showed a low polydispersity. Unbound vasopressin was removed by dialysis and monitored by gel chromatography as above.
PEG-liposome preparations from above were administered intravenously to rats prepared as in Example 13, at liposomal doses 2 ~g (solid squares) 8 ~g (solid triangles), and 24 ~g (closed circles) vasopressin solution. Percent predosage urine flow was measured as above, with the results shown in Figure 14. The data show substantially the same dose-dependent depression in urine production in the first dayafter drug ~m; n~ stration, presumably resulting pre~o~ tly from non-entrapped vasopressin in the liposome formulations.
In contrast to free peptide administration, however, all three formulation produced a significant inhibition in urine production with respect to control (open circles) over a 2-8 day period after liposome ~m; n~ stration.
Example 15 Treatment with ~G-Liposomal Vasopressin:
Effect of Liposome Cholesterol Concentration Large unilamellar liposomes were prepared as in Example 14, with liposomes containing either 33, 16, or 0 mole percent cholesterol. Vasopressin encapsulation, liposome sizing, and free peptide removal was carried out as in Example 1~.
- The three PEG-liposome preparations were administered intravenously to rats prepared as in ~xample 13, at liposomal 30 doses giving 8 ~g vasopressin, and the percent predosage urine production was measured over a 9 day period following liposome ~; n; ~tration. The results are shown in Figure 15, for WO91/OS~5 PCTlUS90/060~
~ ~713 ~
saline control (open circles) and P~G-liposomes with O (solid squares), 16 (solid triangles), and 33 (solid circles) mole percent cholesterol.
The day-1 response shows a marked depend~nce on percent cholesterol, with the greatest effect on urine flow being produced in liposomes with the lowest mole ratio of choleste-rol. This result is consistent with in vitro stability studies of ~asopressin release from PEG-liposomes in serum:
In the presence of serum, little release of vasopressin was seen in liposomes cont~;n;ng greater than 30 mole percent cholesterol. By contrast, formulations containing reduced amounts of cholesterol showed increasingly higher release rates of encapsulated peptide. Thus, it would appear that the significantly higher diuretic effect seen after 1 day with low and no cholesterol formulations is due to the presence of free peptide released from the liposomes in serum.
Interes~ingly, all three formulations produced a marked, and substantially similar diuretic effect over a 2-8 day period following liposome drug ~m;n; stration, as was seen in the method described in Example 14.
~xample 16 Blood Clearance Kinetics of M-CSF from PEG-Liposomes A lipid film cont~ n; ng PEG-DSPE, PH~PC IV-40, cholesterol, and a-tocopherol, in a mole ratio 5:61:33:1, was hydrated with distilled water, and the resulting MLVs were sonicated for 30 minutes to form SWs. M-CS~ was concentrated and a portion of the protein was labeled with U125I-iodine.
E~ual volumes (2 ml) of the protein solution and S Ws 3G were mixed, and t~le mixture was frozen in an acetone/dry bath, and lyophilized overnight. The dried material was rehydrated in 0.8 ml of distilled water, and the resulting liposome WO91/05~5 PCT~US90/~0~
-3 ~
suspension was extruded 1 time through a 0.4 ~ polycarbonate - filter, and 3 times through a 0.2 ~ filter. The sized liposomes were diluted to 10 ml in distilled water, washed two times with high speed centrifugation, and the washed pellet was resuspended in 0.9 ~1 of sterile buffer, to a final con~entration of 40 ~mol lipid/ml and between 0.5 and 1.25 mg protein/ml.
PEG-liposome preparations from above were ~dm; ~; stered intravenously to ~nim~l S as in Example 6, and the blood levels of M-CSF were measured at 1, 2, 4, and 24 hours after injection in rats prepared as in Example i4, at liposomal doses 2 ~g (solid squares) 8 ~g (solid triangles), and 24 ~g (closed circles) vasopressin solution. Similar measurements were made for an equi~alent amount of M-CSF ~m; nistered in solution form. The plasma kinetics for the PEG-liposome formulation cont~t n; ng 30 mole percent cholesterol are shown in Figure 15. The data show rapid clearance of free protein (solid triangles) with less than 1% protein rem~;n;ng in the blood at 24 hours, compared with about 8% for liposome-associated protein ~solid circles). Percent liposomes r~m~ln;~g in the ~loodstream, as judged by percent lipid marker, was slightly greater than 10%.
A comparison of the clearance rates of the lipid and pro-tein markers indicates that about 20~ of the protein marker was released from the liposomes by 24 hours post injection.
The plasma kinetics obtained with cholesterol-free PEG-liposomes is shown in Figure 16. Percent liposomes rem~; n; ng after 24 hours was about 8.5 (solid triangles) compared with about 4.5% for liposome-associated M-CSF. The results indica-ted that about 40-50~ of the originally encapsulated protein leaked from the liposomes in the 24-hour period post injection.
WO gl/05~45 PCr/US90/06034 -2~ ~71 3 3 The radioactive counts in the liposome lipid marker and in the encapsulated protéin were normalized to 100% initial ~alues, and the percent injected dose released into the blood-stream over time was then deter~;neA from the difference be-tween the normalized protein and normalized liposome markerradioactivity levels. A plot of the calculated values of percent protein released at 1, 2, 4, and 24 hours post injec-tion is shown in Figure 17.
The plot for the cholesterol-free formulation (solid triangles~ shows a protein release peak at 2 hours, with a gradual decline in amount released in the 2-24 hour period in the no-cholesterol formulation (solid triangles). The amount of protein released from the liposomes at 24 hours was between 3-4 percent of the total ~m~ n; stered.
The plot for the formulation cont~;n;ng 30 mole percent cholesterol (solid circles) shows a gradual increase in protein release rate over 24 hours. The amount of protein released from the liposomes at 24 hours was about 3 percent of the total ~m; n; stered. Thus, both formulations showed relatively high levels of protein release (3% or greater) at 24 hours.
Example 17 Subcutaneously ~m; n ~ stered Liposomes MLVs were prepared by thin-film hydration as described in Example 5. The lipid composition of the thin film was PEG-DSPE, HEPC, and cholesterol, in a mole ratio 0.15:1.85:1. The thin film was hydrated with an aqueous buffer (5 mM Tris, 100 mM NaCl, 0.1 mM EDTA) containing arginine vasopressin at 7.5 mgs/ml. The MLVs were sized by repeated extrusion through a O.1 micron polycarbonate membrane, and free (non-encapsulated) peptide was removed by gel filtration, as in Example 15. The final concentration of PEG-liposomes in the suspension was 100 E~
WO gl/05545 ' ' PCr/US90/06034 20 ~71 3 3 ~M/ml.
Vasopressin in free form was a~m~ n~ stered subcutaneously (1 ml) to Brattleboro rats, as in Example 13. The site of subcutaneous injection was the dorsal neck region. The doses 5 ~m; n~ stered were 2 ~g (solid triangles), 25 ~g ~solid circles), 50 ~g (solid squares), and 100 ~g (solid diamonds).
The percent of predosage urine flow observed is plotted in Figure 18A.
vasopressin encapsulated in PEG-liposomes, prepared as above, was ~m;n;stered subcutaneously (1 ml) to ~nim~ls as above. The doses ~m; n; stered were 25 ~g (solid triangles), 100 ~g (solid circles), and 400 ~g (solid squares). The percent of predosage urine flow observed is plotted in Figure lBB.
Although the in~ention has been described and illustrated with respect to specific liposome formulations, liposome-entrapped compounds, and treatment methods, it will be apparent that a variety of related compositions, compounds and treatment methods without departing from the invention.
B
Claims (25)
1. A liposome composition effective to extend to at least 24 hours, the period of effective activity of a therapeutic compound which can be administered intravenously in a therapeutically effective amount and which cleared in free form in the bloodstream with a halflife of less than about 4 hours, comprising liposomes (i) composed of vesicle-forming lipids and between 1-20 mole percent of a vesicle-forming lipid derivatized with polyethyleneglycol, and (ii) having a selected mean particle diameter in the size range between about 0.1 to 0.4 µm (microns), and the compound in liposome-entrapped form, for intravenous administration at a dose of the composition which contains an amount of the liposome-entrapped compound which is at least three times such therapeutically effective amount.
2. The composition of claim 1, wherein the polyethyl-eneglycol has a molecular weight between about 1,000-5,000 daltons.
3. The composition of claim 1, wherein the polyethyl-eneglycol is derivatized to a phospholipid.
4. A liposome composition effective to extend to at least 48 hours, the period of effective activity of a therapeutic compound which can be administered intravenously in a therapeutically effective amount, which is cleared in the bloodstream with a halflife of less than about 4 hours, and whose therapeutically active blood concentration is in the picogram-nanogram/ml concentration range, comprising liposomes (i) composed of vesicle-forming lipids and between 1-20 mole percent of a vesicle-forming lipid derivatized with polyethyleneglycol, and (ii) having a selected mean particle diameter in the size range between about 0.1 to 0.4 µm (microns), and the polypeptide in liposome-entrapped form, for intravenous administration at a dose of the composition which contains an amount of the liposome-entrapped compound which is at least three times such therapeutically effective amount.
5. The composition of claim 4, wherein the polyethyleneglycol has a molecular weight between about 1,000-5,000 daltons.
6. The composition of claim 4, wherein the polypeptide is a peptide hormone which is therapeutically active at a plasma concentration in the picogram/ml range, and the liposome composition is effective to release the hormone in a therapeutically effective dose for a period of at least five days after intravenous administration of the composition.
7. The composition of claim 6, wherein the peptide hormone is vasopressin.
8. The composition of claim 1, wherein the compound is a protein selected from the group consisting of superoxide dismutase, glucocerebrosidase, asparaginase, adenosine deaminase, interferons (alpha, beta, and gamma), interluekin (1,2,3,4,5,6,7), tissue necrosis factor (TNF - alpha, beta), colony stimulating factors M-CSF (macrophage), G-CSF (granulocyte), GM-CSF (granulocyte, macrophage), TPA, prourokinase, and urokinase, HIV-1 vaccine, hepatitis B vaccine, malaria vaccine, and melanoma vaccine, erythropoietin (EPO), factor VIII, bone growth factor, fibroblast growth factor, insulin-like growth factor, nerve growth factor, platelet-derived growth factor, tumor growth factors (alpha, beta), somatomedin C (IGF-1), and a ribosome inhibitor protein.
9. The composition of claim 8, wherein the protein is macrophage colony stimulating factor.
10. A liposome composition containing liposomes (i) composed of vesicle-forming lipids and between 1-20 mole percent of a vesicle-forming lipid derivatized with a hydrophilic polymer which is polyethyleneglycol, polylactic acid or polyglycolic acid, and (ii) having a selected mean particle diameter in the size range between about 0.1 to 0.4 µm (microns), and at least about 70% in liposome-entrapped form of a therapeutic compound which can be administered intravenously in a therapeutically effective amount, and which has a halflife in the bloodstream in free form of less than about 4 hours, for use in medical treatment by administering the composition intravenously to a subject at a dose which contains an amount of the compound which is at least three times such therapeutically effective amount.
11. The composition of claim 10, wherein the hydrophilic polymer is polyethyleneglycol having a molecular weight between about 1,000-5,000 daltons.
12. The composition of claim 10, wherein the polymer is selected from the group consisting of polylactic acid and polyglycolic acid.
13. The composition of claim 10, wherein the compound is a peptide hormone which is therapeutically active at a plasma concentration in the picogram-to-nanogram/ml range, and administration is effective to release the hormone in a therapeutically effective dose for a period of at least five days.
14. The composition of claim 13, wherein the peptide hormone is vasopressin.
15. The composition of claim 10, wherein the compound is a protein selected from the group consisting of superoxide dismutase, glucocerebrosidase, asparaginase, adenosine deaminase, interferons (alpha, beta, and gamma), interleukin (1,2,3,4,5,6,7), tissue necrosis factor (TNF - alpha, beta), colony stimulating factors (M-CSF
(macrophage), G-CSF (granulocyte), GM-CSF (granulocyte, macrophage)), TPA, prourokinase, and urokinase, HIV-1 vaccine, hepatitis B vaccine, malaria vaccine, and melanoma vaccine, erythropoietin (EPO), factor VIII, bone growth factor, fibroblast growth factor, insulin-like growth factor, nerve growth factor, platelet-derived growth factor, tumor growth factors (alpha, beta), somatomedin C (IGF-1), and a ribosome inhibitor protein.
(macrophage), G-CSF (granulocyte), GM-CSF (granulocyte, macrophage)), TPA, prourokinase, and urokinase, HIV-1 vaccine, hepatitis B vaccine, malaria vaccine, and melanoma vaccine, erythropoietin (EPO), factor VIII, bone growth factor, fibroblast growth factor, insulin-like growth factor, nerve growth factor, platelet-derived growth factor, tumor growth factors (alpha, beta), somatomedin C (IGF-1), and a ribosome inhibitor protein.
16. The composition of claim 15, wherein the protein is macrophage colony stimulating factor.
17. A liposome composition effective to extend to at least one week, the period of effective activity of a therapeutic compound which can be administered in a therapeutically effective amount, comprising liposomes (i) composed of vesicle-forming lipids and between 1-20 mole percent of a vesicle-forming lipid derivatized with polyethyleneglycol, and (ii) having a selected mean particle diameter in the size range between about 0.07-0.15 µm (microns), the compound in liposome-entrapped form, for subcutaneous administration at a dose of the composition which contains an amount of the liposome-entrapped compound which is at least ten times such therapeutically effective intravenously administered amount.
18. The composition of claim 17, wherein the compound is a polypeptide selected from the group consisting of superoxide dismutase, glucocerebrosidase, asparaginase, adenosine deaminase, interferons (alpha, beta, and gamma), interleukin (1,2,3,4,5,6,7), tissue necrosis factor (TNF - alpha, beta), colony stimulating factors (M-CSF
(macrophage), G-CSF (granulocyte), GM-CSF (granulocyte, macrophage)), TPA, prourokinase, and urokinase, HIV-1 vaccine, hepatitis B vaccine, malaria vaccine, and melanoma vaccine, erythropoietin (EPO), factor VIII, bone growth factor, fibroblast growth factor, insulin-like growth factor, nerve growth factor, platelet-derived growth factor, tumor growth factors (alpha, beta), somatomedin C (IGF-1), and a ribosome inhibitor protein.
(macrophage), G-CSF (granulocyte), GM-CSF (granulocyte, macrophage)), TPA, prourokinase, and urokinase, HIV-1 vaccine, hepatitis B vaccine, malaria vaccine, and melanoma vaccine, erythropoietin (EPO), factor VIII, bone growth factor, fibroblast growth factor, insulin-like growth factor, nerve growth factor, platelet-derived growth factor, tumor growth factors (alpha, beta), somatomedin C (IGF-1), and a ribosome inhibitor protein.
19. The composition of claim 18, wherein the polypeptide is vasopressin.
20. A liposome composition containing liposomes (i) composed of vesicle-forming lipids and between 1-20 mole percent of a vesicle-forming lipid derivatized with a hydrophilic polymer which is polyethyleneglycol, polylactic acid or polyglycolic acid, and (ii) having a selected mean particle diameter in the size range between about 0.07 to 0.15 µm (microns), and at least about 70% in liposome-entrapped form of a therapeutic compound which can be administered intravenously in a therapeutically effective amount, for use in medical treatment by administering the composition subcutaneously to a subject at a dose which contains an amount of the compound which is at least ten times such therapeutically effective amount.
21. The composition of claim 20, wherein the compound is a peptide hormone selected from the group consisting of superoxide dismutase, glucocerebrosidase, asparaginase, adenosine deaminase, interferons (alpha, beta, and gamma), interleukin (1,2,3,4,5,6,7), tissue necrosis factor (TNF - alpha, beta), colony stimulating factors (M-CSF
(macrophage), G-CSF (granulocyte), GM-CSF (granulocyte, macrophage)), TPA, prourokinase, and urokinase, HIV-1 vaccine, hepatitis B vaccine, malaria vaccine, and melanoma vaccine, erythropoietin (EPO), factor VIII, bone growth factor, fibroblast growth factor, insulin-like growth factor, nerve growth factor, platelet-derived growth factor, tumor growth factors (alpha, beta), somatomedin C (IGF-1), and a ribosome inhibitor protein.
(macrophage), G-CSF (granulocyte), GM-CSF (granulocyte, macrophage)), TPA, prourokinase, and urokinase, HIV-1 vaccine, hepatitis B vaccine, malaria vaccine, and melanoma vaccine, erythropoietin (EPO), factor VIII, bone growth factor, fibroblast growth factor, insulin-like growth factor, nerve growth factor, platelet-derived growth factor, tumor growth factors (alpha, beta), somatomedin C (IGF-1), and a ribosome inhibitor protein.
22. The composition of claim 21, wherein the polypeptide is vasopressin.
23. A liposome composition composed of vesicle-forming lipids and between 1-20 mole percent of a vesicle-forming lipid derivatized with a hydrophilic polymer selected from the group consisting of polylactic acid and polyglycolic acid.
24. A lipid composition composed of a diacyl-chain lipid having a polar head group, and a polylactic acid moiety derivatized to said head group.
25. A lipid composition composed of a diacyl-chain lipid having a polar head group, and a polyglycolic acid moiety derivatized to said head group.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/425,224 US5013556A (en) | 1989-10-20 | 1989-10-20 | Liposomes with enhanced circulation time |
US425,224 | 1989-10-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2067133A1 CA2067133A1 (en) | 1991-04-21 |
CA2067133C true CA2067133C (en) | 1998-07-21 |
Family
ID=23685679
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002067133A Expired - Lifetime CA2067133C (en) | 1989-10-20 | 1990-10-19 | Liposome microreservoir composition and method |
CA002067178A Expired - Lifetime CA2067178C (en) | 1989-10-20 | 1990-10-19 | Solid tumor treatment method and composition |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002067178A Expired - Lifetime CA2067178C (en) | 1989-10-20 | 1990-10-19 | Solid tumor treatment method and composition |
Country Status (18)
Country | Link |
---|---|
US (2) | US5013556A (en) |
EP (2) | EP0496835B1 (en) |
JP (4) | JP2667051B2 (en) |
KR (2) | KR920703013A (en) |
AT (2) | ATE122229T1 (en) |
AU (2) | AU642679B2 (en) |
CA (2) | CA2067133C (en) |
DE (3) | DE69019366T2 (en) |
DK (1) | DK0496835T3 (en) |
ES (1) | ES2071976T3 (en) |
FI (2) | FI105151B (en) |
GR (1) | GR3017060T3 (en) |
HK (1) | HK14097A (en) |
IL (2) | IL96069A (en) |
LU (1) | LU88854I2 (en) |
NL (1) | NL960031I2 (en) |
NO (3) | NO921213L (en) |
WO (2) | WO1991005545A1 (en) |
Families Citing this family (1597)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5882330A (en) * | 1984-05-25 | 1999-03-16 | Lemelson; Jerome H. | Drugs and methods for treating diseases |
US5456663A (en) * | 1984-05-25 | 1995-10-10 | Lemelson; Jerome H. | Drugs and methods for treating diseases |
US5925375A (en) * | 1987-05-22 | 1999-07-20 | The Liposome Company, Inc. | Therapeutic use of multilamellar liposomal prostaglandin formulations |
JPH0720857B2 (en) * | 1988-08-11 | 1995-03-08 | テルモ株式会社 | Liposome and its manufacturing method |
US6132763A (en) * | 1988-10-20 | 2000-10-17 | Polymasc Pharmaceuticals Plc | Liposomes |
GB8824593D0 (en) * | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Liposomes |
US5153000A (en) * | 1988-11-22 | 1992-10-06 | Kao Corporation | Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome |
US5843473A (en) * | 1989-10-20 | 1998-12-01 | Sequus Pharmaceuticals, Inc. | Method of treatment of infected tissues |
US5356633A (en) * | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
US20010051183A1 (en) * | 1989-10-20 | 2001-12-13 | Alza Corporation | Liposomes with enhanced circulation time and method of treatment |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5620689A (en) * | 1989-10-20 | 1997-04-15 | Sequus Pharmaceuuticals, Inc. | Liposomes for treatment of B-cell and T-cell disorders |
US5527528A (en) * | 1989-10-20 | 1996-06-18 | Sequus Pharmaceuticals, Inc. | Solid-tumor treatment method |
US6088613A (en) | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
US6146657A (en) | 1989-12-22 | 2000-11-14 | Imarx Pharmaceutical Corp. | Gas-filled lipid spheres for use in diagnostic and therapeutic applications |
US5469854A (en) * | 1989-12-22 | 1995-11-28 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
US5656211A (en) * | 1989-12-22 | 1997-08-12 | Imarx Pharmaceutical Corp. | Apparatus and method for making gas-filled vesicles of optimal size |
US5585112A (en) * | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
US5705187A (en) * | 1989-12-22 | 1998-01-06 | Imarx Pharmaceutical Corp. | Compositions of lipids and stabilizing materials |
US5305757A (en) * | 1989-12-22 | 1994-04-26 | Unger Evan C | Gas filled liposomes and their use as ultrasonic contrast agents |
US5773024A (en) * | 1989-12-22 | 1998-06-30 | Imarx Pharmaceutical Corp. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
US6551576B1 (en) | 1989-12-22 | 2003-04-22 | Bristol-Myers Squibb Medical Imaging, Inc. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
US5922304A (en) * | 1989-12-22 | 1999-07-13 | Imarx Pharmaceutical Corp. | Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents |
US5441746A (en) * | 1989-12-22 | 1995-08-15 | Molecular Bioquest, Inc. | Electromagnetic wave absorbing, surface modified magnetic particles for use in medical applications, and their method of production |
US5580575A (en) * | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US5733572A (en) * | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US5776429A (en) * | 1989-12-22 | 1998-07-07 | Imarx Pharmaceutical Corp. | Method of preparing gas-filled microspheres using a lyophilized lipids |
US6001335A (en) * | 1989-12-22 | 1999-12-14 | Imarx Pharmaceutical Corp. | Contrasting agents for ultrasonic imaging and methods for preparing the same |
US5352435A (en) * | 1989-12-22 | 1994-10-04 | Unger Evan C | Ionophore containing liposomes for ultrasound imaging |
US5882678A (en) * | 1990-01-12 | 1999-03-16 | The Liposome Co, Inc. | Interdigitation-fusion liposomes containing arachidonic acid metabolites |
US5162361A (en) * | 1990-04-10 | 1992-11-10 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Method of treating diseases associated with elevated levels of interleukin 1 |
US20060084797A1 (en) * | 1990-06-11 | 2006-04-20 | Gilead Sciences, Inc. | High affinity TGFbeta nucleic acid ligands and inhibitors |
US6465188B1 (en) * | 1990-06-11 | 2002-10-15 | Gilead Sciences, Inc. | Nucleic acid ligand complexes |
US20030113369A1 (en) * | 1991-01-16 | 2003-06-19 | Martin Francis J. | Liposomes with enhanced circulation time and method of treatment |
US5205290A (en) | 1991-04-05 | 1993-04-27 | Unger Evan C | Low density microspheres and their use as contrast agents for computed tomography |
US5874062A (en) * | 1991-04-05 | 1999-02-23 | Imarx Pharmaceutical Corp. | Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents |
JP3220180B2 (en) * | 1991-05-23 | 2001-10-22 | 三菱化学株式会社 | Drug-containing protein-bound liposomes |
GB9111611D0 (en) * | 1991-05-30 | 1991-07-24 | Sandoz Ltd | Liposomes |
DE69333434T2 (en) | 1992-04-03 | 2005-03-03 | The Regents Of The University Of California, Oakland | SELF-ORGANIZING SYSTEM FOR THE ADMINISTRATION OF POLYNUCLEOTIDES CONTAINING AN AMPHIPHATIC PEPTIDE |
ZA933926B (en) * | 1992-06-17 | 1994-01-03 | Amgen Inc | Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules |
ATE179185T1 (en) * | 1992-08-05 | 1999-05-15 | Meito Sangyo Kk | SMALL DIAMETER COMPOSITE MATERIAL CONTAINING A WATER SOLUBLE CARBOXYLPOLYSACCHARIDE AND MAGNETIC IRON OXIDE |
NL9201722A (en) * | 1992-10-05 | 1994-05-02 | Stichting Tech Wetenschapp | Pharmaceutical composition for the site-bound release of a clot dissolving protein and method for its preparation. |
DE4236237A1 (en) * | 1992-10-27 | 1994-04-28 | Behringwerke Ag | Prodrugs, their preparation and use as medicines |
US6764693B1 (en) * | 1992-12-11 | 2004-07-20 | Amaox, Ltd. | Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants |
JP3351476B2 (en) * | 1993-01-22 | 2002-11-25 | 三菱化学株式会社 | Phospholipid derivatives and liposomes containing the same |
US5395619A (en) * | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
US6326353B1 (en) * | 1993-03-23 | 2001-12-04 | Sequus Pharmaceuticals, Inc. | Enhanced circulation effector composition and method |
US6180134B1 (en) * | 1993-03-23 | 2001-01-30 | Sequus Pharmaceuticals, Inc. | Enhanced ciruclation effector composition and method |
AU6368394A (en) * | 1993-03-23 | 1994-10-11 | Liposome Technology, Inc. | Polymer-polypeptide composition and method |
AU6785094A (en) * | 1993-05-07 | 1994-12-12 | Sequus Pharmaceuticals, Inc. | Subcutaneous liposome delivery method |
US20050181976A1 (en) * | 1993-05-10 | 2005-08-18 | Ekwuribe Nnochiri N. | Amphiphilic oligomers |
US5681811A (en) * | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
US6191105B1 (en) | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
ATE210966T1 (en) * | 1993-05-21 | 2002-01-15 | Liposome Co Inc | REDUCING PHYSIOLOGICAL COUNTERREACTIONS INDUCED BY LIPOSOMES |
US5514670A (en) * | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
US5744155A (en) * | 1993-08-13 | 1998-04-28 | Friedman; Doron | Bioadhesive emulsion preparations for enhanced drug delivery |
DE69424680T2 (en) * | 1993-10-25 | 2000-09-28 | Liposome Co Inc | LIPOSOMAL DEFENSINE |
US5415869A (en) * | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
US5468499A (en) * | 1993-11-15 | 1995-11-21 | Ohio State University | Liposomes containing the salt of phosphoramide mustard and related compounds |
US7083572B2 (en) * | 1993-11-30 | 2006-08-01 | Bristol-Myers Squibb Medical Imaging, Inc. | Therapeutic delivery systems |
EP0741580A4 (en) * | 1993-12-14 | 2001-07-11 | Univ Johns Hopkins Med | Controlled release of pharmaceutically active substances for immunotherapy |
US6773719B2 (en) | 1994-03-04 | 2004-08-10 | Esperion Luv Development, Inc. | Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias |
US6312719B1 (en) * | 1994-03-04 | 2001-11-06 | The University Of British Columbia | Liposome compositions and methods for the treatment of atherosclerosis |
US20010055581A1 (en) * | 1994-03-18 | 2001-12-27 | Lawrence Tamarkin | Composition and method for delivery of biologically-active factors |
US5736121A (en) * | 1994-05-23 | 1998-04-07 | Imarx Pharmaceutical Corp. | Stabilized homogenous suspensions as computed tomography contrast agents |
DE4423131A1 (en) * | 1994-07-01 | 1996-01-04 | Bayer Ag | New hIL-4 mutant proteins as antagonists or partial agonists of human interleukin 4 |
US5626862A (en) | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
US5512294A (en) * | 1994-08-05 | 1996-04-30 | Li; King C. | Targeted polymerized liposome contrast agents |
US6132764A (en) * | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US6048837A (en) * | 1994-08-17 | 2000-04-11 | The Rockefeller University | OB polypeptides as modulators of body weight |
US6124439A (en) * | 1994-08-17 | 2000-09-26 | The Rockefeller University | OB polypeptide antibodies and method of making |
US6124448A (en) * | 1994-08-17 | 2000-09-26 | The Rockfeller University | Nucleic acid primers and probes for the mammalian OB gene |
US6471956B1 (en) | 1994-08-17 | 2002-10-29 | The Rockefeller University | Ob polypeptides, modified forms and compositions thereto |
US6001968A (en) | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
US6350730B1 (en) | 1994-08-17 | 2002-02-26 | The Rockefeller University | OB polypeptides and modified forms as modulators of body weight |
US5820873A (en) * | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
US5785992A (en) * | 1994-09-30 | 1998-07-28 | Inex Pharmaceuticals Corp. | Compositions for the introduction of polyanionic materials into cells |
US5885613A (en) * | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
CN1080575C (en) * | 1994-10-14 | 2002-03-13 | 蛋白质传送股份有限公司 | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
JPH10507450A (en) * | 1994-10-14 | 1998-07-21 | ザ リポソーム カンパニー、インコーポレーテッド | Ether lipid liposomes and their therapeutic use |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US6743779B1 (en) | 1994-11-29 | 2004-06-01 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
US5827531A (en) * | 1994-12-02 | 1998-10-27 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Microcapsules and methods for making |
US5795587A (en) * | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US6008202A (en) * | 1995-01-23 | 1999-12-28 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US5830430A (en) * | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
IL112834A (en) * | 1995-03-01 | 2000-12-06 | Yeda Res & Dev | Pharmaceutical compositions for controlled release of soluble receptors |
US5658588A (en) * | 1995-03-31 | 1997-08-19 | University Of Cincinnati | Fibrinogen-coated liposomes |
GB9509016D0 (en) * | 1995-05-03 | 1995-06-21 | Royal Free Hosp School Med | Tissue entrapment |
US8071737B2 (en) * | 1995-05-04 | 2011-12-06 | Glead Sciences, Inc. | Nucleic acid ligand complexes |
US6420549B1 (en) | 1995-06-06 | 2002-07-16 | Isis Pharmaceuticals, Inc. | Oligonucleotide analogs having modified dimers |
US5997898A (en) * | 1995-06-06 | 1999-12-07 | Imarx Pharmaceutical Corp. | Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery |
US6673364B1 (en) | 1995-06-07 | 2004-01-06 | The University Of British Columbia | Liposome having an exchangeable component |
US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
AU723163B2 (en) * | 1995-06-07 | 2000-08-17 | Tekmira Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US5981501A (en) * | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
US6231834B1 (en) | 1995-06-07 | 2001-05-15 | Imarx Pharmaceutical Corp. | Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same |
US6033645A (en) * | 1996-06-19 | 2000-03-07 | Unger; Evan C. | Methods for diagnostic imaging by regulating the administration rate of a contrast agent |
US6521211B1 (en) | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
US6139819A (en) | 1995-06-07 | 2000-10-31 | Imarx Pharmaceutical Corp. | Targeted contrast agents for diagnostic and therapeutic use |
AU705644B2 (en) * | 1995-08-01 | 1999-05-27 | Novartis Ag | Liposomal oligonucleotide compositions |
US6051600A (en) * | 1995-09-12 | 2000-04-18 | Mayhew; Eric | Liposomal hydrolysis-promoting hydrophobic taxane derivatives |
US6107332A (en) | 1995-09-12 | 2000-08-22 | The Liposome Company, Inc. | Hydrolysis-promoting hydrophobic taxane derivatives |
US5834025A (en) | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
US5858397A (en) * | 1995-10-11 | 1999-01-12 | University Of British Columbia | Liposomal formulations of mitoxantrone |
JP2002515856A (en) * | 1995-10-11 | 2002-05-28 | タラリア セラピューティックス インコーポレーテッド | Liposome compositions and methods of using them |
US20030040467A1 (en) * | 1998-06-15 | 2003-02-27 | Mary Ann Pelleymounter | Ig/ob fusions and uses thereof. |
US6936439B2 (en) * | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
US5626654A (en) | 1995-12-05 | 1997-05-06 | Xerox Corporation | Ink compositions containing liposomes |
US5817856A (en) * | 1995-12-11 | 1998-10-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiation-protective phospholipid and method |
US20040014709A1 (en) * | 1996-01-08 | 2004-01-22 | Canji, Inc. | Methods and compositions for interferon therapy |
US6392069B2 (en) | 1996-01-08 | 2002-05-21 | Canji, Inc. | Compositions for enhancing delivery of nucleic acids to cells |
WO1997025425A1 (en) | 1996-01-08 | 1997-07-17 | Genentech, Inc. | Wsx receptor and ligands |
US7002027B1 (en) | 1996-01-08 | 2006-02-21 | Canji, Inc. | Compositions and methods for therapeutic use |
US5789244A (en) * | 1996-01-08 | 1998-08-04 | Canji, Inc. | Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems |
US6096336A (en) * | 1996-01-30 | 2000-08-01 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
US5908624A (en) * | 1996-06-27 | 1999-06-01 | Albany Medical College | Antigenic modulation of cells |
US6667053B1 (en) | 1996-02-16 | 2003-12-23 | Elan Pharmaceuticals, Inc. | D and L etherlipid stereoisomers and liposomes |
US5942246A (en) * | 1996-02-16 | 1999-08-24 | The Liposome Company, Inc. | Etherlipid containing multiple lipid liposomes |
US5965159A (en) * | 1996-02-16 | 1999-10-12 | The Liposome Company, Inc. | Etherlipid-containing multiple lipid liposomes |
USRE39042E1 (en) * | 1996-02-16 | 2006-03-28 | The Liposome Company, Inc. | Etherlipid-containing multiple lipid liposomes |
US6007839A (en) * | 1996-02-16 | 1999-12-28 | The Liposome Company, Inc. | Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes |
EP0914094A4 (en) | 1996-03-28 | 2000-03-01 | Univ Illinois | Materials and methods for making improved liposome compositions |
WO1997040679A1 (en) | 1996-05-01 | 1997-11-06 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US20070275921A1 (en) * | 1996-06-06 | 2007-11-29 | Isis Pharmaceuticals, Inc. | Oligomeric Compounds That Facilitate Risc Loading |
US20050042647A1 (en) * | 1996-06-06 | 2005-02-24 | Baker Brenda F. | Phosphorous-linked oligomeric compounds and their use in gene modulation |
US5919480A (en) | 1996-06-24 | 1999-07-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposomal influenza vaccine composition and method |
US8007784B1 (en) | 1996-06-27 | 2011-08-30 | Albany Medical College | Antigenic modulation of cells |
US7368129B1 (en) | 1996-08-14 | 2008-05-06 | Nutrimed Biotech | Amphiphilic materials and liposome formulations thereof |
US6284267B1 (en) | 1996-08-14 | 2001-09-04 | Nutrimed Biotech | Amphiphilic materials and liposome formulations thereof |
US6159462A (en) * | 1996-08-16 | 2000-12-12 | Genentech, Inc. | Uses of Wnt polypeptides |
US5851984A (en) * | 1996-08-16 | 1998-12-22 | Genentech, Inc. | Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides |
WO1998007409A1 (en) * | 1996-08-23 | 1998-02-26 | Sequus Pharmaceuticals, Inc. | Liposomes containing a cisplatin compound |
CA2264140A1 (en) | 1996-08-26 | 1998-03-05 | Transgene S.A. | Cationic lipid-nucleic acid complexes |
US6414139B1 (en) | 1996-09-03 | 2002-07-02 | Imarx Therapeutics, Inc. | Silicon amphiphilic compounds and the use thereof |
CA2263568C (en) * | 1996-09-11 | 2008-12-02 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a contrast agent and a renal vasodilator |
US5846517A (en) * | 1996-09-11 | 1998-12-08 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a renal contrast agent and a vasodilator |
EP0932390A1 (en) * | 1996-10-11 | 1999-08-04 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method |
US6056973A (en) * | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
TW520297B (en) * | 1996-10-11 | 2003-02-11 | Sequus Pharm Inc | Fusogenic liposome composition and method |
US6224903B1 (en) | 1996-10-11 | 2001-05-01 | Sequus Pharmaceuticals, Inc. | Polymer-lipid conjugate for fusion of target membranes |
US6339069B1 (en) * | 1996-10-15 | 2002-01-15 | Elan Pharmaceuticalstechnologies, Inc. | Peptide-lipid conjugates, liposomes and lipsomal drug delivery |
HUP0000150A3 (en) * | 1996-10-15 | 2002-07-29 | Liposome Company Inc Princeton | Peptide-lipid conjugates,liposomes and liposomal drug delivery |
CA2270120A1 (en) * | 1996-10-28 | 1998-05-07 | Pal Rongved | Improvements in or relating to diagnostic/therapeutic agents |
US6261537B1 (en) | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
US6331289B1 (en) | 1996-10-28 | 2001-12-18 | Nycomed Imaging As | Targeted diagnostic/therapeutic agents having more than one different vectors |
US20070036722A1 (en) * | 1996-10-28 | 2007-02-15 | Pal Rongved | Separation processes |
US5827533A (en) * | 1997-02-06 | 1998-10-27 | Duke University | Liposomes containing active agents aggregated with lipid surfactants |
WO1998035828A1 (en) * | 1997-02-14 | 1998-08-20 | The Regents Of The University Of California | Lamellar gels and methods for making and regulating |
US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
US6143276A (en) * | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
US6537246B1 (en) | 1997-06-18 | 2003-03-25 | Imarx Therapeutics, Inc. | Oxygen delivery agents and uses for the same |
US6090800A (en) | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
NZ500649A (en) | 1997-04-03 | 2001-05-25 | Guilford Pharm Inc | Biodegradable terephthalate polyester-poly(phosphate) polymers, compositions, articles, and methods for making a biosorbable suture, an orthopedic appliance or bone cement for repairing injuries to bone or connective tissue |
WO1998045331A2 (en) | 1997-04-07 | 1998-10-15 | Genentech, Inc. | Anti-vegf antibodies |
IL132239A0 (en) | 1997-04-07 | 2001-03-19 | Genentech Inc | Humanized antibodies and methods for forming humanized antibodies |
AU7104598A (en) * | 1997-04-09 | 1998-10-30 | Philipp Lang | New technique to monitor drug delivery noninvasively (in vivo) |
US20020039594A1 (en) * | 1997-05-13 | 2002-04-04 | Evan C. Unger | Solid porous matrices and methods of making and using the same |
US6416740B1 (en) | 1997-05-13 | 2002-07-09 | Bristol-Myers Squibb Medical Imaging, Inc. | Acoustically active drug delivery systems |
US6287591B1 (en) * | 1997-05-14 | 2001-09-11 | Inex Pharmaceuticals Corp. | Charged therapeutic agents encapsulated in lipid particles containing four lipid components |
DE19724796A1 (en) * | 1997-06-06 | 1998-12-10 | Max Delbrueck Centrum | Antitumor therapy agents |
US6663899B2 (en) * | 1997-06-13 | 2003-12-16 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
US6113947A (en) * | 1997-06-13 | 2000-09-05 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
US6217886B1 (en) | 1997-07-14 | 2001-04-17 | The Board Of Trustees Of The University Of Illinois | Materials and methods for making improved micelle compositions |
US6548047B1 (en) | 1997-09-15 | 2003-04-15 | Bristol-Myers Squibb Medical Imaging, Inc. | Thermal preactivation of gaseous precursor filled compositions |
NZ503513A (en) * | 1997-09-18 | 2004-12-24 | Skyepharma Inc | Sustained-release liposomal anesthetic compositions |
US6734171B1 (en) | 1997-10-10 | 2004-05-11 | Inex Pharmaceuticals Corp. | Methods for encapsulating nucleic acids in lipid bilayers |
US6083923A (en) * | 1997-10-31 | 2000-07-04 | Isis Pharmaceuticals Inc. | Liposomal oligonucleotide compositions for modulating RAS gene expression |
US7229841B2 (en) | 2001-04-30 | 2007-06-12 | Cytimmune Sciences, Inc. | Colloidal metal compositions and methods |
US20020039596A1 (en) | 1997-11-14 | 2002-04-04 | Hartoun Hartounian | Production of multivesicular liposomes |
US7192589B2 (en) | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
ATE364049T1 (en) | 1997-11-21 | 2007-06-15 | Genentech Inc | ANTIGENS RELATED TO A33 AND THEIR PHARMACEUTICAL USES |
CA2312778A1 (en) * | 1997-12-04 | 1999-06-10 | Hadasit Medical Research Services And Development Ltd. | Combined chemo-immunotherapy with liposomal drugs and cytokines |
US6787132B1 (en) * | 1997-12-04 | 2004-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combined chemo-immunotherapy with liposomal drugs and cytokines |
EP1947119A3 (en) | 1997-12-12 | 2012-12-19 | Genentech, Inc. | Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent |
US6123923A (en) | 1997-12-18 | 2000-09-26 | Imarx Pharmaceutical Corp. | Optoacoustic contrast agents and methods for their use |
US20010003580A1 (en) | 1998-01-14 | 2001-06-14 | Poh K. Hui | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
CA2318857C (en) | 1998-02-04 | 2013-09-24 | Genentech, Inc. | Use of heregulin as an epithelial cell growth factor |
NZ506051A (en) * | 1998-02-09 | 2003-08-29 | Bracco Res S | Targeted delivery of biologically active media |
US6942859B2 (en) | 1998-03-13 | 2005-09-13 | University Of Southern California | Red blood cells covalently bound with polymers |
US6312685B1 (en) | 1998-03-13 | 2001-11-06 | Timothy C. Fisher | Red blood cells covalently bound with two different polyethylene glycol derivatives |
DK1064382T3 (en) | 1998-03-17 | 2008-12-08 | Genentech Inc | Homologous polypeptides for VEGF and BMP1 |
CA2324347A1 (en) * | 1998-03-25 | 1999-09-30 | Nahid Waleh | Benzoates derivatives for inhibiting angiogenesis |
US6433012B1 (en) * | 1998-03-25 | 2002-08-13 | Large Scale Biology Corp. | Method for inhibiting inflammatory disease |
US6858706B2 (en) * | 1998-04-07 | 2005-02-22 | St. Jude Children's Research Hospital | Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof |
JP4545928B2 (en) * | 1998-04-27 | 2010-09-15 | ジリップ・ファーマ・ビー.ブイ. | Pharmaceutical composition containing factor VIII and neutral liposomes |
US6986902B1 (en) * | 1998-04-28 | 2006-01-17 | Inex Pharmaceuticals Corporation | Polyanionic polymers which enhance fusogenicity |
US6331407B1 (en) | 1998-05-06 | 2001-12-18 | St. Jude Children's Research Hospital | Antibiotics and methods of using the same |
US6448224B1 (en) | 1998-05-06 | 2002-09-10 | St. Jude Children's Research Hospital | Antibiotics and methods of using the same |
US6169078B1 (en) * | 1998-05-12 | 2001-01-02 | University Of Florida | Materials and methods for the intracellular delivery of substances |
CA2328496C (en) | 1998-05-15 | 2016-01-05 | Genentech, Inc. | Il-17 homologous polypeptides and therapeutic uses thereof |
EP1865061A3 (en) | 1998-05-15 | 2007-12-19 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
EP3112468A1 (en) | 1998-05-15 | 2017-01-04 | Genentech, Inc. | Il-17 homologous polypeptides and therapeutic uses thereof |
DE69941453D1 (en) | 1998-06-12 | 2009-11-05 | Genentech Inc | MONOCLONAL ANTIBODIES, CROSS-REACTIVE ANTIBODIES AND THEIR PRODUCTION PROCESS |
US6726925B1 (en) * | 1998-06-18 | 2004-04-27 | Duke University | Temperature-sensitive liposomal formulation |
US6200598B1 (en) * | 1998-06-18 | 2001-03-13 | Duke University | Temperature-sensitive liposomal formulation |
US20040229363A1 (en) * | 1998-06-24 | 2004-11-18 | Ed Nolan | High efficiency transfection based on low electric field strength, long pulse length |
US20040247662A1 (en) * | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
US20030022854A1 (en) * | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
DE69940735D1 (en) | 1998-07-17 | 2009-05-28 | Pacira Pharmaceuticals Inc | BIODEGRADABLE ARRANGEMENTS FOR THE CONTROLLED RELEASE OF INCLUDED SUBSTANCES |
US20020172678A1 (en) | 2000-06-23 | 2002-11-21 | Napoleone Ferrara | EG-VEGF nucleic acids and polypeptides and methods of use |
US6703381B1 (en) * | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
KR100679906B1 (en) * | 1998-09-16 | 2007-02-07 | 알자 코포레이션 | Liposome-entrapped topoisomerase inhibitors |
US6077709A (en) | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
US6419709B1 (en) | 1998-10-02 | 2002-07-16 | Guilford Pharmaceuticals, Inc. | Biodegradable terephthalate polyester-poly(Phosphite) compositions, articles, and methods of using the same |
US6153212A (en) | 1998-10-02 | 2000-11-28 | Guilford Pharmaceuticals Inc. | Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
KR100719202B1 (en) | 1998-10-23 | 2007-05-16 | 키린-암젠 인코포레이티드 | A COMPOUND BINDING TO MPl RECEPTOR AND A PHARMACEUTICAL COMPOSITION THEREOF |
SI1135498T1 (en) | 1998-11-18 | 2008-06-30 | Genentech Inc | Antibody variants with higher binding affinity compared to parent antibodies |
WO2000030628A2 (en) * | 1998-11-20 | 2000-06-02 | Genentech, Inc. | Method of inhibiting angiogenesis |
US6773911B1 (en) | 1998-11-23 | 2004-08-10 | Amgen Canada Inc. | Apoptosis-inducing factor |
EP2075335A3 (en) | 1998-12-22 | 2009-09-30 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
WO2000037502A2 (en) | 1998-12-22 | 2000-06-29 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists and uses thereof |
US6350464B1 (en) * | 1999-01-11 | 2002-02-26 | Guilford Pharmaceuticals, Inc. | Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same |
US6818227B1 (en) * | 1999-02-08 | 2004-11-16 | Alza Corporation | Liposome composition and method for administration of a radiosensitizer |
US6537585B1 (en) | 1999-03-26 | 2003-03-25 | Guilford Pharmaceuticals, Inc. | Methods and compositions for treating solid tumors |
US6379698B1 (en) | 1999-04-06 | 2002-04-30 | Isis Pharmaceuticals, Inc. | Fusogenic lipids and vesicles |
US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
US7112337B2 (en) | 1999-04-23 | 2006-09-26 | Alza Corporation | Liposome composition for delivery of nucleic acid |
DE60008234T2 (en) * | 1999-04-29 | 2004-12-30 | Alza Corp., Mountain View | LIPOSOME COMPOSITIONS FOR IMPROVED ACTIVE SUBSTANCE |
CA2270600A1 (en) | 1999-05-03 | 2000-11-03 | Infectio Recherche Inc. | Method and formulations for the treatment of diseases, particularly those caused by human immunodeficiency virus and leishmania |
EP1645291A1 (en) | 1999-05-07 | 2006-04-12 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to B cell surface markers |
AU4430200A (en) * | 1999-05-11 | 2000-11-21 | Sankyo Company Limited | Liposome preparation of fat-soluble antitumor drug |
US6974684B2 (en) * | 2001-08-08 | 2005-12-13 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
US20040023874A1 (en) * | 2002-03-15 | 2004-02-05 | Burgess Catherine E. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
US20040229779A1 (en) * | 1999-05-14 | 2004-11-18 | Ramesh Kekuda | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
US20040067490A1 (en) * | 2001-09-07 | 2004-04-08 | Mei Zhong | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
EP1978029A3 (en) | 1999-06-15 | 2008-10-15 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids endoding the same |
US7169889B1 (en) | 1999-06-19 | 2007-01-30 | Biocon Limited | Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin |
US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
AU780194B2 (en) * | 1999-06-24 | 2005-03-10 | Kyowa Hakko Kirin Co., Ltd. | Method of regulating leakage of drug encapsulated in liposomes |
DK1189641T5 (en) | 1999-06-25 | 2011-04-11 | Genentech Inc | Humanized ANTI-ErbB2 antibodies and treatment with ANTI-ErbB2 antibodies |
US6352996B1 (en) | 1999-08-03 | 2002-03-05 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
GB9918670D0 (en) | 1999-08-06 | 1999-10-13 | Celltech Therapeutics Ltd | Biological product |
MXPA02002037A (en) | 1999-08-27 | 2002-10-31 | Genentech Inc | DOSAGES FOR TREATMENT WITH ANTI ErbB2 ANTIBODIES. |
NZ523206A (en) * | 1999-08-31 | 2004-12-24 | Genentech Inc | Antibodies that bind to tumor gene sequences |
ES2287028T3 (en) * | 1999-09-03 | 2007-12-16 | Amgen Inc. | COMPOSITIONS AND METHODS FOR THE PREVENTION OR TREATMENT OF CANCER AND OSEA LOSS ASSOCIATED WITH CANCER. |
AU7868400A (en) | 1999-10-08 | 2001-04-23 | Alza Corporation | Neutral-cationic lipid for nucleic acid and drug delivery |
IT1315253B1 (en) * | 1999-10-22 | 2003-02-03 | Novuspharma Spa | LIPOSOMIAL PREPARATION OF 6,9-BIS- (2-AMINOXYL) AMINO | BENZOG | ISOCHINOLIN-5,10-DIONE DIMALEATO |
US7067111B1 (en) | 1999-10-25 | 2006-06-27 | Board Of Regents, University Of Texas System | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging |
US6511676B1 (en) | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
EP3225632B1 (en) | 1999-11-30 | 2020-05-06 | Mayo Foundation for Medical Education and Research | Antibodies binding to b7-h1, a novel immunoregulatory molecule |
CA2494705A1 (en) | 1999-12-01 | 2001-06-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6593308B2 (en) * | 1999-12-03 | 2003-07-15 | The Regents Of The University Of California | Targeted drug delivery with a hyaluronan ligand |
AU2136501A (en) * | 1999-12-10 | 2001-06-18 | Celator Technologies Inc. | Lipid carrier compositions with protected surface reactive functions |
EP1897946B1 (en) | 1999-12-23 | 2012-07-11 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
JP2003520210A (en) * | 2000-01-05 | 2003-07-02 | イマレックス セラピューティクス, インコーポレイテッド | Pharmaceutical formulations for delivery of drugs with low water solubility |
US20040009229A1 (en) * | 2000-01-05 | 2004-01-15 | Unger Evan Charles | Stabilized nanoparticle formulations of camptotheca derivatives |
ATE424457T1 (en) | 2000-01-13 | 2009-03-15 | Genentech Inc | HUMAN STRA6 POLYPEPTIDES |
US6261840B1 (en) | 2000-01-18 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
US20020055479A1 (en) | 2000-01-18 | 2002-05-09 | Cowsert Lex M. | Antisense modulation of PTP1B expression |
DE60110057T2 (en) * | 2000-01-28 | 2005-09-08 | Alza Corp., Mountain View | LIPOSOMES INCLUDED AN INCLUDED CONNECTION IN OUTSTANDING SOLUTION |
US20030176385A1 (en) * | 2000-02-15 | 2003-09-18 | Jingfang Ju | Antisense modulation of protein expression |
JP4922824B2 (en) * | 2000-04-03 | 2012-04-25 | 参天製薬株式会社 | Delivery substance and drug delivery system using the same |
BR0110610A (en) | 2000-04-11 | 2003-04-29 | Genentech Inc | Isolated antibodies, immunoconjugates, polypeptide chains, isolated nucleic acid, vector, host cell, antibody or polypeptide chain production process, method of treating mammalian dysfunction, method of inducing apoptosis of a cancer cell, method of killing a cell b, method for killing a cell expressing an erbb receptor and uses of isolated antibodies |
DE60132184T2 (en) * | 2000-04-12 | 2009-01-15 | Liplasome Pharma A/S | LIPIDEN-BASED DRUG DISPENSING SYSTEMS AGAINST PARASITIC INFECTIONS |
WO2001081376A2 (en) | 2000-04-21 | 2001-11-01 | Amgen Inc. | Apo-ai/aii peptide derivatives |
US6667300B2 (en) * | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
US7030219B2 (en) * | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
AU2001258106A1 (en) * | 2000-05-11 | 2001-11-20 | Celator Technologies Inc. | Lipid carrier compositions for improved drug retention |
US6680172B1 (en) | 2000-05-16 | 2004-01-20 | Regents Of The University Of Michigan | Treatments and markers for cancers of the central nervous system |
BRPI0111220B8 (en) * | 2000-06-02 | 2021-07-27 | Univ Texas | drug conjugates with ethylenedicysteine (ec) |
AU6531101A (en) | 2000-06-02 | 2001-12-17 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030072794A1 (en) * | 2000-06-09 | 2003-04-17 | Teni Boulikas | Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes |
AU2001268363B2 (en) | 2000-06-20 | 2006-08-17 | Biogen Idec Inc. | Treatment of B cell associated diseases |
EP2792747A1 (en) | 2000-06-23 | 2014-10-22 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
EP2075253A1 (en) | 2000-06-23 | 2009-07-01 | Genentech, Inc. | Compositions and methds for the diagnosis and treatment of disorders involving angiogensis |
US20040023259A1 (en) * | 2000-07-26 | 2004-02-05 | Luca Rastelli | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
ATE412009T1 (en) | 2000-08-24 | 2008-11-15 | Genentech Inc | METHOD FOR INHIBITING IL-22 INDUCED PAP1 |
EP1944317A3 (en) | 2000-09-01 | 2008-09-17 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030133972A1 (en) * | 2000-10-11 | 2003-07-17 | Targesome, Inc. | Targeted multivalent macromolecules |
US7045283B2 (en) | 2000-10-18 | 2006-05-16 | The Regents Of The University Of California | Methods of high-throughput screening for internalizing antibodies |
EP2174954B1 (en) | 2000-10-18 | 2016-03-23 | Robert Sackstein | Hematopoietic cell e-selectin/l-selectin ligand polypeptides and methods of use thereof |
EP1341497A4 (en) * | 2000-11-02 | 2005-10-19 | Smithkline Beecham Corp | Receptor antagonist-lipid conjugates and delivery vehicles containing same |
DE10056136A1 (en) * | 2000-11-07 | 2002-05-16 | Nemod New Modalities | Inhibiting leukocyte or tumor cell adhesion to vascular endothelial cells e.g. for combating inflammation or metastasis, using e.g. pregnancy proteins or selectin binding liposomes containing calcium-binding compound |
US7625584B2 (en) * | 2000-11-30 | 2009-12-01 | The Research Foundation Of State University Of New York | Method of complexing a protein by the use of a dispersed system and proteins thereof |
US8110218B2 (en) * | 2000-11-30 | 2012-02-07 | The Research Foundation Of State University Of New York | Compositions and methods for less immunogenic protein-lipid complexes |
US20020132982A1 (en) * | 2000-11-30 | 2002-09-19 | Balasubramanian Sathyamangalam V. | AHF associated dispersion system and method for preparation |
AU2002248190A1 (en) * | 2000-11-30 | 2002-08-12 | The Research Foundation Of State University Of New York | Method of complexing a protein by the use of a dispersed system and proteins thereof |
WO2002059145A1 (en) * | 2000-12-18 | 2002-08-01 | Cubist Pharmaceuticals, Inc. | Methods for preparing purified lipopeptides |
IL156394A0 (en) * | 2000-12-18 | 2004-01-04 | Cubist Pharm Inc | Methods for preparing purified lipopeptides |
US20060014674A1 (en) | 2000-12-18 | 2006-01-19 | Dennis Keith | Methods for preparing purified lipopeptides |
US20040077604A1 (en) * | 2001-12-19 | 2004-04-22 | Lenard Lichtenberger | Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity |
US6964849B2 (en) | 2001-01-11 | 2005-11-15 | Curagen Corporation | Proteins and nucleic acids encoding same |
US20040043928A1 (en) * | 2001-08-02 | 2004-03-04 | Ramesh Kekuda | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
US20020159996A1 (en) | 2001-01-31 | 2002-10-31 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
AR035779A1 (en) | 2001-02-06 | 2004-07-14 | Genetics Inst Llc | FUSION POLYPEPTIDES DERIVED FROM GLICOPROTEIN IB PLATE ALFA AND METHODS OF USE OF THE SAME |
US6867183B2 (en) * | 2001-02-15 | 2005-03-15 | Nobex Corporation | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
US7060675B2 (en) * | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
AU2002245629A1 (en) * | 2001-03-08 | 2002-09-24 | Targesome, Inc. | Stabilized therapeutic and imaging agents |
IL158160A0 (en) * | 2001-03-26 | 2004-03-28 | Alza Corp | Liposome composition for improved intracellular delivery of a therapeutic agent |
US20040126900A1 (en) * | 2001-04-13 | 2004-07-01 | Barry Stephen E | High affinity peptide- containing nanoparticles |
AU2002256398A2 (en) * | 2001-04-30 | 2002-11-11 | Targeted Genetics Corporation | Lipid-comprising drug delivery complexes and methods for their production |
US20030077829A1 (en) * | 2001-04-30 | 2003-04-24 | Protiva Biotherapeutics Inc.. | Lipid-based formulations |
GB0111279D0 (en) * | 2001-05-10 | 2001-06-27 | Nycomed Imaging As | Radiolabelled liposomes |
CN1970077A (en) | 2001-05-11 | 2007-05-30 | 安姆根有限公司 | Peptides and related molecules that bind to tall-1 |
WO2002092554A1 (en) * | 2001-05-15 | 2002-11-21 | Transgene S.A. | Complexes for transferring substances of interest into a cell |
WO2002094376A2 (en) * | 2001-05-22 | 2002-11-28 | Duke University | Compositions and methods for promoting or inhibiting ndpk |
WO2002094194A2 (en) * | 2001-05-22 | 2002-11-28 | Duke University | Compositions and methods for inhibiting metastasis |
KR20040049829A (en) | 2001-05-30 | 2004-06-12 | 제넨테크, 인크. | Anti-ngf antibodies for the treatment of various disorders |
IL158819A0 (en) * | 2001-05-31 | 2004-05-12 | Skyepharma Inc | Encapsulation of nanosuspensions in liposomes and microspheres |
US6828297B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US7713932B2 (en) * | 2001-06-04 | 2010-05-11 | Biocon Limited | Calcitonin drug-oligomer conjugates, and uses thereof |
US6858580B2 (en) * | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6828305B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6835802B2 (en) * | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
US6713452B2 (en) * | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US20070160576A1 (en) | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
AU2002312410A1 (en) * | 2001-06-08 | 2002-12-23 | Target Protein Technologies, Inc. | Tissue-specific endothelial membrane proteins |
CA2633171C (en) | 2001-06-20 | 2012-11-20 | Genentech, Inc. | Antibodies against tumor-associated antigenic target (tat) polypeptides |
US20050107595A1 (en) * | 2001-06-20 | 2005-05-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US7803915B2 (en) * | 2001-06-20 | 2010-09-28 | Genentech, Inc. | Antibody compositions for the diagnosis and treatment of tumor |
AU2002315393A1 (en) | 2001-06-21 | 2003-01-08 | Isis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
CN1827766B (en) | 2001-06-28 | 2010-08-25 | 徐荣祥 | In vitro cell cultivation method |
US20040029790A1 (en) * | 2001-07-05 | 2004-02-12 | Meera Patturajan | Novel human proteins, polynucleotides encoding them and methods of using the same |
US20030087274A1 (en) * | 2001-07-05 | 2003-05-08 | Anderson David W. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
US20030133903A1 (en) * | 2001-07-19 | 2003-07-17 | Wenbin Dang | Compositions for treatment of prostate cancers and methods of making and using the same |
WO2003007915A2 (en) * | 2001-07-19 | 2003-01-30 | Guilford Pharmaceuticals, Inc. | Compositions for treatment of head and neck cancers, and methods of making and using the same |
US7425545B2 (en) | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
US6964950B2 (en) | 2001-07-25 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of C-reactive protein expression |
NZ530904A (en) * | 2001-07-29 | 2005-09-30 | Yissum Res Dev Co | Use of oligopeptides corresponding to the C-terminal portion of OGP that enhance treatments such as engraftment of bone marrow transplants and haematopoietic reconstruction |
US20030096772A1 (en) | 2001-07-30 | 2003-05-22 | Crooke Rosanne M. | Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression |
US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
US20040030096A1 (en) * | 2001-08-02 | 2004-02-12 | Linda Gorman | Novel human proteins, polynucleotides encoding them and methods of using the same |
US7227014B2 (en) | 2001-08-07 | 2007-06-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
CA2456746A1 (en) * | 2001-08-20 | 2003-02-27 | Transave, Inc. | Method for treating lung cancers |
CA2459161A1 (en) | 2001-08-31 | 2003-03-13 | The Rockefeller University | Phosphodiesterase activity and regulation of phosphodiesterase 1b-mediated signaling in brain |
US20040235068A1 (en) * | 2001-09-05 | 2004-11-25 | Levinson Arthur D. | Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders |
US7166571B2 (en) * | 2001-09-07 | 2007-01-23 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US6913903B2 (en) | 2001-09-07 | 2005-07-05 | Nobex Corporation | Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US7196059B2 (en) * | 2001-09-07 | 2007-03-27 | Biocon Limited | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
US7312192B2 (en) * | 2001-09-07 | 2007-12-25 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US7547673B2 (en) * | 2001-09-13 | 2009-06-16 | The Johns Hopkins University | Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production |
DE60238143D1 (en) | 2001-09-18 | 2010-12-09 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS OF TUMORS |
US7981863B2 (en) | 2001-09-19 | 2011-07-19 | Neuronova Ab | Treatment of Parkinson's disease with PDGF |
DE10148065A1 (en) * | 2001-09-28 | 2003-04-17 | Max Planck Gesellschaft | (Ester) -lysolecithins in liposomes |
PL369545A1 (en) * | 2001-09-28 | 2005-05-02 | Esperion Therapeutics, Inc. | Methods and apparatus for extrusion of vesicles at high pressure |
US6750019B2 (en) | 2001-10-09 | 2004-06-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of insulin-like growth factor binding protein 5 expression |
US20030199442A1 (en) * | 2001-10-09 | 2003-10-23 | Alsobrook John P. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
NZ577565A (en) | 2001-10-09 | 2010-10-29 | Isis Pharmaceuticals Inc | Antisense modulation of insulin-like growth factor binding protein 5 expressions |
US7332474B2 (en) * | 2001-10-11 | 2008-02-19 | Amgen Inc. | Peptides and related compounds having thrombopoietic activity |
WO2004033620A2 (en) | 2001-11-02 | 2004-04-22 | Insert Therapeutics, Inc. | Methods and compositions for therapeutic use of rna interference |
US20030125292A1 (en) * | 2001-11-07 | 2003-07-03 | Sean Semple | Mucoscal vaccine and methods for using the same |
US20040219201A1 (en) * | 2001-12-06 | 2004-11-04 | Yechezkel Barenholz | Tempamine compositions and methods of use |
US6965025B2 (en) | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
WO2003057160A2 (en) | 2002-01-02 | 2003-07-17 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
JP4508645B2 (en) | 2002-01-04 | 2010-07-21 | ザ ロックフェラー ユニバーシティー | Compositions and methods for the prevention and treatment of amyloid-beta peptide related diseases |
US7781396B2 (en) * | 2002-01-31 | 2010-08-24 | Tel Aviv University Future Technology Development L.P. | Peptides directed for diagnosis and treatment of amyloid-associated disease |
US20040052928A1 (en) * | 2002-09-06 | 2004-03-18 | Ehud Gazit | Peptides and methods using same for diagnosing and treating amyloid-associated diseases |
AU2003215254A1 (en) | 2002-02-13 | 2003-09-04 | Immunology Laboratories, Inc. | Compositions and methods for treatment of microbial infections |
US20040258678A1 (en) | 2002-02-22 | 2004-12-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US20100311954A1 (en) * | 2002-03-01 | 2010-12-09 | Xencor, Inc. | Optimized Proteins that Target Ep-CAM |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US20090042291A1 (en) * | 2002-03-01 | 2009-02-12 | Xencor, Inc. | Optimized Fc variants |
US20030180712A1 (en) | 2002-03-20 | 2003-09-25 | Biostratum Ab | Inhibition of the beta3 subunit of L-type Ca2+ channels |
US20040009216A1 (en) * | 2002-04-05 | 2004-01-15 | Rodrigueza Wendi V. | Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease |
MXPA04010092A (en) | 2002-04-16 | 2004-12-13 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor. |
CA2483476A1 (en) * | 2002-04-22 | 2003-10-30 | Absorber, Ab | Fusion polypeptides and methods for inhibiting microbial adhesion |
US20040009944A1 (en) * | 2002-05-10 | 2004-01-15 | Inex Pharmaceuticals Corporation | Methylated immunostimulatory oligonucleotides and methods of using the same |
US7199107B2 (en) | 2002-05-23 | 2007-04-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of kinesin-like 1 expression |
EP2305710A3 (en) | 2002-06-03 | 2013-05-29 | Genentech, Inc. | Synthetic antibody phage libraries |
AU2003236521A1 (en) * | 2002-06-13 | 2003-12-31 | Nobex Corporation | Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus |
ES2354607T3 (en) | 2002-06-28 | 2011-03-16 | Protiva Biotherapeutics Inc. | PROCEDURE AND APPLIANCE TO PRODUCE LIPOSOMES. |
WO2004004635A2 (en) * | 2002-07-02 | 2004-01-15 | Board Of Regents, The University Of Texas System | Radiolabeled compounds and liposomes and their methods of making and using the same |
US20050169979A1 (en) * | 2002-07-03 | 2005-08-04 | Dov Michaeli | Liposomal vaccine |
US20040208920A1 (en) * | 2002-07-03 | 2004-10-21 | Dov Michaeli | Liposomal vaccine |
US20040247661A1 (en) * | 2002-07-03 | 2004-12-09 | Dov Michaeli | Liposomal vaccine |
EP1572130A4 (en) | 2002-07-08 | 2008-07-02 | Genentech Inc | Compositions and methods for the treatment of immune related diseases |
US20040175378A1 (en) * | 2002-07-15 | 2004-09-09 | Board Of Regents, The University Of Texas System | Selected antibody compositions and methods for binding to aminophospholipids |
US7625563B2 (en) * | 2002-07-15 | 2009-12-01 | Board Of Regents, The University Of Texas System | Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids |
US7622118B2 (en) * | 2002-07-15 | 2009-11-24 | Board Of Regents, The University Of Texas System | Cancer treatment methods using selected antibodies to aminophospholipids |
US7572448B2 (en) * | 2002-07-15 | 2009-08-11 | Board Of Regents, The University Of Texas System | Combined cancer treatment methods using selected antibodies to aminophospholipids |
ES2376165T3 (en) | 2002-07-15 | 2012-03-09 | F. Hoffmann-La Roche Ag | TREATMENT OF THE C�? NCER WITH THE ANTIBODY DIRECTED AGAINST ERBB2 RHUMAB 2C4. |
US7615223B2 (en) * | 2002-07-15 | 2009-11-10 | Board Of Regents, The University Of Texas System | Selected immunoconjugates for binding to aminophospholipids |
US7678386B2 (en) * | 2002-07-15 | 2010-03-16 | Board Of Regents The University Of Texas | Liposomes coated with selected antibodies that bind to aminophospholipids |
US7714109B2 (en) * | 2002-07-15 | 2010-05-11 | Board Of Regents, The University Of Texas System | Combinations and kits for cancer treatment using selected antibodies to aminophospholipids |
EP1546184A4 (en) * | 2002-07-16 | 2006-08-23 | Univ South Florida | Human immunosuppressive protein |
US20040161423A1 (en) * | 2002-07-18 | 2004-08-19 | Sanjeev Kumar (Mendiratta) | Polymer modified anti-angiogenic serpins |
US9186322B2 (en) * | 2002-08-02 | 2015-11-17 | Insmed Incorporated | Platinum aggregates and process for producing the same |
EP1545459A4 (en) * | 2002-08-02 | 2007-08-22 | Transave Inc | Platinum aggregates and process for producing the same |
WO2004016750A2 (en) | 2002-08-14 | 2004-02-26 | Macrogenics, Inc. | FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
EP1393720A1 (en) * | 2002-08-27 | 2004-03-03 | Universiteit Utrecht | Vesicle-encapsulated corticosteroids for treatment of cancer |
AU2003259995B2 (en) | 2002-08-28 | 2009-07-02 | Immunex Corporation | Compositions and methods for treating cardiovascular disease |
US20070231379A1 (en) * | 2002-08-29 | 2007-10-04 | Slater James L | Liposome-entrapped topoisomerase inhibitors |
AR036316A1 (en) * | 2002-08-29 | 2004-08-25 | Monte Verde S A | A PHARMACEUTICAL COMPOSITION OF SMALL SIZE LIPOSOMES AND PREPARATION METHOD |
US20080214437A1 (en) * | 2002-09-06 | 2008-09-04 | Mohapatra Shyam S | Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
AU2003268531A1 (en) | 2002-09-06 | 2004-03-29 | University Of South Florida | Materials and methods for treatment of allergic diseases |
CA2498008C (en) | 2002-09-11 | 2014-02-04 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
EP2116551A1 (en) | 2002-09-11 | 2009-11-11 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
CN1694959B (en) | 2002-09-13 | 2013-09-18 | 雷普利瑟公司 | Non-sequence complementary antiviral oligonucleotides |
US20050196382A1 (en) * | 2002-09-13 | 2005-09-08 | Replicor, Inc. | Antiviral oligonucleotides targeting viral families |
US20070010434A1 (en) | 2002-09-16 | 2007-01-11 | Genetech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
US6919426B2 (en) | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
EP2500438A3 (en) | 2002-09-25 | 2012-11-28 | Genentech, Inc. | Novel compositions and methods for the treatment of psoriasis |
EP1549767A4 (en) | 2002-09-26 | 2006-06-07 | Amgen Inc | Modulation of forkhead box o1a expression |
EP2364996B1 (en) | 2002-09-27 | 2016-11-09 | Xencor Inc. | Optimized FC variants and methods for their generation |
US8129330B2 (en) * | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
US20040062748A1 (en) * | 2002-09-30 | 2004-04-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
US20060147450A1 (en) * | 2002-10-04 | 2006-07-06 | Shelton David L | Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists |
US7432351B1 (en) | 2002-10-04 | 2008-10-07 | Mayo Foundation For Medical Education And Research | B7-H1 variants |
UA80447C2 (en) * | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
AU2003304238A1 (en) | 2002-10-08 | 2005-01-13 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same |
RU2338555C2 (en) | 2002-10-08 | 2008-11-20 | Ринат Ньюросайенс Корп. | Method of treatment of postoperative pain by administering of antagonist of factor of growth of nerves and compositions containing factor of growth of nerves |
AU2003279216A1 (en) * | 2002-10-09 | 2004-05-04 | Rinat Neuroscience Corp. | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
WO2004110345A2 (en) * | 2002-10-29 | 2004-12-23 | Pharmacia Corporation | Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same |
EP2322201A3 (en) | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
CA2504720C (en) | 2002-11-05 | 2013-12-24 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
CA2504929C (en) | 2002-11-05 | 2014-07-22 | Charles Allerson | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
US20040093198A1 (en) * | 2002-11-08 | 2004-05-13 | Carbon Design Systems | Hardware simulation with access restrictions |
EP2364716A3 (en) | 2002-11-08 | 2012-01-11 | Genentech, Inc. | Compositions and methods for the treatment of natural killer cell related diseases |
US20040152769A1 (en) * | 2002-11-09 | 2004-08-05 | Ekwuribe Nnochiri Nkem | Modified carbamate-containing prodrugs and methods of synthesizing same |
ES2420914T3 (en) | 2002-11-13 | 2013-08-27 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
EP2336318B1 (en) | 2002-11-13 | 2013-04-24 | Genzyme Corporation | Antisense modulation of apolipoprotein b expression |
US20050158375A1 (en) * | 2002-11-15 | 2005-07-21 | Toshikiro Kimura | Pharmaceutical composition containing liposomes for treating cancer |
US7144999B2 (en) | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
CA2504287A1 (en) | 2002-11-26 | 2004-06-10 | Nobex Corporation | Natriuretic compounds, conjugates, and uses thereof |
EP2308968A1 (en) | 2002-11-26 | 2011-04-13 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US7648962B2 (en) * | 2002-11-26 | 2010-01-19 | Biocon Limited | Natriuretic compounds, conjugates, and uses thereof |
US7491699B2 (en) | 2002-12-09 | 2009-02-17 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures and methods of generating and using the same |
JP2006517917A (en) * | 2002-12-19 | 2006-08-03 | アルザ・コーポレーシヨン | Method of treating angiogenic tissue growth |
SI1575517T1 (en) * | 2002-12-24 | 2012-06-29 | Rinat Neuroscience Corp | Anti-ngf antibodies and methods using same |
US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
US7569364B2 (en) * | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
US8980310B2 (en) * | 2002-12-31 | 2015-03-17 | Bharat Serums and Vaccines, Ltd. | Non-pegylated long-circulating liposomes |
MXPA05007102A (en) | 2002-12-31 | 2005-08-26 | Bharat Serums & Vaccines Ltd | Non-pegylated long-circulating liposomes. |
WO2004060791A1 (en) * | 2003-01-07 | 2004-07-22 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures encapsulating a foreign material and method of manufacturing same |
US7169892B2 (en) | 2003-01-10 | 2007-01-30 | Astellas Pharma Inc. | Lipid-peptide-polymer conjugates for long blood circulation and tumor specific drug delivery systems |
WO2004063216A1 (en) * | 2003-01-10 | 2004-07-29 | Yamanouchi Pharmaceutical Co., Ltd. | Conjugate for retention in blood and cancer tissue-specific drug delivery |
ES2400033T3 (en) | 2003-02-11 | 2013-04-05 | Antisense Therapeutics Ltd | Modulation of insulin-like growth factor I receptor expression |
PL379983A1 (en) | 2003-02-19 | 2006-11-27 | Rinat Neuroscience Corp. | Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same |
US7803781B2 (en) | 2003-02-28 | 2010-09-28 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
US7968115B2 (en) | 2004-03-05 | 2011-06-28 | Board Of Regents, The University Of Texas System | Liposomal curcumin for treatment of cancer |
US20040185559A1 (en) | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
US20060198882A1 (en) * | 2003-03-21 | 2006-09-07 | Yechezkel Barenholz | Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer |
AU2004227847A1 (en) | 2003-03-31 | 2004-10-21 | Alza Corporation | Lipid particles having asymmetric lipid coating and method of preparing same |
KR101208291B1 (en) | 2003-04-04 | 2012-12-05 | 노파르티스 아게 | High concentration antibody and protein formulations |
ZA200507805B (en) | 2003-04-09 | 2006-12-27 | Genentech Inc | Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor |
ES2307009T3 (en) * | 2003-04-15 | 2008-11-16 | Opperbas Holding B.V. | PHARMACEUTICAL COMPOSITION CONTAINING PROTEINS AND / OR COLOID POLYPEPTIDES AND PARTICLES. |
US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
WO2004094457A2 (en) * | 2003-04-16 | 2004-11-04 | Arizona Board Of Regents, Acting For And On Behalf Of, Arizona State University | Stable rgd peptidomimetic composition |
WO2004093788A2 (en) * | 2003-04-17 | 2004-11-04 | The Trustees Of Columbia University In The City Ofnew York | Desmoglein 4 is a novel gene involved in hair growth |
US7399853B2 (en) | 2003-04-28 | 2008-07-15 | Isis Pharmaceuticals | Modulation of glucagon receptor expression |
WO2004100997A2 (en) | 2003-05-12 | 2004-11-25 | Affymax, Inc. | Spacer moiety for poly(ethylene glycol) -modified peptides |
MXPA05012315A (en) | 2003-05-12 | 2006-04-18 | Affymax Inc | Novel poly(ethylene glycol) modified compounds and uses thereof. |
EP1629014A2 (en) * | 2003-05-30 | 2006-03-01 | Genentech, Inc. | Polypeptides that bind an anti-tissue factor antibody and uses thereof |
CN1829741A (en) | 2003-05-30 | 2006-09-06 | 健泰科生物技术公司 | Treatment with anti-VEGF antibodies |
BRPI0410886A (en) | 2003-06-03 | 2006-07-04 | Isis Pharmaceuticals Inc | double stranded compound, pharmaceutical composition, pharmaceutically acceptable salt, methods of modifying human survivin-encoding nucleic acid, inhibiting suvivin expression in cells or tissues, and treating a condition associated with suvivin expression or overexpression, and single stranded RNA oligonucleotide |
AU2004245074A1 (en) * | 2003-06-04 | 2004-12-16 | Canji, Inc | Methods and compositions for interferon therapy |
WO2005001486A1 (en) | 2003-06-06 | 2005-01-06 | Genentech, Inc. | Modulating the interaction between hgf beta chain and c-met |
MXPA05013509A (en) | 2003-06-11 | 2006-04-05 | Wyeth Corp | Platelet glycoprotein ib alpha variant fusion polypeptides and methods of use thereof. |
US7939058B2 (en) * | 2003-07-03 | 2011-05-10 | University Of Southern California | Uses of IL-12 in hematopoiesis |
WO2005007812A2 (en) | 2003-07-03 | 2005-01-27 | University Of Medicine And Dentistry Of New Jersey | Genes as diagnostic tools for autism |
EP2277908A3 (en) | 2003-07-08 | 2011-12-14 | Genentech, Inc. | IL-17A/F heterologous polypeptides, antibodies and therapeutic uses thereof |
CN101291653B (en) * | 2003-07-16 | 2012-06-27 | 普洛体维生物治疗公司 | Lipid encapsulated interfering rna |
CN100431525C (en) * | 2003-07-17 | 2008-11-12 | 台湾东洋药品工业股份有限公司 | Production method of liposome suspended liquid and products thereof |
CA2533701A1 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
KR20090077984A (en) * | 2003-07-31 | 2009-07-16 | 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 | Sterile preparations of phospholipids and anti-inflammatory pharmaceuticals |
WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US20050054614A1 (en) * | 2003-08-14 | 2005-03-10 | Diacovo Thomas G. | Methods of inhibiting leukocyte accumulation |
US20050043239A1 (en) * | 2003-08-14 | 2005-02-24 | Jason Douangpanya | Methods of inhibiting immune responses stimulated by an endogenous factor |
US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
ATE422880T1 (en) * | 2003-08-26 | 2009-03-15 | Smithkline Beecham Corp | HETEROFUNCTIONAL COPOLYMERS OF GLYCEROL AND POLYETHYLENE GLYCOL, THEIR CONJUGATES AND COMPOSITIONS |
US8986731B2 (en) * | 2003-08-26 | 2015-03-24 | Biolitec Pharma Marketing Ltd | Pegylated liposomal formulations of hydrophobic photosensitizers for photodynamic therapy |
US20060115523A1 (en) * | 2004-12-01 | 2006-06-01 | Konduri Kameswari S | Sterically stabilized liposome and triamcinolone composition for treating the respiratory tract of a mammal |
US11324698B2 (en) | 2003-08-28 | 2022-05-10 | Vgsk Technologies, Inc. | Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal |
US8846079B1 (en) | 2004-12-01 | 2014-09-30 | Vgsk Technologies, Inc. | Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal |
JP4804923B2 (en) * | 2003-09-03 | 2011-11-02 | 協和発酵キリン株式会社 | Compounds modified with glycerol derivatives |
US20050233435A1 (en) * | 2003-09-04 | 2005-10-20 | Nyu Medical Center | Plasmodium axenic liver stages as a noninfectious whole organism malaria vaccine |
US20070123480A1 (en) * | 2003-09-11 | 2007-05-31 | Replicor Inc. | Oligonucleotides targeting prion diseases |
CA2551022C (en) * | 2003-09-15 | 2013-06-04 | Protiva Biotherapeutics, Inc. | Polyethyleneglycol-modified lipid compounds and uses thereof |
US7425544B2 (en) | 2003-09-18 | 2008-09-16 | Eli Lilly And Company | Modulation of eIF4E expression |
EP1663199B1 (en) * | 2003-09-25 | 2013-04-03 | Tel Aviv University Future Technology Development L.P. | Compositions and methods using same for treating amyloid-associated diseases |
US8101720B2 (en) * | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
WO2005031362A2 (en) * | 2003-10-02 | 2005-04-07 | Ramot At Tel Aviv University Ltd. | Novel antibacterial agents and methods of identifying and utilizing same |
NZ546272A (en) | 2003-10-10 | 2009-05-31 | Alchemia Oncology Pty Ltd | The modulation of hyaluronan synthesis and degradation in the treatment of disease |
WO2005034979A2 (en) * | 2003-10-11 | 2005-04-21 | Inex Pharmaceuticals Corporation | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
TW200517114A (en) | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
WO2005041870A2 (en) * | 2003-10-24 | 2005-05-12 | Ader Enterprises, Inc. | Composition and method for the treatment of eye disease |
US20050175683A1 (en) * | 2003-10-24 | 2005-08-11 | Yuanpeng Zhang | Preparation of lipid particles |
WO2005040163A1 (en) * | 2003-10-28 | 2005-05-06 | Dr. Reddy's Laboratories Ltd | Heterocyclic compounds that block the effects of advanced glycation end products (age) |
US20050191653A1 (en) | 2003-11-03 | 2005-09-01 | Freier Susan M. | Modulation of SGLT2 expression |
US7915227B2 (en) * | 2003-11-14 | 2011-03-29 | Het Nederlands Kanker Instituut | Pharmaceutical formulations employing short-chain sphingolipids and their use |
US20050129753A1 (en) * | 2003-11-14 | 2005-06-16 | Gabizon Alberto A. | Method for drug loading in liposomes |
EP1689432B1 (en) | 2003-11-17 | 2009-12-30 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
WO2005060520A2 (en) * | 2003-11-25 | 2005-07-07 | Dana-Farber Cancer Institute, Inc. | ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF |
EP1701979A2 (en) * | 2003-12-03 | 2006-09-20 | Xencor, Inc. | Optimized antibodies that target the epidermal growth factor receptor |
US9050378B2 (en) * | 2003-12-10 | 2015-06-09 | Board Of Regents, The University Of Texas System | N2S2 chelate-targeting ligand conjugates |
US7312320B2 (en) | 2003-12-10 | 2007-12-25 | Novimmune Sa | Neutralizing antibodies and methods of use thereof |
CA2548282A1 (en) | 2003-12-11 | 2005-06-30 | Genentech, Inc. | Methods and compositions for inhibiting c-met dimerization and activation |
KR20070001932A (en) | 2003-12-23 | 2007-01-04 | 리나트 뉴로사이언스 코퍼레이션 | Agonist anti-trkc antibodies and methods using same |
EP2311873B1 (en) | 2004-01-07 | 2018-08-29 | Novartis Vaccines and Diagnostics, Inc. | M-csf-specific monoclonal antibody and uses thereof |
JP2007520481A (en) * | 2004-01-15 | 2007-07-26 | アルザ・コーポレーシヨン | Liposome composition for delivering therapeutic agents |
WO2005071080A2 (en) | 2004-01-20 | 2005-08-04 | Isis Pharmaceuticals, Inc. | Modulation of glucocorticoid receptor expression |
US7468431B2 (en) | 2004-01-22 | 2008-12-23 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP2 expression |
US20050181035A1 (en) * | 2004-02-17 | 2005-08-18 | Dow Steven W. | Systemic immune activation method using non CpG nucleic acids |
EP1727556A2 (en) * | 2004-02-17 | 2006-12-06 | University Of South Florida | Materials and methods for treatment of inflammatory and cell proliferation disorders |
EP2168986A3 (en) | 2004-02-19 | 2010-07-28 | Genentech, Inc. | CDR-repaired antibodies |
US8784881B2 (en) | 2004-03-05 | 2014-07-22 | Board Of Regents, The University Of Texas System | Liposomal curcumin for treatment of diseases |
US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
EP1735009A4 (en) * | 2004-03-12 | 2011-03-30 | Alnylam Pharmaceuticals Inc | iRNA AGENTS TARGETING VEGF |
US8790919B2 (en) | 2004-03-15 | 2014-07-29 | Isis Pharmaceuticals, Inc. | Compositions and methods for optimizing cleavage of RNA by RNase H |
EP1579850A3 (en) * | 2004-03-15 | 2009-12-16 | Nipro Corporation | A pharmaceutical composition containing liposomes for treating a cancer |
US20070065522A1 (en) * | 2004-03-18 | 2007-03-22 | Transave, Inc. | Administration of high potency platinum compound formulations by inhalation |
WO2005089448A2 (en) * | 2004-03-18 | 2005-09-29 | Transave, Inc. | Administration of cisplatin by inhalation |
DK1730280T3 (en) * | 2004-03-26 | 2019-02-04 | Curis Inc | RNA interference modulators for hedgehog signaling and applications thereof |
CN1938048B (en) * | 2004-03-26 | 2010-05-12 | 泰尔茂株式会社 | Liposome preparation |
US20050244869A1 (en) * | 2004-04-05 | 2005-11-03 | Brown-Driver Vickie L | Modulation of transthyretin expression |
US7794713B2 (en) | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
JP5301152B2 (en) | 2004-04-07 | 2013-09-25 | ライナット ニューロサイエンス コーポレイション | Method for treating bone cancer pain by administering a nerve growth factor antagonist |
AU2005247303A1 (en) * | 2004-04-16 | 2005-12-08 | Genentech, Inc. | Treatment of polychondritis and mononeuritis multiplex with anti-CD20 antibodies |
US20150017671A1 (en) | 2004-04-16 | 2015-01-15 | Yaping Shou | Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity |
KR101223366B1 (en) | 2004-05-03 | 2013-01-16 | 헤르메스 바이오사이언스, 인코포레이티드 | Liposomes useful for drug delivery |
US8658203B2 (en) * | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
ES2607804T3 (en) | 2004-05-13 | 2017-04-04 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
DE602005018043D1 (en) * | 2004-05-17 | 2010-01-14 | Tekmira Pharmaceuticals Corp | LIPOSOMAL FORMULATIONS WITH DIHYDROSPHENOMYLININ AND METHOD FOR THEIR USE |
US20060292554A1 (en) * | 2004-05-18 | 2006-12-28 | Genentech, Inc. | Major coat protein variants for C-terminal and bi-terminal display |
US20050260260A1 (en) * | 2004-05-19 | 2005-11-24 | Edward Kisak | Liposome compositions for the delivery of macromolecules |
EP1755623A4 (en) * | 2004-05-21 | 2007-10-17 | Transave Inc | Treatment of lung diseases and pre-lung disease conditions |
JP2008500338A (en) * | 2004-05-25 | 2008-01-10 | イコス・コーポレイション | Method for treating and / or preventing abnormal proliferation of hematopoietic cells |
JP2008500358A (en) * | 2004-05-25 | 2008-01-10 | メタボレックス インコーポレーティッド | Bicyclic substituted triazoles as modulators of PPARs and methods for their preparation |
ZA200610650B (en) * | 2004-05-25 | 2009-04-29 | Metabolex Inc | Substituted triazoles as modulators of PPAR and methods of their preparation |
ES2623362T3 (en) * | 2004-05-28 | 2017-07-11 | Human Biomolecular Research Institute | Metabolically stable pain relievers and pain medications |
US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
CA2569419A1 (en) * | 2004-06-03 | 2005-12-22 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
CA2569036A1 (en) * | 2004-06-03 | 2005-12-22 | Balkrishen Bhat | Chimeric gapped oligomeric compositions |
US20090048192A1 (en) * | 2004-06-03 | 2009-02-19 | Isis Pharmaceuticals, Inc. | Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation |
RU2384345C2 (en) | 2004-06-04 | 2010-03-20 | Дженентек, Инк. | Method of treating multiple sclerosis |
CA2569645C (en) | 2004-06-07 | 2014-10-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
WO2005121348A1 (en) * | 2004-06-07 | 2005-12-22 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
CA2579756C (en) * | 2004-06-19 | 2013-04-30 | Human Biomolecular Research Institute | Modulators of central nervous system neurotransmitters |
WO2006002262A2 (en) | 2004-06-21 | 2006-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder |
US20060019893A1 (en) * | 2004-07-02 | 2006-01-26 | Genentech, Inc. | Factor VIIa variants |
CA2572439A1 (en) | 2004-07-02 | 2006-01-12 | Protiva Biotherapeutics, Inc. | Immunostimulatory sirna molecules and uses therefor |
MX2007000216A (en) * | 2004-07-08 | 2007-03-15 | Amgen Inc | Therapeutic peptides. |
WO2006006172A2 (en) * | 2004-07-15 | 2006-01-19 | Ramot At Tel Aviv University Ltd. | Use of anti-amyloid agents for treating and typing pathogen infections |
CN101014619B (en) | 2004-07-15 | 2010-11-03 | 赞科股份有限公司 | Optimized fc variants |
ES2618028T3 (en) * | 2004-07-19 | 2017-06-20 | Biocon Limited | Insulin-oligomer conjugates, formulations and uses thereof. |
WO2006007712A1 (en) * | 2004-07-19 | 2006-01-26 | Protiva Biotherapeutics, Inc. | Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents |
NZ552956A (en) | 2004-07-20 | 2010-03-26 | Genentech Inc | Inhibitors of angiopoietin-like 4 protein (ANGPTL4), combinations, and their use for treating cancer |
KR101222254B1 (en) | 2004-07-26 | 2013-01-16 | 제넨테크, 인크. | Methods and compositions for mudulating hepatocyte growth factor activation |
TWI355389B (en) * | 2004-07-30 | 2012-01-01 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide a |
US9132116B2 (en) * | 2004-08-02 | 2015-09-15 | Willowcroft Pharm Inc. | Mast cell stabilizers to prevent or treat laminitis |
EP1781310B1 (en) | 2004-08-02 | 2015-10-14 | Ramot at Tel Aviv University Ltd. | Articles of peptide nanostructures and method of forming the same |
EP1778144B1 (en) | 2004-08-17 | 2011-01-19 | Tyco Healthcare Group LP | Anti-adhesion barrier |
JP2006056807A (en) * | 2004-08-18 | 2006-03-02 | Konica Minolta Medical & Graphic Inc | Preparation for use in photodynamic therapy |
WO2006018850A2 (en) | 2004-08-19 | 2006-02-23 | Tel Aviv University Future Technology Development L.P. | Compositions for treating amyloid associated diseases |
JP4715133B2 (en) * | 2004-08-26 | 2011-07-06 | コニカミノルタエムジー株式会社 | Anti-tumor liposome preparation and production method thereof |
JP2006069929A (en) * | 2004-08-31 | 2006-03-16 | Konica Minolta Medical & Graphic Inc | Preparation for treating mycosis and method for producing the same |
US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
US7786086B2 (en) | 2004-09-08 | 2010-08-31 | Ramot At Tel-Aviv University Ltd. | Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same |
EP1793805A1 (en) * | 2004-09-09 | 2007-06-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposomal formulations comprising an amphipathic weak base like tempamine for treatment of neurodegenerative conditions |
EP1793804A2 (en) * | 2004-09-09 | 2007-06-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of liposomal glucocorticoids for treating inflammatory states |
US6998028B1 (en) * | 2004-09-24 | 2006-02-14 | Superpower, Inc. | Methods for forming superconducting conductors |
SI1797127T1 (en) * | 2004-09-24 | 2017-09-29 | Amgen Inc. | Modified fc molecules |
US8435948B2 (en) | 2004-09-29 | 2013-05-07 | Mount Sinai School Of Medicine Of New York University | Methods for inhibiting osteoclastic bone resorption and bone loss comprising administration of an anti-FSH or anti-FSHR antibody |
CN101087807A (en) | 2004-10-05 | 2007-12-12 | 健泰科生物技术公司 | Method for treating vasculitis |
US9315862B2 (en) * | 2004-10-05 | 2016-04-19 | California Institute Of Technology | Aptamer regulated nucleic acids and uses thereof |
MX2007004176A (en) * | 2004-10-06 | 2007-06-15 | Mayo Foundation | B7-h1 and methods of diagnosis, prognosis, and treatment of cancer. |
JP2008515929A (en) * | 2004-10-08 | 2008-05-15 | アルザ コーポレイション | A method for inserting a lipid assembly into which a lipid linking part is preformed using microwaves |
TW200612993A (en) * | 2004-10-08 | 2006-05-01 | Alza Corp | Lipopolymer conjugates |
JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
BRPI0518250A2 (en) * | 2004-10-26 | 2008-11-11 | Pharma Mar Sa | anticancer treatments |
US20060110441A1 (en) * | 2004-10-28 | 2006-05-25 | Harry Wong | Lyophilized liposome formulations and method |
PL1658848T3 (en) | 2004-10-29 | 2007-12-31 | Pharma Mar Sa | Formulations comprising ecteinascidin and a disaccharide |
US20090285878A1 (en) | 2004-11-05 | 2009-11-19 | Tekmira Pharmaceuticals Corporation | Compositions and methods for stabilizing liposomal drug formulations |
TW200618820A (en) * | 2004-11-05 | 2006-06-16 | Alza Corp | Liposome formulations of boronic acid compounds |
EP1811963A4 (en) * | 2004-11-08 | 2010-01-06 | Transave Inc | Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally |
EA200700990A1 (en) * | 2004-11-11 | 2008-04-28 | Афимакс, Инк. | NEW PEPTIDES THAT BIND THE ERYTHROPOIETIN RECEPTOR |
JP2008520560A (en) * | 2004-11-15 | 2008-06-19 | イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム | Combination therapy |
AU2005306533B2 (en) * | 2004-11-17 | 2012-05-31 | Arbutus Biopharma Corporation | siRNA silencing of apolipoprotein B |
US20070298094A1 (en) * | 2004-11-18 | 2007-12-27 | Terumo Kabushiki Kaisha | Medicinal Composition, Preparation and Combined Preparation |
US7361752B2 (en) * | 2004-12-14 | 2008-04-22 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of MLL-AF4 and uses thereof |
DE602006013275D1 (en) | 2005-01-07 | 2010-05-12 | Diadexus Inc | OVR110 ANTIBODY COMPOSITIONS AND USER METHOD THEREFOR |
WO2006076471A2 (en) * | 2005-01-12 | 2006-07-20 | Nobex Corporation | Bnp conjugates and methods of use |
KR20190110637A (en) | 2005-01-21 | 2019-09-30 | 제넨테크, 인크. | Fixed dosing of her antibodies |
WO2006080452A1 (en) * | 2005-01-28 | 2006-08-03 | Kyowa Hakko Kogyo Co., Ltd. | Method for producing fine particle surface-modified with water-soluble substance |
EP2042186A1 (en) | 2005-01-31 | 2009-04-01 | Vaxinnate Corporation | Novel polypeptide ligands for toll-like receptor 2 (TLR2) |
US8029783B2 (en) * | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
WO2006086667A2 (en) | 2005-02-09 | 2006-08-17 | Avi Bio Pharma, Inc. | Antisense composition and method for treating muscle atrophy |
WO2006089133A2 (en) | 2005-02-15 | 2006-08-24 | Duke University | Anti-cd19 antibodies and uses in oncology |
CA2598409A1 (en) * | 2005-02-17 | 2006-08-24 | Icos Corporation | Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation |
WO2006089141A2 (en) | 2005-02-18 | 2006-08-24 | Dana-Farber Cancer Institute | Antibodies against cxcr4 and methods of use thereof |
EP1854807A4 (en) * | 2005-02-18 | 2009-04-01 | Univ Tokushima | Polyoxyalkylene chain-containing lipid derivative and lipid film structure containing such derivative |
SI1850874T1 (en) | 2005-02-23 | 2014-01-31 | Genentech, Inc. | Extending time to disease progression or survival in ovarian cancer patients using pertuzumab |
TW200714289A (en) * | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
WO2006096861A2 (en) * | 2005-03-08 | 2006-09-14 | Genentech, Inc. | METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs) |
JP2006248978A (en) * | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | New liposome preparation |
CN101175769A (en) | 2005-03-10 | 2008-05-07 | 健泰科生物技术公司 | Methods and compositions for modulating vascular integrity |
US20090110633A1 (en) * | 2005-03-14 | 2009-04-30 | Shiladitya Sengupta | Nanocells for Diagnosis and Treatment of Diseases and Disorders |
WO2006102426A2 (en) | 2005-03-21 | 2006-09-28 | Metabolex, Inc. | Methods for avoiding edema in the treatment of metabolic, inflammatory, and cardiovascular disorders |
CN1840193B (en) * | 2005-03-29 | 2010-05-12 | 中国科学院生物物理研究所 | Nanometer capsule of anthracene nucleus anticancer antibiotic with polyethylene glycol-phospholipid |
EP1866414B9 (en) | 2005-03-31 | 2012-10-03 | Calando Pharmaceuticals, Inc. | Inhibitors of ribonucleotide reductase subunit 2 and uses thereof |
UY29504A1 (en) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | DIRECTED ANTIBODIES AGAINST BETA AMYLOID PEPTIDE AND METHODS USING THE SAME. |
EP2221316A1 (en) | 2005-05-05 | 2010-08-25 | Duke University | Anti-CD19 antibody therapy for autoimmune disease |
BRPI0611069A2 (en) | 2005-05-06 | 2010-11-09 | Zymogenetics Inc | monoclonal antibody, humanized antibody, antibody fragment, use of an antagonist, and hybridoma |
EP3263581B1 (en) | 2005-05-17 | 2020-11-04 | University of Connecticut | Compositions and methods for immunomodulation in an organism |
US7919461B2 (en) * | 2005-06-03 | 2011-04-05 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
US8324159B2 (en) * | 2005-06-03 | 2012-12-04 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
US7550433B2 (en) | 2005-06-03 | 2009-06-23 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
EP1871163A2 (en) | 2005-06-06 | 2008-01-02 | Genentech, Inc. | Transgenic models for different genes and their use for gene characterization |
WO2007005754A2 (en) * | 2005-07-01 | 2007-01-11 | Alza Corporation | Liposomal delivery vehicle for hydrophobic drugs |
CA2652434A1 (en) | 2005-07-08 | 2007-01-18 | Xencor, Inc. | Optimized proteins that target ep-cam |
KR20080039929A (en) | 2005-07-22 | 2008-05-07 | 와이스 테라퓨틱스 가부시키가이샤 | Anti-cd26 antibodies and methods of use thereof |
EP1913028B1 (en) * | 2005-07-28 | 2015-03-04 | Novartis AG | Use of antibody to m-csf |
EP1913027B1 (en) * | 2005-07-28 | 2015-03-04 | Novartis AG | M-csf specific monoclonal antibody and uses thereof |
US20070055199A1 (en) | 2005-08-10 | 2007-03-08 | Gilbert Scott J | Drug delivery device for buccal and aural applications and other areas of the body difficult to access |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
JP2009504183A (en) | 2005-08-15 | 2009-02-05 | ジェネンテック・インコーポレーテッド | Gene disruption and related compositions and methods |
US20070054873A1 (en) * | 2005-08-26 | 2007-03-08 | Protiva Biotherapeutics, Inc. | Glucocorticoid modulation of nucleic acid-mediated immune stimulation |
US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
EP1973928A2 (en) * | 2005-10-11 | 2008-10-01 | Ramot at Tel-Aviv University Ltd. | Self-assembled fmoc-ff hydrogels |
AR056142A1 (en) * | 2005-10-21 | 2007-09-19 | Amgen Inc | METHODS TO GENERATE THE MONOVALENT IGG ANTIBODY |
US7875602B2 (en) * | 2005-10-21 | 2011-01-25 | Sutter West Bay Hospitals | Camptothecin derivatives as chemoradiosensitizing agents |
AU2006308870B2 (en) | 2005-10-31 | 2012-08-16 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
GB0522082D0 (en) | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
CA2627585A1 (en) | 2005-11-01 | 2007-05-10 | Alnylam Pharmaceuticals, Inc. | Rnai inhibition of influenza virus replication |
CN101346393B (en) * | 2005-11-02 | 2015-07-22 | 普洛体维生物治疗公司 | Modified siRNA molecules and uses thereof |
US7879212B2 (en) * | 2005-11-03 | 2011-02-01 | Ramot At Tel-Aviv University Ltd. | Peptide nanostructure-coated electrodes |
DE102005053066A1 (en) * | 2005-11-04 | 2007-05-10 | Basf Ag | Use of copolymers as solubilizers for sparingly water-soluble compounds |
US20070190180A1 (en) * | 2005-11-08 | 2007-08-16 | Pilkiewicz Frank G | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously |
US9107824B2 (en) | 2005-11-08 | 2015-08-18 | Insmed Incorporated | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
US20070190181A1 (en) * | 2005-11-08 | 2007-08-16 | Pilkiewicz Frank G | Methods of treating cancer with lipid-based platinum compound forumulations administered intravenously |
WO2007056264A2 (en) * | 2005-11-08 | 2007-05-18 | Transave, Inc. | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
JP5366554B2 (en) | 2005-11-12 | 2013-12-11 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | FGF2-related methods for diagnosing and treating depression |
DK3045182T3 (en) | 2005-11-14 | 2018-03-19 | Teva Pharmaceuticals Int Gmbh | ANTAGONIST ANTIBODIES AGAINST CALCITONIN GEN-RELATED PEPTIDE TO TREAT HEAT |
PE20070684A1 (en) | 2005-11-14 | 2007-08-06 | Amgen Inc | RANKL-PTH / PTHrP ANTIBODY CHEMERICAL MOLECULES |
MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
WO2007056858A1 (en) | 2005-11-18 | 2007-05-24 | Glenmark Pharmaceuticals S.A. | Anti-alpha2 integrin antibodies and their uses |
JP2009516710A (en) | 2005-11-21 | 2009-04-23 | アイシス ファーマシューティカルズ, インコーポレーテッド | Modulating the expression of eIF4E-BP2 |
CA2630432A1 (en) | 2005-11-21 | 2007-07-19 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
US20070122350A1 (en) * | 2005-11-30 | 2007-05-31 | Transave, Inc. | Safe and effective methods of administering therapeutic agents |
EP1979379B1 (en) | 2005-12-02 | 2013-09-18 | Dana-Farber Cancer Institute | Carbonic anhydrase ix (g250) antibodies and methods of use thereof |
JP2009518314A (en) | 2005-12-02 | 2009-05-07 | ジェネンテック・インコーポレーテッド | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling comprising antibodies that bind IL-22 and antibodies that bind IL-22R |
CN101365424A (en) * | 2005-12-08 | 2009-02-11 | 耶路撒冷希伯来大学伊森姆研究发展公司 | Methods for affecting liposome composition by ultrasound irradiation |
EP1962908A2 (en) * | 2005-12-09 | 2008-09-03 | Basf Se | Use of polyvinyl lactam-polyoxyalkylene block copolymers as solubilisers for poorly water-soluble compounds |
US9149543B2 (en) | 2005-12-15 | 2015-10-06 | The Trustees Of The University Of Pennsylvania | Methods and models for rapid, widespread delivery of genetic material to the CNS using non-viral, cationic lipid-mediated vectors |
WO2007082154A2 (en) * | 2006-01-05 | 2007-07-19 | Mayo Foundation For Medical Education And Research | B7-h1 and b7-h4 in cancer |
CA2636149A1 (en) * | 2006-01-05 | 2007-07-19 | Novartis Ag | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
WO2007082144A2 (en) * | 2006-01-05 | 2007-07-19 | Mayo Foundation For Medical Education And Research | B7-h1 and survivin in cancer |
PT2264060E (en) | 2006-01-26 | 2014-07-28 | Recopharma Ab | Compositions and methods for inhibiting viral adhesion |
EP2422819B1 (en) | 2006-01-26 | 2017-03-01 | Ionis Pharmaceuticals, Inc. | Compositions and their uses directed to Huntingtin |
US7829097B2 (en) * | 2006-02-06 | 2010-11-09 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of HMGB1 for protection against ischemia reperfusion injury |
CA2638821A1 (en) | 2006-02-17 | 2007-10-11 | Genentech, Inc. | Gene disruptons, compositions and methods relating thereto |
EP2650306A1 (en) | 2006-03-06 | 2013-10-16 | Aeres Biomedical Limited | Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
US20070218116A1 (en) * | 2006-03-14 | 2007-09-20 | Schwendener Reto A | Compositions and methods for the treatment of tumors and tumor metastases |
US9119782B2 (en) | 2006-03-20 | 2015-09-01 | Mary P. McCourt | Drug delivery means |
PL1989231T3 (en) | 2006-03-21 | 2015-10-30 | Genentech Inc | Combinatorial therapy involving alpha5beta1 antagonists |
EP2389946A1 (en) | 2006-03-23 | 2011-11-30 | Novartis AG | Anti-tumor cell antigen antibody therapeutics |
EP2527354A1 (en) | 2006-03-31 | 2012-11-28 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Eg5 gene |
WO2007126455A2 (en) | 2006-04-05 | 2007-11-08 | Genentech, Inc. | Method for using boc/cdo to modulate hedgehog signaling |
EP2082645A1 (en) | 2006-04-19 | 2009-07-29 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
US8758723B2 (en) | 2006-04-19 | 2014-06-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for cellular imaging and therapy |
WO2007124361A2 (en) * | 2006-04-20 | 2007-11-01 | Mayo Foundation For Medical Education And Research | Soluble b7-h1 |
EP2881468B1 (en) | 2006-04-21 | 2017-04-12 | Intervet International B.V. | Pestivirus species |
EP2051585A4 (en) * | 2006-04-28 | 2010-06-02 | Univ South Florida | Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor |
WO2007127428A2 (en) * | 2006-04-28 | 2007-11-08 | University Of Florida Research Foundation, Inc. | Double-stranded/self-complementary vectors with a truncated cba promoter and methods of gene delivery |
US7691824B2 (en) | 2006-04-28 | 2010-04-06 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a gene from the JC virus |
WO2008018932A2 (en) * | 2006-05-01 | 2008-02-14 | The Board Of Trustees Of The Leland Stanford Junior University | Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury |
MX2008014005A (en) * | 2006-05-03 | 2009-01-27 | Baltic Technology Dev Ltd | Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease. |
US20070264322A1 (en) * | 2006-05-10 | 2007-11-15 | Huang Ken S | Method for making liposomes conjugated with temperature-sensitive ligands |
EP2522678A1 (en) | 2006-05-15 | 2012-11-14 | Sea Lane Biotechnologies, LLC | Neutralizing antibodies to influenza viruses |
EP2023813A4 (en) * | 2006-05-15 | 2013-03-13 | Dmitri B Kirpotin | Magnetic microparticles comprising organic substances |
US8106013B2 (en) * | 2006-05-19 | 2012-01-31 | Georgia Tech Research Corporation | ABC transporter ligand GATX1 |
CA2652770A1 (en) | 2006-05-19 | 2007-11-29 | Alnylam Pharmaceuticals, Inc. | Rnai modulation of aha and therapeutic uses thereof |
WO2007137220A2 (en) * | 2006-05-22 | 2007-11-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of ikk-b gene |
US20090209625A1 (en) * | 2006-05-23 | 2009-08-20 | Sanjay Bhanot | Modulation of chrebp expression |
US8598333B2 (en) * | 2006-05-26 | 2013-12-03 | Alnylam Pharmaceuticals, Inc. | SiRNA silencing of genes expressed in cancer |
US7862812B2 (en) | 2006-05-31 | 2011-01-04 | Lpath, Inc. | Methods for decreasing immune response and treating immune conditions |
US7915399B2 (en) * | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
KR101376634B1 (en) | 2006-06-19 | 2014-03-27 | 더 존스 홉킨스 유니버시티 | Tumor-specific delivery of therapeutic agents via liposomase |
US7981425B2 (en) * | 2006-06-19 | 2011-07-19 | Amgen Inc. | Thrombopoietic compounds |
WO2008019199A2 (en) | 2006-06-26 | 2008-02-14 | Macrogenics, Inc. | FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
ES2376396T3 (en) | 2006-06-26 | 2012-03-13 | Amgen Inc. | METHOD TO TREAT ATEROSCLEROSIS. |
JP5072275B2 (en) * | 2006-07-03 | 2012-11-14 | テルモ株式会社 | Method for separating closed vesicles, method for producing preparation and evaluation method |
JP5248494B2 (en) | 2006-07-11 | 2013-07-31 | ユニバーシティ・オブ・メディシン・アンド・デンティストリー・オブ・ニュージャージー | Protein, nucleic acid encoding it and related methods of use |
EP2049138A4 (en) * | 2006-07-14 | 2011-11-09 | Georgia Tech Res Inst | Clc channel ligand |
US8343539B2 (en) | 2006-07-14 | 2013-01-01 | Regents Of The University Of Minnesota | Compounds that bind α5β1 integrin and methods of use |
US8198253B2 (en) | 2006-07-19 | 2012-06-12 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to HBXIP |
EP2046809B1 (en) | 2006-07-19 | 2016-12-07 | The Trustees Of The University Of Pennsylvania | Wsx-1/il-27 as a target for anti-inflammatory responses |
JP4936312B2 (en) * | 2006-07-20 | 2012-05-23 | 株式会社島津製作所 | Novel amphiphile, drug delivery system and molecular imaging system using the same |
WO2008013918A2 (en) * | 2006-07-26 | 2008-01-31 | Myelin Repair Foundation, Inc. | Cell cycle regulation and differentiation |
RU2009107707A (en) | 2006-08-04 | 2010-09-10 | Новартис АГ (CH) | SPECIFIC TO EphB3 ANTIBODY AND ITS APPLICATION |
AU2007284651B2 (en) | 2006-08-09 | 2014-03-20 | Institute For Systems Biology | Organ-specific proteins and methods of their use |
DK2383297T5 (en) | 2006-08-14 | 2022-07-04 | Xencor Inc | Optimized antibodies directed against CD19 |
EP3415532A1 (en) | 2006-08-18 | 2018-12-19 | XOMA Technology Ltd. | Prlr-specific antibody and uses thereof |
EP2423332A1 (en) | 2006-08-25 | 2012-02-29 | Oncotherapy Science, Inc. | Prognostic markers and therapeutic targets for lung cancer |
KR101314362B1 (en) | 2006-08-28 | 2013-10-10 | 라 졸라 인스티튜트 포 앨러지 앤드 이뮤놀로지 | Antagonistic human light-specific human monoclonal antibodies |
EP2056856B1 (en) | 2006-08-29 | 2015-01-14 | Genentech, Inc. | Use of tenecteplase for treating acute ischemic stroke |
CN101522713A (en) | 2006-09-01 | 2009-09-02 | 津莫吉尼蒂克斯公司 | Variable region sequences of IL-31 monoclonal antibodies and methods of use |
CA2600220C (en) * | 2006-09-07 | 2014-12-09 | Canadian Blood Services | Surface cross-linked lipidic particles, methods of production and uses therefor |
SI2066694T1 (en) | 2006-09-29 | 2016-02-29 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
CN101557818A (en) | 2006-10-03 | 2009-10-14 | 新泽西医科和牙科大学 | ATAP peptides, nucleic acids encoding the same and associated methods of use |
US10925977B2 (en) | 2006-10-05 | 2021-02-23 | Ceil>Point, LLC | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
AU2007343796A1 (en) * | 2006-10-25 | 2008-07-24 | Amgen Inc. | Toxin peptide therapeutic agents |
PT2087002E (en) * | 2006-10-27 | 2014-11-26 | Lpath Inc | Compositions and methods for binding sphingosine-1-phosphate |
WO2008055072A2 (en) | 2006-10-27 | 2008-05-08 | Lpath, Inc. | Compositions and methods for treating ocular diseases and conditions |
US8158595B2 (en) | 2006-11-09 | 2012-04-17 | California Institute Of Technology | Modular aptamer-regulated ribozymes |
CA2669088C (en) * | 2006-11-10 | 2016-04-05 | Dimerix Bioscience Pty Ltd | Detection system and uses therefor |
US20100216820A1 (en) * | 2006-11-13 | 2010-08-26 | White Stephen L | Thienopyrimidiones for treatment of inflammatory disorders and cancers |
EP2962697A1 (en) | 2006-11-27 | 2016-01-06 | diaDexus, Inc. | Ovr110 antibody compositions and methods of use |
BRPI0720437A2 (en) | 2006-12-07 | 2014-01-07 | Novartis Ag | ANHPHONE ANTIBODIES AGAINST EPHB3 |
EP1932517A3 (en) * | 2006-12-11 | 2008-07-16 | Universiteit Utrecht Holding B.V. | Liposomes containing a polyphenol derivative such as caffeic acid and a method of post-loading thereof |
WO2008076964A1 (en) * | 2006-12-18 | 2008-06-26 | The Johns Hopkins University | Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of atp production |
US8278415B2 (en) | 2006-12-21 | 2012-10-02 | Centocor, Inc. | Dimeric high affinity EGFR constructs and uses thereof |
WO2008079982A2 (en) | 2006-12-21 | 2008-07-03 | Centocor, Inc. | Liposome composition for targeting egfr receptor |
US8536113B2 (en) * | 2006-12-21 | 2013-09-17 | Janssen Biotech, Inc. | EGFR binding peptides and uses thereof |
US20100129358A1 (en) | 2006-12-22 | 2010-05-27 | University Of Utah Research Foundation | Method of detecting ocular diseases and pathologic conditions and treatment of same |
US8440185B2 (en) * | 2006-12-26 | 2013-05-14 | The Johns Hopkins University | Compositions and methods for the treatment of immunologic disorders |
WO2008083239A2 (en) * | 2006-12-27 | 2008-07-10 | The Johns Hopkins University | Compositions and methods for stimulating an immune response |
US20090142342A1 (en) * | 2006-12-27 | 2009-06-04 | Johns Hopkins University | B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases |
US7989173B2 (en) | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
US7638541B2 (en) * | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
EP2118118B1 (en) * | 2007-01-19 | 2017-09-27 | Exiqon A/S | Mediated cellular delivery of lna oligonucleotides |
US20100329664A1 (en) * | 2007-01-23 | 2010-12-30 | Lim Dae-Soon | Shutter device for camera |
US20100093836A1 (en) | 2007-01-29 | 2010-04-15 | Isis Pharmaceuticals, Inc | Compounds and methods for modulating protein expression |
US8389482B2 (en) | 2007-01-30 | 2013-03-05 | New York University | Short peptides useful for treatment of ischemia/reperfusion injury and other tissue damage conditions associated with nitric oxide and its reactive species |
ES2556380T3 (en) | 2007-02-22 | 2016-01-15 | Genentech, Inc. | Procedures to detect inflammatory bowel disease |
CN103432580A (en) | 2007-03-02 | 2013-12-11 | 健泰科生物技术公司 | Predicting response to a HER dimerisation inhibitor based on low HER3 expression |
WO2008114274A1 (en) * | 2007-03-19 | 2008-09-25 | Fresenius Kabi Onclology Ltd. | Proliposomal and liposomal compositions |
JP4510842B2 (en) * | 2007-03-26 | 2010-07-28 | キヤノン株式会社 | Polyhydroxyalkanoate-coated liposome |
AU2008232891B2 (en) | 2007-03-29 | 2012-01-12 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a gene from the Ebola |
EP2164868B1 (en) | 2007-05-04 | 2015-03-25 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA | Engineered rabbit antibody variable domains and uses thereof |
RU2549701C2 (en) | 2007-05-07 | 2015-04-27 | Медиммун, Ллк | Anti-icos antibodies and their application in treatment of oncological, transplantation-associated and autoimmune diseases |
US20090196913A1 (en) * | 2007-05-11 | 2009-08-06 | Ken Shi Kun Huang | Anti-Alpha-V Immunoliposome Composition, Methods, and Uses |
WO2008141278A1 (en) * | 2007-05-11 | 2008-11-20 | Centocor, Inc. | Method for preparing antibody conjugates |
US20090175784A1 (en) * | 2007-05-11 | 2009-07-09 | Joshua Goldstein | Anti-Alpha V Immunoliposome Composition, Methods, and Uses |
US8546539B2 (en) | 2007-05-14 | 2013-10-01 | Novimmune S.A. | Fc receptor-binding polypeptides with modified effector functions |
EP2160200B1 (en) | 2007-05-14 | 2013-07-10 | The University of Chicago | Antibody-LIGHT fusion products as cancer therapeutics |
WO2008153745A2 (en) | 2007-05-22 | 2008-12-18 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
WO2008148023A2 (en) * | 2007-05-23 | 2008-12-04 | Medical College Of Georgia Research Institute, Inc. | Compositions and methods for treating neurological disorders |
US8956825B2 (en) | 2007-05-24 | 2015-02-17 | The United States Of America As Represented By The Department Of Veterans Affairs | Intranuclear protein transduction through a nucleoside salvage pathway |
US8158124B2 (en) * | 2007-05-30 | 2012-04-17 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
EP3392273A1 (en) | 2007-05-30 | 2018-10-24 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
US9163091B2 (en) * | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
AR066984A1 (en) * | 2007-06-15 | 2009-09-23 | Novartis Ag | INHIBITION OF THE EXPRESSION OF THE ALFA SUBUNITY OF THE SODIUM EPITELIAL CHANNEL (ENAC) THROUGH ARNI (INTERFERENCE RNA) |
TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
CN101784564B (en) | 2007-07-13 | 2014-07-02 | 约翰霍普金斯大学 | B7-DC variants |
ES2381788T3 (en) | 2007-07-16 | 2012-05-31 | Genentech, Inc. | Anti-CD79b and immunoconjugate antibodies and methods of use |
SG183044A1 (en) | 2007-07-16 | 2012-08-30 | Genentech Inc | Humanized anti-cd79b antibodies and immunoconjugatesand methods of use |
WO2009011855A2 (en) * | 2007-07-16 | 2009-01-22 | California Institute Of Technology | Selection of nucleic acid-based sensor domains within nucleic acid switch platform |
AU2008279447A1 (en) * | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders |
JP2010534730A (en) * | 2007-07-26 | 2010-11-11 | ビーエーエスエフ ソシエタス・ヨーロピア | Process for the preparation of solid-form copolymers based on polyethers obtained by graft polymerization in solution |
CA2694590A1 (en) | 2007-07-26 | 2009-01-29 | Amgen Inc. | Modified lecithin-cholesterol acyltransferase enzymes |
US7666973B2 (en) | 2007-07-30 | 2010-02-23 | Tyco Healthcare Group Lp | Carbonate copolymers |
EP2537529B1 (en) | 2007-08-02 | 2018-10-17 | Gilead Biologics, Inc. | Loxl2 inhibitory antibodies and uses thereof |
KR20100046185A (en) * | 2007-08-09 | 2010-05-06 | 다이이찌 산쿄 가부시키가이샤 | Immunoliposome inducing apoptosis into cell expressing death domain-containing receptor |
US20090048423A1 (en) * | 2007-08-15 | 2009-02-19 | Tyco Healthcare Group Lp | Phospholipid Copolymers |
US8268958B2 (en) | 2007-08-15 | 2012-09-18 | Tyco Healthcare Group Ip | Phospholipid copolymers |
US8367815B2 (en) * | 2007-08-28 | 2013-02-05 | California Institute Of Technology | Modular polynucleotides for ligand-controlled regulatory systems |
US20120165387A1 (en) | 2007-08-28 | 2012-06-28 | Smolke Christina D | General composition framework for ligand-controlled RNA regulatory systems |
EP2197890A1 (en) * | 2007-09-07 | 2010-06-23 | Gencia Corporation | Mitochondrial compositions and uses thereof |
US8865667B2 (en) * | 2007-09-12 | 2014-10-21 | California Institute Of Technology | Higher-order cellular information processing devices |
AU2008302035A1 (en) * | 2007-09-21 | 2009-03-26 | Cytimmune Sciences, Inc. | Nanotherapeutic colloidal metal compositions and methods |
US20110014118A1 (en) * | 2007-09-21 | 2011-01-20 | Lawrence Tamarkin | Nanotherapeutic colloidal metal compositions and methods |
JP5731198B2 (en) * | 2007-09-27 | 2015-06-10 | イムノバクシーン・テクノロジーズ・インコーポレイテッドImmunovaccine Technologies Inc. | Use of liposomes in carriers containing a continuous hydrophobic phase for delivery of polynucleotides in vivo |
CN101878229A (en) | 2007-09-28 | 2010-11-03 | 巴塞尔大学医院 | Immunoliposomes for treatment of cancer |
EP2205741A2 (en) | 2007-10-02 | 2010-07-14 | Amgen Inc. | Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof |
US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
AU2008313248B2 (en) * | 2007-10-16 | 2012-04-26 | Biocon Limited | An orally administerable solid pharmaceutical composition and a process thereof |
US8361465B2 (en) * | 2007-10-26 | 2013-01-29 | Lpath, Inc. | Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents |
CA2703705A1 (en) | 2007-11-05 | 2009-05-14 | Medimmune, Llc | Methods of treating scleroderma |
JP2011502502A (en) * | 2007-11-05 | 2011-01-27 | バルティック テクロノジー デヴェロプメント,リミテッド | Use of oligonucleotides containing modified bases in nucleic acid hybridization |
AU2008323770B2 (en) | 2007-11-07 | 2014-08-07 | Genentech, Inc. | Compositions and methods for treatment of microbial disorders |
MX2010005244A (en) | 2007-11-12 | 2010-10-25 | Theraclone Sciences Inc | Compositions and methods for the therapy and diagnosis of influenza. |
US20110033476A1 (en) * | 2007-11-12 | 2011-02-10 | Theraclone Sciences Inc. | Compositions and methods for the therapy and diagnosis of influenza |
US8598165B2 (en) * | 2007-11-26 | 2013-12-03 | University Of Kansas | Morpholines as selective inhibitors of cytochrome P450 2A13 |
AU2008338691B2 (en) | 2007-12-06 | 2015-01-22 | Burnham Institute For Medical Research | Antibodies against influenza virus and methods of use thereof |
ME03057B (en) | 2007-12-07 | 2019-01-20 | Zymogenetics Inc | Humanized antibody molecules specific for il-31 |
JP5530933B2 (en) | 2007-12-10 | 2014-06-25 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | Compositions and methods for inhibiting factor VII gene expression |
US9029524B2 (en) * | 2007-12-10 | 2015-05-12 | California Institute Of Technology | Signal activated RNA interference |
JP5737944B2 (en) | 2007-12-17 | 2015-06-17 | ファイザー・リミテッドPfizer Limited | Treatment of interstitial cystitis |
WO2009086514A1 (en) | 2007-12-28 | 2009-07-09 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
WO2009086558A1 (en) | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
US20090181094A1 (en) * | 2008-01-15 | 2009-07-16 | Eric Yueh-Lang Sheu | Molecular Cage for Sustained Release Control of Pharmaceutical and Cosmetic Agents |
AR070141A1 (en) * | 2008-01-23 | 2010-03-17 | Glenmark Pharmaceuticals Sa | SPECIFIC HUMANIZED ANTIBODIES FOR VON WILLEBRAND FACTOR |
TWI472339B (en) | 2008-01-30 | 2015-02-11 | Genentech Inc | Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof |
UA106586C2 (en) | 2008-01-31 | 2014-09-25 | Дженентек, Інк. | Anti-cd79b antibodies and imunokonugate and methods for their use |
WO2009111315A2 (en) * | 2008-02-29 | 2009-09-11 | Mayo Foundation For Medical Education And Research | Methods for reducing granulomatous inflammation |
EA019531B1 (en) | 2008-03-05 | 2014-04-30 | Элнилэм Фармасьютикалз, Инк. | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES |
CA2718878A1 (en) | 2008-03-10 | 2009-09-17 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of cytomegalovirus |
EP2105145A1 (en) * | 2008-03-27 | 2009-09-30 | ETH Zürich | Method for muscle-specific delivery lipid-conjugated oligonucleotides |
AU2009228058A1 (en) | 2008-03-28 | 2009-10-01 | Sea Lane Biotechnologies, Llc | Neutralizing molecules to viral antigens |
JP5711655B2 (en) * | 2008-03-31 | 2015-05-07 | シマベイ セラピューティクス, インコーポレーテッド | Oxymethylene aryl compounds and uses thereof |
BRPI0911332A2 (en) | 2008-04-04 | 2019-09-24 | Calando Pharmaceuticals Inc | compositions and use of epas1 inhibitors |
MX364200B (en) | 2008-04-09 | 2019-04-16 | Genentech Inc | Novel compositions and methods for the treatment of immune related diseases. |
EP2274437B1 (en) | 2008-04-10 | 2015-12-23 | Cell Signaling Technology, Inc. | Compositions and methods for detecting egfr mutations in cancer |
JP5475753B2 (en) | 2008-04-15 | 2014-04-16 | プロチバ バイオセラピューティクス インコーポレイティッド | Lipid formulations for nucleic acid delivery |
EP2280995A2 (en) * | 2008-04-29 | 2011-02-09 | Wyeth LLC | Methods for treating inflammation |
US8324366B2 (en) | 2008-04-29 | 2012-12-04 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for delivering RNAI using lipoproteins |
WO2009136297A2 (en) * | 2008-05-09 | 2009-11-12 | Recopharma Ab | Compositions and methods for inhibiting toxin a from clostridium difficile |
AU2009245358A1 (en) * | 2008-05-09 | 2009-11-12 | Recopharma Ab | Compositions and methods for inhibiting shiga toxin and shiga-like toxin |
EP2279004B1 (en) | 2008-05-16 | 2015-01-14 | F. Hoffmann-La Roche AG | Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists |
US8093018B2 (en) | 2008-05-20 | 2012-01-10 | Otsuka Pharmaceutical Co., Ltd. | Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same |
WO2009140853A1 (en) * | 2008-05-23 | 2009-11-26 | The University Of Hong Kong | Combination therapy for the treatment of influenza |
EP2296696B1 (en) | 2008-06-05 | 2014-08-27 | ImmunoVaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
WO2009148121A1 (en) | 2008-06-05 | 2009-12-10 | 株式会社 島津製作所 | Novel molecular assembly, molecular probe for molecular imaging and molecular probe for drug delivery system using the same, and molecular imaging system and drug delivery system |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
WO2009150623A1 (en) | 2008-06-13 | 2009-12-17 | Pfizer Inc | Treatment of chronic prostatitis |
WO2009155431A1 (en) * | 2008-06-18 | 2009-12-23 | University Of Louisville Research Foundation, Inc. | Methods for targeted cancer treatment and detection |
US20100003315A1 (en) | 2008-07-02 | 2010-01-07 | Willeford Kenneth L | Method and Composition for the Treatment of Skin Conditions |
US8435513B2 (en) | 2008-07-08 | 2013-05-07 | Oncomed Pharmaceuticals, Inc. | NOTCH1 receptor antibodies and methods of treatment |
KR101647334B1 (en) * | 2008-07-10 | 2016-08-10 | 세리나 쎄라퓨틱스, 인코포레이티드 | Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds |
US20100008900A1 (en) * | 2008-07-14 | 2010-01-14 | The University Of Hong Kong | Annexin ii compositions for treating or monitoring inflammation or immune-mediated disorders |
US8815818B2 (en) | 2008-07-18 | 2014-08-26 | Rxi Pharmaceuticals Corporation | Phagocytic cell delivery of RNAI |
US20110237646A1 (en) * | 2008-08-07 | 2011-09-29 | Isis Pharmaceuticals, Inc. | Modulation of transthyretin expression for the treatment of cns related disorders |
US8652843B2 (en) | 2008-08-12 | 2014-02-18 | Oncomed Pharmaceuticals, Inc. | DDR1-binding agents and methods of use thereof |
AU2009282451B2 (en) | 2008-08-15 | 2014-02-13 | Georgetown University | Fluorescent regulators of RASSF1A expression and human cancer cell proliferation |
US9492417B2 (en) * | 2008-08-21 | 2016-11-15 | The Johns Hopkins University | Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer |
EP2367812B1 (en) | 2008-08-22 | 2015-09-16 | Sanofi | [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4trifluoromethoxy-1h-indol-3-yl]methanone as an inhibitor of mast cell tryptase |
US20110159023A1 (en) * | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
WO2010027818A2 (en) | 2008-08-25 | 2010-03-11 | Dana-Farber Cancer Institute, Inc. | Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use |
AU2009275387B2 (en) | 2008-08-25 | 2010-07-08 | Excaliard Pharmaceuticals, Inc. | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
EP2331690B1 (en) | 2008-09-02 | 2016-01-13 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of mutant egfr gene |
CN102149728B (en) | 2008-09-10 | 2014-10-15 | 霍夫曼-拉罗奇有限公司 | Methods for inhibiting ocular angiogenesis |
TWI516501B (en) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9 antagonists |
TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
CN108165548B (en) | 2008-09-22 | 2022-10-14 | 菲奥医药公司 | Reduced size self-delivering RNAi compounds |
EP2334793B1 (en) | 2008-09-25 | 2016-04-06 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of serum amyloid a gene |
EP2743265B1 (en) | 2008-10-09 | 2017-03-15 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
JP2012505243A (en) | 2008-10-09 | 2012-03-01 | ノースイースタン・ユニバーシティ | Multifunctional self-assembled polymer nanosystem |
IL302142B1 (en) | 2008-10-20 | 2024-03-01 | Alnylam Pharmaceuticals Inc | Compositions and Methods for Inhabiting Expression of TRANSTHYRETIN |
JP5382380B2 (en) * | 2008-10-21 | 2014-01-08 | インターナショナル ワクチン インスティテュート | Novel Shigella protein antigen and method |
JP2012506386A (en) | 2008-10-21 | 2012-03-15 | メタボレックス, インコーポレイテッド | Aryl GPR120 receptor agonist and uses thereof |
US8871202B2 (en) | 2008-10-24 | 2014-10-28 | Lpath, Inc. | Prevention and treatment of pain using antibodies to sphingosine-1-phosphate |
MX2011004696A (en) * | 2008-11-06 | 2011-10-14 | Glenmark Pharmaceuticals Sa | Treatment with anti-alpha2 integrin antibodies. |
EP3207944B1 (en) | 2008-11-10 | 2020-01-15 | Arbutus Biopharma Corporation | Novel lipids and compositions for the delivery of therapeutics |
US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
WO2010057048A1 (en) | 2008-11-13 | 2010-05-20 | Calistoga Pharmaceuticals Inc. | Therapies for hematologic malignancies |
CA2744158A1 (en) | 2008-11-22 | 2010-05-27 | Genentech, Inc. | Anti-angiogenesis therapy for the treatment of breast cancer |
US20110230399A1 (en) * | 2008-11-25 | 2011-09-22 | Bowen Richard L | Methods for Treating Obesity Related Disease |
US20110160222A1 (en) * | 2008-11-26 | 2011-06-30 | Metabolex, Inc. | Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders |
EP2370580B1 (en) | 2008-12-04 | 2019-09-11 | CuRNA, Inc. | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1 |
CN102317458B (en) | 2008-12-04 | 2018-01-02 | 库尔纳公司 | Pass through treatment of the suppression of erythropoietin(EPO) (EPO) natural antisense transcript to EPO relevant diseases |
WO2010065787A2 (en) | 2008-12-04 | 2010-06-10 | Curna, Inc. | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
WO2010068680A1 (en) | 2008-12-10 | 2010-06-17 | Mount Sinai School Of Medicine Of New York University | Thelper cell type 17 lineage-specific adjuvants, compositions and methods |
AU2009324534B2 (en) | 2008-12-10 | 2015-07-30 | Alnylam Pharmaceuticals, Inc. | GNAQ targeted dsRNA compositions and methods for inhibiting expression |
AR074760A1 (en) * | 2008-12-18 | 2011-02-09 | Metabolex Inc | GPR120 RECEIVER AGONISTS AND USES OF THE SAME IN MEDICINES FOR THE TREATMENT OF DIABETES AND METABOLIC SYNDROME. |
AR074776A1 (en) | 2008-12-18 | 2011-02-09 | Sanofi Aventis | METHOD TO TREAT MACULAR DEGENERATION; MODULATING THE PATIENT'S IMMUNE SYSTEM |
RU2532341C2 (en) * | 2008-12-22 | 2014-11-10 | Креабилис С.А. | Synthesis of polymer conjugates of indolocarbazole compounds |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
CA2748057C (en) | 2008-12-23 | 2018-07-03 | Pharmasset, Inc. | Nucleoside phosphoramidates |
NZ617066A (en) * | 2008-12-23 | 2015-02-27 | Gilead Pharmasset Llc | Nucleoside analogs |
EP2671888A1 (en) | 2008-12-23 | 2013-12-11 | Gilead Pharmasset LLC | 3',5'-cyclic nucleoside phosphate analogues |
WO2010078536A1 (en) | 2009-01-05 | 2010-07-08 | Rxi Pharmaceuticals Corporation | Inhibition of pcsk9 through rnai |
WO2010088537A2 (en) | 2009-01-29 | 2010-08-05 | Alnylam Pharmaceuticals, Inc. | Improved lipid formulation |
WO2010086828A2 (en) | 2009-02-02 | 2010-08-05 | Rinat Neuroscience Corporation | Agonist anti-trkb monoclonal antibodies |
WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
CA2752239C (en) | 2009-02-12 | 2021-03-30 | Opko Curna, Llc | Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf |
JP5766126B2 (en) | 2009-02-12 | 2015-08-19 | クルナ・インコーポレーテッド | Treatment of brain-derived neurotrophic factor (BDNF) -related diseases by suppression of natural antisense transcripts against BDNF |
US8329882B2 (en) | 2009-02-18 | 2012-12-11 | California Institute Of Technology | Genetic control of mammalian cells with synthetic RNA regulatory systems |
US20120041051A1 (en) | 2009-02-26 | 2012-02-16 | Kevin Fitzgerald | Compositions And Methods For Inhibiting Expression Of MIG-12 Gene |
WO2010101951A1 (en) | 2009-03-02 | 2010-09-10 | Alnylam Pharmaceuticals, Inc. | Nucleic acid chemical modifications |
EP2403946A4 (en) | 2009-03-04 | 2012-11-14 | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1 | |
EP2228059A1 (en) | 2009-03-12 | 2010-09-15 | Universitätsspital Basel | Chemotherapeutic composition for the treatment of cancer |
US20100267806A1 (en) | 2009-03-12 | 2010-10-21 | David Bumcrot | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES |
CN102482677B (en) | 2009-03-16 | 2017-10-17 | 库尔纳公司 | Nuclear factor (red blood cell derives 2) sample 2 (NRF2) relevant disease is treated by suppressing NRF2 natural antisense transcript |
SI3260136T1 (en) | 2009-03-17 | 2021-05-31 | Theraclone Sciences, Inc. | Human immunodeficiency virus (hiv) -neutralizing antibodies |
CN102549159B (en) | 2009-03-17 | 2016-08-10 | 库尔纳公司 | By suppressing to treat the disease that DLK1 is correlated with for the natural antisense transcript of δ sample 1 congener (DLK1) |
EP2411391A1 (en) | 2009-03-24 | 2012-02-01 | Gilead Calistoga LLC | Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use |
TWI504409B (en) | 2009-03-25 | 2015-10-21 | Genentech Inc | Novel anti-α5β1 antibodies and uses thereof |
EP2413967A1 (en) | 2009-04-01 | 2012-02-08 | F. Hoffmann-La Roche AG | Treatment of insulin-resistant disorders |
RU2587621C2 (en) | 2009-04-01 | 2016-06-20 | Дженентек, Инк. | ANTI-FcRH5 ANTIBODIES, IMMUNOCONJUGATES THEREOF AND METHODS FOR USE THEREOF |
US9145555B2 (en) | 2009-04-02 | 2015-09-29 | California Institute Of Technology | Integrated—ligand-responsive microRNAs |
WO2010123931A1 (en) * | 2009-04-20 | 2010-10-28 | Calistoga Pharmaceuticals Inc. | Methods of treatment for solid tumors |
EP3248618A1 (en) | 2009-04-22 | 2017-11-29 | Massachusetts Institute Of Technology | Innate immune suppression enables repeated delivery of long rna molecules |
WO2010124163A2 (en) | 2009-04-23 | 2010-10-28 | Theraclone Sciences, Inc. | Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies |
CN102459346B (en) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | The method manufacturing heteromultimers molecule |
EP2248903A1 (en) | 2009-04-29 | 2010-11-10 | Universitat Autònoma De Barcelona | Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages |
US8524784B2 (en) * | 2009-04-30 | 2013-09-03 | Intezyne Technologies, Incorporated | Polymer micelles containing anthracylines for the treatment of cancer |
US8524783B2 (en) | 2009-04-30 | 2013-09-03 | Intezyne Technologies, Incorporated | Polymer micelles containing anthracylines for the treatment of cancer |
DK2424987T3 (en) | 2009-05-01 | 2018-02-26 | Curna Inc | TREATMENT OF HEMOGLOBIN (HBF / HBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPTION TO HBF / HBG |
JP6053517B2 (en) | 2009-05-05 | 2016-12-27 | ノヴィミュンヌ エスア | Anti-IL-17F antibodies and methods for their use |
NZ596186A (en) | 2009-05-05 | 2014-03-28 | Alnylam Pharmaceuticals Inc | Lipid compositions |
AU2010245933B2 (en) | 2009-05-05 | 2016-06-16 | Arbutus Biopharma Corporation | Methods of delivering oligonucleotides to immune cells |
WO2010129799A2 (en) | 2009-05-06 | 2010-11-11 | Curna, Inc. | Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene |
ES2609655T3 (en) | 2009-05-06 | 2017-04-21 | Curna, Inc. | Treatment of diseases related to tristetraproline (TTP) by inhibition of natural antisense transcript for TTP |
EP2432881B1 (en) | 2009-05-18 | 2017-11-15 | CuRNA, Inc. | Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor |
TWI576352B (en) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | Nucleoside phosphoramidates |
EP2432499A2 (en) | 2009-05-20 | 2012-03-28 | Schering Corporation | Modulation of pilr receptors to treat microbial infections |
JP2012527473A (en) | 2009-05-20 | 2012-11-08 | セラクローン サイエンシーズ, インコーポレイテッド | Compositions and methods for the treatment and diagnosis of influenza |
WO2010135695A2 (en) | 2009-05-22 | 2010-11-25 | Curna, Inc. | TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3 |
ES2618576T3 (en) | 2009-05-28 | 2017-06-21 | Curna, Inc. | Treatment of diseases related to an antiviral gene by inhibiting a natural antisense transcript to an antiviral gene |
HUE038796T2 (en) | 2009-06-10 | 2018-11-28 | Arbutus Biopharma Corp | Improved lipid formulation |
EP2440250A1 (en) | 2009-06-11 | 2012-04-18 | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. | Targeted liposomes comprising n-containing bisphosphonates and uses thereof |
WO2010148050A2 (en) | 2009-06-16 | 2010-12-23 | Curna, Inc. | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
JP6128846B2 (en) | 2009-06-16 | 2017-05-17 | クルナ・インコーポレーテッド | Treatment of PON1 gene-related diseases by suppression of natural antisense transcripts against paraoxonase (PON1) |
WO2010146511A1 (en) | 2009-06-17 | 2010-12-23 | Pfizer Limited | Treatment of overactive bladder |
WO2010151671A2 (en) | 2009-06-24 | 2010-12-29 | Curna, Inc. | Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
CA2765815A1 (en) | 2009-06-26 | 2010-12-29 | Opko Curna, Llc | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
WO2010151808A1 (en) | 2009-06-26 | 2010-12-29 | Sea Lane Biotechnologies, Llc | Expression of surrogate light chains |
US8487083B2 (en) | 2009-06-30 | 2013-07-16 | OOO “Oncomax” | Monoclonal antibodies capable of simultaneously binding domains II and IIIc of type 1 fibroblast growth factor receptor |
US9018187B2 (en) | 2009-07-01 | 2015-04-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
ES2613498T3 (en) | 2009-07-01 | 2017-05-24 | Protiva Biotherapeutics Inc. | New lipid formulations for the delivery of therapeutic agents to solid tumors |
WO2011000106A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Improved cationic lipids and methods for the delivery of therapeutic agents |
WO2011005715A1 (en) | 2009-07-07 | 2011-01-13 | Genentech, Inc. | Diagnosis and treatment of autoimmune demyelinating diseases |
JP5872466B2 (en) * | 2009-07-17 | 2016-03-01 | テクニカル ユニバーシティ オブ デンマークTechnical University Of Denmark | Encapsulation method for producing radionuclide-containing nanoparticles |
EP2456443A1 (en) | 2009-07-21 | 2012-05-30 | Gilead Calistoga LLC | Treatment of liver disorders with pi3k inhibitors |
US9937128B2 (en) * | 2009-08-03 | 2018-04-10 | The University Of North Carolina At Chapel Hill | Liposomes comprising a calcium phosphate-containing precipitate |
CA2769665A1 (en) | 2009-08-05 | 2011-02-10 | Opko Curna, Llc | Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins) |
EP2464336A4 (en) | 2009-08-14 | 2013-11-20 | Alnylam Pharmaceuticals Inc | Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus |
BR112012003346A2 (en) | 2009-08-15 | 2016-11-16 | Genentech Inc | treatment method of a previously treated metastatic breast cancer diagnostic patient previously treated metastatic breast cancer treatment kit in a human patient method to instruct a human cancer patient promotional method and commercial method |
FR2955324A1 (en) | 2010-01-15 | 2011-07-22 | Sanofi Aventis | DISUBSTITUTED 4- (5-AMINOMETHYL-PHENYL) -PIPERIDIN-1-YL] -1H-INDOL-3-YL] -METHANONES |
KR101892760B1 (en) | 2009-08-25 | 2018-08-28 | 큐알엔에이, 인크. | Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap |
CN102666581A (en) | 2009-08-31 | 2012-09-12 | 艾普利穆恩公司 | Methods and compositions for the inhibition of transplant rejection |
US20110059111A1 (en) | 2009-09-01 | 2011-03-10 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Mammalian receptors as targets for antibody and active vaccination therapy against mold infections |
AU2010289400B2 (en) | 2009-09-02 | 2014-10-23 | Curis, Inc. | Mutant smoothened and methods of using the same |
CN102666553B (en) | 2009-10-01 | 2015-05-06 | 赛马拜制药公司 | Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts |
EP4089169A1 (en) | 2009-10-12 | 2022-11-16 | Larry J. Smith | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
RU2573896C2 (en) * | 2009-10-15 | 2016-01-27 | Дженентек, Инк. | Chimeric fibroblast growth factors with changed receptor specificity |
DK2488204T3 (en) | 2009-10-16 | 2016-06-06 | Oncomed Pharm Inc | Therapeutic combination and use of DLL4 antagonist antibodies and blood pressure lowering agents |
WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
CA2778442A1 (en) | 2009-10-22 | 2011-04-28 | Genentech, Inc. | Methods and compositions for modulating hepsin activation of macrophage-stimulating protein |
WO2011053468A1 (en) | 2009-10-30 | 2011-05-05 | Sanofi-Aventis | Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders |
PL2496567T3 (en) | 2009-11-05 | 2018-01-31 | Rhizen Pharmaceuticals S A | Novel benzopyran kinase modulators |
WO2011056234A1 (en) | 2009-11-06 | 2011-05-12 | Fibrogen, Inc. | Treatment for radiation-induced disorders |
CN102770529B (en) | 2009-11-17 | 2018-06-05 | Musc研究发展基金会 | For the human monoclonal antibodies of people's paranuclein |
CN102741294A (en) | 2009-11-30 | 2012-10-17 | 霍夫曼-拉罗奇有限公司 | Antibodies for treating and diagnosing tumors expressing SLC34A2 (TAT211 = SEQID 2) |
WO2011071957A1 (en) | 2009-12-07 | 2011-06-16 | Sea Lane Biotechnologies, Llc | Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties |
WO2011071860A2 (en) | 2009-12-07 | 2011-06-16 | Alnylam Pharmaceuticals, Inc. | Compositions for nucleic acid delivery |
JP2013513588A (en) | 2009-12-11 | 2013-04-22 | ジーンコード エーエス | Method for facilitating survival of neural cells using mimic or RET signaling pathway activators of GDNF family ligand (GFL) |
WO2011081904A1 (en) | 2009-12-14 | 2011-07-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Delivery of transthyretin across the blood-brain barrier as a treatment for alzheimer's disease |
NO2513310T3 (en) | 2009-12-16 | 2018-03-31 | ||
WO2011084357A1 (en) | 2009-12-17 | 2011-07-14 | Schering Corporation | Modulation of pilr to treat immune disorders |
US20130017223A1 (en) | 2009-12-18 | 2013-01-17 | The University Of British Columbia | Methods and compositions for delivery of nucleic acids |
EA027502B1 (en) | 2009-12-23 | 2017-08-31 | Зиниммуне Гмбх | Anti-flt3 antibodies and methods of using the same |
CN102791702A (en) | 2009-12-23 | 2012-11-21 | 赛诺菲 | Prodrugs of [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1H-pyrrolo-pyridin-yl)-methanones and synthesis thereof |
CN102869776B (en) | 2009-12-23 | 2017-06-23 | 库尔纳公司 | HGF relevant diseases are treated by suppressing the natural antisense transcript of HGF (HGF) |
SG181594A1 (en) | 2009-12-23 | 2012-07-30 | Sanofi Sa | [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof |
US9068183B2 (en) | 2009-12-23 | 2015-06-30 | Curna, Inc. | Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2 |
ES2701626T3 (en) | 2009-12-28 | 2019-02-25 | Oncotherapy Science Inc | Anti-CDH3 antibodies and their uses |
CA2785173A1 (en) | 2009-12-29 | 2011-07-28 | Curna, Inc. | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
KR101853508B1 (en) | 2009-12-29 | 2018-06-20 | 큐알엔에이, 인크. | TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63 |
US20110159588A1 (en) | 2009-12-30 | 2011-06-30 | Kui Lin | Methods for Modulating a PDGF-AA Mediated Biological Response |
US8946181B2 (en) | 2010-01-04 | 2015-02-03 | Curna, Inc. | Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8 |
RU2612161C2 (en) | 2010-01-06 | 2017-03-02 | Курна, Инк. | Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to pancreatic developmental gene |
JPWO2011083845A1 (en) * | 2010-01-08 | 2013-05-16 | 富士フイルム株式会社 | Targeting agent for tumor site |
WO2011085347A2 (en) | 2010-01-11 | 2011-07-14 | Opko Curna, Llc | Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg |
TWI535445B (en) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt antagonists and methods of treatment and screening |
WO2011088215A2 (en) | 2010-01-13 | 2011-07-21 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
WO2011090971A2 (en) | 2010-01-19 | 2011-07-28 | The Trustees Of Columbia University In The City Of New York | Osteocalcin as a treatment for male reproductive disorders |
WO2011089211A1 (en) | 2010-01-22 | 2011-07-28 | Synimmune Gmbh | Anti-cd133 antibodies and methods of using the same |
CN102782135A (en) | 2010-01-25 | 2012-11-14 | 库尔纳公司 | Treatment of RNase H1 related diseases by inhibition of natural antisense transcript to RNase H1 |
US8198337B2 (en) * | 2010-01-27 | 2012-06-12 | Momentive Performance Materials Inc. | Demulsifier compositions and methods for separating emulsions using the same |
EP2531175A2 (en) | 2010-02-01 | 2012-12-12 | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. | Liposomes comprising amphipathic drugs and method for their preparation |
CA2790506A1 (en) | 2010-02-22 | 2011-08-25 | Curna, Inc. | Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1 |
BR112012021261A2 (en) | 2010-02-23 | 2020-01-07 | Sanofi | HUMANIZED ANTI-ALFA2 INTEGRIN ANTIBODY, USE OF THE SAME, ISOLATED NUCLEIC ACID ENCODING AN ANTI-ALFA2BETA1 INTEGRIN ANTIBODY, VECTOR, HOST CELL, COMPOSITION, KIT AND ANTIBODY |
PE20130214A1 (en) | 2010-02-23 | 2013-03-11 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS |
EP3696194A1 (en) | 2010-02-23 | 2020-08-19 | F. Hoffmann-La Roche AG | Anti-angiogenesis therapy for the treatment of ovarian cancer |
US8298535B2 (en) | 2010-02-24 | 2012-10-30 | Rinat Neuroscience Corp. | Anti-IL-7 receptor antibodies |
WO2011106702A2 (en) | 2010-02-25 | 2011-09-01 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
PE20130393A1 (en) | 2010-03-11 | 2013-04-07 | Rinat Neuroscience Corp | ANTIBODIES WITH PH-DEPENDENT ANTIGEN UNION |
KR102218495B1 (en) | 2010-03-22 | 2021-02-19 | 제넨테크, 인크. | Compositions and methods useful for stabilizing protein-containing formulations |
WO2011119852A1 (en) | 2010-03-24 | 2011-09-29 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering rnai compounds |
EP2550362B1 (en) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
JP2013523098A (en) | 2010-03-29 | 2013-06-17 | ザイムワークス,インコーポレイテッド | Antibody with enhanced or suppressed effector function |
AU2011235276B2 (en) | 2010-03-29 | 2015-09-03 | Alnylam Pharmaceuticals, Inc. | SiRNA therapy for transthyretin (TTR) related ocular amyloidosis |
CL2011000716A1 (en) | 2010-03-31 | 2012-04-20 | Gilead Pharmasset Llc | Crystalline forms 1 6 of (s) -isopropyl-2 - (((s) - (((2r.3r.4r.5r) -5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2h) -yl) -4-fluoro-3-hydroxy-4-methyl tetrahydrofuran-2-yl) methoxy) (phenoxy) phosphoryl) amino) propanoate; pharmaceutical composition and combination; and its use to treat a hepatitis c virus infection. |
JP5872539B2 (en) | 2010-03-31 | 2016-03-01 | ギリアド ファーマセット エルエルシー | Purine nucleoside phosphoramidate |
DK2796467T3 (en) | 2010-03-31 | 2018-05-07 | Boehringer Ingelheim Int | Anti-CD40 antibodies |
PL3290428T3 (en) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate |
WO2011123621A2 (en) | 2010-04-01 | 2011-10-06 | Alnylam Pharmaceuticals Inc. | 2' and 5' modified monomers and oligonucleotides |
EP2556085A2 (en) | 2010-04-05 | 2013-02-13 | Bar-Ilan University | Protease-activatable pore-forming polypeptides |
TWI644675B (en) | 2010-04-09 | 2018-12-21 | 可娜公司 | Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21 |
WO2011133876A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising acyclic and abasic nucleosides and analogs |
US20130260460A1 (en) | 2010-04-22 | 2013-10-03 | Isis Pharmaceuticals Inc | Conformationally restricted dinucleotide monomers and oligonucleotides |
WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
EP2563393B1 (en) | 2010-04-26 | 2016-06-08 | Abraxis BioScience, LLC | Sparc binding antibodies and uses thereof |
US20130195962A1 (en) * | 2010-04-28 | 2013-08-01 | National University Corporation Hokkaido University | Lipid membrane structure |
MX343559B (en) | 2010-04-29 | 2016-11-10 | Ionis Pharmaceuticals Inc | Modulation of transthyretin expression. |
US20130156845A1 (en) | 2010-04-29 | 2013-06-20 | Alnylam Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
SI2563813T1 (en) | 2010-04-30 | 2015-12-31 | Alexion Pharmaceuticals, Inc. | Anti-c5a antibodies and methods for using the antibodies |
MX342239B (en) | 2010-05-03 | 2016-09-21 | Genentech Inc * | Compositions and methods for the diagnosis and treatment of tumor. |
CN107988228B (en) | 2010-05-03 | 2022-01-25 | 库尔纳公司 | Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to Sirtuin (SIRT) |
BR112012027828A2 (en) | 2010-05-03 | 2016-08-09 | Genentech Inc | matter composition, article of manufacture and method of reducing the viscosity of a protein containing formulation and preparing an aqueous protein containing formulation |
JP5866106B2 (en) | 2010-05-12 | 2016-02-17 | コロンビア ユニヴァーシティ | Method for producing enteroendocrine cells that produce and secrete insulin |
TWI531370B (en) | 2010-05-14 | 2016-05-01 | 可娜公司 | Treatment of par4 related diseases by inhibition of natural antisense transcript to par4 |
CN107674073B (en) | 2010-05-17 | 2021-09-10 | 印蔻真治疗公司 | 3, 5-disubstituted-3H-imidazo [4,5-B ] pyridine compounds as modulators of protein kinases |
EP2571516B1 (en) | 2010-05-18 | 2017-11-15 | Neumedicines, Inc | Il-12 formulations for enhancing hematopoiesis |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
DK2576783T3 (en) | 2010-05-26 | 2018-03-12 | Curna Inc | TREATMENT OF ATONAL HOMOLOGY 1- (ATOH1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS AT ATOH1 |
AU2011261396B2 (en) | 2010-06-02 | 2015-11-05 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
EP2576579B1 (en) | 2010-06-02 | 2018-08-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods directed to treating liver fibrosis |
WO2011153243A2 (en) | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Anti-angiogenesis therapy for treating gastric cancer |
KR20190039347A (en) | 2010-06-03 | 2019-04-10 | 알닐람 파마슈티칼스 인코포레이티드 | Biodegradable lipids for the delivery of active agents |
US8299117B2 (en) | 2010-06-16 | 2012-10-30 | Metabolex Inc. | GPR120 receptor agonists and uses thereof |
ES2526124T3 (en) | 2010-06-16 | 2015-01-07 | Cymabay Therapeutics, Inc. | GPR120 receptor agonists and their uses |
WO2011160110A1 (en) | 2010-06-19 | 2011-12-22 | Western University Of Health Sciences | Novel formulation of pegylated-liposome encapsulated glycopeptide antibiotics |
EP2585048B1 (en) | 2010-06-23 | 2018-04-11 | CymaBay Therapeutics, Inc. | Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
WO2011163458A2 (en) | 2010-06-24 | 2011-12-29 | Genentech, Inc. | Compositions and methods for stabilizing protein-containing formulations |
CN102309448B (en) * | 2010-06-29 | 2014-07-09 | 中国人民解放军军事医学科学院毒物药物研究所 | Pulmonary delivery ciprofloxacin pharmaceutical composition and preparation method thereof |
US9006417B2 (en) | 2010-06-30 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
HUE029284T2 (en) | 2010-07-06 | 2017-02-28 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of rna |
PT3243526T (en) | 2010-07-06 | 2020-03-04 | Glaxosmithkline Biologicals Sa | Delivery of rna to trigger multiple immune pathways |
ES2934240T3 (en) | 2010-07-06 | 2023-02-20 | Glaxosmithkline Biologicals Sa | Virion-like delivery particles for self-replicating RNA molecules |
MX2013000164A (en) | 2010-07-06 | 2013-03-05 | Novartis Ag | Liposomes with lipids having an advantageous pka- value for rna delivery. |
AU2011277999A1 (en) | 2010-07-12 | 2013-01-10 | Covx Technologies Ireland Limited | Multifunctional Antibody Conjugates |
NO2593547T3 (en) | 2010-07-14 | 2018-04-14 | ||
EP2596026B1 (en) | 2010-07-23 | 2020-04-08 | Trustees of Boston University | Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery |
WO2012016188A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
WO2012016184A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
WO2012019093A1 (en) | 2010-08-05 | 2012-02-09 | Human Biomolecular Research Institute | Synthetic compounds and methods to decrease nicotine self-administration |
EP2420250A1 (en) | 2010-08-13 | 2012-02-22 | Universitätsklinikum Münster | Anti-Syndecan-4 antibodies |
US8900590B2 (en) | 2010-08-12 | 2014-12-02 | Theraclone Sciences, Inc. | Anti-hemagglutinin antibody compositions and methods of use thereof |
HUE059214T2 (en) | 2010-08-31 | 2022-10-28 | Glaxosmithkline Biologicals Sa | Small liposomes for delivery of immunogen-encoding rna |
PT3556396T (en) | 2010-08-31 | 2022-07-04 | Scripps Research Inst | Human immunodeficiency virus (hiv)-neutralizing antibodies |
MX2013002336A (en) * | 2010-08-31 | 2013-03-18 | Novartis Ag | Pegylated liposomes for delivery of immunogen-encoding rna. |
US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
WO2012047968A2 (en) | 2010-10-05 | 2012-04-12 | Genentech, Inc. | Mutant smoothened and methods of using the same |
RU2624048C2 (en) | 2010-10-06 | 2017-06-30 | Курна, Инк. | Treatment of diseases associated with the sialidase 4 (neu4) gene, by gene neu4 natural antisense transcript inhibition |
BR112013008700B8 (en) | 2010-10-11 | 2022-10-04 | Novartis Ag | SELF-REPLICATING RNA MOLECULE, ALPHAVIRUS REPLICON PARTICLE, COMPOSITION, RECOMBINANT DNA MOLECULE, USE OF SELF-REPLICATING RNA MOLECULE |
JP6049623B2 (en) | 2010-10-22 | 2016-12-21 | カッパーアールエヌエー,インコーポレイテッド | Treatment of IDUA-related diseases by inhibition of natural antisense transcripts to α-L-iduronidase (IDUA) |
WO2012061129A1 (en) | 2010-10-25 | 2012-05-10 | Genentech, Inc | Treatment of gastrointestinal inflammation and psoriasis a |
KR101913232B1 (en) | 2010-10-27 | 2018-10-30 | 큐알엔에이, 인크. | Treatment of interferon-related developmental regulator 1(ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1 |
HUE030916T2 (en) | 2010-11-04 | 2017-06-28 | Boehringer Ingelheim Int | Anti-il-23 antibodies |
US20140134181A1 (en) | 2010-11-05 | 2014-05-15 | Kenneth E. Lipson | Treatment Method For Lung Remodeling Diseases |
CN110123830A (en) | 2010-11-09 | 2019-08-16 | 阿尔尼拉姆医药品有限公司 | Composition and method for inhibiting the lipid of the expression of Eg5 and VEGF gene to prepare |
US9518114B2 (en) | 2010-11-12 | 2016-12-13 | Purdue Research Foundation | Treating bladder tumor cells using fibronectin attachment protein as a target |
US20140199682A1 (en) | 2010-11-17 | 2014-07-17 | Sea Lane Biotechnologies, Llc | Influenza neutralizing agents |
RU2018102375A (en) | 2010-11-18 | 2019-02-21 | Зе Дженерал Хоспитал Корпорейшен | NEW COMPOSITIONS AND APPLICATIONS OF ANTIHYPERTENSIVE MEDICINES FOR CANCER THERAPY |
JP6071893B2 (en) | 2010-11-23 | 2017-02-01 | カッパーアールエヌエー,インコーポレイテッド | Treatment of NANOG-related diseases by inhibition of natural antisense transcripts to NANOG |
AU2011336632B2 (en) | 2010-11-30 | 2015-09-03 | Gilead Pharmasset Llc | Compounds |
US9127275B2 (en) | 2010-12-10 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of klf-1 and bcl11a genes |
US9193973B2 (en) | 2010-12-10 | 2015-11-24 | Alynylam Pharmaceuticals, Inc. | Compositions and methods for increasing erythropoietin (EPO) production |
EP2651447B1 (en) | 2010-12-14 | 2018-08-29 | Technical University of Denmark | Entrapment of radionuclides in nanoparticle compositions |
EP2468259A1 (en) * | 2010-12-23 | 2012-06-27 | Traslational Cancer Drugs Pharma, S.L. | Pharmaceutical compositions of pyridinium and quinolinium derivatives |
CA2834968C (en) | 2011-01-05 | 2018-01-09 | Livon Laboratories | Methods of making liposomes, liposome compositions made by the methods, and methods of using the same |
EP4215194A1 (en) | 2011-01-11 | 2023-07-26 | Dimerix Bioscience Pty Ltd | Combination therapy |
DK2663548T3 (en) | 2011-01-11 | 2017-07-24 | Alnylam Pharmaceuticals Inc | PEGYLED LIPIDS AND THEIR USE FOR PHARMACEUTICAL SUPPLY |
MX365647B (en) | 2011-02-02 | 2019-06-10 | Excaliard Pharmaceuticals Inc | Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf). |
RU2440142C1 (en) | 2011-02-07 | 2012-01-20 | Общество С Ограниченной Ответственностью "Онкомакс" | Antibody, stopping or retarding tumour growth (versions), method of suppressing tumour growth, method of diagnosing malignant lesions |
WO2012109495A1 (en) | 2011-02-09 | 2012-08-16 | Metabolic Solutions Development Company, Llc | Cellular targets of thiazolidinediones |
KR20140012098A (en) | 2011-02-14 | 2014-01-29 | 테라클론 사이언시스, 아이엔씨. | Compositions and methods for the therapy and diagnosis of influenza |
PL226015B1 (en) * | 2011-03-03 | 2017-06-30 | Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną | Liposome preparation containing anticancer active substance, process for the preparation thereof and pharmaceutical compositions containing thereof |
KR20190006083A (en) | 2011-03-09 | 2019-01-16 | 셀 시그널링 테크놀러지, 인크. | Methods and reagents for creating monoclonal antibodies |
WO2012125614A1 (en) | 2011-03-15 | 2012-09-20 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of influenza |
AP2013007173A0 (en) | 2011-03-16 | 2013-10-31 | Amgen Inc | Potent and selective inhibitors of NAV1.3 and NAV1.7 |
US10184942B2 (en) | 2011-03-17 | 2019-01-22 | University Of South Florida | Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer |
US9181308B2 (en) | 2011-03-28 | 2015-11-10 | St. Jude Children's Research Hospital | Methods and compositions employing immunogenic fusion proteins |
KR102365961B1 (en) | 2011-03-29 | 2022-02-23 | 알닐람 파마슈티칼스 인코포레이티드 | Compositions and methods for inhibiting expression of tmprss6 gene |
RU2016127812A (en) | 2011-03-31 | 2018-12-06 | Дженентек, Инк. | INTEGRIN BETA7 ANTAGONISTS INTRODUCTION METHODS |
EP2508176A1 (en) | 2011-04-08 | 2012-10-10 | Lipotarg Gmbh | Novel combination treatment of cancer |
CN105886506A (en) | 2011-04-13 | 2016-08-24 | Isis制药公司 | Antisense modulation of PTP1B expression |
KR101589135B1 (en) | 2011-04-20 | 2016-01-29 | 주식회사 셀앤바이오 | Humanized anti-EMAPII antibodies and uses thereof |
EP2699264B1 (en) | 2011-04-20 | 2018-03-14 | Medlmmune, LLC | Antibodies and other molecules that bind b7-h1 and pd-1 |
CN107337659A (en) | 2011-05-04 | 2017-11-10 | 理森制药股份公司 | Compounds as protein kinase modulators |
US8846042B2 (en) | 2011-05-16 | 2014-09-30 | Fabion Pharmaceuticals, Inc. | Multi-specific FAB fusion proteins and methods of use |
EP3354343B1 (en) | 2011-06-02 | 2023-09-06 | President and Fellows of Harvard College | Methods and uses for ex vivo tissue culture systems |
CN103620036B (en) | 2011-06-09 | 2016-12-21 | 库尔纳公司 | FXN relevant disease is treated by the natural antisense transcript of suppression Frataxin (FXN) |
EP2691530B1 (en) | 2011-06-10 | 2018-03-07 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
WO2012174476A2 (en) | 2011-06-16 | 2012-12-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of fibroblast growth factor receptor 4 expression |
US20140275211A1 (en) | 2011-06-21 | 2014-09-18 | Alnylam Pharmaceuticals, Inc. | Assays and methods for determining activity of a therapeutic agent in a subject |
CA3191066A1 (en) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes |
EP2723351B1 (en) | 2011-06-21 | 2018-02-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of expression of protein c (proc) genes |
EP2537532A1 (en) | 2011-06-22 | 2012-12-26 | J. Stefan Institute | Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use |
EP2723390B1 (en) | 2011-06-23 | 2017-12-27 | Alnylam Pharmaceuticals, Inc. | Serpina1 sirnas: compositions of matter and methods of treatment |
JP2014527036A (en) | 2011-06-27 | 2014-10-09 | ザ ジャクソン ラボラトリー | Methods and compositions for the treatment of cancer and autoimmune diseases |
WO2013003647A2 (en) | 2011-06-28 | 2013-01-03 | Sea Lane Biotechnologies, Llc | Multispecific stacked variable domain binding proteins |
EP3332802A1 (en) | 2011-07-06 | 2018-06-13 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
RS61235B1 (en) | 2011-07-13 | 2021-01-29 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Liposomes co-encapsulating a bisphosphonate and an amphipathic agent |
WO2013008185A1 (en) | 2011-07-14 | 2013-01-17 | Pfizer Inc. | Treatment with anti-pcsk9 antibodies |
WO2013015821A1 (en) | 2011-07-22 | 2013-01-31 | The Research Foundation Of State University Of New York | Antibodies to the b12-transcobalamin receptor |
US9120858B2 (en) | 2011-07-22 | 2015-09-01 | The Research Foundation Of State University Of New York | Antibodies to the B12-transcobalamin receptor |
US20130022551A1 (en) | 2011-07-22 | 2013-01-24 | Trustees Of Boston University | DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS |
JP2014526887A (en) | 2011-08-01 | 2014-10-09 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | How to improve the success rate of hematopoietic stem cell transplantation |
AU2012296613B2 (en) | 2011-08-15 | 2016-05-12 | Amplimmune, Inc. | Anti-B7-H4 antibodies and their uses |
FR2979239A1 (en) * | 2011-08-25 | 2013-03-01 | Trophos | LIPOSOME COMPRISING AT LEAST ONE CHOLESTEROL DERIVATIVE |
US8822651B2 (en) | 2011-08-30 | 2014-09-02 | Theraclone Sciences, Inc. | Human rhinovirus (HRV) antibodies |
HUE037829T2 (en) | 2011-08-31 | 2018-09-28 | St Jude Childrens Res Hospital | Methods and compositions to detect the level of lysosomal exocytosis activity and methods of use |
AU2012305807B2 (en) | 2011-09-09 | 2015-08-20 | Department of Medical Sciences (DMSc) | Dengue-virus serotype neutralizing antibodies |
EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
US9434753B2 (en) | 2011-09-19 | 2016-09-06 | Gencia Corporation | Modified creatine compounds |
KR101840512B1 (en) | 2011-09-20 | 2018-03-20 | 아이오니스 파마수티컬즈, 인코포레이티드 | Antisense modulation of gcgr expression |
JP2014533929A (en) | 2011-09-23 | 2014-12-18 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハー | Bispecific binding molecules for 5T4 and CD3 |
AU2013201095C1 (en) | 2011-09-23 | 2019-12-05 | Oncomed Pharmaceuticals, Inc. | VEGF/DLL4 binding agents and uses thereof |
AU2012310328A1 (en) | 2011-09-23 | 2014-04-10 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. | Anti-Tumor Necrosis Factor-alpha agents and uses thereof |
US9701623B2 (en) | 2011-09-27 | 2017-07-11 | Alnylam Pharmaceuticals, Inc. | Di-aliphatic substituted pegylated lipids |
CA2850187C (en) | 2011-09-29 | 2021-12-07 | Plx Pharma Inc. | Ph dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same |
US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
CN113876945A (en) | 2011-10-06 | 2022-01-04 | 免疫疫苗技术有限公司 | Liposome composition comprising adjuvant for activating or increasing TLR2 activity and application thereof |
RS57645B1 (en) | 2011-10-14 | 2018-11-30 | Hoffmann La Roche | Anti-htra1 antibodies and methods of use |
US8883989B2 (en) | 2011-10-18 | 2014-11-11 | Regents Of The University Of Minnesota | Fractalkine binding polynucleotides and methods of use |
WO2013063313A1 (en) | 2011-10-25 | 2013-05-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of gccr expression |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
SG11201401815XA (en) | 2011-10-28 | 2014-05-29 | Genentech Inc | Therapeutic combinations and methods of treating melanoma |
CN109078182B (en) | 2011-10-31 | 2022-08-12 | 弗·哈夫曼-拉罗切有限公司 | Antibody formulations |
US10980798B2 (en) | 2011-11-03 | 2021-04-20 | Taiwan Liposome Company, Ltd. | Pharmaceutical compositions of hydrophobic camptothecin derivatives |
EP2773346B1 (en) * | 2011-11-03 | 2021-10-27 | Taiwan Liposome Company, Ltd. | Pharmaceutical compositions of hydrophobic camptothecin derivatives |
SG11201401699WA (en) | 2011-11-11 | 2014-09-26 | Rinat Neuroscience Corp | Antibodies specific for trop-2 and their uses |
TWI679212B (en) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | Binding molecules for e3 of bcma and cd3 |
PL2780373T3 (en) | 2011-11-16 | 2020-03-31 | Boehringer Ingelheim International Gmbh | Anti il-36r antibodies |
JP2015501839A (en) | 2011-12-15 | 2015-01-19 | ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago | Methods and compositions for cancer therapy using mutant LIGHT molecules with increased affinity for receptors |
EP2794659A1 (en) | 2011-12-22 | 2014-10-29 | Rinat Neuroscience Corp. | Human growth hormone receptor antagonist antibodies and methods of use thereof |
WO2013093693A1 (en) | 2011-12-22 | 2013-06-27 | Rinat Neuroscience Corp. | Staphylococcus aureus specific antibodies and uses thereof |
ES2721882T3 (en) | 2011-12-23 | 2019-08-06 | Pfizer | Constant regions of genetically engineered antibody for site-specific conjugation and procedures and uses thereof |
WO2013101771A2 (en) | 2011-12-30 | 2013-07-04 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
WO2013105013A1 (en) | 2012-01-09 | 2013-07-18 | Covx Technologies Ireland Limited | Mutant antibodies and conjugation thereof |
US9636381B2 (en) | 2012-01-18 | 2017-05-02 | Neumedicines, Inc. | Methods for radiation protection by administering IL-12 |
CA2862292C (en) | 2012-01-20 | 2019-10-08 | Sea Lane Biotechnologies, Llc | Binding molecule conjugates |
WO2013114377A1 (en) | 2012-02-02 | 2013-08-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd | Stable liposomes for drug delivery |
ME03512B (en) | 2012-02-06 | 2020-04-20 | Inhibrx Inc | Cd47 antibodies and methods of use thereof |
EP2814464B1 (en) * | 2012-02-17 | 2019-12-18 | Celsion Corporation | Thermosensitive nanoparticle formulations and method of making the same |
US9138492B2 (en) * | 2012-02-23 | 2015-09-22 | Canon Kabushiki Kaisha | Particle containing hydrophobic dye having cyanine structure, and contrast agent containing the particle |
US20150037334A1 (en) | 2012-03-01 | 2015-02-05 | Amgen Research (Munich) Gmbh | Long life polypeptide binding molecules |
EA201690461A1 (en) | 2012-03-05 | 2016-11-30 | Джилид Калистога Ллс | POLYMORPHIC FORMS (S) -2- (1- (9H-PURIN-6-ILAMINO) PROPYL) -5-FTOR-3-PHENYL-CHINAZOLIN-4 (3H) -OH |
ES2694592T3 (en) | 2012-03-15 | 2018-12-21 | Curna, Inc. | Treatment of diseases related to brain-derived neurotrophic factor (BDNF) by inhibition of the natural antisense transcript of BDNF |
WO2013149111A2 (en) | 2012-03-29 | 2013-10-03 | Novimmune S.A. | Anti-tlr4 antibodies and uses thereof |
SG11201406185WA (en) | 2012-03-30 | 2014-11-27 | Rhizen Pharmaceuticals Sa | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases |
WO2013151649A1 (en) | 2012-04-04 | 2013-10-10 | Sialix Inc | Glycan-interacting compounds |
US9133461B2 (en) | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
AU2013252909B2 (en) | 2012-04-24 | 2017-09-28 | University Of Miami | Perforin 2 defense against invasive and multidrug resistant pathogens |
PL3326649T3 (en) | 2012-05-03 | 2022-04-25 | Boehringer Ingelheim International Gmbh | Anti-il-23p19 antibodies |
AU2013256010B2 (en) | 2012-05-04 | 2018-01-04 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use |
WO2013166498A1 (en) | 2012-05-04 | 2013-11-07 | The Johns Hopkins University | Lipid-based drug carriers for rapid penetration through mucus linings |
US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
EP2861256B1 (en) | 2012-06-15 | 2019-10-23 | The Brigham and Women's Hospital, Inc. | Compositions for treating cancer and methods for making the same |
WO2013192546A1 (en) | 2012-06-22 | 2013-12-27 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and mehtods of using the same |
EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
CA2879139C (en) * | 2012-07-18 | 2021-05-11 | Onyx Therapeutics, Inc. | Liposomal compositions of epoxyketone-based proteasome inhibitors |
US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
CN110464709A (en) | 2012-08-10 | 2019-11-19 | 德克萨斯州大学系统董事会 | For treating the neuroprotective liposome composition and method of apoplexy |
SG11201408340SA (en) | 2012-08-14 | 2015-01-29 | Univ Nanyang Tech | Angiopoietin-like 4 antibody and a method of its use in cancer treatment |
CN112451486A (en) | 2012-09-04 | 2021-03-09 | 埃莱森制药有限责任公司 | Prevention of pulmonary recurrence of cancer with cisplatin lipid complexes |
US20160136159A1 (en) | 2012-09-17 | 2016-05-19 | Chemedest Ltd. | Method for Treating Peripheral Neuropathy |
KR101947702B1 (en) | 2012-10-04 | 2019-02-14 | 다나-파버 캔서 인스티튜트 인크. | Human monoclonal anti-pd-l1 antibodies and methods of use |
JP6449161B2 (en) | 2012-10-05 | 2019-01-09 | ジェネンテック, インコーポレイテッド | Diagnostic and therapeutic methods for inflammatory bowel disease |
JP2015536933A (en) | 2012-10-23 | 2015-12-24 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Methods of treating neuroendocrine tumors using Wnt pathway binding agents |
WO2014071018A1 (en) | 2012-10-31 | 2014-05-08 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a dll4 antagonist |
CN110183534A (en) | 2012-12-03 | 2019-08-30 | 诺夫免疫股份有限公司 | Anti-cd 47 antibody and its application method |
CA2894846A1 (en) | 2012-12-12 | 2014-06-19 | Temple University - Of The Commonwealth System Of Higher Education | Compositions and methods for treatment of cancer |
CA2894879A1 (en) | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
ES2764090T3 (en) | 2012-12-19 | 2020-06-02 | Univ New York State Res Found | Compositions and Procedure for Light Activated Release of Nanovesicle Materials |
GB201223053D0 (en) | 2012-12-20 | 2013-02-06 | Medical Res Council | Receptor |
US20160067347A1 (en) | 2012-12-20 | 2016-03-10 | Amgen Inc. | Apj receptor agonists and uses thereof |
CA2896091C (en) | 2012-12-21 | 2018-06-19 | Amplimmune, Inc. | Anti-h7cr antibodies |
AU2014203873A1 (en) | 2013-01-07 | 2015-07-30 | Biomedical Research Models, Inc. | Therapeutic vaccines for treating herpes simplex virus type 2 infections |
ES2728936T3 (en) | 2013-01-25 | 2019-10-29 | Amgen Inc | Antibodies directed against CDH19 for melanoma |
JO3519B1 (en) | 2013-01-25 | 2020-07-05 | Amgen Inc | Antibody constructs for CDH19 and CD3 |
WO2014124006A1 (en) | 2013-02-05 | 2014-08-14 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
PE20151408A1 (en) | 2013-02-06 | 2015-10-15 | Inhibrx Llc | CD47 ANTIBODIES THAT DO NOT EXHAUST PLATELETS OR RED BALLOONS AND METHODS OF USING THEM |
US9534041B2 (en) | 2013-02-12 | 2017-01-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that neutralize a norovirus |
TW201446792A (en) | 2013-03-12 | 2014-12-16 | Amgen Inc | Potent and selective inhibitors of Nav1.7 |
MX2015011462A (en) | 2013-03-14 | 2016-05-31 | Jerome J Schentag | Cholestosome vesicles for incorporation of molecules into chylomicrons. |
US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
US20160122436A1 (en) | 2013-03-15 | 2016-05-05 | Amgen Research (Munich) Gmbh | Single chain binding molecules comprising n-terminal abp |
WO2014145037A1 (en) * | 2013-03-15 | 2014-09-18 | M. Alphabet 3, L.L.C. | Methods and compositions for enhancing oxygen levels in tissues |
WO2014140368A1 (en) | 2013-03-15 | 2014-09-18 | Amgen Research (Munich) Gmbh | Antibody constructs for influenza m2 and cd3 |
AU2014227952A1 (en) | 2013-03-15 | 2015-10-22 | Gencia Corporation | Compositions and methods for treating conditions that affect epidermis |
AR095374A1 (en) | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | UNION MOLECULES FOR BCMA AND CD3 |
US20140283157A1 (en) | 2013-03-15 | 2014-09-18 | Diadexus, Inc. | Lipoprotein-associated phospholipase a2 antibody compositions and methods of use |
WO2014152497A2 (en) | 2013-03-15 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | Osteocalcin as a treatment for cognitive disorders |
CN105051068A (en) | 2013-03-15 | 2015-11-11 | 戴埃克斯有限公司 | Anti-plasma kallikrein antibodies |
MX367668B (en) | 2013-03-15 | 2019-08-30 | Dana Farber Cancer Inst Inc | Flavivirus neutralizing antibodies and methods of use thereof. |
WO2014145654A1 (en) | 2013-03-15 | 2014-09-18 | The Trustees Of The University Of Pennsylvania | Method for the site-specific covalent cross-linking of antibodies to surfaces |
EP2978446B1 (en) | 2013-03-27 | 2020-03-04 | The General Hospital Corporation | Anti-cd33 antibody for use in treating alzheimer's disease |
CN105143876B (en) | 2013-03-27 | 2018-04-20 | 豪夫迈·罗氏有限公司 | Biomarker is used to assess the purposes with 7 integrin antagonists of β treatment gastrointestinal inflammatory illness |
KR20150142012A (en) | 2013-04-12 | 2015-12-21 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | Method for treating post-traumatic stress disorder |
EP2992000B1 (en) | 2013-05-03 | 2020-07-08 | The Regents of The University of California | Cyclic di-nucleotide induction of type i interferon |
AR096203A1 (en) | 2013-05-06 | 2015-12-16 | Alnylam Pharmaceuticals Inc | DOSAGES AND METHODS FOR MANAGING NUCLEIC ACID MOLECULES FORMULATED IN LIPIDS |
JP2016521283A (en) | 2013-05-06 | 2016-07-21 | スカラー ロック インコーポレイテッドScholar Rock,Inc. | Compositions and methods for growth factor modulation |
RU2015147721A (en) | 2013-05-07 | 2017-06-15 | Ринат Нейросаенз Корпорэйшн | ANTIBODIES AGAINST GLUCAGON RECEPTOR AND METHODS OF USING THEM |
EP2994163B1 (en) | 2013-05-09 | 2019-08-28 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use |
CA2913312A1 (en) | 2013-05-24 | 2014-11-27 | Medimmune, Llc | Anti-b7-h5 antibodies and their uses |
MX369758B (en) | 2013-05-31 | 2019-11-20 | Genentech Inc | Anti-wall teichoic antibodies and conjugates. |
RS60256B1 (en) | 2013-05-31 | 2020-06-30 | Genentech Inc | Anti-wall teichoic antibodies and conjugates |
SG11201509982UA (en) | 2013-06-06 | 2016-04-28 | Igenica Biotherapeutics Inc | |
ES2862125T3 (en) | 2013-06-13 | 2021-10-07 | Antisense Therapeutics Ltd | Combination therapy for acromegaly |
US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
WO2015013671A1 (en) | 2013-07-25 | 2015-01-29 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
US20160193148A1 (en) * | 2013-08-01 | 2016-07-07 | University Of Georgia Research Foundation, Inc. | Liposomal formulations for the treatment of bacterial infections |
AR097102A1 (en) | 2013-08-02 | 2016-02-17 | Pfizer | ANTI-CXCR4 ANTIBODY AND ANTIBODY AND DRUG CONJUGATES |
US10093978B2 (en) | 2013-08-12 | 2018-10-09 | Genentech, Inc. | Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms |
AU2014306564B2 (en) | 2013-08-14 | 2019-10-17 | Stephane ANGERS | Antibodies against frizzled proteins and methods of use thereof |
US10111871B2 (en) * | 2013-08-27 | 2018-10-30 | Northeastern University | Nanoparticle drug delivery system and method of treating cancer and neurotrauma |
EP3041958B1 (en) | 2013-09-04 | 2019-12-04 | Cold Spring Harbor Laboratory | Reducing nonsense-mediated mrna decay |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
CA2922838A1 (en) | 2013-09-05 | 2015-03-12 | Sarepta Therapeutics, Inc. | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
AR097648A1 (en) | 2013-09-13 | 2016-04-06 | Amgen Inc | COMBINATION OF EPIGENETIC FACTORS AND BIESPECTIVE COMPOUNDS THAT HAVE LIKE DIANA CD33 AND CD3 IN THE TREATMENT OF MYELOID LEUKEMIA |
HRP20211564T1 (en) * | 2013-09-16 | 2022-01-21 | Glycomine, Inc. | Pharmaceutical preparation of carbohydrates for therapeutic use |
DE102013015334A1 (en) * | 2013-09-17 | 2015-03-19 | Fresenius Medical Care Deutschland Gmbh | Magnesium-liposome complexes |
US10036020B2 (en) | 2013-09-19 | 2018-07-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Compositions and methods for inhibiting JC virus (JCV) |
RU2020106752A (en) | 2013-09-25 | 2020-03-11 | Сайтомкс Терапьютикс, Инк. | SUBSTRATES OF MATRIX METALLOPROTEINASES AND OTHER DISSOLIDABLE FRAGMENTS AND METHODS FOR USING THEM |
EP3470081A1 (en) | 2013-10-01 | 2019-04-17 | Mayo Foundation for Medical Education and Research | Methods for treating cancer in patients with elevated levels of bim |
US10077444B2 (en) | 2013-10-02 | 2018-09-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the LECT2 gene |
LT3052628T (en) | 2013-10-04 | 2020-09-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the alas1 gene |
US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
JPWO2015068781A1 (en) | 2013-11-06 | 2017-03-09 | 国立大学法人大阪大学 | Antibodies with broad neutralizing activity against group 1 of influenza virus type A |
WO2015087187A1 (en) | 2013-12-10 | 2015-06-18 | Rinat Neuroscience Corp. | Anti-sclerostin antibodies |
EP3080611B1 (en) | 2013-12-13 | 2018-11-14 | The General Hospital Corporation | Soluble high molecular weight (hmw) tau species and applications thereof |
AU2014364410B2 (en) | 2013-12-20 | 2017-11-16 | Gilead Calistoga Llc | Process methods for phosphatidylinositol 3-kinase inhibitors |
JP2017500319A (en) | 2013-12-20 | 2017-01-05 | ギリアード カリストガ エルエルシー | Polymorphic form of the hydrochloride salt of (S) -2- (1- (9H-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3H) -one |
JP6552509B2 (en) | 2014-01-14 | 2019-07-31 | ザ・ジョンズ・ホプキンス・ユニバーシティー | Cyclodextrin compositions encapsulating selective ATP inhibitors and uses thereof |
WO2015116902A1 (en) | 2014-01-31 | 2015-08-06 | Genentech, Inc. | G-protein coupled receptors in hedgehog signaling |
AU2015315834B2 (en) | 2014-01-31 | 2019-12-12 | Boehringer Ingelheim International Gmbh | Novel anti-BAFF antibodies |
EP4176896A1 (en) | 2014-01-31 | 2023-05-10 | Cytomx Therapeutics Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
JP6736467B2 (en) | 2014-02-04 | 2020-08-05 | ジェネンテック, インコーポレイテッド | Smoothing mutant and method of using the same |
EP3450571B1 (en) | 2014-02-24 | 2023-04-05 | Celgene Corporation | Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
EP3119804A2 (en) | 2014-03-19 | 2017-01-25 | Dana-Farber Cancer Institute, Inc. | Immunogenetic restriction on elicitation of antibodies |
PE20161439A1 (en) | 2014-03-21 | 2017-01-26 | Teva Pharmaceuticals Int Gmbh | ANTIBODIES ANTAGONISTS DIRECTED AGAINST THE PEPTIDE RELATED TO THE CALCITONIN GENE AND METHODS USING THE SAME |
EP3122377A4 (en) | 2014-03-27 | 2018-03-14 | F.Hoffmann-La Roche Ag | Methods for diagnosing and treating inflammatory bowel disease |
BR112016022499A2 (en) | 2014-04-03 | 2017-08-15 | Invictus Oncology Pvt Ltd | SUPRAMOLECULAR COMBINATORY THERAPEUTIC PRODUCTS |
EP3134111B1 (en) | 2014-04-25 | 2022-06-08 | Dana-Farber Cancer Institute, Inc. | Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof |
ES2856927T3 (en) | 2014-04-30 | 2021-09-28 | Pfizer | Anti-PTK7 Drug-Antibody Conjugates |
US10308697B2 (en) | 2014-04-30 | 2019-06-04 | President And Fellows Of Harvard College | Fusion proteins for treating cancer and related methods |
WO2015171918A2 (en) | 2014-05-07 | 2015-11-12 | Louisiana State University And Agricultural And Mechanical College | Compositions and uses for treatment thereof |
WO2015173756A2 (en) | 2014-05-16 | 2015-11-19 | Pfizer Inc. | Bispecific antibodies |
WO2015179654A1 (en) | 2014-05-22 | 2015-11-26 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti b7-h1 antibodies |
EA028614B1 (en) | 2014-05-22 | 2017-12-29 | Общество С Ограниченной Ответственностью "Русские Фармацевтические Технологии" | Selective inhibitors interfering with fibroblast growth factor receptor and frs2 interaction for the prevention and treatment of cancer |
CN106714830B (en) | 2014-05-30 | 2020-08-25 | 上海复宏汉霖生物技术股份有限公司 | anti-Epidermal Growth Factor Receptor (EGFR) antibodies |
AU2015274574B2 (en) | 2014-06-10 | 2019-10-10 | Amgen Inc. | Apelin polypeptides |
CN106456772A (en) | 2014-06-11 | 2017-02-22 | 吉利德科学公司 | Methods for treating cardiovascular diseases |
MX2016016530A (en) | 2014-06-13 | 2017-03-27 | Gilead Sciences Inc | Phosphatidylinositol 3-kinase inhibitors. |
TWI695011B (en) | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | Monoclonal antibodies against her2 epitope and methods of use thereof |
CN114057857A (en) | 2014-06-20 | 2022-02-18 | 豪夫迈·罗氏有限公司 | CHAGASIN-based scaffold compositions, methods and uses |
EP3160503B1 (en) | 2014-06-26 | 2021-02-17 | The Trustees of Columbia University in the City of New York | Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells |
US10517875B2 (en) | 2014-07-23 | 2019-12-31 | Mayo Foundation for Medical Engineering and Research | Targeting DNA-PKcs and B7-H1 to treat cancer |
WO2016014974A2 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
AR101669A1 (en) | 2014-07-31 | 2017-01-04 | Amgen Res (Munich) Gmbh | ANTIBODY CONSTRUCTS FOR CDH19 AND CD3 |
AR101936A1 (en) | 2014-07-31 | 2017-01-25 | Amgen Res (Munich) Gmbh | SPECIFIC BIESPECIFIC CHAIN ANTIBODY CONSTRUCTS SPECIFIED FOR OPTIMIZED CROSSED SPECIES |
CA2956991A1 (en) | 2014-08-06 | 2016-02-11 | Rinat Neuroscience Corp. | Methods for reducing ldl-cholesterol |
WO2016020799A1 (en) | 2014-08-06 | 2016-02-11 | Rinat Neuroscience Corp. | Methods for reducing ldl-cholesterol |
WO2016033424A1 (en) | 2014-08-29 | 2016-03-03 | Genzyme Corporation | Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b |
WO2016034968A1 (en) | 2014-09-02 | 2016-03-10 | Pfizer Inc. | Therapeutic antibody |
WO2016046684A1 (en) | 2014-09-23 | 2016-03-31 | Pfizer Inc. | Treatment with anti-pcsk9 antibodies |
MX2017004311A (en) | 2014-10-03 | 2017-12-07 | Dana Farber Cancer Inst Inc | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof. |
AU2015328273B2 (en) | 2014-10-06 | 2020-09-17 | Dana-Farber Cancer Institute, Inc. | Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof |
GB201417589D0 (en) | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
JP6827415B2 (en) | 2014-10-31 | 2021-02-10 | メレオ バイオファーマ 5 インコーポレイテッド | Combination therapy for the treatment of the disease |
US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
WO2016077566A1 (en) | 2014-11-12 | 2016-05-19 | Research Institute At Nationwide Children's Hospital | Modulation of alternative mdm2 splicing |
MX2017006167A (en) | 2014-11-12 | 2018-03-23 | Siamab Therapeutics Inc | Glycan-interacting compounds and methods of use. |
EP3226889A4 (en) | 2014-11-19 | 2018-11-21 | The Trustees of Columbia University in the City of New York | Osteocalcin as a treatment for frailty associated with aging |
RU2017118792A (en) | 2014-12-03 | 2019-01-09 | Дженентек, Инк. | ANTIBODY CONJUGATES TO STAPHYLOCOCCUS AUREUS WITH RIFAMICINE AND THEIR APPLICATION |
RU2731055C2 (en) | 2014-12-03 | 2020-08-28 | Дженентек, Инк. | Conjugates of antibodies to staphylococcus aureus with rifamycin and use thereof |
US10072070B2 (en) | 2014-12-05 | 2018-09-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Potent anti-influenza A neuraminidase subtype N1 antibody |
TWI595006B (en) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | Anti-pd-1 antibodies and methods of use thereof |
PT3333191T (en) | 2014-12-11 | 2020-12-15 | Pf Medicament | Anti-c10orf54 antibodies and uses thereof |
TW201702218A (en) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease |
WO2016100392A1 (en) | 2014-12-15 | 2016-06-23 | The Johns Hopkins University | Sunitinib formulations and methods for use thereof in treatment of ocular disorders |
EP3234141A4 (en) | 2014-12-18 | 2018-06-20 | Alnylam Pharmaceuticals, Inc. | Reversir tm compounds |
WO2016118476A1 (en) | 2015-01-20 | 2016-07-28 | The Children's Medical Center Corporation | Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing |
MA41374A (en) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | MATRIX METALLOPROTEASE CLIVABLE AND SERINE PROTEASE CLIVABLE SUBSTRATES AND METHODS OF USE THEREOF |
JP6846351B2 (en) | 2015-01-27 | 2021-03-24 | ザ・ジョンズ・ホプキンス・ユニバーシティー | Hypotonic hydrogel formulation for enhanced transport of active agents on mucosal surfaces |
JP2018506275A (en) | 2015-01-28 | 2018-03-08 | ジェネンテック, インコーポレイテッド | Gene expression markers and treatment of multiple sclerosis |
CN107428818A (en) | 2015-01-29 | 2017-12-01 | 密西根州立大学校董会 | Hide polypeptide and application thereof |
EP3258913A1 (en) * | 2015-02-17 | 2017-12-27 | Mallinckrodt Nuclear Medicine LLC | Modified docetaxel liposome formulations and uses thereof |
US10550173B2 (en) | 2015-02-19 | 2020-02-04 | Compugen, Ltd. | PVRIG polypeptides and methods of treatment |
SG11201706583PA (en) | 2015-02-19 | 2017-09-28 | Compugen Ltd | Anti-pvrig antibodies and methods of use |
MX2017010336A (en) | 2015-02-26 | 2017-12-20 | Genentech Inc | Integrin beta7 antagonists and methods of treating crohn's disease. |
EP3265059A4 (en) | 2015-03-03 | 2018-08-29 | Cureport Inc. | Combination liposomal pharmaceutical formulations |
WO2016141161A1 (en) * | 2015-03-03 | 2016-09-09 | Cureport, Inc. | Dual loaded liposomal pharmaceutical formulations |
PL3265123T3 (en) | 2015-03-03 | 2023-03-13 | Kymab Limited | Antibodies, uses & methods |
CN108112254B (en) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | anti-PDL 1 antibodies, activatable anti-PDL 1 antibodies, and methods of use thereof |
CA2985330A1 (en) | 2015-03-17 | 2016-09-22 | Lipomedix Pharmaceuticals Ltd. | Methods for the treatment of bladder cancer |
MA41795A (en) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | EXCLUSION OF AN EXON INDUCED BY ANTISENSE COMPOUNDS IN MYOSTATIN |
EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
US9758575B2 (en) | 2015-04-06 | 2017-09-12 | Yung Shin Pharmaceutical Industrial Co. Ltd. | Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof |
EP3280730B1 (en) | 2015-04-08 | 2024-01-03 | Dana-Farber Cancer Institute, Inc. | Humanized influenza monoclonal antibodies and methods of use thereof |
TWI787645B (en) | 2015-04-13 | 2022-12-21 | 美商輝瑞股份有限公司 | Cd3-specific antibodies, therapeutic bispecific antibodies and their uses |
EP3283524B1 (en) | 2015-04-17 | 2023-04-05 | Amgen Research (Munich) GmbH | Bispecific antibody constructs for cdh3 and cd3 |
CN107849134B (en) | 2015-05-01 | 2022-05-03 | 达纳-法伯癌症研究所公司 | Methods of mediating cytokine expression with anti-CCR 4 antibodies |
AU2016258988A1 (en) | 2015-05-04 | 2017-12-07 | Cytomx Therapeutics, Inc | Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof |
IL310251A (en) | 2015-05-04 | 2024-03-01 | Cytomx Therapeutics Inc | Anti-cd71 antibodies, activatable anti-cd71 antibodies, compositions comprising same and uses thereof |
US10745481B2 (en) | 2015-05-04 | 2020-08-18 | Cytomx Therapeutics, Inc. | Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof |
US20180104331A1 (en) | 2015-05-11 | 2018-04-19 | The Johns Hopkins University | Autoimmune antibodies for use in inhibiting cancer cell growth |
WO2016180986A1 (en) | 2015-05-14 | 2016-11-17 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (Cnic) | Mirna compositions for the treatment of mature b-cell neoplasms |
US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
WO2016196381A1 (en) | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Pd-l1 promoter methylation in cancer |
MA50829A (en) | 2015-06-01 | 2018-04-11 | Sarepta Therapeutics Inc | EXCLUSION OF EXON INDUCED BY ANTISEN TECHNOLOGY IN TYPE VII COLLAGEN |
KR20180021784A (en) | 2015-06-10 | 2018-03-05 | 엘리시움 헬스, 인크. | Nicotinamide riboside and phthalostilbene compositions and methods for the treatment of dermatoses |
WO2017004538A1 (en) | 2015-07-02 | 2017-01-05 | Otsuka Pharmaceutical Co., Ltd. | Lyophilized pharmaceutical compositions |
AU2016294440B2 (en) | 2015-07-13 | 2022-10-13 | Cytomx Therapeutics, Inc | Anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of use thereof |
EP3971211A1 (en) | 2015-07-13 | 2022-03-23 | Compugen Ltd. | Hide1 compositions and methods |
CA3205381A1 (en) | 2015-07-17 | 2017-01-26 | Alnylam Pharmaceuticals, Inc. | Multi-targeted single entity conjugates |
CN108137705B (en) | 2015-07-21 | 2022-11-08 | 武田药品工业株式会社 | Monoclonal antibody inhibitor of factor XIIA |
ES2828694T3 (en) | 2015-07-29 | 2021-05-27 | Allergan Inc | Heavy chain-only antibodies to ANG-2 |
TWI829617B (en) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for flt3 and cd3 |
TWI717375B (en) | 2015-07-31 | 2021-02-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for cd70 and cd3 |
TWI793062B (en) | 2015-07-31 | 2023-02-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for dll3 and cd3 |
TWI744242B (en) | 2015-07-31 | 2021-11-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for egfrviii and cd3 |
TWI796283B (en) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for msln and cd3 |
AU2016307943A1 (en) | 2015-08-14 | 2018-02-15 | Allergan, Inc. | Heavy chain only antibodies to PDGF |
KR20180037210A (en) | 2015-08-20 | 2018-04-11 | 입센 바이오팜 리미티드 | Combination therapy using liposomal irinotecan and PARP inhibitor for cancer treatment |
EP3337478B1 (en) | 2015-08-21 | 2020-08-12 | Ipsen Biopharm Ltd. | Drug combination comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil and leucovorin for treating metastatic pancreatic cancer |
PL3344655T3 (en) | 2015-09-01 | 2024-02-19 | Boehringer Ingelheim International Gmbh | Use of anti-cd40 antibodies for treatment of lupus nephritis |
TW201718857A (en) | 2015-09-14 | 2017-06-01 | 艾爾妮蘭製藥公司 | Compositions and methods for inhibiting expression of the ALAS1 gene |
TWI799366B (en) | 2015-09-15 | 2023-04-21 | 美商建南德克公司 | Cystine knot scaffold platform |
EP3350220B1 (en) | 2015-09-15 | 2021-05-19 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
CA2999160A1 (en) | 2015-09-23 | 2017-03-30 | Oncomed Pharmaceuticals, Inc. | Methods and compositions for treatment of cancer |
WO2017058881A1 (en) | 2015-09-28 | 2017-04-06 | The Trustees Of Columbia University In The City Of New York | Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma |
WO2017055966A1 (en) | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Low viscosity antibody compositions |
EP3359572A2 (en) | 2015-10-06 | 2018-08-15 | H. Hoffnabb-La Roche Ag | Method for treating multiple sclerosis |
WO2017062835A2 (en) | 2015-10-09 | 2017-04-13 | Sarepta Therapeutics, Inc. | Compositions and methods for treating duchenne muscular dystrophy and related disorders |
GB201518170D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent |
GB201518171D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for topical administration with therapeutic agent |
GB201518172D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for use in medicine |
WO2017066714A1 (en) | 2015-10-16 | 2017-04-20 | Compugen Ltd. | Anti-vsig1 antibodies and drug conjugates |
KR20180063255A (en) | 2015-10-16 | 2018-06-11 | 입센 바이오팜 리미티드 | Stabilization of camptothecin pharmaceutical composition |
WO2017075037A1 (en) | 2015-10-27 | 2017-05-04 | Scholar Rock, Inc. | Primed growth factors and uses thereof |
WO2017075045A2 (en) | 2015-10-30 | 2017-05-04 | Mayo Foundation For Medical Education And Research | Antibodies to b7-h1 |
PE20181009A1 (en) | 2015-10-30 | 2018-06-26 | Genentech Inc | ANTI-HtrA1 ANTIBODIES AND METHODS OF USE OF THEM |
ES2938883T3 (en) | 2015-11-05 | 2023-04-17 | Los Angeles Childrens Hospital | Oligo antisense for use in the treatment of acute myeloid leukemia |
EP3370712A4 (en) | 2015-11-06 | 2019-10-09 | The Johns Hopkins University | Methods of treating liver fibrosis by administering 3-bromopyruvate |
AU2016352874B2 (en) | 2015-11-10 | 2021-06-24 | Children's Research Institute, Children's National Medical Center | Echinomycin formulation, method of making and method of use thereof |
MX2018005932A (en) | 2015-11-12 | 2019-05-20 | Graybug Vision Inc | Aggregating microparticles for therapy. |
KR20180088381A (en) | 2015-11-12 | 2018-08-03 | 시아맙 쎄라퓨틱스, 인코포레이티드 | Glycan-interacting compounds and methods of use |
US10689458B2 (en) | 2015-11-30 | 2020-06-23 | Pfizer Inc. | Site specific HER2 antibody drug conjugates |
US20170216452A1 (en) | 2015-11-30 | 2017-08-03 | Pfizer Inc. | Antibodies and antibody fragments for site-specific conjugation |
CN109415437B (en) | 2015-12-02 | 2022-02-01 | 斯特库伯株式会社 | Antibodies and molecules that immunospecifically bind to BTN1A1 and therapeutic uses thereof |
CN108925136B (en) | 2015-12-02 | 2022-02-01 | 斯特赛恩斯公司 | Antibodies specific for glycosylated BTLA (B and T lymphocyte attenuating factor) |
WO2017100562A1 (en) | 2015-12-09 | 2017-06-15 | Alexion Pharmaceuticals, Inc, | Modified mrna encoding a uridine diphopsphate glucuronosyl transferase and uses thereof |
US10548844B2 (en) | 2015-12-14 | 2020-02-04 | Massachusetts Institute Of Technology | pH-responsive mucoadhesive polymeric encapsulated microorganisms |
WO2017106630A1 (en) | 2015-12-18 | 2017-06-22 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
EP3395370B1 (en) | 2015-12-21 | 2021-01-20 | FUJIFILM Corporation | Liposome and liposome composition |
EP4310503A3 (en) | 2015-12-30 | 2024-03-20 | Momenta Pharmaceuticals, Inc. | Methods related to biologics |
CN109071645A (en) | 2016-01-08 | 2018-12-21 | 供石公司 | Anti- Promyostatin/latent flesh amicine antibody and its application method |
EP3405579A1 (en) | 2016-01-22 | 2018-11-28 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
TWI797073B (en) | 2016-01-25 | 2023-04-01 | 德商安美基研究(慕尼黑)公司 | Pharmaceutical composition comprising bispecific antibody constructs |
EA039859B1 (en) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Bispecific antibody constructs binding egfrviii and cd3 |
SG11201806150RA (en) | 2016-02-03 | 2018-08-30 | Amgen Res Munich Gmbh | Psma and cd3 bispecific t cell engaging antibody constructs |
MD3411402T2 (en) | 2016-02-03 | 2022-05-31 | Amgen Res Munich Gmbh | BCMA and CD3 bispecific T cell engaging antibody constructs |
WO2017136558A1 (en) | 2016-02-04 | 2017-08-10 | Curis, Inc. | Mutant smoothened and methods of using the same |
US11633502B2 (en) * | 2016-03-07 | 2023-04-25 | Memorial Sloan Kettering Cancer Center | Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use |
CN109071669A (en) | 2016-03-07 | 2018-12-21 | 查尔斯顿制药有限责任公司 | Anti- paranuclein antibody |
WO2017156500A1 (en) | 2016-03-11 | 2017-09-14 | Scholar Rock, Inc. | Tgfb1-binding immunoglobulins and use thereof |
CA3017776A1 (en) | 2016-03-15 | 2017-09-21 | Generon (Shanghai) Corporation Ltd. | Multispecific fab fusion proteins and use thereof |
MX2018012695A (en) | 2016-04-18 | 2019-06-20 | Sarepta Therapeutics Inc | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene. |
CN109069473B (en) | 2016-04-21 | 2022-09-16 | 港大科桥有限公司 | Compositions and methods for lightening skin and reducing hyperpigmentation |
EP3468997B1 (en) | 2016-06-08 | 2023-09-13 | Xencor, Inc. | Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b |
ITUA20164630A1 (en) | 2016-06-23 | 2017-12-23 | Paolo Blasi | PHARMACOLOGICAL ADIUVANTS FOR TUMOR THERMAL WELDING |
WO2018004517A1 (en) | 2016-06-27 | 2018-01-04 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children and adolescents |
US11246832B2 (en) | 2016-06-28 | 2022-02-15 | Verily Life Sciences Llc | Serial filtration to generate small cholesterol-containing liposomes |
US11046777B2 (en) | 2016-07-22 | 2021-06-29 | Dana-Farber Cancer Institute, Inc. | Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof |
EP3493807A1 (en) | 2016-08-03 | 2019-06-12 | CymaBay Therapeutics, Inc. | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
TWI754659B (en) | 2016-08-08 | 2022-02-11 | 台灣微脂體股份有限公司 | Delivery vehicle, method and kit for preparing a liposomal composition containing mild acidic agent |
WO2018045379A1 (en) | 2016-09-02 | 2018-03-08 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating b cell disorders |
WO2018048939A1 (en) | 2016-09-06 | 2018-03-15 | Dana-Farber Cancer Institute, Inc. | Methods of treating or preventing zika virus infection |
WO2018049248A1 (en) | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus equipped with bispecific engager molecules |
JP2019534858A (en) | 2016-09-09 | 2019-12-05 | ジェネンテック, インコーポレイテッド | Selective peptide inhibitor of FRIZZLED |
WO2018053180A2 (en) | 2016-09-14 | 2018-03-22 | The Trustees Of The University Of Pennsylvania | Proximity-based sortase-mediated protein purification and ligation |
CA3037144A1 (en) | 2016-09-16 | 2018-03-22 | Shanghai Henlius Biotech, Inc. | Anti-pd-1 antibodies |
AU2017331592A1 (en) | 2016-09-23 | 2019-04-11 | Teva Pharmaceuticals International Gmbh | Treating cluster headache |
AU2017331593B2 (en) | 2016-09-23 | 2022-04-28 | Teva Pharmaceuticals International Gmbh | Treating refractory migraine |
JP2019532657A (en) | 2016-10-26 | 2019-11-14 | モデルナティーエックス, インコーポレイテッド | Messenger ribonucleic acid for enhancing immune response and method of use thereof |
EP3535026A1 (en) | 2016-11-02 | 2019-09-11 | Ipsen Biopharm Limited | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
WO2018083535A1 (en) | 2016-11-04 | 2018-05-11 | Novimmune Sa | Anti-cd19 antibodies and methods of use thereof |
CN109996809A (en) | 2016-11-14 | 2019-07-09 | 诺华股份有限公司 | Composition relevant to fusogenic protein MINION, method and therapeutical uses |
WO2018094143A1 (en) | 2016-11-17 | 2018-05-24 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
WO2018106738A1 (en) | 2016-12-05 | 2018-06-14 | Massachusetts Institute Of Technology | Brush-arm star polymers, conjugates and particles, and uses thereof |
US10772926B2 (en) | 2016-12-16 | 2020-09-15 | Nutragen Health Innovations, Inc. | Natural drugs for the treatment of inflammation and melanoma |
RS63849B9 (en) | 2016-12-16 | 2023-06-30 | Pfizer | Glp-1 receptor agonists and uses thereof |
WO2018129395A1 (en) | 2017-01-06 | 2018-07-12 | Scholar Rock, Inc. | Methods for treating metabolic diseases by inhibiting myostatin activation |
EP4218817A3 (en) | 2017-01-06 | 2023-09-06 | Scholar Rock, Inc. | Methods for treating metabolic diseases by inhibiting myostatin activation |
JP7157744B2 (en) | 2017-01-06 | 2022-10-20 | スカラー ロック インコーポレイテッド | Isoform-specific, context-tolerant TGFβ1 inhibitors and uses thereof |
BR112019015797A2 (en) | 2017-02-01 | 2020-03-17 | Modernatx, Inc. | IMMUNOMODULATORY THERAPEUTIC MRNA COMPOSITIONS THAT CODE ACTIVATING ONCOGEN MUTATION PEPTIDES |
JOP20190189A1 (en) | 2017-02-02 | 2019-08-01 | Amgen Res Munich Gmbh | Low ph pharmaceutical composition comprising t cell engaging antibody constructs |
WO2018152496A1 (en) | 2017-02-17 | 2018-08-23 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Compositions and methods for the diagnosis and treatment of zika virus infection |
US11198735B2 (en) | 2017-03-03 | 2021-12-14 | Rinat Neuroscience Corp. | Anti-GITR antibodies and methods of use thereof |
EP3589319A4 (en) | 2017-03-03 | 2021-07-14 | Seagen Inc. | Glycan-interacting compounds and methods of use |
EP3592775A1 (en) | 2017-03-09 | 2020-01-15 | CytomX Therapeutics, Inc. | Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof |
WO2018183173A1 (en) | 2017-03-27 | 2018-10-04 | Boehringer Ingelheim International Gmbh | Anti il-36r antibodies combination therapy |
US11359200B2 (en) | 2017-04-09 | 2022-06-14 | The Cleveland Clinic Foundation | Cancer treatment by MALAT1 inhibition |
JP2020512825A (en) | 2017-04-12 | 2020-04-30 | ファイザー・インク | Antibodies with conditional affinity and methods of use thereof |
CA3059938A1 (en) | 2017-04-14 | 2018-10-18 | Kodiak Sciences Inc. | Complement factor d antagonist antibodies and conjugates thereof |
US11866506B2 (en) | 2017-04-21 | 2024-01-09 | Mellitus, Llc | Anti-CD59 antibodies |
EP4230649A3 (en) | 2017-04-25 | 2023-10-25 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Antibodies and methods for the diagnosis and treatment of epstein barr virus infection |
AR111773A1 (en) | 2017-05-05 | 2019-08-21 | Amgen Inc | PHARMACEUTICAL COMPOSITION THAT INCLUDES CONSTRUCTS OF BISPECTIFIC ANTIBODIES FOR STORAGE AND ADMINISTRATION |
US11318190B2 (en) | 2017-05-05 | 2022-05-03 | United States Government As Represented By The Department Of Veterans Affairs | Methods and compositions for treating liver disease |
RU2019139817A (en) | 2017-05-10 | 2021-06-10 | Грейбуг Вижн, Инк. | DELAYED RELEASE MICROPARTICLES AND THEIR SUSPENSIONS FOR DRUG THERAPY |
WO2018209288A1 (en) | 2017-05-12 | 2018-11-15 | Massachusetts Institute Of Technology | Argonaute protein-double stranded rna complexes and uses related thereto |
WO2018208553A1 (en) | 2017-05-12 | 2018-11-15 | Augusta University Research Institute, Inc. | Human alpha fetoprotein-specific t cell receptors and uses thereof |
CA3065008A1 (en) | 2017-05-26 | 2018-11-29 | Novimmune Sa | Anti-cd47 x anti-mesothelin antibodies and methods of use thereof |
CA3065301A1 (en) | 2017-05-31 | 2018-12-06 | Stcube & Co., Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
CN111051346A (en) | 2017-05-31 | 2020-04-21 | 斯特库伯株式会社 | Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1a1 |
KR20200016899A (en) | 2017-06-01 | 2020-02-17 | 싸이톰스 테라퓨틱스, 인크. | Activatable anti-PDL1 antibody, and methods of using the same |
US11542331B2 (en) | 2017-06-06 | 2023-01-03 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands |
GB201710838D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
BR112019023650A2 (en) | 2017-07-06 | 2020-06-02 | Arrowhead Pharmaceuticals, Inc. | RNAI AGENTS TO INHIBIT ALFA-ENAC EXPRESSION AND METHODS OF USE |
BR112020000679A2 (en) | 2017-07-13 | 2020-07-14 | Massachusetts Institute Of Technology | targeting the hdac2-sp3 complex to enhance synaptic function |
AU2018300237A1 (en) | 2017-07-14 | 2020-01-16 | Cytomx Therapeutics, Inc. | Anti-CD166 antibodies and uses thereof |
CN111094334A (en) | 2017-07-19 | 2020-05-01 | 美国卫生与公众服务部 | Antibodies and methods for diagnosis and treatment of hepatitis B virus infection |
AU2018304711A1 (en) | 2017-07-20 | 2020-01-16 | Cytomx Therapeutics, Inc. | Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereof |
WO2019016784A1 (en) | 2017-07-21 | 2019-01-24 | Universidade De Coimbra | Anti-nucleolin antibody |
MA49634A (en) | 2017-07-21 | 2020-05-27 | Modernatx Inc | MODIFIED RNA CODING FOR A PROPIONYL-COA-CARBOXYLASE AND ASSOCIATED USES |
US20200179494A1 (en) | 2017-07-24 | 2020-06-11 | Modernatx, Inc. | Modified mRNA Encoding a Glucose 6 Phosphatase and Uses Thereof |
WO2019023564A1 (en) | 2017-07-27 | 2019-01-31 | Alexion Pharmaceutical, Inc. | High concentration anti-c5 antibody formulations |
EP3658583A1 (en) | 2017-07-28 | 2020-06-03 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof |
RU2020108580A (en) | 2017-08-03 | 2021-09-03 | Оцука Фармасьютикал Ко., Лтд. | MEDICINAL COMPOUNDS AND METHODS OF ITS PURIFICATION |
US11135187B2 (en) | 2017-08-22 | 2021-10-05 | National Institutes Of Health (Nih) | Compositions and methods for treating diabetic retinopathy |
US20190117789A1 (en) | 2017-08-30 | 2019-04-25 | Cytomx Therapeutics, Inc. | Activatable anti-cd166 antibodies and methods of use thereof |
EP3679070A1 (en) | 2017-09-07 | 2020-07-15 | Augusta University Research Institute, Inc. | Antibodies to programmed cell death protein 1 |
US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
CA3078974A1 (en) | 2017-10-12 | 2019-04-18 | Immunowake Inc. | Vegfr-antibody light chain fusion protein |
BR112020007309A2 (en) | 2017-10-14 | 2020-09-29 | Cytomx Therapeutics, Inc. | antibodies, activable antibodies, bispecific antibodies and bispecific activable antibodies and methods of using them |
WO2019077496A1 (en) | 2017-10-17 | 2019-04-25 | Rhizen Pharmaceuticals Sa | Crac channel modulators for treating esophageal cancer |
WO2019079637A2 (en) | 2017-10-18 | 2019-04-25 | Sarepta Therapeutics, Inc. | Antisense oligomer compounds |
WO2019082124A1 (en) | 2017-10-26 | 2019-05-02 | Rhizen Pharmaceuticals Sa | Composition and method for treating diffuse large b-cell lymphoma |
SG11202003246WA (en) | 2017-10-27 | 2020-05-28 | Pfizer | Antibodies and antibody-drug conjugates specific for cd123 and uses thereof |
JP2021501160A (en) | 2017-10-30 | 2021-01-14 | ルヒゼン ファーマスティカルズ エスエー | Calcium Release Activated Calcium Channel Modulator for the Treatment of Hematological and Solid Cancers |
WO2019086626A1 (en) | 2017-11-03 | 2019-05-09 | Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) | MIRNAs AND COMBINATIONS THEREOF FOR USE IN THE TREATMENT OF HUMAN B CELL NEOPLASIAS |
MX2020005771A (en) | 2017-12-06 | 2020-10-28 | Rhizen Pharmaceuticals Sa | Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphoma. |
US11946094B2 (en) | 2017-12-10 | 2024-04-02 | Augusta University Research Institute, Inc. | Combination therapies and methods of use thereof |
JP7344206B2 (en) | 2017-12-11 | 2023-09-13 | アムジェン インコーポレイテッド | Continuous manufacturing process for bispecific antibody products |
TW201940518A (en) | 2017-12-29 | 2019-10-16 | 美商安進公司 | Bispecific antibody construct directed to MUC17 and CD3 |
WO2019165101A1 (en) | 2018-02-22 | 2019-08-29 | Verily Life Sciences Llc | Combining orthogonal chemistries for preparation of multiplexed nanoparticles |
KR20200128116A (en) | 2018-02-28 | 2020-11-11 | 화이자 인코포레이티드 | IL-15 variants and uses thereof |
WO2019173771A1 (en) | 2018-03-09 | 2019-09-12 | Cytomx Therapeutics, Inc. | Activatable cd147 antibodies and methods of making and use thereof |
US11203646B2 (en) | 2018-03-14 | 2021-12-21 | Novimmune Sa | Anti-CD3 epsilon antibodies and methods of use thereof |
CN112166123B (en) | 2018-03-14 | 2022-09-30 | 北京轩义医药科技有限公司 | Anti-claudin 18.2 antibodies |
US20210000936A1 (en) | 2018-03-21 | 2021-01-07 | Colorado State University Research Foundation | Cancer vaccine compositions and methods of use thereof |
US10722528B2 (en) | 2018-03-28 | 2020-07-28 | Augusta University Research Institute, Inc. | Compositions and methods for inhibiting metastasis |
AU2019247490A1 (en) | 2018-04-06 | 2020-10-22 | Children's Medical Center Corporation | Compositions and methods for somatic cell reprogramming and modulating imprinting |
CN112334485A (en) | 2018-04-06 | 2021-02-05 | 百进生物科技公司 | Anti-tetraspanin 33agents and compositions thereof and methods of making and using |
US20210115156A1 (en) | 2018-04-13 | 2021-04-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fc-engineered anti-human ige antibodies and methods of use |
US20210171610A1 (en) | 2018-05-02 | 2021-06-10 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection |
CA3100829A1 (en) | 2018-05-23 | 2019-11-28 | Pfizer Inc. | Antibodies specific for gucy2c and uses thereof |
EP3797121A1 (en) | 2018-05-23 | 2021-03-31 | Pfizer Inc | Antibodies specific for cd3 and uses thereof |
WO2019234680A1 (en) | 2018-06-08 | 2019-12-12 | Pfizer Inc. | Methods of treating iron metabolic disease with a neutralizing antibody binding erhythroferrone |
TWI707683B (en) | 2018-06-13 | 2020-10-21 | 美商輝瑞股份有限公司 | Glp-1 receptor agonists and uses thereof |
AU2019285570B2 (en) | 2018-06-15 | 2022-03-24 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
CN112533629A (en) | 2018-06-19 | 2021-03-19 | 阿尔莫生物科技股份有限公司 | Compositions and methods for combined use of IL-10 agents with chimeric antigen receptor cell therapy |
JP2021529518A (en) | 2018-06-28 | 2021-11-04 | クリスパー セラピューティクス アーゲー | Compositions and Methods for Genome Editing by Insertion of Donor polynucleotide |
KR20210027436A (en) | 2018-06-29 | 2021-03-10 | 베링거 인겔하임 인터내셔날 게엠베하 | Anti-CD40 antibodies for use in treating autoimmune diseases |
CN112384282A (en) | 2018-07-06 | 2021-02-19 | 辉瑞公司 | Process for producing pyrrolo [2,3-d ] pyrimidine compound, intermediate and use thereof |
PT3677278T (en) | 2018-07-11 | 2022-02-03 | Scholar Rock Inc | Isoform selective tgfbeta1 inhibitors and use thereof |
EP3820896A1 (en) | 2018-07-11 | 2021-05-19 | Scholar Rock, Inc. | TGFbeta1 INHIBITORS AND USE THEREOF |
JP2021531254A (en) | 2018-07-11 | 2021-11-18 | スカラー ロック インコーポレイテッドScholar Rock, Inc. | High affinity isoform-selective TGFβ1 inhibitor, and its use |
WO2020016459A1 (en) | 2018-07-20 | 2020-01-23 | Pierre Fabre Medicament | Receptor for vista |
US20210348162A1 (en) | 2018-08-16 | 2021-11-11 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
EP3849515A1 (en) * | 2018-09-11 | 2021-07-21 | Memorial Sloan Kettering Cancer Center | Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use |
WO2020068557A1 (en) | 2018-09-25 | 2020-04-02 | BioLegend, Inc. | Anti-tlr9 agents and compositions and methods for making and using the same |
US20210338728A1 (en) | 2018-09-27 | 2021-11-04 | Phosphogam, Inc. | Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells |
AU2019349874A1 (en) | 2018-09-28 | 2021-04-29 | Lyvgen Biopharma Holdings Limited | Anti-CD40 binding molecules having engineered Fc domains and therapeutic uses thereof |
US20210380923A1 (en) | 2018-10-10 | 2021-12-09 | Boehringer Ingelheim International Gmbh | Method for membrane gas transfer in high density bioreactor culture |
SG11202103275YA (en) | 2018-10-11 | 2021-04-29 | Amgen Inc | Downstream processing of bispecific antibody constructs |
US11427591B2 (en) | 2018-10-17 | 2022-08-30 | Insilico Medicine Ip Limited | Kinase inhibitors |
BR112021007765A2 (en) | 2018-10-23 | 2021-08-03 | Scholar Rock, Inc. | selective rgmc inhibitors and their use |
WO2020087064A2 (en) * | 2018-10-26 | 2020-04-30 | University Of Connecticut | A continuous processing system and methods for internal and external modifications to nanoparticles |
CA3118445A1 (en) | 2018-11-02 | 2020-05-07 | Cytomx Therapeutics, Inc. | Activatable anti-cd166 antibodies and methods of use thereof |
WO2020103815A1 (en) | 2018-11-22 | 2020-05-28 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
US20220024999A1 (en) | 2018-11-29 | 2022-01-27 | Flagship Pioneering Innovations V, Inc. | Methods of modulating rna |
BR112021010433A2 (en) | 2018-12-06 | 2021-08-24 | Cytomx Therapeutics, Inc. | Cleavable matrix metalloprotease and serine or cysteine protease substrates and methods of using them |
BR112021012172A2 (en) | 2018-12-12 | 2021-08-31 | Kite Pharma, Inc. | CHIMERIC AND T-CELL ANTIGEN RECEPTORS AND METHODS OF USE |
JP2022523051A (en) | 2019-01-22 | 2022-04-21 | マサチューセッツ インスティテュート オブ テクノロジー | In vitro human blood-brain barrier |
JP2020117502A (en) | 2019-01-28 | 2020-08-06 | ファイザー・インク | Method of treating signs and symptoms of osteoarthritis |
SG11202108099WA (en) | 2019-01-30 | 2021-08-30 | Scholar Rock Inc | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF |
TWI820301B (en) | 2019-02-15 | 2023-11-01 | 美商輝瑞股份有限公司 | Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1] octanylmethanone compound and use thereof |
JP2020143045A (en) | 2019-02-18 | 2020-09-10 | ファイザー・インク | Method of treatment of chronic low back pain |
US20220275059A1 (en) | 2019-02-20 | 2022-09-01 | Harbour Antibodies Bv | Antibodies |
US11795160B2 (en) | 2019-02-22 | 2023-10-24 | Insilico Medicine Ip Limited | Kinase inhibitors |
CN113677372A (en) | 2019-02-26 | 2021-11-19 | 西托姆克斯治疗公司 | Combination therapy of activatable immune checkpoint inhibitors and conjugated activatable antibodies |
WO2020181058A1 (en) | 2019-03-05 | 2020-09-10 | Massachusetts Institute Of Technology | Dna launched rna replicon system (drep) and uses thereof |
WO2020185293A1 (en) | 2019-03-08 | 2020-09-17 | Massachusetts Institute Of Technology | Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy |
EP3947441A1 (en) | 2019-03-27 | 2022-02-09 | UMC Utrecht Holding B.V. | Engineered iga antibodies and methods of use |
WO2020205716A1 (en) | 2019-04-01 | 2020-10-08 | Genentech, Inc. | Compositions and methods for stabilizing protein-containing formulations |
AU2020251841A1 (en) | 2019-04-02 | 2021-10-07 | Array Biopharma Inc. | Protein tyrosine phosphatase inhibitors |
CA3144848C (en) | 2019-06-28 | 2023-11-21 | Pfizer Inc. | 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases |
TW202115086A (en) | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk inhibitors |
LT6699B (en) | 2019-07-15 | 2020-02-10 | UAB "Valentis" | Method for production of proliposomes by using up to 5% ethanol and the use thereof for encapsulation of lipophilic substances |
CN112300279A (en) | 2019-07-26 | 2021-02-02 | 上海复宏汉霖生物技术股份有限公司 | Methods and compositions directed to anti-CD 73 antibodies and variants |
US10758329B1 (en) | 2019-08-20 | 2020-09-01 | Raymond L. Wright, III | Hydrating mouth guard |
MX2022002689A (en) | 2019-09-03 | 2022-04-07 | Alnylam Pharmaceuticals Inc | Compositions and methods for inhibiting expression of the lect2 gene. |
CN114650844A (en) | 2019-09-23 | 2022-06-21 | 西托姆克斯治疗公司 | anti-CD 47 antibodies, activatable anti-CD 47 antibodies, and methods of use thereof |
WO2021062092A1 (en) | 2019-09-26 | 2021-04-01 | Massachusetts Institute Of Technology | Trans-activated functional rna by strand displacement and uses thereof |
WO2021062323A1 (en) | 2019-09-26 | 2021-04-01 | Stcube & Co. | Antibodies specific to glycosylated ctla-4 and methods of use thereof |
US11492622B2 (en) | 2019-09-26 | 2022-11-08 | Massachusetts Institute Of Technology | MicroRNA-based logic gates and uses thereof |
US20220356234A1 (en) | 2019-10-02 | 2022-11-10 | Alexion Pharmaceuticals, Inc. | Complement inhibitors for treating drug-induced complement-mediated response |
EP4038189A1 (en) | 2019-10-04 | 2022-08-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing ugt1a1 gene expression |
TWI771766B (en) | 2019-10-04 | 2022-07-21 | 美商輝瑞股份有限公司 | Diacylglycerol acyltransferase 2 inhibitor |
US20240050529A1 (en) | 2019-10-07 | 2024-02-15 | University Of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
JP2022552282A (en) | 2019-10-09 | 2022-12-15 | エスティーキューブ アンド カンパニー | Antibodies specific for glycosylated LAG3 and methods of use thereof |
CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
EP4041773A1 (en) | 2019-10-11 | 2022-08-17 | Beth Israel Deaconess Medical Center, Inc. | Anti-tn antibodies and uses thereof |
CN114828842A (en) | 2019-10-21 | 2022-07-29 | 理森制药股份公司 | Composition comprising DHODH inhibitor for the treatment of acute myeloid leukemia |
US20230040920A1 (en) | 2019-11-01 | 2023-02-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing dnajb1-prkaca fusion gene expression |
MX2022007105A (en) | 2019-12-10 | 2022-07-11 | Pfizer | Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[ d] [1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)me thyl)-1h-benzo[d] imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt. |
WO2021142448A2 (en) | 2020-01-11 | 2021-07-15 | Scholar Rock,Inc. | Tgf-beta inhibitors and use thereof |
BR112022013733A2 (en) | 2020-01-11 | 2022-11-01 | Scholar Rock Inc | TGFBETA INHIBITORS AND THEIR USE |
CN115315273A (en) | 2020-01-14 | 2022-11-08 | 辛德凯因股份有限公司 | IL-2 orthologs and methods of use thereof |
CN115427447A (en) | 2020-01-17 | 2022-12-02 | 百进生物科技公司 | anti-TLR 7 agents and compositions and methods of making and using the same |
US20230067811A1 (en) | 2020-01-24 | 2023-03-02 | University Of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
CA3170377A1 (en) | 2020-02-10 | 2021-08-19 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing vegf-a expression |
JP2022058085A (en) | 2020-02-24 | 2022-04-11 | ファイザー・インク | Combination of inhibitors of diacylglycerol acyltransferase 2 and inhibitors of acetyl-coa carboxylase |
AU2021232062A1 (en) | 2020-03-06 | 2022-09-29 | Colorado State University Research Foundation | Production of vaccines comprising inactivated SARS-CoV-2 viral particles |
CA3174908A1 (en) | 2020-03-09 | 2021-09-16 | Pfizer Inc. | Fusion proteins and uses thereof |
GB202003632D0 (en) | 2020-03-12 | 2020-04-29 | Harbour Antibodies Bv | SARS-Cov-2 (SARS2, COVID-19) antibodies |
US20230095383A1 (en) | 2020-03-17 | 2023-03-30 | Dst Pharma, Inc. | Methods and compositions for treating viral infections |
MX2022011743A (en) | 2020-03-26 | 2022-12-08 | Plx Opco Inc | PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND- METHODS FOR MAKING AND USING SAME. |
IL296694A (en) | 2020-03-27 | 2022-11-01 | Pfizer | Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
WO2021202443A2 (en) | 2020-03-30 | 2021-10-07 | Alnylam Pharmaceucticals, Inc. | Compositions and methods for silencing dnajc15 gene expression |
BR112022020145A2 (en) | 2020-04-06 | 2023-01-03 | Alnylam Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR SILENCING THE MYOC EXPRESSION |
WO2021207189A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing scn9a expression |
US20230159539A1 (en) | 2020-04-08 | 2023-05-25 | Pfizer Inc. | Crystalline forms of 3-cyano-1-[4-[6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1h-pyrazol-1-yl]cyclobutaneacetonitrile, and use thereof |
CA3176425A1 (en) | 2020-04-24 | 2021-10-28 | Millennium Pharmaceuticals, Inc. | Anti-cd19 antibodies and uses thereof |
WO2021224850A1 (en) | 2020-05-06 | 2021-11-11 | Crispr Therapeutics Ag | Mask peptides and masked anti-ptk7 antibodies comprising such |
CA3178965A1 (en) | 2020-05-15 | 2021-11-18 | Christian COBAUGH | Messenger rna encoding cas9 for use in genome-editing systems |
EP4153746A1 (en) | 2020-05-21 | 2023-03-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting marc1 gene expression |
WO2021242817A1 (en) | 2020-05-27 | 2021-12-02 | Qilu Regor Therapeutics Inc. | Salt and crystal forms of glp-1r agonists and uses thereof |
BR112022024527A2 (en) | 2020-06-09 | 2022-12-27 | Pfizer | SPYRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF |
KR20230025898A (en) | 2020-06-26 | 2023-02-23 | 화이자 인코포레이티드 | Methods of using TL1A antibodies to treat inflammatory bowel disease |
WO2022006562A1 (en) | 2020-07-03 | 2022-01-06 | Dana-Farber Cancer Institute, Inc. | Multispecific coronavirus antibodies |
JP2023533793A (en) | 2020-07-17 | 2023-08-04 | ファイザー・インク | Therapeutic antibodies and their uses |
US20230295257A1 (en) | 2020-07-24 | 2023-09-21 | Strand Therapeutics Inc. | Lipid nanoparticle comprising modified nucleotides |
MX2023001274A (en) | 2020-07-28 | 2023-04-24 | Jazz Pharmaceuticals Ireland Ltd | Chiral synthesis of fused bicyclic raf inhibitors. |
MX2023001275A (en) | 2020-07-28 | 2023-04-24 | Jazz Pharmaceuticals Ireland Ltd | Fused bicyclic raf inhibitors and methods for use thereof. |
WO2022031884A2 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il2rg binding molecules and methods of use |
EP4192489A2 (en) | 2020-08-05 | 2023-06-14 | Synthekine, Inc. | Il2rb binding molecules and methods of use |
CN116322754A (en) | 2020-08-05 | 2023-06-23 | 辛德凯因股份有限公司 | IL10RA binding molecules and methods of use |
CA3190420A1 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Compositions and methods related to il27 receptor binding |
TW202214622A (en) | 2020-08-06 | 2022-04-16 | 大陸商上海齊魯銳格醫藥研發有限公司 | Glp-1r agonists and uses thereof |
AU2021326504A1 (en) | 2020-08-14 | 2023-02-23 | Kite Pharma, Inc | Improving immune cell function |
EP4211164A1 (en) | 2020-09-14 | 2023-07-19 | Vor Biopharma Inc. | Single domain antibodies against cd33 |
EP4213939A1 (en) | 2020-09-21 | 2023-07-26 | Boehringer Ingelheim International GmbH | Use of anti-cd40 antibodies for treatment of inflammatory conditions |
JP2023544200A (en) | 2020-10-06 | 2023-10-20 | ゼンコー・インコーポレイテッド | Biomarkers, methods, and compositions for treating autoimmune diseases including systemic lupus erythematosus (SLE) |
JP2023546125A (en) | 2020-10-14 | 2023-11-01 | キル・レガー・セラピューティクス・インコーポレーテッド | Crystal forms of GLP-1R agonists and their uses |
WO2022093641A1 (en) | 2020-10-30 | 2022-05-05 | BioLegend, Inc. | Anti-nkg2a agents and compositions and methods for making and using the same |
WO2022093640A1 (en) | 2020-10-30 | 2022-05-05 | BioLegend, Inc. | Anti-nkg2c agents and compositions and methods for making and using the same |
EP4251170A1 (en) | 2020-11-25 | 2023-10-04 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids, and related methods of use |
US11058637B1 (en) * | 2020-11-25 | 2021-07-13 | King Abdulaziz University | Surface-modified emulsomes for intranasal delivery of drugs |
IL303741A (en) | 2020-12-18 | 2023-08-01 | Momenta Pharmaceuticals Inc | Antibodies against integrin alpha 11 beta 1 |
KR20230129479A (en) | 2021-01-08 | 2023-09-08 | 스트랜드 세러퓨틱스 인코포레이티드 | Expression constructs and uses thereof |
US11357727B1 (en) | 2021-01-22 | 2022-06-14 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
US11033495B1 (en) | 2021-01-22 | 2021-06-15 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
US11278494B1 (en) | 2021-01-22 | 2022-03-22 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
CN117062836A (en) | 2021-02-05 | 2023-11-14 | 勃林格殷格翰国际有限公司 | anti-IL 1RAP antibodies |
US11530199B2 (en) | 2021-02-24 | 2022-12-20 | Insilico Medicine Ip Limited | Analogs for the treatment of disease |
IL305571A (en) | 2021-03-11 | 2023-10-01 | Kite Pharma Inc | Improving immune cell function |
WO2022195504A1 (en) | 2021-03-19 | 2022-09-22 | Pfizer Inc. | Method of treating osteoarthritis pain with an anti ngf antibody |
US11952461B2 (en) | 2021-03-22 | 2024-04-09 | Sunbio, Inc. | Siloxy polyethylene glycol and derivatives thereof |
EP4314065A1 (en) | 2021-03-22 | 2024-02-07 | Novimmune S.A. | Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof |
CA3212599A1 (en) | 2021-03-22 | 2022-09-29 | Novimmune S.A. | Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof |
WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
JP2024515066A (en) | 2021-04-09 | 2024-04-04 | 武田薬品工業株式会社 | Antibodies targeting complement factor D and uses thereof |
WO2022226291A1 (en) | 2021-04-22 | 2022-10-27 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating cancer |
EP4330283A1 (en) | 2021-04-26 | 2024-03-06 | Millennium Pharmaceuticals, Inc. | Anti-adgre2 antibodies and uses thereof |
AR125451A1 (en) | 2021-04-26 | 2023-07-19 | Millennium Pharm Inc | ANTI-CLEC12A ANTIBODIES AND USES THEREOF |
EP4334354A1 (en) | 2021-05-06 | 2024-03-13 | Dana-Farber Cancer Institute, Inc. | Antibodies against alk and methods of use thereof |
US20230115257A1 (en) | 2021-05-17 | 2023-04-13 | Curia Ip Holdings, Llc | Sars-cov-2 spike protein antibodies |
WO2022245859A1 (en) | 2021-05-17 | 2022-11-24 | Curia Ip Holdings, Llc | Sars-cov-2 spike protein antibodies |
EP4348260A2 (en) | 2021-06-03 | 2024-04-10 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
WO2022271867A1 (en) | 2021-06-23 | 2022-12-29 | Scholar Rock, Inc. | A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders |
WO2023283403A2 (en) | 2021-07-09 | 2023-01-12 | Alnylam Pharmaceuticals, Inc. | Bis-rnai compounds for cns delivery |
TW202306985A (en) | 2021-07-12 | 2023-02-16 | 美商建南德克公司 | Structures for reducing antibody-lipase binding |
WO2023288277A1 (en) | 2021-07-14 | 2023-01-19 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgfb1 and uses thereof |
WO2023007374A1 (en) | 2021-07-27 | 2023-02-02 | Pfizer Inc. | Method of treatment of cancer pain with tanezumab |
GB202111759D0 (en) | 2021-08-17 | 2021-09-29 | Cantab Biopharmaceuticals Patents Ltd | Modified colloidal particles |
GB202111758D0 (en) | 2021-08-17 | 2021-09-29 | Cantab Biopharmaceuticals Patents Ltd | Modified colloidal particles for use in the treatment of haemophilia A |
GB202111757D0 (en) | 2021-08-17 | 2021-09-29 | Cantab Biopharmaceuticals Patents Ltd | Modified colloidal particles for use in the treatment of haemophilia A |
AU2022336407A1 (en) | 2021-08-31 | 2024-02-22 | Pfizer Inc. | Solid forms of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt |
WO2023034901A1 (en) | 2021-09-01 | 2023-03-09 | The Broad Institute, Inc. | Tumor avatar vaccine compositions and uses thereof |
WO2023036982A1 (en) | 2021-09-10 | 2023-03-16 | Harbour Antibodies Bv | Anti-sars2-s antibodies |
GB202112935D0 (en) | 2021-09-10 | 2021-10-27 | Harbour Antibodies Bv | Sars-cov-2 (sars2, covid-19) heavy chain only antibodies |
WO2023068382A2 (en) | 2021-10-20 | 2023-04-27 | Takeda Pharmaceutical Company Limited | Compositions targeting bcma and methods of use thereof |
WO2023077148A1 (en) | 2021-11-01 | 2023-05-04 | Tome Biosciences, Inc. | Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo |
WO2023081471A1 (en) | 2021-11-05 | 2023-05-11 | Dana-Farber Cancer Institute, Inc. | Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof |
WO2023097024A1 (en) | 2021-11-24 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Antibodies against ctla-4 and methods of use thereof |
TW202337429A (en) | 2021-12-01 | 2023-10-01 | 美商輝瑞股份有限公司 | Bckdk inhibitors and/or degraders |
WO2023105387A1 (en) | 2021-12-06 | 2023-06-15 | Pfizer Inc. | Melanocortin 4 receptor antagonists and uses thereof |
WO2023105371A1 (en) | 2021-12-08 | 2023-06-15 | Array Biopharma Inc. | Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide |
WO2023114544A1 (en) | 2021-12-17 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Antibodies and uses thereof |
WO2023114543A2 (en) | 2021-12-17 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Platform for antibody discovery |
WO2023111817A1 (en) | 2021-12-17 | 2023-06-22 | Pfizer Inc. | Crystalline forms of [(1r,5s,6r)-3-{2-[(2s)-2-methylazetidin-1-yl]-6-(trifluoromethyl) pyrimidin-4-yl}-3-azabicyclo[3.1.0]hex-6-yl]acetic acid |
WO2023122764A1 (en) | 2021-12-22 | 2023-06-29 | Tome Biosciences, Inc. | Co-delivery of a gene editor construct and a donor template |
WO2023178357A1 (en) | 2022-03-18 | 2023-09-21 | Evolveimmune Therapeutics, Inc. | Bispecific antibody fusion molecules and methods of use thereof |
WO2023201238A1 (en) | 2022-04-11 | 2023-10-19 | Vor Biopharma Inc. | Binding agents and methods of use thereof |
WO2023205744A1 (en) | 2022-04-20 | 2023-10-26 | Tome Biosciences, Inc. | Programmable gene insertion compositions |
WO2023212618A1 (en) | 2022-04-26 | 2023-11-02 | Strand Therapeutics Inc. | Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof |
WO2023215831A1 (en) | 2022-05-04 | 2023-11-09 | Tome Biosciences, Inc. | Guide rna compositions for programmable gene insertion |
WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
WO2023225670A2 (en) | 2022-05-20 | 2023-11-23 | Tome Biosciences, Inc. | Ex vivo programmable gene insertion |
WO2023228023A1 (en) | 2022-05-23 | 2023-11-30 | Pfizer Inc. | Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof |
WO2023235852A1 (en) | 2022-06-03 | 2023-12-07 | Zenas Biopharma, Inc. | Methods and compositions for treating igg4- related diseases |
WO2024020051A1 (en) | 2022-07-19 | 2024-01-25 | BioLegend, Inc. | Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same |
WO2024030847A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
WO2024030845A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
WO2024030850A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
WO2024030843A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
WO2024030858A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
WO2024030829A1 (en) | 2022-08-01 | 2024-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind to the underside of influenza viral neuraminidase |
WO2024039672A2 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against msln and methods of use thereof |
WO2024039670A1 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against cldn4 and methods of use thereof |
WO2024040114A2 (en) | 2022-08-18 | 2024-02-22 | BioLegend, Inc. | Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same |
WO2024059165A1 (en) | 2022-09-15 | 2024-03-21 | Alnylam Pharmaceuticals, Inc. | 17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3993754A (en) * | 1974-10-09 | 1976-11-23 | The United States Of America As Represented By The United States Energy Research And Development Administration | Liposome-encapsulated actinomycin for cancer chemotherapy |
US4426330A (en) * | 1981-07-20 | 1984-01-17 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
US4534899A (en) * | 1981-07-20 | 1985-08-13 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
US4501728A (en) * | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
JPS60100516A (en) * | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | Preparation of sustained release microcapsule |
US4885172A (en) * | 1985-06-26 | 1989-12-05 | The Liposome Company, Inc. | Composition for targeting, storing and loading of liposomes |
IE58981B1 (en) * | 1985-10-15 | 1993-12-15 | Vestar Inc | Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles |
US4797285A (en) * | 1985-12-06 | 1989-01-10 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem | Lipsome/anthraquinone drug composition and method |
GB8601100D0 (en) * | 1986-01-17 | 1986-02-19 | Cosmas Damian Ltd | Drug delivery system |
US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US4920016A (en) * | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
US4863739A (en) * | 1987-05-19 | 1989-09-05 | Board Of Regents, The University Of Texas System | Liposome compositions of anthracycline derivatives |
JPH0696636B2 (en) * | 1988-03-30 | 1994-11-30 | 富士写真フイルム株式会社 | 2,4-bis (o-methoxypolyethylene glycol) -6-cholesteryl-S-triazine compound |
AU616040B2 (en) * | 1988-08-11 | 1991-10-17 | Terumo Kabushiki Kaisha | Agents for inhibiting adsorption of proteins on the liposome surface |
JPH0720857B2 (en) * | 1988-08-11 | 1995-03-08 | テルモ株式会社 | Liposome and its manufacturing method |
GB8824593D0 (en) * | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Liposomes |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
-
1989
- 1989-10-20 US US07/425,224 patent/US5013556A/en not_active Expired - Lifetime
-
1990
- 1990-10-19 WO PCT/US1990/006034 patent/WO1991005545A1/en not_active Application Discontinuation
- 1990-10-19 DE DE69019366T patent/DE69019366T2/en not_active Expired - Lifetime
- 1990-10-19 EP EP91900513A patent/EP0496835B1/en not_active Expired - Lifetime
- 1990-10-19 CA CA002067133A patent/CA2067133C/en not_active Expired - Lifetime
- 1990-10-19 JP JP3501034A patent/JP2667051B2/en not_active Expired - Lifetime
- 1990-10-19 AU AU66374/90A patent/AU642679B2/en not_active Expired
- 1990-10-19 DK DK91900513.2T patent/DK0496835T3/en active
- 1990-10-19 KR KR1019920700919A patent/KR920703013A/en not_active Application Discontinuation
- 1990-10-19 JP JP51523890A patent/JP3571335B2/en not_active Expired - Fee Related
- 1990-10-19 DE DE69015207T patent/DE69015207T2/en not_active Revoked
- 1990-10-19 EP EP90916409A patent/EP0496813B1/en not_active Revoked
- 1990-10-19 AT AT91900513T patent/ATE122229T1/en active
- 1990-10-19 DE DE19675048C patent/DE19675048I2/en active Active
- 1990-10-19 KR KR1019920700918A patent/KR0134982B1/en not_active IP Right Cessation
- 1990-10-19 AU AU68982/91A patent/AU654120B2/en not_active Expired
- 1990-10-19 WO PCT/US1990/006211 patent/WO1991005546A1/en active IP Right Grant
- 1990-10-19 CA CA002067178A patent/CA2067178C/en not_active Expired - Lifetime
- 1990-10-19 AT AT90916409T patent/ATE115401T1/en not_active IP Right Cessation
- 1990-10-19 ES ES91900513T patent/ES2071976T3/en not_active Expired - Lifetime
- 1990-10-21 IL IL9606990A patent/IL96069A/en not_active IP Right Cessation
- 1990-10-21 IL IL9607090A patent/IL96070A/en not_active IP Right Cessation
-
1991
- 1991-01-15 US US07/642,321 patent/US5213804A/en not_active Expired - Lifetime
-
1992
- 1992-03-27 NO NO92921213A patent/NO921213L/en unknown
- 1992-03-27 NO NO920996A patent/NO304637B1/en not_active IP Right Cessation
- 1992-04-21 FI FI921764A patent/FI105151B/en active Protection Beyond IP Right Term
- 1992-04-21 FI FI921763A patent/FI921763A/en not_active Application Discontinuation
-
1995
- 1995-08-09 GR GR950402186T patent/GR3017060T3/en unknown
-
1996
- 1996-12-13 LU LU88854C patent/LU88854I2/en unknown
- 1996-12-18 NL NL960031C patent/NL960031I2/en unknown
-
1997
- 1997-02-05 HK HK14097A patent/HK14097A/en not_active IP Right Cessation
- 1997-03-17 JP JP9063661A patent/JP2889549B2/en not_active Expired - Lifetime
-
1999
- 1999-02-23 NO NO1999003C patent/NO1999003I1/en unknown
-
2001
- 2001-01-11 JP JP2001004291A patent/JP3921050B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2067133C (en) | Liposome microreservoir composition and method | |
US5225212A (en) | Microreservoir liposome composition and method | |
EP0632719B1 (en) | Method of treatment of infected tissues | |
EP0662820B1 (en) | Compositions for treatmewnt of inflamed tissues | |
KR910004580B1 (en) | Small particle aerosol liposome and liposome-drug combinations for medical use | |
EP0706374B1 (en) | Method for preparing liposomes | |
JP2001510451A (en) | Ion carrier carrying weakly basic drug-liposome in the middle | |
US20030113369A1 (en) | Liposomes with enhanced circulation time and method of treatment | |
JPH04244018A (en) | Liposome preparation transitional to liver | |
KR20010014163A (en) | Proliposome Powders for Inhalation Stabilised by Tocopherol | |
US20010051183A1 (en) | Liposomes with enhanced circulation time and method of treatment | |
WO2000009071A2 (en) | A novel liposomal formulation useful in treatment of cancer and other proliferation diseases | |
WO2005021012A1 (en) | Drug carrier having gemcitabine enclosed therein | |
JPH04244017A (en) | Liposome preparation | |
ZA200507816B (en) | Liposome composition for reduction of liposome-induced complement activation | |
WO2003022250A2 (en) | Unilamellar vesicles stabilized with short chain hydrophilic polymers | |
Mim | Potential of liposomes for the treatment of lung cancer-a review | |
KR100768265B1 (en) | Heparin coated liposomes to prolong circulation time in bloodstream and preparation method thereof | |
JPH11222424A (en) | Medical liposome, and minute aerosol particle of medicament-containing liposome | |
EP1089727A1 (en) | Liposomal formulations of busulphan | |
JPH11222423A (en) | Medical liposome, and minute aerosol particle of medicament-containing liposome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |